

DRAFT

DRAFT

DRAFT



Morbidity and Mortality Weekly Report

Recommendations and Reports

Month, 2005 / Vol. ?? / No. RR-??

**Guidelines for Preventing the
Transmission of *Mycobacterium
tuberculosis* in Health-Care Settings,
2005**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION**

Table of Contents

I.	INTRODUCTION	14
A.	Overview of the Document	14
A.1	HCWs who may be included in a TB screening program	16
A.2	Settings where HCWs may require a TB screening program	17
B.	Pathogenesis, Epidemiology, and Transmission of <i>M. tuberculosis</i>	19
B.1	Persons at higher risk for exposure to and infection with <i>M. tuberculosis</i>	19
B.2	Persons at higher risk for progression from LTBI to TB disease include	20
B.3	Characteristics of a patient with TB disease that enhance infectiousness include	21
B.4	Environmental factors that enhance the probability of transmission of <i>M. tuberculosis</i> include	22
C.	Risk for Health-care–Associated Transmission of <i>M. tuberculosis</i>	22
D.	Fundamentals of TB Infection Control	23
D.1	Administrative controls	23
D.2	Environmental controls	24
D.3	Respiratory protection	24
E.	Relevance to Bioterrorism Preparedness and Other Infections Spread through an Airborne Route	25
II.	RECOMMENDATIONS FOR PREVENTING TRANSMISSION OF <i>M. TUBERCULOSIS</i> IN HEALTH-CARE SETTINGS	25
A.	TB Infection-Control Program	25
A.1	Settings where patients with suspected or confirmed infectious TB disease might be encountered	25
A.1.1	Assign responsibility for the TB infection-control program	26
A.1.2	If supervisory responsibility is assigned to a committee	26
A.1.3	Train the persons responsible for implementing and enforcing	26
A.1.4	Develop a written TB infection-control plan	26
A.1.5	Ensure the prompt recognition of patients	26
A.1.6	Conduct a problem assessment if a case	26
A.1.7	Perform a contact investigation in collaboration with the state	26
A.1.8	Collaborate with the state or local health department	26
A.1.9	Implement and maintain environmental controls	26
A.1.10	Implement a respiratory protection program	26
A.1.11	Perform ongoing training and education of HCWs	26
A.1.12	Accept transfer of patients who have suspected or confirmed ..	26
A.2	Settings where patients with suspected or confirmed infectious TB disease will not be kept beyond initial assessment or care	26
A.2.1	Assign responsibility for the TB infection-	26
A.2.2	Develop a written TB infection-control plan that outlines	26
A.2.3	Separate persons with suspected or confirmed	27
A.2.4	Conduct a problem assessment if a case of suspected	27
A.2.5	Perform an investigation in collaboration	27
A.2.6	Periodically reassess the TB infection-control plan	27

	A.2.7	Implement environmental controls as needed	27
	A.2.8	Provide respiratory protection as needed for HCWs	27
	A.2.9	Perform ongoing training and education	27
B.	TB Risk Assessment		27
B.1	Settings where patients with suspected or confirmed infectious TB disease will be encountered		28
	B.1.1	In collaboration with the state or local health	28
	B.1.2	Review the number of patients with suspected	28
	B.1.3	Determine if persons with unrecognized TB	28
	B.1.4	Determine which HCWs need to be included	28
	B.1.5	Ensure the prompt recognition and evaluation	28
	B.1.6	Identify areas in the setting with an increased risk	28
	B.1.7	Determine the number of AII rooms needed	28
	B.1.8	Determine the types of environmental controls	28
	B.1.9	Determine which HCWs need to be included	28
	B.1.10	Conduct periodic reassessments to ensure	28
	B.1.11	Recognize and correct lapses in infection	28
B.2	Settings where patients with suspected or confirmed infectious TB disease will not be encountered		28
	B.2.1	In collaboration with the state or local health	29
	B.2.2	Review the number of patients with suspected	29
	B.2.3	Determine if persons with unrecognized TB	29
	B.2.4	Determine which HCWs, if any, need to be included	29
	B.2.5	Determine the types of environmental controls	29
	B.2.6	Based on the risk assessment for the setting	29
	B.2.7	Document procedures that ensure the prompt	29
	B.2.8	Conduct periodic reassessments to ensure	29
	B.2.9	Reassess the setting's risk level at least annually	29
	B.2.10	Recognize and correct lapses in infection control	29
B.3	Use of risk classification to determine need for TB screening and frequency of screening HCWs		29
	B.3.1	Estimate the number of patients with TB	32
	B.3.2	For inpatient settings with >200 beds	32
	B.3.3	For inpatient settings with <200 beds	32
	B.3.4	For outpatient, outreach, and home-based health-care settings	32
	B.3.5	For TB clinics, TB outreach programs	32
	B.3.6	For correctional facilities where inmates	32
	B.3.7	For any of the above settings with evidence	32
	B.3.8	If the risk classification for the setting is medium risk	33
	B.3.9	Based on the risk assessment, consider	33
	B.3.10	Based on the risk classification for the setting	34
	B.3.11	Settings that are classified as low risk	34
	B.3.12	Reassess the risk classification	34
B.4	Calculation and use of <i>M. tuberculosis</i> infection conversion rates		44
	B.4.1	Calculate a <i>M. tuberculosis</i> infection test	45
	B.4.2	Identify areas or groups in the setting	45
	B.4.3	Use <i>M. tuberculosis</i> infection test	45
	B.4.4	<i>M. tuberculosis</i> infection test conversion	45
	B.4.5	For settings that no longer perform serial	45
B.5	Evaluation of TB infection-control procedures and identification of problems ..		46
	B.5.1	Review the medical records of a sample	46

	B.5.2	Note previous hospital admissions and outpatient	47
	B.5.3	Determine if all HCWs who should participate	47
	B.5.4	Observe work practices related to AII.....	47
	B.5.5	Use data from the case reviews and observations	47
B.6	Environmental assessment		47
	B.6.1	Review data from the most recent.....	47
	B.6.2	Review environmental control maintenance procedures.....	47
	B.6.3	Compare environmental control design	47
	B.6.4	Use environmental data to assist building.....	47
	B.6.5	Assess the number and types of high-risk.....	47
	B.6.6	Determine if the number of AII rooms present	47
		48
C.	TB Infection-Control Plan.....		48
	C.1	Based on the risk assessment for the setting	48
	C.2	Update an existing TB infection-control plan	48
	C.3	Conduct a TB risk assessment at least annually.....	48
	C.4	After each risk assessment, review all TB infection	48
D.	Managing Patients Who Have Suspected or Confirmed TB Disease: General Recommendations.....		63
D.1	Prompt triage		63
	D.1.1	When taking patients' medical histories	63
	D.1.2	Consider a diagnosis of respiratory TB.....	63
	D.1.3	In settings other than TB clinics, promptly	63
	D.1.4	Keep any patient with pulmonary or laryngeal	64
	D.1.5	Persons with tuberculous pleural effusions	64
	D.1.6	HIV-infected patients and other immunocompromised	64
D.2	TB AII precautions.....		64
	D.2.1	Settings where patients with suspected or confirmed TB disease will be encountered	64
	D.2.2	Settings where patients with suspected or confirmed TB disease will <i>not</i> be encountered	65
D.3	AII room practices.....		65
	D.3.1	Keep doors to AII rooms closed except	65
	D.3.2	While the room is being used for TB AII.....	66
	D.3.3	Maintain enough AII rooms to isolate.....	66
	D.3.4	Consider grouping AII rooms in one part	66
	D.3.5	Perform diagnostic and treatment procedures	66
	D.3.6	Ensure patient adherence to AII procedures.....	66
	D.3.7	Patients with suspected or confirmed infectious TB	66
D.4	Diagnostic procedures		66
	D.4.1	Clinical diagnosis	66
	D.4.2	Laboratory diagnosis	67
	D.4.3	Special considerations for persons who have a high risk for TB disease	68
D.5	Initiation of treatment.....		69
	D.5.1	For patients who have confirmed TB disease	69
	D.5.2	All inpatient medication should be given by DOT.....	69
E.	Managing Patients Who Have Suspected or Confirmed TB Disease: Additional Considerations for Special Circumstances and Settings.....		70
E.1	Minimum requirements		70

E.1.1	Perform an annual risk assessment for the setting	70
E.1.2	Develop and regularly evaluate and revise a written.....	70
E.1.3	Establish and implement protocols for identifying	70
E.1.4	Ensure that HCWs receive recommended TB training	70
E.1.5	Establish protocols for problem evaluation.....	70
E.1.6	Collaborate with the state or local health department	70
E.1.7	When possible, postpone non-urgent procedures.....	70
Inpatient settings		71
E.2	Emergency departments and urgent-care settings.....	71
E.2.1	Minimize the amount of time patients with suspected	71
E.2.2	Ensure that patients with suspected or confirmed TB disease ..	71
E.2.3	Before a patient leaves an AII room, an assessment	71
E.2.4	Instruct patients who are outside an AII room to wear a surgical	71
E.2.5	HCWs entering an AII room or any room with a patient	71
E.2.6	Air-cleaning technologies, such as HEPA filtration	71
E.2.7	Emergency departments with a high volume of patients.....	71
E.2.8	After the patient with suspected or confirmed TB disease.....	71
E.3	Intensive-care units (ICUs).....	71
E.3.1	Place ICU patients with suspected or confirmed infectious	72
E.3.2	To help reduce the risk of contaminating a ventilator.....	72
E.4	Surgical suites	72
E.4.1	When possible, postpone non-urgent surgical procedures	72
E.4.2	When surgery cannot be postponed, procedures	72
E.4.3	If a surgical suite or an operating room has an anteroom.....	72
E.4.4	If an operating room has no anteroom.....	72
E.4.5	Design the ventilation in the operating room to ensure a sterile	72
E.4.8	When surgical procedures (or other procedures that require a sterile field)	73
E.4.9	Postoperative recovery of a patient with suspected or confirmed TB.....	73
E.5	Laboratories.....	73
E.5.1	In laboratories affiliated with a health-care setting	73
E.5.2	Biosafety Level (BSL)-2 practices and procedures.....	74
E.5.3	Based on the risk assessment for the laboratory.....	74
E.5.4	Based on the risk assessment for the laboratory, use respiratory	74
E.5.5	For laboratories that are considered at least medium risk	74
E.5.6	After documented laboratory accidents, conduct an investigation	75
E.5.7	Laboratories in which specimens for mycobacteriologic	75
E.5.8	BSL-3 practices, containment equipment, and facilities	75
E.5.9	Settings classified as low risk, may classify the laboratory	75
E.6	Bronchoscopy suites.....	75
E.6.1	Avoid bronchoscopy on patients with suspected or confirmed TB	75
E.6.2	When collection of spontaneous sputum specimen is not adequate.....	75
E.6.3	If a bronchoscopy must be performed in a positive-pressure....	75
E.6.4	Whenever possible, perform bronchoscopy in a room that meets the ventilation.....	75

	E.6.5	Perform a physical examination; test for M. tuberculosis	75
	E.6.6	Use respiratory protection while present during a bronchoscopic	76
	E.6.7	In a patient who is intubated and mechanically-ventilated	76
	E.6.8	After bronchoscopy is performed on a patient with suspected..	76
	E.6.9	During the period following bronchoscopy	76
	E.6.10	Keep patients with suspected or confirmed TB disease	76
E.7		Sputum induction and inhalation therapy rooms	76
	E.7.1	Sputum induction procedures for persons with suspected TB ..	76
	E.7.2	HCWs who order or perform sputum induction or inhalation ..	76
	E.7.3	In any setting, cough-inducing procedures in patients	76
	E.7.4	At least an N95 disposable respirator should be worn	76
E.8		Autopsy suites and embalming rooms	76
	E.8.1	Autopsies should not be performed on persons	77
	E.8.2	Settings where autopsies and embalming are performed	77
	E.8.3	As an added administrative measure, when performing autopsies	77
	E.8.4	The use of local exhaust ventilation should be considered	77
	E.8.5	For HCWs performing an autopsy on a corpse with suspected or	77
	E.8.6	After an autopsy is performed on a corpse with suspected	77
		Outpatient settings	77
E.9		TB treatment facilities	77
	E.9.1	The same principles of triage used in emergency departments ..	77
	E.9.2	Clinics that provide care for patients with suspected	78
	E.9.3	Persons with suspected or confirmed infectious TB	78
	E.9.4	When patients with suspected or confirmed infectious TB	78
	E.9.5	Patients with suspected or confirmed infectious TB disease should	78
	E.9.6	Immunosuppressed patients with suspected or confirmed	78
	E.9.7	All cough-inducing and aerosol-generating procedures	78
	E.9.8	Screen all TB clinic staff for M. tuberculosis infection	78
	E.9.9	Implement a respiratory protection program for all HCWs	78
E.10		Medical settings in correctional facilities	78
	E.10.1	Follow the recommendations for inpatient and outpatient	79
	E.10.2	Collaborate with the state or local health department	79
	E.10.3	Collaborate with the state or local health department	79
	E.10.3	Develop a TB infection-control plan that is setting-specific	79
	E.10.4	Correctional facilities should be classified as at least medium risk	79
	E.10.5	Collect sputum samples in AII rooms or sputum induction booths	79
	E.10.6	Ensure the availability of at least one AII room	79
	E.10.7	Inmates with suspected or confirmed infectious TB	79
	E.10.8	When transporting a patient with suspected or confirmed	79
	E.10.9	Correctional facilities should maintain a tracking system	79
	E.10.10	Ensure the confidentiality of inmates during screening	80
E.11		Dental-care settings	80
	E.11.1	Develop infection-control policies for each dental health-care setting	80
	E.11.2	Dental HCWs should routinely document	80

	E.11.3 During clinical assessment and evaluation, a patient.....	80
	E.11.4 If urgent dental care must be provided for a patient	80
	E.11.5 In dental health-care settings that routinely provide care	80
E.12	Medical offices and ambulatory care settings	80
	E.12.1 Due to the potential for <i>M. tuberculosis</i>	81
	E.12.2 Use the risk assessment to determine	81
F.	Training and Education of HCWs	84
G.	HCW screening programs for TB support surveillance and clinical care	87
	G.5 HCWs with a newly recognized positive test for <i>M. tuberculosis</i> infection or signs or symptoms of TB disease	90
	G.6 HCWs with medical conditions associated with increased risk for progression to TB disease	93
H.	Problem Evaluation	94
I.	Collaboration with the State or Local Health Department	105
	I.1 Establish communication with staff at the state or local health department's TB control program before a problem arises. Coordinate with the local TB control program for assistance with the planning and implementation of TB control activities in the health-care setting and for names of experts to help with policies, procedures, and program evaluation.	105
	I.2 By law, the state or local health department must be notified when TB disease is suspected or confirmed in a patient or HCW so that follow-up can be arranged and a community contact investigation can be conducted. Notify the state or local health department as early as possible before patient discharge to facilitate follow-up, continuation of therapy, and arrangements for DOT (23).	105
	I.3 For inpatient facilities, coordinate a discharge plan with the patient (including a patient who is an HCW with TB disease) and the TB control program of the state or local health department.	105
J.	Environmental Controls	106
	J.1 Local exhaust ventilation	106
	J.2 General ventilation	106
	J.3 Air-cleaning methods	107
	J.4 Program issues	109
K.	Respiratory protection	109
	K.1 Indications for use	110
	K.2 Respiratory protection program	110
	K.3 Respirator options: general recommendations	112
	K.4 Respirator options: special circumstances.....	112
L.	Cough-Inducing and Aerosol-Generating Procedures.....	114
	L.1 General recommendations.....	114
	L.2 Special considerations for bronchoscopy	115
	L.3 Special considerations for administration of aerosolized pentamidine and other medications.....	115
	SUPPLEMENT 1: ESTIMATING THE INFECTIOUSNESS OF A TB PATIENT....	116
	I. General Principles.....	116
	II. Suspected TB disease	117
	III. Confirmed TB disease.....	117

IV. Discharge to home of patients with suspected or confirmed TB disease	118
V. Release setting.....	118
VI. Drug-Resistant TB disease	118
SUPPLEMENT 2: DIAGNOSIS AND TREATMENT OF LATENT TB INFECTION	
(LTBI) AND TB DISEASE.....	120
A. Tuberculin skin test (TST)	121
A.1 Adherence to TST and Treatment of LTBI	121
A.2 Administering the TST	121
A.3 Reading the TST result.....	123
A.4 Interpreting the TST result and its positive-predictive value ..	124
A.5 Interpreting the TST result in HCWs	124
A.6 Quality Control (QC) Program for techniques of TST	
administration and reading TST results.....	129
A.7 Special considerations in tuberculin skin testing	135
B. The QuantiFERON-TB test (QFT) and other cytokine-based assays	139
C. Chest radiography	145
D. Evaluation of sputum samples.....	146
E. Bronchoscopy.....	148
II. Treatment for Latent TB Infection (LTBI)	148
A. Candidates for Treatment of LTBI.....	149
B. Treatment regimens for LTBI	151
C. Pretreatment evaluation and monitoring of treatment	153
III. Treatment for TB Disease	153
IV. Reporting of Serious Adverse Events.....	154
SUPPLEMENT 3: ENVIRONMENTAL CONTROLS	
I. Overview	154
II. Local exhaust ventilation	155
A. Enclosing devices	156
B. Exterior devices	157
C. Discharge of exhaust from booths, tents, and hoods	157
III. General Ventilation.....	158
A. Dilution and removal of contaminated air.....	158
A.1 Ventilation systems for air dilution and removal	158
A.2 Delivery of general ventilation.....	158
A.3 Ventilation rates	159
B. Control of airflow direction in a health-care setting	160
B.1 Directional airflow	160
B.2 Negative pressure for achieving directional airflow	161
C. Control of airflow patterns in rooms	161
D. Achieving negative pressure in rooms	162
D.3 Monitoring negative pressure.....	165
E. All rooms and other negative pressure rooms.....	168
E.1 Preventing the escape of droplet nuclei.....	168
E.2 Reducing the concentration of droplet nuclei.....	168
E.3 Exhaust from All rooms and other negative-pressure rooms..	169
E.4 Alternatives to negative-pressure rooms	169
F. Other selected settings.....	169
IV. Air-Cleaning Methods	170
A. High-efficiency particulate air (HEPA) filtration.....	170
A.1 Use of HEPA filtration when exhausting air to the outside	170

A.2	Recirculation of HEPA-filtered air	170
A.3	Installing, maintaining, and monitoring HEPA filters.....	173
B.	Ultraviolet germicidal irradiation (UVGI)	174
B.1	Applications of UVGI.....	175
B.2	Effectiveness of UVGI.....	177
B.3	Health and safety issues	180
B.4	Exposure criteria	181
B.5	Labeling, maintenance, and monitoring.....	181
B.6	Upper-Air UVGI Systems and Portable Room-Air Recirculation Units	183
V.	Environmental Controls: Program Issues	184
SUPPLEMENT 4: RESPIRATORY PROTECTION		184
I.	Considerations for Selection of Respirators	184
A.	Performance criteria for respirators.....	185
B.	Types of respiratory protection for TB.....	186
B.1	Nonpowered air-purifying respirators	186
B.2	Powered air-purifying respirators (PAPRs)	186
B.3	Atmosphere-supplying respirators	186
C.	Effectiveness of respiratory protection devices.....	187
C.1	Face-seal efficacy	187
C.2	Filter leakage	188
D.	Training and periodic fit testing	188
E.	Maintenance and reuse of respirators	189
II.	Implementing a Respiratory Protection Program.....	189
A.	Assignment of responsibility.....	190
B.	Standard operating procedures	190
C.	Screening.....	190
D.	Training	190
F.	Fit testing.....	192
G.	Inspection and maintenance	192
H.	Evaluation.....	192
SUPPLEMENT 5: CLEANING, DISINFECTING, AND STERILIZING.....		196
PATIENT-CARE EQUIPMENT AND ROOMS		196
I.	General.....	196
A.	Critical medical instruments.....	196
B.	Semicritical medical instruments	196
C.	Noncritical medical instruments or devices	196
II.	Disinfection	196
SUPPLEMENT 6: FREQUENTLY ASKED QUESTIONS (FAQs).....		198
I.	Tuberculin Skin Testing (TST).....	198
II.	Risk Assessment.....	205
III.	Treatment for latent TB infection (LTBI).....	206
IV.	Environmental Controls.....	207
V.	Respiratory protection.....	209
SUPPLEMENT 8: GLOSSARY.....		216
List of Tables		235
List of Figures		236

Acknowledgements

Drafts of this document have been reviewed by leaders of numerous medical, scientific, public health and labor organizations and others expert in tuberculosis, acquired immunodeficiency syndrome, infection control, hospital epidemiology, microbiology, ventilation, industrial hygiene, nursing, dental practice, or emergency medical services.

We thank the many organizations and individuals for their thoughtful comments, suggestions, and assistance.

Prepared for publication by

Paul A. Jensen, PhD
Michael F. Iademarco, MD
Lauren A. Lambert, MPH
Renee Ridzon, MD

TB Infection-Control Guidelines Contributors

Diane I. Bennett, MD
Michael F. Iademarco, MD
Paul A. Jensen, PhD
Lauren A. Lambert, MPH
Beverly Metchock, DrPH
Renee Ridzon, MD
National Center for HIV, STD and TB Prevention (NCHSTP)

Paul M. Arguin, MD
Denise M. Cardo, MD
Amy Curtis, MPH
Adelisa L. Panlilio, MD
Patricia M. Simone, MD
National Center for Infectious Diseases (NCID)

Jennifer L. Cleveland, DMD, MPH
Amy Collins, RN, MPH
National Center for Chronic Disease Prevention and Health Promotion (NCCDPHP)

G. Scott Earnest, PhD
Teri Palermo, RN
Teresa A. Seitz, MPH, CIH
National Institute for Occupational Safety and Health (NIOSH)

Yona Hackl, RN, MS
Jonathan Y. Richmond, PhD
Office of the Director (OD)

DRAFT

DRAFT

DRAFT

John C. Ridderhof, DrPH
Public Health Practice Program Office (PHPPPO)

Allison Greenspan
Writer/Editor

A large number of persons provided assistance with review, editing, referencing of the Guidelines and attended public meetings. Persons with extensive contributions are listed below

External

James August, MPH
Scott Barnhart, MD
Joe Bick, MD
Henry Blumberg, MD
Dorothy Dougherty
Amanda L. Edens, MPH
Kevin Fennelly, MD
Victoria Fraser, MD
Mary Gilchrist, PhD
Robert Good, PhD
Robert Harrison, MD
Denise Ingman
Pam Kellner, RN, MPH
James McAuley, MD
Roy McKay, PhD
Dick Menzies, MD
Shelly Miller, PhD
Jose Montero, MD
Edward Nardell, MD
Mark Nicas, PhD
Paul Ninomura, BS
Tholeif O'Flaherty
Nick Pavelcheck, MS
Jean Pottinger, RN, MA
Gina Pugliese, RN, MS
Jane Siegel, MD
Kent Sepkowitz, MD
Andy Streifel, MS
Rachel Stricof, MT, MPH
Michael Tapper, MD
Robert Weinstein, MD
Sharon Welbel, MD
Karen Worthington, RN, MS

DRAFT

DRAFT

DRAFT

CDC

Heinz William Ahlers, MS
Gabrielle Benenson, MPH
Roland BerryAnn, BS
Regina Bess
Yvonne Boudreau, MD, MSPH
Kenneth G. Castro, MD
L. Casey Chosewood, MD
Chris Coffey, PhD
Charlie Dunn
Maria Fraire, MPH, CHES
Judy Gibson, MSN, RN
Connie Henderson
William R. Jarvis, MD
John A. Jereb, MD
Margaret Kitt, MD
Mark Lobato, MD
Suzanne Marks, MPH, MA
Kenneth F. Martinez, MSEE, CIH
Jerry Mazurek, MD
R. Leroy Mickelsen, MS, PE
Vincent Mortimer, MS, PE
Glenda Newell
Tanja Popovic, MD, PhD, FAAM
Laurence D. Reed, MS
Apavoo Rengasamy, BS, MS, PhD
Millie P. Schafer, PhD
Phillip Spradling, MD
Carol M. Stephenson, PhD
Zachary Taylor, MD
Tonya Thrash
Douglas B. Trout, MD, MHS
Andrew Vernon, MD, MHS
Gregory R. Wagner, MD
Wanda Walton, MPH, PhD
Angela M. Weber, MS, CIH
Robbin S. Weyant, PhD
John J. Whalen, MS

I. INTRODUCTION

A. Overview of the Document

In 1994, the Centers for Disease Control and Prevention (CDC) published the *Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Facilities, 1994 (1)*. The guidelines were issued in response to a resurgence of tuberculosis (TB) disease that occurred in the United States in the mid-1980s and early 1990s, the documentation of several high-profile health-care–associated (previously termed “nosocomial”) outbreaks related to an increase in the prevalence of TB disease and human immunodeficiency virus (HIV) coinfection, lapses in infection-control practices, delays in the diagnosis and treatment of persons with infectious TB disease (2;3), and the appearance and transmission of multidrug-resistant (MDR) TB strains (4;5).

The 1994 guidelines, which followed statements issued in 1982 and 1990 (1;6;7), presented recommendations for TB infection control based on a risk assessment process that classified health-care facilities according to categories of TB risk with a corresponding series of administrative, environmental, and respiratory protective control measures.

The TB infection-control measures recommended by CDC in 1994 were implemented widely in health-care facilities nationwide (8-15). The result has been a decrease in the number of TB outbreaks in health-care settings reported to CDC and a reduction in health-care–associated transmission of *Mycobacterium (M.) tuberculosis* to patients and health-care workers (HCWs) (9;16-20). Concurrent with this success, mobilization of the nation’s TB control programs succeeded in reversing the upsurge in reported cases of TB disease, and case rates have declined in the subsequent ten years(4;5), however the decline in case rate from 2002 to 2003 was the smallest decline since 1992(4;5). The threat of MDR TB is decreasing, and the transmission of *M. tuberculosis* in health-care facilities continues to decrease due to implementation of infection controls and reductions in community rates of TB(4;5). Despite the general decline in TB rates in recent years, a marked geographic variation in TB case rates persists, which means that HCWs in different areas face different risks (10). Case rates varied from 0.9 per 100,000 population in North Dakota to 7.5 per 100,000 in NY and 9.0 per 100,000 in CA(4;5). In addition, despite this progress, the 2002 rate in the United States of 5.2 per 100,000 population remained higher than the 2000 goal of 3.5, set as part of the national strategic plan for TB elimination (final goal of <1 case per 1,000,000 by 2010)(4;5).

Given these changes and a request by the Advisory Council for the Elimination of Tuberculosis (ACET) for review and updating of the 1994 TB infection control document, CDC has reassessed the TB infection-control guidelines for health-care facilities. The resulting document, *Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005*, updates TB control recommendations reflecting shifts in the epidemiology of TB (21), advances in our scientific understanding, and changes in health-care practice that have occurred in the United States in the last decade. In the context of diminished risk for health-care–associated transmission of *M. tuberculosis*, this document places emphasis on actions to maintain momentum and expertise needed to avert another TB resurgence and to eliminate the lingering threat to HCWs, which is mainly from patients or others with unsuspected and undiagnosed infectious TB disease.

The 1994 CDC guidelines were aimed primarily at hospital-based facilities. The 2005 CDC guidelines have been expanded to address a broader concept; health-care-associated settings go beyond the previously defined facilities. Settings encompass both physical and organizational relationships. **Inpatient settings** include emergency departments, hospital rooms, urgent-care settings, intensive care units, surgical suites, laboratories, bronchoscopy suites, sputum induction or inhalation therapy rooms, and autopsy suites. **Outpatient settings** include TB treatment facilities, medical settings in correctional facilities (e.g., prisons, jails, and detention centers), dental-care settings, medical offices, ambulatory-care settings, and dialysis units. And **non-traditional facility-based settings** include emergency medical services (EMS), home-based health-care and outreach settings, long-term care settings (e.g., hospices, skilled nursing facilities), and homeless shelters. Some of the newly included settings are low-risk, and therefore, specific recommendations are detailed (Section A.2). CDC prepared the current guidelines in consultation with experts in TB, infection control, environmental control, and occupational health.

In this document, “health-care workers” (HCWs) refers to all paid and unpaid persons working in health-care settings who have the potential for exposure to *M. tuberculosis* through air space shared with persons with infectious TB disease (See Section A.1).

The term “health-care setting” includes many types, such as inpatient settings, outpatient settings, TB clinics, settings in correctional facilities where health care is delivered, settings where home-based healthcare and emergency medical services are provided, and laboratories handling clinical specimens that may contain *M. tuberculosis* (See Section A.2). The term “setting” has been chosen over the term “facility,” used in the previous guidelines, to broaden the potential places for which these guidelines apply. The definition of health-care “setting” is meant to describe any relationship (physical or organizational) where HCWs encounter patients, and where the potential for exposure to *M. tuberculosis* through air space shared with persons with infectious TB disease or with specimens exists. The concept is complicated because several different setting types may be present in one facility (which more often refers to a physical building or set of buildings) or be dispersed across different geographic locations; or a setting may be part of a contracted service for a large health-care delivery system.

Original and primary references, citing evidence-based science as much as possible, are used throughout this document to support explanatory material and recommendations. Review articles (which include original and primary references) are used in some places for the sake of editorial style and brevity.

This document replaces all previous CDC guidelines for TB infection control in health-care facilities (1;6;7). Notable changes that differentiate it from the earlier guidelines include:

- The risk assessment process which includes the assessment of more aspects of infection control.
- The document uses the term “tuberculin skin test” (TST) instead of “PPD” (or purified protein derivative).
- The whole-blood interferon gamma assay, QuantiFERON-TB (QFT), is an Federal Drug Administration (FDA)-approved in vitro cytokine-based assay for cell-mediated immune reactivity to *M. tuberculosis* and has been included as an

option for detecting *M. tuberculosis* infection. QFT may be used in place of the TST in TB screening programs for HCWs.

- The frequency of TB screening for HCWs has been decreased for many settings, and the criteria for determination of screening frequency have been changed.
- The scope of settings to which the guidelines apply has been broadened to include laboratories and additional outpatient and non-traditional facility-based settings.
- This document more clearly defines the HCWs who need to have serial tests for *M. tuberculosis* infection performed. In many settings, this change will decrease the number of HCWs who need serial TB screening.
- In general, these recommendations apply to an entire health-care setting rather than to areas within a setting.
- The document uses the recently introduced terms “airborne infection isolation” (AII) and “airborne infection isolation room” (AII room).
- Recommendations for annual respirator training and periodic respirator user seal-checking (formerly called “fit testing”) have been revised.
- The document recognizes the accumulating evidence that addresses respirator fit based on different manufacturers’ products.
- Information on ultraviolet germicidal irradiation (UVGI) and room-air recirculation units has been expanded.
- Additional information regarding MDR TB and HIV infection has been included.

Implementation of all recommendations in this document must safeguard the confidentiality and civil rights of all HCWs and patients who have infection with *M. tuberculosis* and TB disease in accordance with relevant local, state, and federal laws.

A.1 HCWs who may be included in a TB screening program

Part-time, temporary, contract, as well as full-time HCWs should be included in TB screening screening programs¹. The list of workers (or job classifications) includes, but is not limited to:²

Administrators or managers
 Anesthesiologists
 Bronchoscopy staff
 Clerical staff
 Computer programmers
 Construction staff
 Correctional officers
 Craft or repair staff
 Dental staff
 Dietician or dietary staff
 Emergency department (ED) staff
 Engineers
 Food service staff
 Health aides
 Health and safety staff
 Housekeeping or custodial staff
 Infection-control staff
 Intensive-care unit (ICU) staff

Janitorial staff
 Laboratory staff
 Maintenance staff
 Morgue staff
 Nurses
 Outreach staff
 Pathologist
 Pathology laboratory staff
 Patient transport staff
 Pharmacists
 Phlebotomists
 Physical and occupational therapists
 Physicians (assistant, attending, fellow, resident or intern)
 Psychiatrists
 Psychologists
 Public health educators or teachers
 Public safety staff
 Radiology staff
 Respiratory therapists
 Scientists
 Social workers
 Students (e.g., medical, nursing, technicians)
 Technicians (e.g., health, laboratory, radiology, animal)
 Veterinarians
 Volunteers

¹ In a small number of settings, there may be a choice not to perform baseline TB screening (at the beginning of the HCW's employment) or serial TB screening for HCWs who will **never** be in contact with, or have shared air space with patients who have TB disease (e.g., telephone operators who work in a separate building from patients), or who will never be in contact with clinical specimens that may contain *M. tuberculosis*.

² Not all workers or individuals within the listed classifications may need to be included in the TB screening program. Facility personnel should determine who within these groups and departments needs to be included in the TB screening program based on the risk assessment for the facility.

A.2 Settings where HCWs may require a TB screening program

The list of settings where suspected and confirmed TB patients visit, includes but is not limited to:

Inpatient settings

Autopsy suites
 Bronchoscopy suites
 Emergency departments (ED)
 Geriatric inpatient wards
 Gynecologic wards
 HIV and Acquired immunodeficiency syndrome (AIDS) wards
 Hospices
 Hospitals
 Intensive-care units (ICU)

DRAFT

DRAFT

DRAFT

Laboratory procedure areas
Labor or delivery rooms
Nurseries
Obstetric wards
Oncology wards
Patient rooms
Pediatric wards
Physical medicine or rehabilitation wards
Psychology or substance abuse wards
Pulmonary wards
Sputum induction rooms or inhalation therapy rooms
Surgical (orthopedic, transplant) suites
TB wards
Urgent-care units

Outpatient settings

Administrative offices
Correctional facility medical settings
Dental-care settings
Drug treatment centers
Dialysis units
Employee health offices
Examination rooms
Health department (child, general)
Infusion centers
Intake areas
Interview rooms
Laboratories (e.g., mycobacterial, clinical)
Medical offices or ambulatory-care settings (e.g., HIV and AIDS, oncology, pulmonary, obstetrics or gynecological, pediatric, physical medicine or rehabilitation, psychology or substance abuse, sexually transmitted infections, surgical)
Operating or recovery rooms
Pathology or autopsy rooms
Patient procedure or therapy areas
Radiology areas
TB treatment facilities
Waiting areas

Non-traditional facility-based settings

Emergency medical services (EMS)
Home-based health-care settings
Outreach settings
Long-term care facilities (e.g, hospices, skilled nursing facilities)
Homeless shelters

Other settings where suspected and confirmed TB patients visit, such as:

Cafeterias
General stores
Kitchens
Laundry areas

Maintenance shops
Pharmacies

B. Pathogenesis, Epidemiology, and Transmission of *M. tuberculosis*

M. tuberculosis is carried in airborne particles, called droplet nuclei, which can be generated when persons who have pulmonary or laryngeal TB disease coughs, sneezes, shouts, or sings (22;23). The particles are an estimated 1-5 µm in size; normal air currents can keep them airborne for prolonged periods and spread them throughout a room or building (24). *M. tuberculosis* is generally transmitted only through the air, not by surface contact. Once in the alveoli, local infection may be established, followed by dissemination to draining lymphatics and hematogenous spread throughout the body (25). Infection occurs when a susceptible person inhales droplet nuclei containing *M. tuberculosis*, and the droplet nuclei traverse the mouth or nasal passages, upper respiratory tract, and bronchi to reach the alveoli of the lungs. Persons with tuberculous pleural effusions may have concurrent unsuspected pulmonary or laryngeal TB disease.

Usually within 2-12 weeks after initial infection with *M. tuberculosis*, the immune response limits further multiplication of the tubercle bacilli and immunologic test results for *M. tuberculosis* infection become positive. However, some bacilli remain in the body and are viable for many years. This condition is referred to as latent TB infection (LTBI). Persons with LTBI are usually asymptomatic (they have **no** symptoms of TB disease) and are **not** infectious.

LTBI has been traditionally diagnosed with TST after excluding TB disease. The whole-blood interferon gamma assay QFT is an FDA-approved in vitro cytokine-based assay for cell-mediated immune reactivity to *M. tuberculosis* and has been included as an option for detecting *M. tuberculosis* infection. QFT may be used in place of the TST in TB screening programs for HCWs. Other cytokine-based immunoassays are under development and may be demonstrated to be useful in the diagnosis of *M. tuberculosis* infection. Future FDA licensed products in combination with CDC-issued recommendations may provide additional diagnostic alternatives.

A proportion of persons who become infected with *M. tuberculosis* and are not treated for LTBI will develop TB disease during their lifetimes as a result of their infection. The risk for progression of LTBI to TB disease is greatest during the first several years after infection (26-28).

The prevalence of TB disease is not distributed evenly throughout all segments of the United States population. Some subgroups and persons have a higher risk for developing TB disease either because they are more likely than others to have been recently exposed to and infected with *M. tuberculosis* or because they have clinical conditions that are associated with an increased risk for progression of LTBI to TB disease (29). In some cases, both these factors may be present.

Groups of persons who are at higher risk for exposure to and infection with *M. tuberculosis* and groups of persons who are at higher risk for progression to TB disease once infected are listed below (29;30).

B.1 Persons at higher risk for exposure to and infection with *M. tuberculosis*

Close contacts are persons who share the same air space in a household or other enclosed environment for a prolonged period of time (days or weeks, not minutes or hours) with a person with pulmonary TB disease. A suspect TB patient is a person in whom a diagnosis of TB disease is being considered, whether or not anti-TB therapy has been started. Persons should not remain in this category for >3 months (22;29). Close contacts have also been referred to as "high-priority contacts" since they have the highest risk for infection with *M. tuberculosis*. Other persons at higher risk for exposure to and infection with *M. tuberculosis* include:

- Foreign-born persons, including children, who have arrived to the United States within five years from geographic areas with a high incidence of TB disease (e.g., Asia, Africa, Latin America, Eastern Europe, Russia)
- Residents and employees of high-risk congregate settings (e.g., correctional facilities, homeless shelters, long-term care facilities, such as hospices, skilled nursing facilities, and mental institutions)
- HCWs who serve high-risk clients
- HCWs with unprotected exposure to a patient with TB disease prior to the identification and correct AII of the patient
- Some medically underserved, low-income populations as defined locally
- High-risk racial or ethnic minority populations, defined locally as having an increased incidence of TB (e.g., Asians and Pacific Islanders, African Americans, Hispanics, Native Americans, migrant farm workers)
- Infants, children, and adolescents exposed to adults in high-risk categories
- Persons who inject illicit drugs
- Crack cocaine users (31-36). Persons who use alcohol **may be** at increased risk but given the many other potential risk factors that commonly occur among such persons, alcohol use has been difficult to identify as a separate risk factor

B.2 Persons at higher risk for progression from LTBI to TB disease include

- Persons infected with HIV
- Persons infected with *M. tuberculosis* within the past 2 years
- Infants and children <4 years of age
- Persons with any of the following clinical conditions or immunocompromising conditions: silicosis, diabetes mellitus, chronic renal failure, some hematologic disorders (leukemias and lymphomas), other specific malignancies (e.g., carcinoma of the head, neck, or lung), body weight <10% of ideal body weight, prolonged corticosteroid use, other immunosuppressive treatments, organ transplant, reticuloendothelial diseases, end-stage renal disease (ESRD), intestinal bypass or gastrectomy, chronic malabsorption syndromes
- Persons with a history of untreated or inadequately treated TB disease, including those with chest radiograph findings consistent with prior TB disease
- Persons who inject illicit drugs
- Crack cocaine users

- Persons who use alcohol **may be** at increased risk but given the many other potential risk factors that commonly occur among such persons, alcohol use has been difficult to identify as a separate risk factor

HIV infection is the highest risk factor for progression from LTBI to TB disease (29). Therefore, voluntary HIV counseling, testing, and referral should be routinely offered to all persons at risk for LTBI (1;37) (37;38). Health-care facilities should be particularly aware of the need for preventing transmission of *M. tuberculosis* in settings where persons infected with HIV might be encountered or might work (39).

All HCWs should be informed of the risk of developing TB disease once infected with *M. tuberculosis* (1). However, the rate of TB disease among persons who are HIV-infected and untreated for LTBI in the United States is substantially higher, ranging from 1.7–7.9 TB cases per 100 person-years (40). Persons infected with HIV who are already severely immunocompromised and who become newly infected with *M. tuberculosis* have a greater risk for developing TB disease compared to newly infected persons without HIV infection (29;40–44). Unfortunately, the rate of TB disease among HIV-infected persons who are recent contacts is unknown. Because the risk for disease is particularly high among HIV-infected persons with *M. tuberculosis* infection, HIV-infected contacts of persons with infectious pulmonary or laryngeal TB disease must be evaluated for *M. tuberculosis* infection including the exclusion of TB disease as soon as possible after learning of exposure (29;40).

Although it is well established that HIV infection increases the likelihood of progressing from LTBI to TB disease, it is unknown whether HIV infection increases the risk for becoming infected if exposed to *M. tuberculosis*.

Vaccination with Bacille Calmette-Guérin (BCG) probably does not affect the risk for infection after exposure, but it may decrease the risk for progressing from infection with *M. tuberculosis* to TB disease, notably preventing the development of miliary and meningeal disease in infants and young children (45).

The probability that a person who is exposed to *M. tuberculosis* will become infected depends mainly on the concentration of infectious droplet nuclei in the air and the duration of exposure to a person with infectious TB disease. The closer proximity and the longer duration of exposure, the higher the risk of being infected with *M. tuberculosis*.

B.3 Characteristics of a patient with TB disease that enhance infectiousness include

- Presence of cough
- Cavitation on chest radiograph
- Positive acid-fast bacilli (AFB) sputum smear result
- Respiratory tract disease with involvement of the larynx (very infectious)
- Respiratory tract disease with involvement of the lung or pleura (less infectious)
- Failure to cover the mouth and nose when coughing
- Lack of, incorrect, or short duration of anti-TB treatment

- Undergoing cough-inducing or aerosol-generating procedures (e.g., bronchoscopy, sputum induction, administration of aerosolized medications)

B.4 Environmental factors that enhance the probability of transmission of *M. tuberculosis* include

- Exposure in small, enclosed spaces
- Inadequate local or general ventilation that results in insufficient dilution or removal of infectious droplet nuclei
- Recirculation of air containing infectious droplet nuclei
- Inadequate cleaning of equipment

Characteristics of persons exposed to *M. tuberculosis* that might affect the risk for infection are not as well defined. In general, persons who have been infected with *M. tuberculosis* in the past may be less susceptible to subsequent infection. However, reinfection can occur among previously infected persons (46;47). In low incidence countries such as the United States, this is most clear in persons who are severely immunocompromised (48-52).

C. Risk for Health-care–Associated Transmission of *M. tuberculosis*

Transmission of *M. tuberculosis* is a recognized risk in health-care settings (44;53-71). The magnitude of the risk varies by setting, occupational group, prevalence of TB in the community, patient population, and effectiveness of TB infection-control measures. The risk may be higher in settings in which patients with TB disease might be encountered before diagnosis and before the initiation of anti-TB treatment and AII precautions (e.g., emergency departments, clinic waiting areas) or where procedures that induce coughing are performed. Health-care–associated transmission of *M. tuberculosis* has been linked to close contact with persons with TB disease during high-risk procedures including bronchoscopy (55;72;73), endotracheal intubation, suctioning (58), other respiratory procedures (8;9;74-77), open abscess irrigation (61;74), autopsy (63;64;69), sputum induction and aerosol treatments that induce coughing (78;79).

Of reported TB outbreaks in health-care settings, many involved transmission of MDR TB strains to both patients and HCWs (43;44;62;78;80-83). Most of the patients and some of the HCWs were HIV-infected and progression to TB disease was rapid. Factors contributing to these outbreaks included delayed diagnosis of TB disease, delayed recognition of drug resistance, and delayed initiation of treatment – all of which resulted in prolonged infectiousness, delayed initiation of and inadequate AII, lapses in AII practices and precautions for cough-inducing procedures, and lack of adequate respiratory protection. Several studies suggest that the decline in health-care–associated transmission observed in specific institutions is temporally associated with the rigorous implementation of infection-control measures (11;12;18-20;84-86). Because multiple interventions were implemented simultaneously, however, the effectiveness of each could not be determined.

The release of the 1994 CDC infection-control guidelines was followed by increased implementation of recommended infection-control measures, as documented in several national surveys (13;15;87;88). In one survey of more than 1,000 hospitals, a TST program was present in nearly all sites, and 70% reported having an AII room (13). Other

surveys have documented improvement in the proportion of AII rooms meeting CDC criteria and proportion of HCWs using CDC-recommended respiratory protection and receiving serial TSTs (15;87). A survey of high-burden New York City hospitals showed a decrease in time that patients with TB disease spent in the emergency department before transfer to a hospital room, an increase in the proportion of patients initially placed in AII, an increase in the proportion of patients started on recommended anti-TB treatment and reported to the state or local health department, and an increase in the use of recommended respiratory protection and environmental controls (88). Reports of increased implementation of recommended TB infection controls, combined with decreased reports of outbreaks of TB disease in health-care settings, suggest that the recommended controls are effective in reducing or preventing health-care–associated transmission of *M. tuberculosis*.

Less information is available about the implementation of CDC-recommended TB infection-control measures in settings other than hospitals. One study identified major factors that contribute to the costs of a TST program in health departments and hospitals: personnel costs, HCWs' time off from work for TST administration and reading, and training and education of HCWs (89). Outbreaks have occurred in outpatient settings (i.e., private physicians offices, pediatric settings) where the guidelines were not followed (90-92). CDC-recommended TB infection-control measures are implemented differently in correctional facilities, and variations may be related to resources, expertise, and oversight (93-95).

D. Fundamentals of TB Infection Control

One of the most important risks for health-care–associated transmission of *M. tuberculosis* in health-care settings arises from patients with unrecognized TB disease who are not promptly placed in AII (43;44;82;93), or who are moved from AII too soon, such as patients with unrecognized MDR TB (83). In the United States, the problem of MDR TB has been greatly reduced by the use of standardized anti-TB treatment regimens in the initial phase of therapy, rapid drug-susceptibility testing, directly observed therapy (DOT) and improved infection control practices(1). DOT is an adherence-enhancing strategy in which a HCW or other specially trained person watches a patient swallow each dose of medication and records the dates that the administration was observed. DOT is the standard of care for all patients with TB disease and should be used for all doses during the course of therapy for TB disease and for LTBI whenever feasible.

Effective TB infection control in health-care settings depends on early identification, prompt AII, and treatment of persons with TB disease. All health-care settings need a TB infection-control program designed to detect TB disease early and to isolate and promptly refer or treat persons who have TB disease. Such a program is based on a three-level hierarchy of controls: administrative controls (most important) (77;96).

D.1 Administrative controls

The first level of TB controls, and the most important, is the use of administrative measures to reduce the risk for exposure to persons who may have TB disease. These controls include

- Assigning responsibility for TB infection control in the setting
- Conducting a TB risk assessment of the setting

- Developing and instituting a written TB infection-control plan to ensure prompt detection, AII, and treatment of persons with suspected or confirmed TB disease
- Ensuring the timely availability of recommended laboratory processing, testing and reporting of results
- Implementing effective work practices for the management of patients with suspected or confirmed TB disease
- Ensuring proper cleaning and sterilization or disinfection of potentially contaminated equipment
- Training and educating HCWs about TB
- Screening and evaluating HCWs who are at risk for TB disease or who might be exposed to *M.tuberculosis*
- Applying epidemiologic-based prevention principles including the use of setting-related infection-control data
- Coordinating efforts with the state or local health department

D.2 Environmental controls

The second level of the hierarchy is the use of environmental controls to prevent the spread and reduce the concentration of infectious droplet nuclei in ambient air. These include

- Controlling the source of infection by use of local exhaust ventilation (hoods, tents, or booths)
- Diluting and removing contaminated air by use of general ventilation
- Controlling the airflow to prevent contamination of air in areas adjacent to the source (AII rooms)
- Cleaning the air by use of high-efficiency particulate air (HEPA) filtration or ultraviolet germicidal irradiation (UVGI)

D.3 Respiratory protection

The first two control levels minimize the number of areas where exposure to *M. tuberculosis* may occur and thus, minimize the number of persons exposed. They also reduce, but do not eliminate, the risk in the few areas where exposure can still occur (e.g., AII rooms, locations where cough-inducing or aerosol-generating procedures are performed, and homes of patients with infectious TB disease). Because persons entering these areas may be exposed to *M. tuberculosis*, the third level of the hierarchy is the use of respiratory protective equipment in situations that pose a relatively high risk for exposure. Use of respiratory protection can further reduce risk for exposure of HCWs to infectious droplet nuclei that have been expelled into the air from a patient with infectious TB disease (See Supplement 4). Measures include:

- Implementing a respiratory protection program
- Training HCWs on respiratory protection
- Training patients on respiratory hygiene and cough etiquette procedures

The following recommendations (in Section II below) specify measures to reduce the risk for transmission of *M. tuberculosis* based on this hierarchy. Additional details are provided in Supplements 1-5.

E. Relevance to Bioterrorism Preparedness and Other Infections Spread through an Airborne Route

Multidrug-resistant *M. tuberculosis* is classified as a category C agent of biologic terrorism (97). Implementation of the TB infection-control guidelines in this document is important for the control and prevention of transmission of *M. tuberculosis* in health-care settings. In addition, a new relevance to bioterrorism preparedness exists. Since September 2001, personnel in many health-care institutions are implementing bioterrorism preparedness plans. After episodes of Severe Acute Respiratory Syndrome (SARS) were reported in November 2002, institutions worldwide began addressing revisions of infection-control measures to prevent the transmission of SARS (98). Many of the activities and recommendations for the prevention and control of TB will also be useful for preventing transmission of agents of bioterrorism and diseases such as smallpox and SARS. Since agents of smallpox and SARS, for example, are transmitted by air, implementation of a comprehensive infection-control program, including environmental control measures (e.g., All rooms) and a respiratory protection program, potentially will enhance health-care settings' preparedness for many agents that are transmitted by the airborne route (for the latest information see www.bt.cdc.gov and www.idsociety.org/bt/toc.htm) (98).

II. RECOMMENDATIONS FOR PREVENTING TRANSMISSION OF M. TUBERCULOSIS IN HEALTH-CARE SETTINGS

A. TB Infection-Control Program

Every health-care setting should have a TB infection-control program in place that is part of an overall infection-control program. Based on the risk assessment for the setting, proper administrative, environmental, and respiratory protection policies and measures to prevent health-care-associated transmission of *M. tuberculosis* should be adopted. These policies will form the basis for a setting-specific TB infection-control program (Table 5). Administrative controls are the most important part of the TB infection-control program.

The specific details of the TB infection-control program will differ depending on whether patients with suspected or confirmed TB disease might be encountered in the setting, or whether patients with suspected or confirmed TB disease will be triaged or transferred to another health-care setting. Administrators making this distinction should obtain medical and epidemiologic consultation from state and local health departments.

A.1 Settings where patients with suspected or confirmed infectious TB disease might be encountered

The TB infection-control program should consist of administrative controls, environmental controls, and a respiratory protection program. **Every setting** in which services are provided to persons with suspected or confirmed infectious TB disease, including non-traditional facility-based settings and laboratories that process specimens for mycobacteriologic studies should have a TB infection-control plan. These settings should

- A.1.1** Assign responsibility for the TB infection-control program. Assign supervisory responsibility to a designated person or group with expertise in LTBI and TB disease, infection control, occupational health, environmental controls, and respiratory protection. Give the supervisor or supervisory body the support and authority to conduct a TB risk assessment, implement and enforce TB infection-control policies, and ensure recommended training and education of HCWs.
- A.1.2** If supervisory responsibility is assigned to a committee, designate one person with a backup as the TB resource person to whom questions and problems should be addressed.
- A.1.3** Train the persons responsible for implementing and enforcing the TB infection-control program.
- A.1.4** Develop a written TB infection-control plan, and periodically reassess the plan.
- A.1.5** Ensure the prompt recognition of patients with suspected or confirmed TB disease.
- A.1.6** Conduct a problem assessment if a case of suspected or confirmed TB disease is not promptly recognized or if environmental or respiratory controls fail.
- A.1.7** Perform a contact investigation in collaboration with the state or local health department if health-care–associated transmission of *M. tuberculosis* is suspected (99).
- A.1.8** Collaborate with the state or local health department to develop administrative controls, consisting of the risk assessment, the written TB infection-control plan, management of patients with suspected or confirmed TB disease, training and education of HCWs, screening and evaluation of HCWs, problem evaluation, and coordination.
- A.1.9** Implement and maintain environmental controls, including AII room(s) (Section J and Supplement 3).
- A.1.10** Implement a respiratory protection program.
- A.1.11** Perform ongoing training and education of HCWs.
- A.1.12** Accept transfer of patients who have suspected or confirmed TB disease.

A.2 Settings where patients with suspected or confirmed infectious TB disease will not be kept beyond initial assessment or care

Settings that do **not** plan to keep patients with suspected or confirmed infectious TB disease should still have a TB infection-control program in place consisting of administrative, environmental and respiratory protection controls. These settings should:

- A.2.1** Assign responsibility for the TB infection-control program.
- A.2.2** Develop a written TB infection-control plan that outlines a protocol for the prompt recognition, triage, and transfer of persons with suspected or confirmed TB disease to another health-care setting. The plan should include:
 - A.2.2a** A preferred destination and an alternate destination for persons with suspected or confirmed TB disease. Both

destination settings should provide documentation of intent to cooperate.

- A.2.2b** A preferred transport service that provides documentation of agreement to transport TB patients.
- A.2.3** Separate persons with suspected or confirmed infectious TB disease from other persons in the setting until the time of transfer.
- A.2.4** Conduct a problem assessment if a case of suspected or confirmed TB disease is not promptly recognized, isolated and triaged.
- A.2.5** Perform an investigation in collaboration with the state or local health department if health-care–associated transmission of *M. tuberculosis* is suspected.
- A.2.6** Periodically reassess the TB infection-control plan to ensure that the setting remains one in which persons with suspected or confirmed TB disease are **not** kept and that they are promptly transferred to another health-care setting.
- A.2.7** Implement environmental controls as needed for areas where patients with suspected or confirmed TB disease will stay pending transfer to another health-care setting.
- A.2.8** Provide respiratory protection as needed for HCWs who will be attending to patients with suspected or confirmed TB disease pending transfer to another health-care setting, and provide a surgical mask to persons with suspected or confirmed infectious TB disease.
- A.2.9** Perform ongoing training and education of HCWs.

B. TB Risk Assessment

Every type of health-care setting should conduct initial and ongoing evaluations of the risk for transmission of *M. tuberculosis* regardless of whether or not patients with suspected or confirmed TB disease will be encountered in the setting. The TB risk assessment determines the types of administrative and environmental controls and respiratory protection program needed for a setting, and serves as a tool for the ongoing evaluation of the quality of TB infection control and the need for improved infection-control measures. (Parts of the risk assessment are similar to a program review that is conducted by the local TB control program.) Collaboration with the state or local TB controller(s) is recommended. A TB risk assessment for the setting should be conducted and documented at least annually.

The TB risk assessment determines the risk for health-care–associated transmission of *M. tuberculosis* in the setting by examining a numbers of factors, including: 1) community rate of TB disease, 2) number of patients with TB disease presenting for care in the setting, regardless of whether they stay in the setting or are transferred to another health-care setting, 3) timeliness of the recognition, isolation, and evaluation of patients with suspected or confirmed TB disease, 4) evidence for transmission of *M. tuberculosis* in the setting, and 5) the types and conditions of the environmental controls present in the facility.

The TB Risk Assessment Worksheet (Table 1) may be used as a guide for conducting a risk assessment. This worksheet often does not specify values for acceptable performance indicators due the lack of scientific data. However, a program can use such a tool as part

of quality control and assurance, in consultation with infection control experts, to develop an ongoing performance-based evaluation system.

B.1 Settings where patients with suspected or confirmed infectious TB disease will be encountered

The findings from the risk assessment will form the basis for decisions about the level of administrative, environmental, and respiratory protective measures needed to ensure a safe environment for HCWs, patients, and others. As an ongoing evaluation tool, the risk assessment can identify the need for improved TB infection controls and can serve as a way to monitor administrative, environmental, and respiratory protective measures to ensure their proper operation. To conduct the initial and ongoing risk assessment, follow these steps:

- B.1.1** In collaboration with the state or local health department, review the community profile of TB disease.
- B.1.2** Review the number of patients with suspected or confirmed TB disease who have been treated in the setting over at least the last five years.
- B.1.3** Determine if persons with unrecognized **TB** disease have been admitted to or were encountered in the setting in the last year.
- B.1.4** Determine which HCWs need to be included in a TB screening program and the frequency of screening (based on risk classification, see II.B.3).
- B.1.5** Ensure the prompt recognition and evaluation of suspected episodes of health-care–associated transmission of *M. tuberculosis*.
- B.1.6** Identify areas in the setting with an increased risk for health-care–associated transmission of *M. tuberculosis* and target them for improved TB infection controls.
- B.1.7** Determine the number of AII rooms needed for the facility.
- B.1.8** Determine the types of environmental controls other than AII rooms needed.
- B.1.9** Determine which HCWs need to be included in the respiratory protection program.
- B.1.10** Conduct periodic reassessments to ensure: a) proper implementation of the TB infection-control plan, b) prompt detection and evaluation of suspected TB cases, c) prompt isolation of suspected infectious TB cases, d) recommended medical management of patients with suspected or confirmed TB disease (23), e) functional environmental controls, f) implementation of the respiratory protection program, and g) ongoing HCW training and education about TB.
- B.1.11** Recognize and correct lapses in infection control.

B.2 Settings where patients with suspected or confirmed infectious TB disease will not be encountered

In settings where patients with suspected or confirmed TB disease will **not** be encountered, the initial and ongoing risk assessment should consist of the following steps:

- B.2.1** In collaboration with the state or local health department, review the community profile of TB disease.
- B.2.2** Review the number of patients with suspected or confirmed TB disease presenting to the setting over the past five years.
- B.2.3** Determine if persons with unrecognized TB disease have been admitted to or were encountered in the setting over the last five years.
- B.2.4** Determine which HCWs, if any, need to be included in the TB screening program, and the frequency of screening (based on risk classification, see II.B.3, Table 2).
- B.2.5** Determine the types of environmental controls that are currently in place, and determine which, if any, are needed in the setting. This determination may apply only to areas where patients stay before transfer.
- B.2.6** Based on the risk assessment for the setting, identify areas in the setting with increased risk for health-care–associated transmission of *M. tuberculosis* and target those areas for improved TB infection controls.
- B.2.7** Document procedures that ensure the prompt recognition and evaluation of suspected episodes of health-care–associated transmission of *M. tuberculosis*.
- B.2.8** Conduct periodic reassessments to ensure a) proper implementation of TB infection-control plan, b) prompt detection and evaluation of suspected TB cases, c) prompt isolation of suspected infectious TB cases before transfer, d) prompt transfer of suspected infectious TB cases, e) proper functioning of environmental controls, as applicable, and f) ongoing HCW training and education about TB.
- B.2.9** Reassess the setting’s risk level at least annually.
- B.2.10** Recognize and correct lapses in infection control.

B.3 Use of risk classification to determine need for TB screening and frequency of screening HCWs

The need for a TB screening program for HCWs should be determined for all health-care settings as part of the TB risk assessment. Risk classification should be used to determine the need for a TB screening program and the frequency of screening (Table 2). In general, a risk classification should be determined for the entire setting. In a small number of settings (e.g., large health-care organizations that encompass several sites or types of services), specific areas defined by geography, functional units, patient population, job type, or location within the setting may be classified separately. Examples illustrating the assignment of risk classifications are provided in Table 3.

TB screening programs provide information that is important in managing individual HCWs and information that facilitates detection of *M. tuberculosis* transmission. The TB screening program consists of four main components, 1) baseline testing for *M. tuberculosis* infection, 2) serial testing for *M. tuberculosis*

infection, 3) serial screening for signs or symptoms of TB disease, and 4) TB training and education.

Baseline testing for *M. tuberculosis* infection is recommended for all newly hired HCWs who might have contact with persons with suspected or confirmed TB disease, regardless of the risk classification of the setting. In a small number of settings, there may be a choice not to perform baseline TB screening (at the beginning of the HCW's employment) or serial TB screening for HCWs who will **never** be in contact with, or have shared air space with patients who have TB disease (e.g., telephone operators who work in a separate building from patients), or who will never be in contact with clinical specimens that may contain *M. tuberculosis*.

Baseline testing can be conducted with either the TST or the QFT (100) (Supplement 2). If the TST is used, two-step testing is recommended for newly hired HCWs whose initial TST result is negative. The second step of a two-step TST should be administered 1–3 weeks after the first TST was administered. A second TST is needed at baseline because injection of PPD for the initial TST may “boost” responses to subsequent tests. In general, in the **absence** of a known exposure, a large reaction to the second step of a two-step TST is probably due to boosting as opposed to recent infection with *M. tuberculosis*. A second TST is not needed if an HCW has documentation that a TST has been applied at any time during the previous 12 months and the result was negative. A single negative QFT result is sufficient evidence that the HCW is not infected with *M. tuberculosis* (i.e., two-step baseline QFT is not needed) (See Supplement 1).

It should be noted that the interpretation of TST results may differ when used administratively for infection control as opposed to when used as part of medical evaluation for patient care. For example, a 6 millimeter (mm) TST result may be considered negative for administrative purposes but may be considered positive when deciding to treat an HIV-infected HCW for LTBI. This example highlights the importance of recording actual TST results in mm.

HCWs with documentation of a positive TST or QFT result, or documentation of previous treatment for LTBI or TB disease, do not need any further testing for *M. tuberculosis* infection. Instead of participating in serial skin testing, the HCW should receive a medical evaluation and a symptom screen. A symptom screen is a procedure used during a clinical evaluation in which the HCW is asked if they have experienced any signs or symptoms of TB disease. Symptoms of TB disease include coughing for ≥ 3 weeks, loss of appetite, unexplained weight loss, night sweats, bloody sputum or hemoptysis, hoarseness, fever, fatigue, or chest pain. Persons with tuberculous pleural effusions may have concurrent unsuspected pulmonary or laryngeal TB disease.

Serial testing for *M. tuberculosis* infection, serial screening for signs or symptoms of TB disease, and education are typically accomplished together as part of an ongoing TB screening program for HCWs. The recommended frequency of screening after baseline testing will differ by setting, depending on the risk classification categories (i.e., *low-risk*, *medium-risk*, or *potential ongoing transmission*).

TB screening risk classifications (See Table 2)

❖ Low-risk

- All HCWs should receive baseline TB screening upon hire using baseline two-step TSTs or QFT to test for infection with *M. tuberculosis*.
- HCWs with a baseline positive or newly positive TST result should receive one chest radiograph to exclude a diagnosis of TB disease. After this baseline chest radiograph is performed and the result is documented, repeat radiographs are not needed unless signs or symptoms of TB disease develop, or a clinician recommends a repeat chest radiograph (29;101), or as part of a contact investigation. Instead of participating in serial skin testing, the HCW should receive a medical evaluation and a symptom screen. Offer treatment for LTBI to those who are eligible.
- After baseline testing for infection with *M. tuberculosis*, HCWs in settings classified as *low risk* do not need further TB screening unless an exposure to *M. tuberculosis* occurs.

❖ Medium-risk

- All HCWs should receive baseline TB screening upon hire using two-step TSTs or QFT, to test for infection with *M. tuberculosis*.
- HCWs with a baseline positive or newly positive TST result should receive one chest radiograph to exclude a diagnosis of TB disease. After this baseline chest radiograph is performed and the result is documented, repeat radiographs are not needed unless signs or symptoms of TB disease develop, or a clinician recommends a repeat chest radiograph (29;101), or as part of a contact investigation. Instead of participating in serial skin testing, HCWs with positive TST or QFT results should receive a symptom screen and a medical evaluation. Offer treatment for LTBI to those who are eligible.
- After baseline testing for infection with *M. tuberculosis*, HCWs in settings classified as *medium risk* should receive TB screening annually (i.e., symptom screen and testing for infection with *M. tuberculosis*).

❖ Potential ongoing transmission

- Testing for infection with *M. tuberculosis* may need to be performed every 8–10 weeks until lapses in infection control have been corrected and no further evidence of ongoing transmission is apparent.
- **The classification of *potential ongoing transmission* should be used as a temporary classification only.** It warrants immediate investigation, and corrective steps; after it has been determined that ongoing transmission has ceased, the setting should be reclassified as *medium risk*. It is recommended to maintain the classification of *medium risk* for at least one year.

In general, if uncertain about whether to classify a setting as *low risk* or *medium risk*, classify the setting as *medium risk*. Follow these steps and refer to the TB screening classifications above to determine the risk classification for the setting, and refer to Table 2 for frequency of testing:

- B.3.1 Estimate the number of patients with TB disease** who were seen or treated in the setting during the preceding year. Derive TB patient counts utilizing laboratory surveillance data on *M. tuberculosis* cultures or specimen results positive for AFB, infection-control records, and (in hospitals), databases containing information on discharge diagnoses.
- B.3.2 For inpatient settings with >200 beds**
 - B.3.2a** Classify settings with a TB patient count of <6 for the past year as *low risk*.
 - B.3.2b** Classify those with a TB patient count of >6 for the past year as *medium risk*.
- B.3.3 For inpatient settings with <200 beds**
 - B.3.3a** Classify those with a TB patient count of <3 for the past year as *low risk*.
 - B.3.3b** Classify those with a TB patient count of >3 for the past year as *medium risk*.
- B.3.4 For outpatient, outreach, and home-based health-care settings**
 - B.3.4a** Classify those with a TB patient count of <3 for the past year as *low risk*.
 - B.3.4b** Classify those with a TB patient count of >3 for the past year as *medium risk*.
- B.3.5 For TB clinics, TB outreach programs, and other settings in which HCWs are responsible for the care of patients with TB disease**
Classify these settings as *medium risk*.
- B.3.6 For correctional facilities where inmates with TB disease are cared for or are housed**
Classify these settings as *medium risk*.
- B.3.7 For any of the above settings with evidence suggestive of person-to-person** (e.g., patient-to-patient, patient-to-HCW, HCW-to-patient, or HCW-to-HCW) transmission of *M. tuberculosis* during the preceding year, classify these settings as *potential ongoing transmission*.
 - B.3.7a** Evidence suggestive of person-to-person transmission of *M. tuberculosis* includes: a) clusters of TST or QFT conversions, b) an HCW with suspected or confirmed TB disease, c) increased rates of TST or QFT conversions, d) unrecognized TB disease in patients or HCWs, or e) recognition of an identical strain of *M. tuberculosis* in patients or HCWs with TB disease identified by deoxyribonucleic acid (DNA) fingerprinting.

For the risk assessment, a **TST conversion** is a ≥ 10 mm increase in the size of the TST induration over a two-

year period in an HCW with a documented negative two-step baseline TST result, or in a non-HCW with a negative TST result within two years.

For risk assessment, a **QFT conversion** is a change from a negative to a positive response over a two-year period. Other changes (from negative to conditionally positive, or conditionally positive to positive) are not considered to be QFT conversions for administrative purposes (See Supplement 1).

Conversions in test results for *M. tuberculosis* infection are usually interpreted as presumptive evidence of new *M. tuberculosis* infection, and recent infection is associated with an increased risk for progression to TB disease.

- B.3.7b** Classify these settings as potential ongoing *transmission* (regardless of other factors) until corrective measures have been taken and transmission has been demonstrated to have stopped.
- B.3.7c** **The classification of potential ongoing *transmission* should be used as a temporary classification only.** It warrants immediate investigation, and corrective steps; after it has been determined that ongoing transmission has ceased, the setting should be reclassified as *medium risk*. It is recommended to maintain the classification of *medium risk* for at least one year.
- B.3.7d** If it is possible to identify an area or group of HCWs in the setting in which the health-care–associated transmission is occurring, then the *potential ongoing transmission* classification can be limited to that group or area for efficiency and to decrease unwarranted testing in large settings. Otherwise, apply the classification of *potential ongoing transmission* to the entire setting.
- B.3.8** If the risk classification for the setting is medium risk (indicating the need for a serial screening program to test HCWs for *M. tuberculosis* infection), the program should include all HCWs who:
 - B.3.8a** Have duties that involve face-to-face contact with patients with suspected or confirmed TB disease (including transport staff)
 - B.3.8b** Enter patient rooms or treatment rooms whether or not a patient is present
 - B.3.8c** Participate in high-risk procedures (e.g., bronchoscopy, sputum induction, administration of aerosolized medications)
 - B.3.8d** Install, maintain, or replace environmental controls in areas where people with TB disease are encountered
- B.3.9** Based on the risk assessment, consider any features of the health-care setting that may increase concern about transmission

of *M. tuberculosis* and indicate a need for a higher risk classification. These features include a) relatively high prevalence of immunosuppression among patients or HCWs (e.g., persons infected with HIV, organ transplant recipients), b) relatively high or increasing incidence of TB disease in the community served by the health-care setting, c) relatively high or increasing incidence of TB disease diagnosed in the health-care setting, d) presence of patients with TB disease caused by drug-resistant strains of *M. tuberculosis*.

- B.3.10** Based on the risk classification for the setting, determine the need for and frequency of TB screening (Table 2).
- B.3.11** Settings that are classified as low risk lose the ability to detect conversions in test results for *M. tuberculosis* infection through serial screening. In these settings, maintain attention to other administrative controls to detect or prevent transmission of *M. tuberculosis*. Proper use of environmental controls and respiratory protection should also be maintained.
- B.3.12** Reassess the risk classification for the setting at appropriate intervals, and at least annually.

Table 1. TB risk assessment worksheet

This form is recommended by CDC for use in performing TB risk assessments for health-care facilities. Facilities with more than one distinct type of setting will need to apply this table to each setting.

Incidence of TB cases in your community

What is the incidence of TB cases in your community and how does it compare to the state and national average? (Incidence is the number of TB disease cases in your community last year. A rate of TB cases per 100,000 persons should be obtained for comparison.)* This information may be obtained from the state or local health department.	Community rate: _____ State rate: _____ National rate: _____ Facility rate: _____
Does your health-care setting treat patients with suspected or confirmed TB disease? (Include both inpatient and outpatient services.)	Yes No
If yes , how many patients with suspected or confirmed TB disease are treated in your health-care setting in a year (inpatient and outpatient)? Check laboratory data, infection-control records, and databases containing discharge diagnoses.	Year No. patients 1 year ago _____ 2 years ago _____
If no , does your health-care setting have a plan for the triage of patients with suspected or confirmed TB disease?	Yes No
Currently, does your health-care setting have a cluster of suspected or confirmed TB disease that may be due to ongoing transmission of <i>M. tuberculosis</i> within your setting? (Include both inpatient and outpatient services.)	Yes No

Risk classification

For inpatient settings	
How many inpatient beds are in your health-care setting?	
How many patients with TB disease are treated in the inpatient setting in a year? Review laboratory data, infection-control records, and databases containing discharge diagnoses.	Last year _____ 5 years ago _____
Depending on the number of beds and TB patients treated in a year, what is the risk classification for your health-care setting? (See Table 2 for frequency of TB screening)	<input type="radio"/> Low risk <input type="radio"/> Medium risk <input type="radio"/> Potential ongoing transmission
For outpatient settings	
How many TB patients are seen at your health-care setting in a year? Review laboratory data, infection-control records, databases containing discharge diagnoses.	
Depending on the number of TB patients seen on an outpatient or non-traditional facility basis in a year, what is the risk classification for your health-care setting? (See Table 2 for frequency of TB screening)	<input type="radio"/> Low risk <input type="radio"/> Medium risk <input type="radio"/> Potential ongoing transmission
Is your health-care setting a TB clinic?	Yes No
Is there a relatively high incidence of TB disease in the community that the health-care setting serves?	Yes No
Is there evidence of person-to-person (e.g., patient-to-patient, patient-to-HCW, HCW-to-patient, or HCW-to-HCW) transmission in the health-care setting? Use information from case reports; determine if any recent TST conversions have occurred among HCWs (a TST conversion is a ≥ 10 mm increase in the size of	Yes No

DRAFT

DRAFT

DRAFT

the TST induration over a two-year period in an HCW with a documented negative two-step TST baseline TST result, or in a non-HCW with a negative TST result within two years). A QuantiFERON-TB (QFT) conversion is a change from a negative to a positive response over a two-year period.	
Is there evidence of ongoing or unresolved health-care–associated transmission in the health-care setting (based on case reports)?	Yes No
Is there a high incidence of immunocompromise among patients or HCWs in the health-care setting?	Yes No
Does the health-care setting treat patients with drug-resistant TB disease? Ever? Last two years? Last five years?	Yes No _____
When was the first time a risk classification was done for your health-care setting?	
Considering the following, would your health-care setting need a higher risk classification?	Yes No

DRAFT

DRAFT

DRAFT

Conversion rate for tests for M. tuberculosis infection

Does the health-care setting have a TB screening program for HCWs?	Yes No
If yes, which HCWs are included in the TB screening program? (Check all that apply.) <input type="checkbox"/> Physicians <input type="checkbox"/> Mid-level practitioners (nurse practitioners, physician's assistants) <input type="checkbox"/> Nurses <input type="checkbox"/> Administrators <input type="checkbox"/> Laboratory workers <input type="checkbox"/> Respiratory therapists <input type="checkbox"/> Physical therapists <input type="checkbox"/> Contract staff <input type="checkbox"/> Construction or renovation workers <input type="checkbox"/> Service workers	<input type="checkbox"/> Janitorial staff <input type="checkbox"/> Maintenance or engineering staff <input type="checkbox"/> Transportation staff <input type="checkbox"/> Dietary staff <input type="checkbox"/> Non-employee physicians <input type="checkbox"/> Receptionists <input type="checkbox"/> Trainees and students <input type="checkbox"/> Volunteers <input type="checkbox"/> Others _____
Is baseline skin testing performed with two-step TST for HCWs?	Yes No
Is baseline testing performed with QFT for HCWs?	Yes No
Does the setting have a serial TB screening program for HCWs to test for <i>M. tuberculosis</i> infection?	Yes No
How frequently are eligible HCWs tested for <i>M. tuberculosis</i> infection?	
Are the <i>M. tuberculosis</i> infection test records maintained for HCWs?	Yes No
Where are the <i>M. tuberculosis</i> infection test records maintained for HCWs?	
Who maintains the <i>M. tuberculosis</i> infection test records for HCWs?	
If the setting has a serial TB screening program for HCWs to test for <i>M. tuberculosis</i> infection, what is the conversion rate for the past year? [footnote b]	
List the <i>M. tuberculosis</i> infection test conversion rate for the past five years.	2 years ago _____ 3 years ago _____ 4 years ago _____ 5 years ago _____
Has the <i>M. tuberculosis</i> infection test conversion rate been increasing or decreasing, or has it remained the same over the past five years?	Increasing _____ Decreasing _____ No change _____
Do any areas of the health-care setting or any group of HCWs (e.g., emergency department, waiting rooms, clinics, respiratory therapists, HCWs who attend bronchoscopies) have a particularly high risk for <i>M. tuberculosis</i> infection test conversion?	Yes No If yes, list _____ _____ _____
For HCWs who have positive TST results and who leave employment at the health setting, are efforts made to locate them for follow-up of LTBI treatment?	Yes No

TB infection-control program

Is there a written TB infection-control plan?	Yes No
When was the TB infection-control plan first written?	
When was the TB infection-control plan last reviewed or updated?	
Does the written infection-control plan need to be updated based on timing of last update (i.e., >1 year, changing TB epidemiology of the community or setting, the	Yes No

DRAFT

DRAFT

DRAFT

occurrence of a TB outbreak, change in state or local TB policy, or other factors related to a change in risk for transmission of <i>M. tuberculosis</i> ?				
Is there an infection-control committee (or another committee with infection control responsibilities) for the health-care setting?		Yes No		
If yes, which groups are represented on the infection-control committee? (Check all that apply.) <table border="0" style="width: 100%;"> <tr> <td style="width: 50%;"> <input type="checkbox"/> Physicians <input type="checkbox"/> Nurses <input type="checkbox"/> Epidemiologists <input type="checkbox"/> Engineers </td> <td style="width: 50%;"> <input type="checkbox"/> Laboratory personnel <input type="checkbox"/> Health and safety staff <input type="checkbox"/> Administrator <input type="checkbox"/> Risk assessment <input type="checkbox"/> Quality control <input type="checkbox"/> Others (specify) </td> </tr> </table>			<input type="checkbox"/> Physicians <input type="checkbox"/> Nurses <input type="checkbox"/> Epidemiologists <input type="checkbox"/> Engineers	<input type="checkbox"/> Laboratory personnel <input type="checkbox"/> Health and safety staff <input type="checkbox"/> Administrator <input type="checkbox"/> Risk assessment <input type="checkbox"/> Quality control <input type="checkbox"/> Others (specify)
<input type="checkbox"/> Physicians <input type="checkbox"/> Nurses <input type="checkbox"/> Epidemiologists <input type="checkbox"/> Engineers	<input type="checkbox"/> Laboratory personnel <input type="checkbox"/> Health and safety staff <input type="checkbox"/> Administrator <input type="checkbox"/> Risk assessment <input type="checkbox"/> Quality control <input type="checkbox"/> Others (specify)			
If no, what committee is responsible for infection control in the setting?				

Implementation of TB infection-control plan (based on review by Infection Control Committee)

Is there a designated person responsible for implementation of an infection-control plan in your health-care setting? If yes, name? _____		Yes No																
Based on a review of the medical records of a sample of patients with TB disease, are patients who have suspected or confirmed infectious TB disease detected and placed in AII promptly? Yes No	What is the average number of days from: <table border="0" style="width: 100%;"> <tr> <td>• Presentation of patient until collection of specimen</td> <td>_____</td> </tr> <tr> <td>• Specimen collection to receipt by laboratory</td> <td>_____</td> </tr> <tr> <td>• Receipt by laboratory until smear results are provided to health-care provider</td> <td>_____</td> </tr> <tr> <td>• Receipt by laboratory until culture results are provided to health-care provider</td> <td>_____</td> </tr> <tr> <td>• Receipt by laboratory until drug-susceptibility results are provided to health-care provider</td> <td>_____</td> </tr> <tr> <td>• Receipt of drug-susceptibility results until initiation of anti-TB treatment</td> <td>_____</td> </tr> <tr> <td>• Admission of patient until placement in AII</td> <td>_____</td> </tr> <tr> <td>• Diagnosis of TB disease to initiation of AII</td> <td>_____</td> </tr> </table>		• Presentation of patient until collection of specimen	_____	• Specimen collection to receipt by laboratory	_____	• Receipt by laboratory until smear results are provided to health-care provider	_____	• Receipt by laboratory until culture results are provided to health-care provider	_____	• Receipt by laboratory until drug-susceptibility results are provided to health-care provider	_____	• Receipt of drug-susceptibility results until initiation of anti-TB treatment	_____	• Admission of patient until placement in AII	_____	• Diagnosis of TB disease to initiation of AII	_____
• Presentation of patient until collection of specimen	_____																	
• Specimen collection to receipt by laboratory	_____																	
• Receipt by laboratory until smear results are provided to health-care provider	_____																	
• Receipt by laboratory until culture results are provided to health-care provider	_____																	
• Receipt by laboratory until drug-susceptibility results are provided to health-care provider	_____																	
• Receipt of drug-susceptibility results until initiation of anti-TB treatment	_____																	
• Admission of patient until placement in AII	_____																	
• Diagnosis of TB disease to initiation of AII	_____																	
Through what means (e.g., review of TST conversion rates, patient medical records, time analysis) are lapses in infection control recognized?																		
What mechanisms are in place to correct lapses in infection control?																		
Based on measurement in routine quality control (QC) exercises, is the infection-control plan being properly implemented?	Yes No																	
Is ongoing training and education provided for HCWs about TB infection-control practices?	Yes No																	

Laboratory processing of TB-related specimens, tests, and results (based on laboratory review)

Which of the following tests are either conducted in-house at your health-care setting's laboratory or sent out to a reference laboratory?	In-house	Sent out
a) AFB smears		
b) Culture using liquid media (e.g., Bactec, MB-BacT)		
c) Culture using solid media		
d) Drug-susceptibility testing		

DRAFT

DRAFT

DRAFT

What is the usual transport time for specimens to reach the laboratory for the following tests?							
a) AFB smears	_____						
b) Culture using liquid media (e.g., Bactec, MB-BacT)	_____						
c) Culture using solid media	_____						
d) Drug-susceptibility testing	_____						
e) Other (specify)	_____						
Does the laboratory at your health-care setting or the reference laboratory used by your health-care setting report AFB smear results for all patients within 24 hours of collection? What is the procedure for weekends?	<table border="1"> <tr> <td>Yes</td> <td>No</td> </tr> <tr> <td>_____</td> <td>_____</td> </tr> <tr> <td>_____</td> <td>_____</td> </tr> </table>	Yes	No	_____	_____	_____	_____
Yes	No						
_____	_____						
_____	_____						

Environmental controls

Which environmental controls are in place in your health-care setting? Check all that apply:			
o Local exhaust ventilation (enclosing devices, exterior devices)			
o General ventilation (e.g., single-pass system, recirculation system.)			
o Air-cleaning methods such as high-efficiency particulate air (HEPA) filtration, ultraviolet germicidal irradiation (UVGI)			
o AII rooms			
What are the design and actual air exchange rates (air changes per hour) for various rooms			
Room	Design	Actual	
_____	_____	_____	
_____	_____	_____	
_____	_____	_____	
_____	_____	_____	
_____	_____	_____	
_____	_____	_____	
Which of the following local exhaust ventilation devices are used in your health-care setting? Check all that apply:			
o Exterior devices or Enclosing devices such as			
o Laboratory hoods			
o Booths for sputum induction			
o Tents or hoods for enclosing or placing a patient in AII			
What general ventilation systems are used in your health-care setting?			
o Single-pass system		o Variable air volume (VAV)	
o Recirculation system		o Constant air volume (CAV)	
o Other _____			
What air-cleaning methods are used in your health-care setting?			
HEPA filtration			
o Fixed room-air recirculation systems			
o Portable room-air recirculation systems			
UVGI			
o Duct irradiation			
o Upper-air irradiation			
o Portable room-air cleaners			
How many AII rooms are in the health-care setting?			
What ventilation methods are used for AII rooms? Check all that apply.			
o Single-pass heating, ventilating, and air conditioning (HVAC)			
o Recirculating HVAC systems			
o Fixed room recirculating units			
o HEPA filtration			

DRAFT

DRAFT

DRAFT

o Other _____	
Does your health-care setting employ, have access to, or collaborate with an environmental engineer for consultation on design specifications, installation, maintenance, and evaluation of environmental controls?	Yes No
Are environmental controls regularly checked and maintained with results recorded in maintenance logs?	Yes No
Are AII rooms checked daily for negative pressure when in use?	Yes No
Is directional airflow in AII rooms checked with a smoke tube?	Yes No
If yes, daily?	Yes No
Are these results readily available?	Yes No
What procedures are in place if the AII room pressure is not negative?	_____
Do AII rooms meet the recommended pressure differential of 0.01 inch water column negative to surrounding structures?	Yes No

Respiratory protection program

Is there a respiratory protection program?		Yes No
Which HCWs are included in the respiratory protection program? Check all that apply. o Physicians o Mid-level practitioners (NP, PA) o Nurses o Administrators o Laboratory personnel o Contract staff o Construction or renovation staff o Service personnel o Janitorial staff o Maintenance or engineering staff o Transportation staff o Dietary staff o Non-employee physicians o Students o Others (specify) _____ _____ _____		
What types of respirators are used in this setting for all HCWs working with TB patients (include manufacturer, model, and specific application such as ABC model 1234 for bronchoscopy; DEF model N95)? _____ _____ _____		
Is there annual respiratory protection training for HCWs performed by a trained fit tester?		Yes No
Is there initial fit testing for HCWs?	Yes No	
If yes, when and how frequently is it conducted	_____	
Is there periodic fit testing for HCWs?	Yes No	
What method of fit testing is used? Describe: _____ _____		

Reassessment of TB risk

How frequently is the TB risk assessment conducted or updated in the health-care setting?	
When was the last TB risk assessment conducted?	
What problems were identified at the last TB risk assessment?	
A. _____	
B. _____	

DRAFT

DRAFT

DRAFT

C. _____ D. _____ E. _____ F. _____	
What actions were taken to control the problems identified at the last TB risk assessment?	
A. _____ B. _____ C. _____ D. _____ E. _____ F. _____	
Is qualitative fit testing used?	Yes No
Is quantitative fit testing used?	Yes No
Did the risk classification need to be revised as a result of the last TB risk assessment?	Yes No

- a. If the population served by the health-care facility is not representative of the community in which the facility is located, an alternate comparison population may be appropriate.
- b. TST conversion rate is calculated by dividing the number of conversions among HCWs by the number of HCWs who were tested during a certain time period. A QuantiFERON-TB (QFT) test conversion is a change from a negative to a positive result over a two-year period.

DRAFT

DRAFT

DRAFT

Table 2. Risk classifications for health-care settings and recommended frequency of screening for *M. tuberculosis* infection among HCWs¹

Setting Type	Risk Classification ²		
	<i>Low risk</i>	<i>Medium risk</i>	<i>Potential ongoing transmission</i> ³
Inpatient <200 Beds	<ul style="list-style-type: none">• <3 TB patients/year	<ul style="list-style-type: none">• ≥3 TB patients/year	<ul style="list-style-type: none">• Evidence of ongoing <i>M. tuberculosis</i> transmission, regardless of setting
Inpatient ≥200 beds	<ul style="list-style-type: none">• <6 TB patients/year	<ul style="list-style-type: none">• ≥6 patients/year	
Outpatient settings and Non-traditional facility-based settings	<ul style="list-style-type: none">• <3 TB patients/year	<ul style="list-style-type: none">• ≥3 TB patients/year	
TB treatment facilities	Settings where <ul style="list-style-type: none">• Persons who will be treated have been demonstrated to have LTBI and not TB disease,• No cough-inducing procedures are performed, and• A system is in place to promptly detect and triage persons who have signs or symptoms of TB disease to a setting where persons with TB disease are treated	<ul style="list-style-type: none">• Settings where persons with TB disease are encountered• Settings that do not otherwise meet the criteria for <i>low risk</i>	
Laboratories	<ul style="list-style-type: none">• Laboratories where clinical specimens that might contain <i>M. tuberculosis</i> are not manipulated	<ul style="list-style-type: none">• Laboratories where clinical specimens that might contain <i>M. tuberculosis</i> are manipulated	
Recommendations for Screening Frequency			
Baseline two-step TST or QFT ⁴	Yes, for all HCWs upon hire	Yes, for all HCWs upon hire	Yes, for all HCWs upon hire
TST for HCWs upon unprotected exposure to <i>M. tuberculosis</i>	Perform a contact investigation, i.e., administer one TST as soon as possible at the time of exposure, and if the TST result is negative, place another TST 8–10 weeks after the end of exposure to <i>M. tuberculosis</i> ⁵		
Serial TST or QFT screening of HCWs	No ^{6,7}	Every 12 months ⁶	As needed in the investigation of <i>potential ongoing transmission</i> ^{3,8}

- ¹ The term “HCWs” refers to all paid and unpaid persons working in health-care settings who have the potential for exposure to *M. tuberculosis* through air space shared with persons with infectious TB disease.
- ² Settings that serve communities with a relatively high incidence of TB disease, that treat high-risk populations such as those with HIV infection or other immunocompromising conditions, or that treat patients with drug-resistant TB disease may need to be classified as *medium risk* even if they meet the low risk criteria.
- ³ A classification of *potential ongoing transmission* should be applied to a specific group of HCWs or to an area of the health-care setting in which evidence of ongoing transmission is apparent, if such a group or area can be identified. Otherwise, a classification of *potential ongoing transmission* should be applied to the entire setting. **The classification of *potential ongoing transmission* should be used as a temporary classification only. It warrants immediate investigation, and corrective steps; after it has been determined that ongoing transmission has ceased, the setting should be reclassified as *medium-risk*.** It is recommended to maintain the classification of *medium risk* for at least one year.
- ⁴ Baseline two-step TST or QFT is recommended for all newly hired HCWs. In a small number of settings, there may be a choice not to perform baseline TB screening (at the beginning of the HCW’s employment) or serial TB screening for HCWs who will **never** be in contact with, or have shared air space with patients who have TB disease (e.g., telephone operators who work in a separate building from patients), or who will never be in contact with clinical specimens that may contain *M. tuberculosis*. Establishment of a reliable baseline result can be beneficial if subsequent screening is needed after an unexpected exposure to *M. tuberculosis*.
- ⁵ Procedures for contact investigations should not be confused with the “two-step TST,” which is used for newly hired HCWs. In contact investigations, contacts receive one TST as soon as possible after the exposure, and if the TST result is negative, another TST should be placed 8–10 weeks after the end of exposure.
- ⁶ HCWs whose duties do not include contact with patients or TB specimens do not need to be included in the serial TB screening program.
- ⁷ Because the positive predictive value of QFT and TST (Supplement 2, A.4) is low where prevalence of LTBI is low, serial TST screening of HCWs in these settings might yield high rates of false-positive results.
- ⁸ The frequency of testing for infection with *M. tuberculosis* will be determined by the risk assessment for the setting. During an investigation of potential ongoing transmission of *M. tuberculosis*, testing for *M. tuberculosis* infection may need to be performed every 8–10 weeks until lapses in infection controls have been corrected and no further evidence of ongoing transmission is apparent.

Figure X. Risk classification examples

The following eight hypothetical situations illustrate the way in which assessment data are used to assign a risk classification. The risk classifications are for settings that plan to treat persons with TB disease.

Example A. A 150-bed hospital is located in a small city. During the preceding year, the hospital admitted two patients with a diagnosis of TB disease. One was admitted directly to AII and one stayed on a medical ward for two days before being placed in an AII room. A contact investigation of exposed HCWs by hospital infection-control personnel in consultation with the state or local health department did not identify any health-care-associated transmission. *Risk classification: Low risk.*

Example B. The setting is an ambulatory-care site in which a TB clinic is held two days per week. In the preceding year, care was delivered to six patients with TB disease and approximately 50 persons with LTBI. No instances of transmission of *M. tuberculosis* were noted. *Risk classification: Medium risk (because it is a TB clinic).*

Example C. The setting is a large publicly funded hospital in a major metropolitan area. The hospital admits an average of 150 patients with TB disease each year, comprising 35% of the city burden. The setting has a strong TB infection-control program (i.e., annually updates infection-control plan, fully implements infection-control plan, and the setting has enough AII rooms as described in Supplement 3), and an annual *M. tuberculosis* infection test conversion rate among HCWs of 0.5%. The *M. tuberculosis* infection test conversion rate is the percentage of HCWs who have converted their TST or QFT results within a specified time period calculated by dividing the number of *M. tuberculosis* infection test conversions among HCWs in the setting in a specified period of time (numerator) by the number of HCWs who received TSTs or QFTs in the setting over the same period of time (denominator) multiplied by 100. No evidence of health-care-associated transmission is apparent. The hospital has strong collaborative linkages with the state or local health department. *Risk classification: Medium risk, with close ongoing*

surveillance for episodes of transmission from unrecognized cases of TB disease, *M. tuberculosis* infection test conversions in HCWs as a result of health-care–associated transmission, and specific groups or areas in which a higher risk for health-care–associated transmission exists.

Example D. The setting is an inpatient area of a correctional facility. A proportion of the inmates were born in countries where TB disease is endemic. Two cases of TB disease were diagnosed in inmates during the preceding year. *Risk classification: Medium risk.* Correctional facilities should be classified as at least *medium risk*.

Example E. A hospital located in a large city admits 35 patients with TB disease per year and has an overall HCW *M. tuberculosis* infection test conversion rate of 1.0%. However, on annual testing, three of the 20 respiratory therapists tested had *M. tuberculosis* infection test conversions, for a rate of 15%. All of the respiratory therapists who tested positive received medical evaluations, had TB disease excluded, were diagnosed with LTBI, and were offered and completed a course of treatment for LTBI. None of the respiratory therapists had known exposures to *M. tuberculosis* outside the hospital. The problem evaluation revealed that: 1) the respiratory therapists who converted had spent part of their time in the pulmonary function laboratory where induced sputum specimens were collected, and 2) the ventilation in the laboratory was inadequate. *Risk classification: Potential ongoing transmission for the respiratory therapists* (due to evidence of health-care–associated transmission). The rest of the setting was classified as *medium risk*. To address the problem, booths were installed for sputum induction. No *M. tuberculosis* infection test conversions were noted at the repeat testing three months later, and the respiratory therapists were then reclassified back to *medium risk*.

Example F. The setting is an ambulatory-care center associated with a large health maintenance organization (HMO). The patient volume is high, and the HMO is located in the inner city where TB rates are the highest in the state. During the preceding year, one patient who was known to have TB disease presented to the center. The person was recognized as a TB patient on his first visit and was promptly triaged to an emergency department with AII capacity. While in the clinic, the patient was held in an area separate from HCWs and other patients and instructed to wear a surgical mask. A contact investigation was conducted among exposed staff, and no *M. tuberculosis* infection test conversions were noted. *Risk classification: Low risk.*

Example G. The setting is a clinic for the care of persons infected with HIV. The clinic serves a large metropolitan area and a patient population of 2,000. The clinic has an AII room and a TB infection-control program. All patients are screened for TB disease upon enrollment, and anyone with respiratory complaints is placed in AII while being evaluated. During the past year, seven patients who received care in the clinic were subsequently found to have TB disease. All patients were promptly isolated in an AII room and no contact investigations were performed. The local health department was promptly notified in all cases. Annual testing has shown a *M. tuberculosis* infection test conversion rate of 0.3%, which is relatively low compared to the rate seen in the hospital with which the clinic is associated. *Risk classification: Medium risk* (because persons infected with HIV may be encountered here).

Example H. A home health-care agency employs 125 workers who perform duties including nursing, physical therapy, and basic home care. The agency did not care for any patients with suspected or confirmed TB disease in the prior year. Approximately 30% of the agency's workers are foreign-born, many who have immigrated within the last five years. At baseline two-step testing, four had a positive initial TST result, and two had a positive second-step TST results. All except one of these workers was foreign-born. Upon further screening, none were found to have TB disease. The home health-care agency is based in a major metropolitan area and delivers care to a mostly poor, medically under-served community with TB case rates that are higher than the community as a whole. *Risk classification: Low risk.* Given that workers might be from populations at higher risk for LTBI and subsequent progression to TB disease due to foreign birth and recent immigration, or HIV-infected clients may be over-represented, *medium risk* could be considered.

B.4 Calculation and use of *M. tuberculosis* infection conversion rates

The *M. tuberculosis* infection conversion rate is the percentage of HCWs who have converted their test for *M. tuberculosis* infection (i.e., positive TST or QFT result) within a specified time period. Timely detection of *M. tuberculosis*

infection in HCWs not only facilitates treatment for LTBI, but also can indicate the need for a contact investigation and a revision of the risk assessment for the setting.

For administrative purposes, a **TST conversion** is ≥ 10 millimeter (mm) increase in the size of the TST induration over a two-year period in an HCW with a documented negative (< 10 mm) two-step baseline TST result, or in a non-HCW with a negative (< 10 mm) TST result within two years.

For administrative purposes, a **QFT conversion** is a change from a negative to a positive response over a two-year period. Other changes (from negative to conditionally positive or conditionally positive to positive) are not considered to be QFT conversions for administrative purposes. Conversion in test results for *M. tuberculosis* are usually interpreted as presumptive evidence of new *M. tuberculosis* infection and recent infections are associated with an increased risk for progression to TB disease.

In settings conducting serial testing for *M. tuberculosis* infection, follow these steps to estimate the risk for test conversion in HCWs:

- B.4.1** Calculate a *M. tuberculosis* infection test conversion rate by dividing the number of conversions among HCWs in the setting in a specified period of time (numerator) by the number of HCWs who were tested in the setting over the same period of time (denominator) multiplied by 100.
- B.4.2** Identify areas or groups in the setting with a potentially high risk for *M. tuberculosis* infection test conversions by comparing conversion rates in HCWs with potential exposure to patients with TB disease to conversion rates in HCWs for whom health-care–associated exposure to *M. tuberculosis* is unlikely.
- B.4.3** Use *M. tuberculosis* infection test conversion data to identify lapses in infection control.
- B.4.4** *M. tuberculosis* infection test conversion rates above the baseline level should trigger an epidemiologic investigation to evaluate the likelihood of health-care–associated transmission (II.H). If *M. tuberculosis* infection test conversions are determined to be the result of well-documented community exposure or probable false-positive test results, the setting’s risk classification does not need to be adjusted.
- B.4.5** For settings that no longer perform **serial** testing for *M. tuberculosis* infection among HCWs, reassessment of the setting’s risk is important to ensure that the infection-control program is effective. The facility should have ongoing communication with the state or local health department regarding incidence and epidemiology of TB in the population served, and ensure that timely contact investigations are performed for HCWs or patients with unprotected exposure to a person with TB disease.

TST or QFT conversion criteria for administrative (surveillance) purposes are not applicable for medical evaluation of HCWs for the diagnosis of LTBI.

B.5 Evaluation of TB infection-control procedures and identification of problems

Periodic evaluations of the TB infection-control plan are needed to ensure the proper implementation of the plan and to recognize and correct lapses in infection control.

B.5.1 Review the medical records of a sample of patients with suspected and confirmed TB disease who were treated or examined at the setting to identify possible problems in TB infection control. As applicable, base the review on factors such as

- *Time interval from*
 - o Suspicion of TB disease and patient triage to proper AII or referral center (for settings that do not provide care for patients with suspected or confirmed TB disease)
 - o Admission until TB disease was suspected
 - o Admission until medical evaluation for TB disease was performed
 - o Admission until specimens for AFB smears and polymerase chain reaction (PCR)-based nucleic acid amplification (NAA) tests for *M. tuberculosis* were ordered
 - o Admission until specimens for mycobacterial culture were ordered
 - o Ordering of AFB smears, NAA tests, and mycobacterial culture until collection of specimens
 - o Collection of specimens until performance and reporting of AFB smear results
 - o Collection of specimens until performance and reporting of culture results
 - o Collection of specimens until species identification reported
 - o Collection of specimens until drug-susceptibility test results reported
 - o Admission until initiation of AII
 - o Admission until initiation of anti-TB treatment
- Duration of AII
- Measurement of meeting criteria for discontinuing AII (note: some patients may be correctly discharged from an AII room to home)
- Patient history of prior admission
- Adequacy of anti-TB treatment regimens
- Adequacy of procedures for collection of follow-up sputum specimens
- Adequacy of discharge planning

- Number of visits to outpatient setting from the start of symptoms until TB disease was suspected (for outpatient settings)
- B.5.2** Note previous hospital admissions and outpatient visits of patients with TB disease before the onset of TB symptoms. Suspect patient-to-patient transmission if: a) TB disease occurred in a patient who was previously hospitalized and exposed in the hospital to another patient with TB disease who was not placed in an AII room, b) two or more TB patients had overlapping visits to an outpatient setting, or c) isolates from two or more TB patients had identical drug-resistance or DNA fingerprint patterns.
- B.5.3** Determine if all HCWs who should participate in TB screening are included in the program and in any investigation of possible health-care–associated transmission of *M. tuberculosis*.
- B.5.4** Observe work practices related to AII to determine if employers are enforcing all practices, if HCWs are adhering to infection-control policies and if patient adherence to AII is being enforced.
- B.5.5** Use data from the case reviews and observations in the periodic risk assessment to determine the need to modify: a) administrative controls, protocols, and practices for identifying and isolating patients with suspected or confirmed infectious TB disease, b) laboratory procedures, c) protocols for patient management, or d) TB training and education programs for HCWs.

B.6 Environmental assessment

- B.6.1** Review data from the most recent environmental evaluation to determine if recommended environmental controls are in place (Table 4).
- B.6.2** Review environmental control maintenance procedures and logs to determine if maintenance is conducted properly and regularly.
- B.6.3** Compare environmental control design specifications with guidelines from the American Institute of Architects (AIA) and other ventilation guidelines (Table S3-2) and the installed system performance.
- B.6.4** Use environmental data to assist building managers and engineers in evaluating the performance of the installed system(s).
- B.6.5** Assess the number and types of high-risk procedures (e.g., bronchoscopy, sputum induction, administration of aerosolized medications) performed in the setting.
- B.6.6** Determine if the number of AII rooms present is suitable for the setting, based on AIA Guidelines and the facility risk assessment. JCAHO has adapted the AIA guidelines when accrediting facilities(102).

Table 4. Environmental controls record and evaluation ¹

Type of environmental control ²	Number ³	Location in the health-care setting ⁴	How often maintained ⁵	How often evaluated	Last evaluation date	Next evaluation due

¹ Not all settings will be able to supply information for all parts of the table.

² For example, UVGI, AII room, HEPA filters, in each location in the health-care setting.

³ Number of UVGI units, AII rooms, HEPA filters, in each location in the health-care setting.

⁴ For example, inpatient rooms, emergency departments, bronchoscopy suites, sputum induction rooms, outpatient areas, waiting areas.

⁵ Daily, weekly, monthly, annually.

C. TB Infection-Control Plan

- C.1 Based on the risk assessment for the setting, decide on proper administrative, environmental, and respiratory protection policies and measures to prevent health-care–associated transmission of *M. tuberculosis*. These decisions will form the basis for a setting-specific TB infection-control plan (Table 5).**
- C.2 Update an existing TB infection-control plan, or write a new plan if none exists.**
- C.3 Conduct a TB risk assessment at least annually, and more frequently in settings where health-care–associated transmission of *M. tuberculosis* is suspected or confirmed. Based on the results, conduct a problem evaluation and take recommended action. If necessary, also revise the risk classification as indicated.**
- C.4 After each risk assessment, review all TB infection-control policies to ensure that they are effective and meet current needs. Revise the written TB infection-control plan as indicated.**

DRAFT

DRAFT

DRAFT

Table 5. Administrative, environmental, and respiratory controls for selected health-care settings

Settings where patients with suspected or confirmed tuberculosis (TB) disease are only triaged and NOT treated			
Setting	Administrative Controls ^a	Environmental Controls ^b	Respiratory Protection ^c
Triage only: Initial evaluation of patients who will transfer to another setting	<ul style="list-style-type: none"> Implement a written plan for triage of patients with suspected or confirmed TB disease. Update annually. Promptly recognize and transfer patients with suspected or confirmed TB disease to a facility that treats persons with TB disease. Prior to transfer out of this setting, hold the patient in an area separate from health-care workers (HCWs) and other patients. 	<ul style="list-style-type: none"> Settings in which patients with suspected or confirmed TB disease are rarely seen do not need an AII room. Place any patient with suspected or confirmed TB disease in an AII room if available or in a separate room with the door closed, apart from other patients and not in an open waiting area. 	<ul style="list-style-type: none"> Settings in which patients with suspected or confirmed TB disease are rarely seen do not need or a respiratory protection program. A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport, in waiting areas, or when others are present.
Settings where patients with suspected or confirmed TB disease are treated			
Inpatient settings			

DRAFT

DRAFT

DRAFT

Patient rooms	<ul style="list-style-type: none"> • Implement an infection-control plan in the setting. Update annually. • Place patients with suspected or confirmed TB disease in an airborne infection isolation (AII) room. 	<ul style="list-style-type: none"> • At least one inpatient room should meet requirements for an AII room to be used for patients with suspected or confirmed TB disease (Supplement 3, Table S3-2). • Air-cleaning technologies such as high efficiency particulate air (HEPA) filtration and ultraviolet germicidal irradiation (UVGI) may be used to increase the number of equivalent air changes per hour (ACH) (Supplement 3). 	<ul style="list-style-type: none"> • For HCWs and visitors^e entering the AII room of a patient with suspected or confirmed TB disease, at least N95 disposable respirators should be worn.
Emergency departments and Urgent-care settings	<ul style="list-style-type: none"> • Implement an infection-control plan in the setting. Update annually. • Promptly recognize and, when possible, transfer patients with suspected or confirmed TB disease to a setting that treats persons with TB disease. 	<ul style="list-style-type: none"> • In settings with medium or higher risk, at least one room should meet requirements for an AII room to be used for patients with suspected or confirmed TB disease (Supplement 3, Table S3-2). • Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3). • Patients with signs or symptoms of infectious TB disease should be moved to an AII room as soon as possible. 	<ul style="list-style-type: none"> • For HCWs and visitors^e entering the AII room of a patient with suspected or confirmed TB disease, at least N95 disposable respirators should be worn. • A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport, in waiting areas, or when others are present.

DRAFT

DRAFT

DRAFT

Intensive-care units (ICU)	<ul style="list-style-type: none">• Implement an infection-control plan in the setting. Update annually.• Promptly recognize and, when possible, transfer patients with suspected or confirmed TB disease to a setting that treats persons for TB disease.• Prior to transfer hold in an ICU AII room separate from HCWs and other patients.	<ul style="list-style-type: none">• In settings with a high volume of patients with suspected or confirmed TB disease, at least one room should meet requirements for an AII room to be used for patients with suspected or confirmed TB disease (Supplement 3, Table S3-2).• Bacterial filters should be used routinely in breathing circuits of patients with suspected or confirmed TB disease and should filter particles 0.3 μm in size in unloaded and loaded states with a filter efficiency of >95%.	<ul style="list-style-type: none">• For HCWs, visitors^e and others entering the AII room of a patient with suspected or confirmed TB disease, at least N95 disposable respirators should be worn.• A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible (if patient is not using a breathing circuit), during transport, in waiting areas, or when others are present.
----------------------------	--	--	---

DRAFT

DRAFT

DRAFT

Surgical suites	<ul style="list-style-type: none">• Implement an infection-control plan in the setting. Update annually.• Postpone surgery for patients with suspected or confirmed TB disease until the patient is determined not to have TB disease or to be noninfectious, if possible.• If surgery is needed, use a room or suite of rooms that meet requirements for AII rooms that would prevent the spread of <i>M. tuberculosis</i> (may involve changing setting of the HVAC system). Some surgical suites allow reversal of air flow to achieve negative pressure.• Otherwise, schedule when a minimum number of HCWs and other patients are present, and schedule the patient as the last surgical case of the day to maximize the time available for removal of airborne contamination (Table S3-1).	<ul style="list-style-type: none">• If an operating room (OR) has an anteroom, the anteroom should be used to move in and out of the operating room if surgery cannot be postponed.• Bacterial filters should be used routinely in breathing circuits of patients with suspected or confirmed TB disease and should filter particles 0.3 µm in size in unloaded and loaded states with a filter efficiency of >95%.• For postoperative recovery, place patients in a room that meets the requirements for an AII room (Supplement 3, Table S3-2).• If an AII or comparable room is not available, air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3).	<ul style="list-style-type: none">• For HCWs present during surgeries on patients with suspected or confirmed TB disease, at least N95 disposable respirators should be worn.• Valved or positive-pressure respirators should not be used, as they do not protect the sterile surgical field.• Standard surgical masks may not have fitting or filtering capacity for adequate protection.• When the procedure involves the organ or tissue of a donor patient with suspected TB disease, a respirator with a level of protection greater than an N95 such as a full-facepiece elastomeric respirator or powered air-purifying respirator (PAPR) should be worn.• A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport, in waiting areas, or when others are present.
-----------------	---	---	---

DRAFT

DRAFT

DRAFT

Laboratories ^f	<ul style="list-style-type: none">• Implement an infection-control plan in the setting. Update annually.• Conduct a laboratory-specific risk assessment.• In general, biosafety level (BSL)-2 practices, procedures, containment equipment, and facilities are required for nonaerosol-producing manipulations of clinical specimens. BSL-3 practices, procedures, and containment equipment may be necessary for certain high-risk manipulations.	<ul style="list-style-type: none">• Should meet requirements for clinical microbiologic laboratories according to guidelines by Biosafety in Microbiological and Biomedical Laboratories (BMBL) and the American Institute of Architects (AIA);• Perform all manipulation of clinical specimens that could result in aerosolization in a certified class I or II biosafety cabinet (BSC).	<ul style="list-style-type: none">• For laboratory workers, who manipulate clinical specimens outside of a BSC, at least N95 disposable respirators should be worn.
---------------------------	--	--	---

DRAFT

DRAFT

DRAFT

Bronchoscopy suites	<ul style="list-style-type: none">• Implement an infection-control plan in the setting. Update annually.• Use a dedicated room to perform bronchoscopy procedures.• If possible, postpone bronchoscopy in patients with suspected or confirmed TB disease until the patient is determined not to have TB disease or to be noninfectious, recognizing that bronchoscopy can generate infectious particles in patients with negative AFB sputum smear results.• If a patient with suspected or confirmed TB disease must undergo bronchoscopy, schedule bronchoscopy when a minimum number of HCWs and other patients are present and at the end of the day to maximize the time available for removal of airborne contamination.• Allow sufficient time for removal of contaminated air before re-entry into the room (Supplement 3, Table S3-1).	<ul style="list-style-type: none">• Bronchoscopy suites should meet ACH requirements for an AII room (Supplement 3, Table S3-2).• Keep patients with suspected or confirmed TB disease in the bronchoscopy suite after bronchoscopy until coughing subsides.• Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3, IV).• Closed ventilatory circuitry and minimizing opening of such circuitry of intubated and mechanically-ventilated patients may minimize exposure.	<ul style="list-style-type: none">• For HCWs present during bronchoscopic procedures on patients with suspected or confirmed TB disease, a respirator with a level of protection of at least an N95 disposable respirator should be used. Protection greater than an N95 such as a full-facepiece elastomeric respirator or PAPR should be considered.• Before and after the procedure, a surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport, in waiting areas, or when others are present.
---------------------	--	--	---

DRAFT

DRAFT

DRAFT

Sputum induction and inhalation therapy rooms	<ul style="list-style-type: none"> • Implement an infection-control plan in the setting. Update annually. • Use a dedicated room to perform sputum induction or inhalation therapy. • Schedule sputum induction or inhalation therapy when a minimum number of HCWs and other patients are present and at the end of the day. • Allow sufficient time for removal of contaminated air before re-entry into the room (Supplement 3, Table S3-1). 	<ul style="list-style-type: none"> • Sputum induction or inhalation therapy rooms should meet requirements for an AII room. • Keep patients with suspected or confirmed TB disease in the sputum induction or inhalation therapy room after sputum collection or inhalation therapy until coughing subsides. • Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3). 	<ul style="list-style-type: none"> • At least an N95 disposable respirator should be worn when performing sputum induction on a patient with suspected or confirmed TB disease, in an uncontrolled environment. Based on the risk assessment, consideration should be given to using a higher level of respiratory protection such as an elastomeric full-facepiece respirator or a PAPR (Supplement 4). • Before and after the procedure, a surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport, in waiting areas, or when others are present.
Autopsy suites and embalming rooms	<ul style="list-style-type: none"> • Implement an infection-control plan in the setting. Update annually. • Ensure proper coordination between attending physician(s) and pathologist(s) for proper infection control and specimen collection during autopsies performed on patients with suspected or confirmed TB disease. 	<ul style="list-style-type: none"> • Autopsy suites should meet ACH requirements for an AII room to be used for patients with suspected or confirmed TB disease (Supplement 3, Table S3-2). • Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3). 	<ul style="list-style-type: none"> • At least an N95 disposable respirator should be worn when performing an autopsy on a person with suspected or confirmed TB disease,. Based on the risk assessment, consideration should be given to using a higher level of respiratory protection such as an elastomeric full-facepiece respirator or a PAPR (Supplement 4). • especially if aerosol generation is likely.

DRAFT

DRAFT

DRAFT

Outpatient settings ^h	Administrative Controls ^b	Environmental Controls ^c	Respiratory Protection ^d
TB treatment facilities ⁱ	<ul style="list-style-type: none"> • Implement an infection-control plan in the setting for triage of patients with suspected or confirmed TB disease. Update annually. • Promptly recognize and transfer patients with suspected or confirmed TB disease to a facility that treats persons with TB disease. • Prior to transfer, hold the patient in an area separate from HCWs and other patients, and place a surgical mask on the patient 	<ul style="list-style-type: none"> • If patients with TB disease are treated in the clinic, at least one room should meet requirements for an AII room; • Perform all cough-inducing or aerosol-generating procedures using environmental controls (e.g., booth) or in an AII room; • Keep patients in the booth or AII room until coughing subsides. • Do not allow another patient to enter the booth or AII room until sufficient time has elapsed for adequate removal of <i>M. tuberculosis</i>-contaminated air (Table S3-1). • When transporting patients with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from rest of the vehicle, have the patient sit in the back seat, and open the windows. 	<ul style="list-style-type: none"> • For HCWs, visitors and others entering the AII room of a patient with suspected or confirmed infectious TB disease, at least N95 disposable respirators should be worn. When the risk assessment indicates the need to wear respirators, at least an N95 disposable respirator should be worn. • For HCWs transporting patients with suspected or confirmed infectious TB disease in a vehicle, at least N95 disposable respirators should be worn. • A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport or in waiting areas.

DRAFT

DRAFT

DRAFT

Medical settings in correctional facilities	<ul style="list-style-type: none"> • Implement an infection-control plan in the setting, which includes TB training for staff. Update annually. • Follow recommendations for inpatient and outpatient settings not in correctional facilities. • In waiting rooms or areas, follow recommendations for TB treatment facilities. • If possible, postpone transporting patients with suspected or confirmed infectious TB disease until they are determined to be noninfectious. 	<ul style="list-style-type: none"> • At least one room should meet requirements for an AII room. • Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3). • When transporting patients with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from rest of the vehicle, have the patient sit in the back seat, and open the windows. 	<ul style="list-style-type: none"> • For HCWs or others entering the AII room of a patient with suspected or confirmed infectious TB disease, at least N95 disposable respirators should be worn. • A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport or in waiting areas.
Dental-care settings	<ul style="list-style-type: none"> • If possible, postpone dental care of patients with suspected or confirmed infectious TB disease until determined not to have TB disease or to be noninfectious. 	<ul style="list-style-type: none"> • Treat patients with suspected or confirmed infectious TB disease in a room that meets requirements for an AII room. • Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase the number of equivalent ACH (Supplement 3). 	<ul style="list-style-type: none"> • For HCWs performing procedures on patients with suspected or confirmed infectious TB disease, at least N95 disposable respirators should be worn.

DRAFT

DRAFT

DRAFT

Medical offices and ambulatory-care settings	<ul style="list-style-type: none">• Implement an infection-control plan in the setting for triage of patients with suspected or confirmed infectious TB disease. Update annually.• Prior to transfer hold in an area separate from HCWs and other patients and place a surgical mask on the patient.	<ul style="list-style-type: none">• Environmental controls should be used as needed in areas where patients with suspected or confirmed infectious TB disease stay prior to transfer.• In medical offices or ambulatory care settings where patients with TB disease are treated, at least one room should meet requirements for an AII room.• Perform all cough-inducing or aerosol-generating procedures using environmental controls (e.g., booth) or in an AII room.• Keep patients in the booth or AII room until coughing subsides (Table S3-1).• Do not allow another patient to enter the booth or AII room until sufficient time has elapsed for adequate removal of <i>M. tuberculosis</i>-contaminated air.	<ul style="list-style-type: none">• For HCWs in medical offices or ambulatory care settings where patients with suspected or confirmed infectious TB disease might be encountered, at least N95 disposable respirators should be worn.• A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport or in waiting areas.
--	---	--	---

DRAFT

DRAFT

DRAFT

Dialysis units	<ul style="list-style-type: none">• Implement a written plan for triage of patients with suspected or confirmed infectious TB disease. Update annually.• Promptly recognize and transfer patients with suspected or confirmed infectious TB disease.• Prior to transfer hold in an area separate from HCWs and other patients and place a surgical mask on the patient.• Schedule dialysis for patients with TB disease when a minimum number of HCWs and other patients are present and at the end of the day to maximize the time available for removal of airborne contamination.	<ul style="list-style-type: none">• Perform dialysis for patients with suspected or confirmed infectious TB disease in a room that meets requirements for an AII room.	<ul style="list-style-type: none">• For HCWs or visitors entering the AII room of a patient with suspected or confirmed infectious TB disease, at least N95 disposable respirators should be worn.• A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport or in waiting areas.
Non-traditional facility-based settings			

DRAFT

DRAFT

DRAFT

Emergency medical services (EMS)	<ul style="list-style-type: none">• Implement an infection-control plan in the setting. Update annually.• Implement a written plan for HCWs who transport patients with suspected or confirmed TB disease.• Include exposed emergency medical HCWs in the contact investigation of patients with suspected or confirmed infectious TB disease.	<ul style="list-style-type: none">• When transporting patients with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from rest of the vehicle, have the patient sit in the back seat, and open the windows.• Use vehicle's ventilation system in the non-recirculating mode and provide as much outside air as possible.• Airflow should be from the cab, across the patient, and out of the vehicle.• If the vehicle has a rear exhaust fan, use this fan during transport.	<ul style="list-style-type: none">• For HCWs transporting patients with suspected or confirmed infectious TB disease, at least N95 disposable respirators should be worn.• A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport or in waiting areas.
----------------------------------	--	--	--

DRAFT

DRAFT

DRAFT

Home-based health-care and outreach settings	<ul style="list-style-type: none"> • Patients and household members should be educated regarding the importance of taking medications, respiratory hygiene and cough etiquette procedures, and proper medical evaluation. • If possible, postpone transporting patients with suspected or confirmed infectious TB disease until they are determined not to have TB disease or to be noninfectious. • Some patients may be instructed to remain at home temporarily until they are determined not to have TB disease or to be noninfectious. 	<ul style="list-style-type: none"> • Do not perform cough-inducing or aerosol-generating procedures unless appropriate infection controls are in place (Supplement 3). • When transporting patients with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from rest of the vehicle, have the patient sit in the back seat, and open the windows. 	<ul style="list-style-type: none"> • For HCWs entering the homes of patients with suspected or confirmed infectious TB disease at least N95 disposable respirators should be worn. • For HCWs transporting patients with suspected or confirmed infectious TB disease in a vehicle, at least N95 disposable respirators should be worn. • A surgical mask should be placed on patients with signs or symptoms of infectious TB disease during transport, in waiting areas, or when others are present.
Long-term care settings (e.g., hospices, skilled nursing facilities)	<ul style="list-style-type: none"> • Patients with suspected or confirmed infectious TB disease should not be treated in a hospice unless proper administrative and environmental controls and a respiratory protection program are in place. 		<ul style="list-style-type: none"> • A surgical mask should be placed on patients with signs or symptoms of infectious TB disease, if possible, during transport, in waiting areas, or when others are present.

^a Administrative controls must be implemented to ensure the effectiveness of environmental controls and respiratory protection programs, and should be in place for all settings where patients with suspected or confirmed TB disease will be encountered. Administrative controls include a written TB infection-control plan (which should be reassessed at least annually), assignment of responsibility for the plan, setting risk assessment, HCW risk classification, HCW training and education, and a screening program to test HCWs for infection with *M. tuberculosis*.

^b Environmental controls include local exhaust and general ventilation (i.e., achieving negative pressure, AII rooms) and air-cleaning methods (i.e., HEPA filtration, UVGI).

^c All settings where patients with suspected or confirmed TB disease will be encountered need to have a respiratory protection program. A respiratory protection program may not be necessary for settings where patients with TB disease are **not** encountered or where a procedure exists for the prompt transfer of patients with suspected or confirmed TB disease to a setting where they can be evaluated.

^d Visitors with suspected or confirmed TB disease should not have contact with patients (including those with suspected or confirmed TB disease).

^e Laboratories that are not based in inpatient settings should observe the same TB infection-control measures as laboratories in inpatient settings.

DRAFT

DRAFT

DRAFT

^f Some bronchoscopy suites are built for positive pressure.

^g Though most of these settings are routinely considered “outpatient”, they may be part of inpatient services in certain settings. If so, follow the recommendations for inpatient settings for patient rooms.

ⁱ TB treatment facilities may include TB clinics, infectious disease clinics, or pulmonary clinics.

D. Managing Patients Who Have Suspected or Confirmed TB Disease: General Recommendations

The primary TB risk to HCWs is the undiagnosed or unsuspected patient with infectious TB disease. A high index of suspicion for TB disease and rapid implementation of precautions are essential to preventing and interrupting transmission. The TB infection-control plan should include specific policies and work practices to ensure the prompt identification, triage, and referral or management of patients with suspected or confirmed TB disease, and measures should be taken to minimize the risk for transmission of *M. tuberculosis* to other patients and HCWs. Specific precautions will vary depending on the setting.

D.1 Prompt triage

All health-care settings should implement and enforce protocols to promptly identify, isolate, and either refer or manage persons with suspected or confirmed infectious TB disease.

- D.1.1** When taking patients' medical histories, routinely ask all patients about a) a history of TB exposure, infection, or disease, b) signs or symptoms of TB disease, and c) medical conditions that increase the risk for TB disease (Supplement 2). The patient's medical history is designed to find a chief complaint. The medical evaluation should include an interview *conducted in the patient's primary language*, with the assistance of a qualified medical interpreter if necessary. HCWs who are the first point of contact should be trained to ask questions that will facilitate detection of persons with suspected or confirmed infectious TB disease. For assistance with language interpretation, contact the state and local health department. Interpretation resources are available (103) (www.atanet.org; www.languageine.com; www.ncihc.org).
- D.1.2** Consider a diagnosis of respiratory TB disease for any patient with signs or symptoms of infection in the lung, pleura, or airways including larynx, including coughing for ≥ 3 weeks, loss of appetite, unexplained weight loss, night sweats, bloody sputum or hemoptysis, hoarseness, fever, fatigue, or chest pain. The index of suspicion for TB disease will vary by geographic area and will depend on the population served by the setting. The index of suspicion should be very high for geographic areas and groups of patients characterized by high TB incidence (104).
- D.1.3** In settings other than TB clinics, promptly refer patients with a medical history or symptoms suggestive of undiagnosed or inadequately treated TB disease to a setting that treats patients with TB disease for medical evaluation. Do not keep these patients in the setting any longer than required to arrange a referral or transfer to an AII room. While in the setting, the patient should wear a surgical mask and should be instructed to observe strict respiratory hygiene and cough etiquette procedures (see Glossary) (105-107).

- D.1.4** Keep any patient with pulmonary or laryngeal TB disease (or in rare cases a cutaneous TB abscess) in AII until the patient has been determined to be noninfectious and has demonstrated a clinical response to a standard multidrug anti-TB treatment regimen (Supplement 1). Since people with extrapulmonary TB disease frequently have coexisting respiratory TB disease, patients suspected to have extra-pulmonary TB should be kept in AII until they are confirmed to be noninfectious.
- D.1.5** Persons with tuberculous pleural effusions may have concurrent unsuspected pulmonary or laryngeal TB disease. These patients should be considered infectious until TB disease is excluded.
- D.1.6** HIV-infected patients and other immunocompromised persons with infectious TB disease should be physically separated from other people to protect both themselves and others. To avoid exposing HIV-infected or otherwise severely immunocompromised persons to *M. tuberculosis*, designate certain times of the day for their appointments, or treat them in separate areas of the setting.

D.2 TB AII precautions

Initiate TB AII precautions for any patient who: a) has signs or symptoms of TB disease, or b) has documented TB disease and has not completed treatment. For patients placed in AII due to suspected infectious TB disease of the lungs, airway, or larynx, AII can be discontinued when the likelihood of infectious TB disease is considered unlikely **and** either 1) another diagnosis is made that explains the clinical syndrome **or** 2) the patient has three negative AFB sputum smear results (108-111). Each of the three sputum specimens should be collected 8–24 hours apart (112), and at least one should be an early morning specimen (because respiratory secretions pool overnight). Generally, this will allow patients with negative sputum smear results to be released from AII in two days.

D.2.1 Settings where patients with suspected or confirmed TB disease will be encountered

Settings that plan to evaluate and manage patients with TB disease should have at least one AII room or enclosure that meets AII requirements (Supplement 3). These settings should:

- D.2.1a** Develop written policies that specify a) indications for AII, b) persons authorized to initiate and discontinue AII, c) AII practices, d) AII room monitoring procedures, e) procedures for managing patients who do not adhere to AII practices, and f) criteria for discontinuing AII.
- D.2.1b** Maintain a high index of suspicion for TB disease. If a patient has suspected or confirmed TB disease, promptly initiate AII procedures.
- D.2.1c** Keep inpatients with suspected or confirmed TB disease in AII until they are determined to be noninfectious and have demonstrated a clinical response to a standard multidrug anti-TB treatment regimen or until an alternative diagnosis is made. If the alternative diagnosis

cannot be clearly established, even with three negative sputum smear results, empiric treatment of TB disease should strongly be considered (Supplement 1).

- D.2.1d** Keep outpatients with suspected or confirmed TB disease in AII until they are transferred or until their visit is complete.

D.2.2 Settings where patients with suspected or confirmed TB disease will *not* be encountered

Settings in which patients with suspected or confirmed TB disease are rarely seen do not need an AII room or a respiratory protection program. Instead, these settings should

- D.2.2a** Develop a written protocol for referring patients with suspected or confirmed TB disease to a collaborating setting where the patient can be evaluated and managed properly. The collaborating facility should provide documentation of intent to collaborate. Review the triage and referral protocol routinely, and revise it as needed.
- D.2.2b** Place any patient with suspected or confirmed TB disease in an AII room if available, or in a room that meets the requirements for AII or in a separate room with the door closed, apart from other patients and not in an open waiting area. Allow adequate time to elapse to ensure removal of *M. tuberculosis*-contaminated room air before allowing entry by staff or another patient (Table S3-1, Supplement 2).
- D.2.2.c** Give the patient a surgical mask to wear that covers the mouth and nose. Instruct the patient to keep the mask on and to change the mask if it becomes wet. If the patient cannot tolerate a mask, they should observe strict respiratory hygiene and cough etiquette procedures.
- D.2.2d** Promptly recognize and transfer patients with suspected or confirmed TB disease to a facility that treats patients with TB disease, according to the written protocol.

D.3 AII room practices

AII rooms should be single-patient rooms in which environmental factors and entry of visitors and HCWs are controlled to minimize the transmission of *M. tuberculosis*. All persons including visitors and non-HCWs who enter an AII room should wear at least N95 disposable respirators (Supplement 4). Visitors should be instructed by HCWs on the use of the respirator prior to entering an AII room. AII rooms have specific requirements for controlled ventilation, negative pressure, and air filtration (102) (Supplement 3). Each inpatient AII room should have a private bathroom. Settings with AII rooms should adhere to the following practices:

- D.3.1** Keep doors to AII rooms closed except when patients, HCWs or others must enter or exit the room.

- D.3.2** While the room is being used for TB AII, monitor and record negative pressure in the room on a daily basis. Record results in a local retrievable document.
- D.3.3** Maintain enough AII rooms to isolate all patients who have suspected or confirmed TB disease. Estimate the number of AII rooms needed based on the results of the risk assessment for the setting.
- D.3.4** Consider grouping AII rooms in one part of the health-care setting to limit costs, reduce the possibility of transmitting *M. tuberculosis* to other patients, facilitate the care of TB patients, and facilitate the installation and maintenance of optimal environmental controls (particularly ventilation). Depending on the architecture and the environmental control systems of a particular setting, AII rooms may be grouped either horizontally (i.e., a wing of a facility), or vertically (i.e., the last few rooms of several wings of a facility).
- D.3.5** Perform diagnostic and treatment procedures such as sputum collection and inhalation therapy in an AII room.
- D.3.6** Ensure patient adherence to AII procedures. *In their primary language*, educate patients who are placed in an AII room about *M. tuberculosis* transmission and the reasons for their AII. Facilitate patient adherence by use of incentives (e.g., provide telephones, televisions, or radios in AII rooms; grant special dietary requests) and other measures. Address problems that could interfere with adherence (e.g., management of withdrawal from addictive substances, including tobacco).
- D.3.7** Patients with suspected or confirmed infectious TB disease who must be transported to another area of the setting or to another facility for a medically essential procedure should bypass the waiting area. While they are being transported to the next setting, patients with suspected or confirmed infectious TB disease should wear surgical masks that cover the mouth and nose during transport. Schedule procedures on patients with TB disease when a minimum number of HCWs and other patients are present and at the end of the day to maximize the time available for removal of airborne contamination. HCWs and transport staff should consider the use of N95 disposable respirators when transporting a patient from one setting to another when within a facility.

D.4 Diagnostic procedures

Diagnostic procedures should be done in settings with appropriate infection-control capabilities where the following recommendations apply for diagnosing TB disease and evaluating patients for potential infectiousness.

D.4.1 Clinical diagnosis

- D.4.1a** Obtain a complete medical history, including exposure to persons with TB disease and prior history of infection with *M. tuberculosis*, TB disease or treatment of LTBI or TB disease.

- D.4.1b** Perform a physical examination, testing for infection with *M. tuberculosis*, chest radiograph, microscopic examination, culture and, when indicated, NAA testing of sputum (29;40;113;114). Other specimens may need to be collected including those obtained via sputum induction with aerosol inhalation, gastric aspiration, or bronchoscopy (109;115-117). Gastric aspiration may be necessary for those patients, particularly children, who cannot produce sputum even with aerosol inhalation (115;116;118;119).
- D.4.1c** Place all patients with suspected or confirmed infectious TB disease in AII until they are determined to be noninfectious (Supplement 1). Adult and adolescent patients who may be infectious include persons who: are coughing, have cavitation on chest radiograph, have positive AFB sputum smear results, have respiratory tract disease with involvement of the lung, pleura or airways including larynx, fail to cover the mouth and nose when coughing, are not on anti-TB treatment, are on incorrect anti-TB treatment, or are undergoing cough-inducing or aerosol-generating procedures (e.g., sputum induction, bronchoscopy, airway suction) (22;120).
- D.4.1d** Evaluate persons diagnosed with extrapulmonary TB disease for the presence of concurrent pulmonary TB disease.
- D.4.1e** Most children with TB disease are not infectious and require only standard precautions. The major concern in infection control relates to adult household members and visitors who may be the source case (121). Pediatric patients, including adolescents, who may be infectious include those who have extensive pulmonary or laryngeal involvement, prolonged cough, positive sputum AFB smears results, or cavitary TB or those for whom cough-inducing procedures are performed (121;122).
- D.4.1f** Evaluate pediatric patients for infectiousness using the same criteria as for adults (i.e., on the basis of pulmonary or laryngeal involvement) (D.4.1c).
- D.4.1g** Report patients with suspected or confirmed TB disease immediately to the local public health authorities so that standard procedures for identifying and evaluating TB contacts can be initiated. Coordinate efforts with the state or local health department to arrange treatment and long-term follow-up and evaluation of contacts.

D.4.2 Laboratory diagnosis

- D.4.2a** For highest quality laboratory results, ensure that laboratories performing mycobacteriologic tests are skilled in both the laboratory and the administrative aspects of specimen processing.

D.4.2b Ensure that laboratories use or have prompt access to the most rapid methods available: a) fluorescent microscopy for AFB smears; b) rapid NAA testing for direct detection of *M. tuberculosis* in patient specimens; c) solid and rapid broth culture methods for isolation of mycobacteria; d) nucleic acid probes or high-pressure liquid chromatography (HPLC) for species identification; and e) rapid broth culture methods for drug-susceptibility testing. Ensure that laboratories incorporate other more rapid or sensitive tests as they become available, practical, and affordable (Supplement 2) (123;124).

D.4.2c In accordance with state and local laws and regulations, laboratories should report (by telephone, fax, or e-mail) positive AFB smear results from any specimens within 24 hours of collection and positive culture results within 24 hours of the notation of the positive culture result (124;125). Some settings perform AFB smears on-site for rapid results and then send specimens or cultures to a referral laboratory for identification and drug-susceptibility testing. This referral practice can speed the receipt of smear results but delay culture identification and drug-susceptibility results. Settings that cannot provide the full range of mycobacteriologic testing services should contract with their referral laboratories to ensure rapid results while maintaining proficiency for on-site testing. In addition, referral laboratories should be instructed to store isolates in case further testing is necessary.

D.4.2.d Report all drug-susceptibility results on *M. tuberculosis* isolates to the state or local health department as soon as these results are available.

D.4.2.e Laboratories that rarely receive specimens for mycobacteriologic analysis should refer specimens to a laboratory that performs these tests routinely. The reference laboratory should provide rapid testing and reporting. Out-of-state reference laboratories should provide all results to the state or local health department from which the specimen originated.

D.4.3 Special considerations for persons who have a high risk for TB disease or in whom TB disease may be difficult to diagnose

D.4.3a The probability of TB disease is greater among patients who: a) have a positive TST result ; b) have other risks of *M. tuberculosis* infection and either a positive or conditionally positive QFT result; c) previously had TB disease or were exposed to *M. tuberculosis*; or d) belong to a group at high risk for TB disease. People with a positive QFT result but no other risk for *M. tuberculosis*

infection should have a TST to help assess their risk. TB disease is strongly suggested if the diagnostic evaluation reveals AFB in sputum or from any other specimen, a chest radiograph suggestive of TB disease, or signs or symptoms of TB disease.

- D.4.3b** TB disease can occur simultaneously in immunocompromised persons who have pulmonary infections caused by other organisms (e.g., *Pneumocystis jirovecii* [formerly *P. carinii*], *M. avium* complex) and should be considered in the diagnostic evaluation of all such patients with signs or symptoms of TB disease (40).
- D.4.3c** TB disease can be difficult to diagnose in persons who have HIV infection (or other conditions associated with severe suppression of cell-mediated immunity) due to extrapulmonary or nonclassical clinical or even normal radiographic presentation or the simultaneous occurrence of other pulmonary infections (e.g., *P. jirovecii* [formerly *P. carinii*], *M. avium* complex) (2). The difficulty in diagnosing TB disease in persons infected with HIV can be compounded by a false-negative TST result for *M. tuberculosis* infection due to impaired host immunity (40;100;126), the possibly lower sensitivity and specificity of sputum smear results for detecting AFB (40;127), and the overgrowth of cultures with *M. avium* complex in specimens from patients infected with both *M. tuberculosis* and *M. avium* complex.

For immunocompromised patients who have respiratory signs or symptoms that are attributed initially to infections or conditions other than TB disease, conduct an evaluation for coexisting TB disease. Repeat the evaluation if the patient does not respond to recommended treatment for the presumed cause(s) of the pulmonary abnormalities (Supplement 2). In some settings where immunocompromised patients and patients with TB disease are seen, it may be prudent to implement AII for all high-risk persons (e.g., persons infected with HIV, symptomatic foreign-born persons who have immigrated within the last five years from TB-endemic countries, and persons with pulmonary infiltrates or signs or symptoms of TB disease).

D.5 Initiation of treatment

- D.5.1** For patients who have confirmed TB disease or who are considered highly probable to have TB disease, start recommended treatment promptly in accordance with current guidelines (Supplement 2) (23). TB treatment decisions should be coordinated with the state or local health department.
- D.5.2** All inpatient medication should be given by DOT and reported to the state or local health department. DOT is an adherence-enhancing strategy in which a trained HCW or other specially

trained person watches a patient swallow each dose of medication and records the dates of the observations. DOT is the standard of care for all patients with TB disease and should be used for all doses during the course of therapy for treatment of TB disease and for LTBI whenever feasible. **All** patients on intermittent (i.e., once- or twice-weekly) treatment for TB disease or LTBI should receive DOT. Rates of relapse and development of drug-resistance are decreased when DOT is used (128-130). Collaborate with the state or local health department on decisions about inpatient DOT and arrangements for outpatient DOT (23).

E. Managing Patients Who Have Suspected or Confirmed TB Disease: Additional Considerations for Special Circumstances and Settings

The recommendations for preventing transmission of *M. tuberculosis* (Recommendations, Sections A-L) are applicable to all health-care settings, including those that are described in this section. Each of these settings should have an independent risk assessment if it they are stand-alone settings, or they should have a detailed section written as part of the risk assessment for the overall setting. Additional TB-infection controls that are applicable to special circumstances and types of health-care delivery settings are described here and summarized in Table 5.

E.1 Minimum requirements

The specific precautions for the settings included in this section vary depending on the setting. Special settings may include **inpatient settings** such as patient room, emergency departments and urgent care settings, intensive care units (ICUs), surgical suites, laboratories, bronchoscopy suites, sputum induction and inhalation therapy rooms, and autopsy suites and embalming rooms; **outpatient settings** such as TB treatment facilities, medical settings in correctional facilities, dental-care settings, medical offices and ambulatory-care settings, and dialysis units; and **non-traditional facility-based settings** such as emergency medical services (EMS), home-based health-care and outreach settings and long-term care facilities (LTCFs) (Recommendations, Table 5). At a minimum, these settings should do the following:

- E.1.1** Perform an annual risk assessment for the setting.
- E.1.2** Develop and regularly evaluate and revise a written TB infection-control plan.
- E.1.3** Establish and implement protocols for identifying and managing patients with suspected or confirmed TB disease.
- E.1.4** Ensure that HCWs receive recommended TB training, education, and screening for *M. tuberculosis* infection as part of the infection-control plan (Recommendations, Section F).
- E.1.5** Establish protocols for problem evaluation.
- E.1.6** Collaborate with the state or local health department when necessary.
- E.1.7** When possible, postpone non-urgent procedures, which may put HCWs at risk, on patients with suspected or confirmed infectious TB disease until the patient is determined not to have TB disease or to be noninfectious.

Inpatient settings**E.2 Emergency departments and urgent-care settings**

In general, the symptoms of TB disease are symptoms for which patients might seek treatment in an emergency department or urgent-care setting. Since TB symptoms are common and non-specific, it is possible that infectious TB disease could be encountered in these settings. The use of emergency department-based TB screening is has not been shown consistently to be effective (131). Due to the potential for *M. tuberculosis* transmission in these settings, the general recommendations (Recommendations, II.D) should be followed.

- E.2.1** Minimize the amount of time patients with suspected or confirmed infectious TB disease spend in emergency departments and urgent-care settings.
- E.2.2** Ensure that patients with suspected or confirmed TB disease are promptly identified, evaluated, and placed away from other patients. Ideally, such patients should be placed in an AII room. When an AII room is not available, use a room with a portable HEPA filtration system, or transfer the patient to a facility or area with recommended infection-control capacity.
- E.2.3** Before a patient leaves an AII room, an assessment should be performed of the patient's need to be out of isolation, the risk for transmission and the patient's ability to observe strict respiratory hygiene and cough etiquette procedures.
- E.2.4** Instruct patients who are outside an AII room to wear a surgical mask. Patients who cannot tolerate masks due to medical conditions should observe strict respiratory hygiene and cough etiquette procedures.
- E.2.5** HCWs entering an AII room or any room with a patient with infectious TB disease should wear at least an N95 disposable respirator.
- E.2.6** Air-cleaning technologies, such as HEPA filtration and UVGI, may be used to increase equivalent air changes per hour (ACH) in waiting areas (Supplement 3).
- E.2.7** Emergency departments with a high volume of patients with suspected or confirmed TB disease should have at least one AII room. See Section B in Risk Assessment to determine high volume.
- E.2.8** After the patient with suspected or confirmed TB disease is transferred from a room with inadequate ventilation, allow adequate time to elapse to ensure removal of *M. tuberculosis*-contaminated room air before allowing entry by staff or another patient (Supplement 2, Table S3-1).

E.3 Intensive-care units (ICUs)

Patients with infectious TB disease may become sick enough to require admission to an ICU.

- E.3.1** Place ICU patients with suspected or confirmed infectious TB disease in an AII room, if possible.
- E.3.2** To help reduce the risk of contaminating a ventilator or discharging *M. tuberculosis* into the ambient air when mechanically ventilating (i.e., with a ventilator or manual resuscitator) a patient with suspected or confirmed TB disease, place a bacterial filter on the patient's endotracheal tube (or at the expiratory side of the breathing circuit of a ventilator) (132-136). In selecting a bacterial filter, give preference to models shown by the manufacturer to filter particles 0.3 µm in size in both the unloaded and loaded states with a filter efficiency of >95% (i.e., filter leakage of <5%), at the maximum design flow rates of the ventilator for the service life of the filter, as specified by the manufacturer.

E.4 Surgical suites

Surgical suites require special infection-control considerations for preventing transmission of *M. tuberculosis*. Normally, the direction of airflow should be from the operating room to the hallway (positive pressure) to minimize contamination of the surgical field. Some hospitals already have procedure rooms with reversible airflow or pressure while others have positive pressure rooms with a negative pressure anteroom. Surgical staff, particularly those close to the surgical field, should use respiratory protection, at least an N95 disposable respirator, to protect themselves and the patient undergoing surgery.

- E.4.1 When possible, postpone non-urgent surgical procedures** on patients with suspected or confirmed TB disease until the patient is determined to be noninfectious or determined not to have TB disease.
- E.4.2 When surgery cannot be postponed, procedures** should be performed in a surgical suite with recommended ventilation controls. On occasion, it may be necessary to schedule patients with suspected or confirmed TB disease as the last surgical case of the day to maximize the time available for removal of airborne contamination.
- E.4.3** If a surgical suite or an operating room has an anteroom, the anteroom should be either a) positive pressure relative to both the corridor and the suite or operating room, or b) negative pressure relative to both the corridor and the suite or operating room.
- E.4.4** If an operating room has no anteroom, keep the doors to the operating room closed, and minimize traffic into and out of the room and in the corridor. Consider using additional air-cleaning technologies, such as HEPA filtration or UVGI, to increase the equivalent ACH. Air-cleaning systems may be placed in the room or in surrounding areas to minimize contamination of the surroundings (Supplement 3, IV).
- E.4.5** Design the ventilation in the operating room to ensure a sterile environment in the surgical field while preventing contaminated air from flowing to other areas in the health-care setting.

- E.4.6** When surgery cannot be postponed, procedures should be performed in a surgical suite with recommended ventilation controls. On occasion, it may be necessary to schedule patients with suspected or confirmed TB disease as the last surgical case of the day to maximize the time available for removal of airborne contamination (Supplement 3, Table S3-1). Schedule procedures on patients with TB disease when a minimum number of HCWs and other patients are present in the surgical suite, and at the end of the day to maximize the time available for removal of airborne contamination.
- E.4.7** Take steps to reduce the risk for contaminating ventilator or anesthesia equipment or discharging tubercle bacilli into the ambient air when operating on a patient with suspected or confirmed TB disease (137). Place a bacterial filter on the patient's endotracheal tube (or at the expiratory side of the breathing circuit of a ventilator or anesthesia machine, if used) (132-136). In selecting a bacterial filter, give preference to models shown by the manufacturer to filter particles 0.3 µm in size in both the unloaded and loaded states with a filter efficiency of >95% (i.e., filter leakage of <5%), at the maximum design flow rates of the ventilator for the service life of the filter, as specified by the manufacturer.
- E.4.8** When surgical procedures (or other procedures that require a sterile field) are performed on patients with suspected or confirmed infectious TB, respiratory protection worn by HCWs must protect the field from the respiratory secretions of HCWs as well as protect HCWs from the infectious droplet nuclei generated from the patient. When selecting respiratory protection, do not use valved or positive-pressure respirators because they do not protect the sterile field. Use a respirator with a valveless filtering facepiece, such as an N95 disposable respirator.
- E.4.9** Postoperative recovery of a patient with suspected or confirmed TB disease should be in an AII room.

E.5 Laboratories

Staff who work in laboratories that handle clinical specimens encounter risks not typically present in other areas of a health-care setting (138;139). Laboratories that handle TB specimens include: a) pass-through facilities that forward specimens to reference laboratories for analysis; b) diagnostic laboratories that process specimens and perform acid-fast staining and primary culture for *M. tuberculosis*; and c) facilities that perform extensive identification, subtyping, and susceptibility studies. Procedures involving the manipulation of specimens or cultures containing *M. tuberculosis* introduce additional significant risks that must be addressed in an effective TB infection-control program. Risks for transmission of *M. tuberculosis* in laboratories include: 1) aerosol formation during any isolate manipulation, and 2) percutaneous inoculation from accidental exposures. Biosafety recommendations for laboratories performing diagnostic testing for TB have been published (66;67;123;140;141).

- E.5.1** In laboratories affiliated with a health-care setting (e.g., a hospital), and in free-standing laboratories, the laboratory

director, in collaboration with the infection-control staff for the setting, and in consultation with the state TB laboratory, should develop a risk-based infection-control plan for the laboratory that minimizes the risk for exposure to *M. tuberculosis*. Consider factors such as: a) incidence of TB disease (including drug-resistant TB) in the community and in patients served by settings that submit specimens to the laboratory, b) design of the laboratory, c) level of TB diagnostic service offered, d) number of specimens processed, and e) whether or not high-risk procedures are performed and the frequency at which they are performed. Referral laboratories should store isolates in case further testing is necessary.

- E.5.2** Biosafety Level (BSL)-2 practices and procedures, containment equipment, and facilities are required for non-aerosol-producing manipulations of clinical specimens (e.g., preparing smears for acid-fast staining) (123). Handle all specimens suspected of containing *M. tuberculosis* (including specimens processed for other microorganisms) in a Class I or II biological safety cabinet (BSC) (142;143).

Conduct all aerosol-generating activities (e.g., preparing smears for acid-fast staining, inoculating culture media, setting up biochemical and antimicrobial susceptibility tests, opening centrifuge cups, performing sonication) in a Class I or II BSC (142).

- E.5.3** Based on the risk assessment for the laboratory, use personal protective equipment recommended by local regulations for each activity.

E.5.3a For activities that have a low risk for generating aerosols, standard personal protective equipment consists of protective laboratory coats, gowns, or smocks designed specifically for use in the laboratory. Leave protective garments in the laboratory before leaving for non-laboratory areas.

E.5.3b Wear disposable gloves for all laboratory procedures. Dispose of the gloves when work is completed, when the gloves are overtly contaminated, or when the integrity of the glove is compromised. State or local regulations should determine procedures for the disposal of gloves.

E.5.3c Use face protection (e.g., goggles, respirator, face shield, or other splatter guard) when manipulating specimens outside a BSC.

- E.5.4** Based on the risk assessment for the laboratory, use respiratory protection for the performance of procedures that can result in aerosolization outside a BSC. The minimum level of respiratory protection is an N95 filtering facepiece respirator. Provide laboratory workers who use respiratory protection with the same training on respirator use and care and the same fit testing as other HCWs.

- E.5.5** For laboratories that are considered at least medium risk (Table 2), conduct testing for *M. tuberculosis* infection at least annually among laboratorians who perform TB diagnostics or manipulate

specimens from which *M. tuberculosis* is commonly isolated (e.g., sputum, lower respiratory secretions or tissues). More frequent testing is recommended in the event of a documented *M. tuberculosis* infection test conversion among laboratory staff or a laboratory accident that poses a risk for exposure to *M. tuberculosis* (e.g., malfunction of a centrifuge leading to aerosolization of a sample).

- E.5.6** After documented laboratory accidents, conduct an investigation of exposed laboratory workers.
- E.5.7** Laboratories in which specimens for mycobacteriologic studies (e.g., AFB smears and cultures) are processed should follow the AIA and CDC/NIH guidelines (102;143) (Supplement 3).
- E.5.8** BSL-3 practices, containment equipment, and facilities are required for the propagation and manipulation of cultures of *M. tuberculosis* or *M. bovis* and for animal studies using primates that are experimentally or naturally infected with *M. tuberculosis* or *M. bovis*. Animal studies utilizing guinea pigs or mice can be conducted at Animal BSL-2 (143).
- E.5.9** Settings classified as low risk, may classify the laboratory as *medium risk* based on the above outlined factors.

E.6 Bronchoscopy suites

Because bronchoscopy is a cough-inducing procedure that is performed on patients with suspected or confirmed TB disease, bronchoscopy suites require special attention (73;144;145). Bronchoscopy can result in the transmission of *M. tuberculosis* either through the airborne route (55;73;77;146) or a contaminated bronchoscope (72;147-153). Closed and effectively filtered ventilatory circuitry and minimizing opening of such circuitry in intubated and mechanically-ventilated patients may minimize exposure (Recommendations, E.3.2)(134).

- E.6.1** Avoid bronchoscopy on patients with suspected or confirmed TB disease, or postpone until the patient is determined to be noninfectious, by confirmation of three negative AFB sputum smear results (108-111).
- E.6.2** When collection of spontaneous sputum specimen is not adequate or possible, sputum induction has been shown to be equivalent to bronchoscopy for obtaining specimens for culture (110). Sputum induction can be costly; one study suggests that sputum induction be reserved for those without a productive cough whose signs or symptoms strongly indicate a diagnosis of TB disease (111).
- E.6.3** If a bronchoscopy must be performed in a positive-pressure room (e.g., operating room), consider using sputum induction instead of bronchoscopy (109).
- E.6.4** Whenever possible, perform bronchoscopy in a room that meets the ventilation requirements for an AII room (Supplement 3). Air-cleaning technologies such as HEPA filtration and UVGI may be used to increase equivalent ACH.
- E.6.5** Perform a physical examination; test for *M. tuberculosis* infection, obtain a chest radiograph, microscopic examination

and culture of sputum or other relevant specimens including gastric aspirates and NAA testing as indicated (40;114;117;119).

- E.6.6** Use respiratory protection while present during a bronchoscopic procedure on a patient with suspected or confirmed TB disease. Due to the increased risk for *M. tuberculosis* transmission during the performance of bronchoscopy procedures on patients with TB disease, consider using a higher level of respiratory protection than an N95 disposable respirator such as an elastomeric full-facepiece respirator or a PAPR (Supplement 4).
- E.6.7** In a patient who is intubated and mechanically-ventilated, minimize the opening of circuitry.
- E.6.8** After bronchoscopy is performed on a patient with suspected or confirmed TB disease, allow adequate time to elapse to ensure removal of *M. tuberculosis*-contaminated room air before performing another procedure in the same room (Table S3-1, Supplement 2).
- E.6.9** During the period following bronchoscopy when the patient is still coughing, collect at least one sputum for AFB to increase the yield of the procedure.
- E.6.10** Keep patients with suspected or confirmed TB disease who are undergoing bronchoscopy in an AII room until coughing subsides.

E.7 Sputum induction and inhalation therapy rooms

Sputum induction and inhalation therapy induces coughing, which increases the potential for transmission of *M. tuberculosis* (78;79). Therefore, appropriate precautions should be taken when working with patients with suspected or confirmed TB disease.

- E.7.1** Sputum induction procedures for persons with suspected TB disease should be pursued only after it is determined that self-produced sputum production is inadequate and that the AFB smear result on other specimens collected is negative.
- E.7.2** HCWs who order or perform sputum induction or inhalation therapy to diagnose conditions, in an uncontrolled environment, other than TB disease should assess the risk for TB disease.
- E.7.3** In any setting, cough-inducing procedures in patients with diagnosed TB should be conducted only after an assessment of infectiousness has been considered for each patient. The criteria for infectiousness used to remove a patient from isolation may not be stringent enough in determining infectiousness of a patient who is to undergo a cough-inducing procedure.
- E.7.4** At least an N95 disposable respirator should be worn when performing sputum induction on a patient with suspected or confirmed TB disease, in an uncontrolled environment. Based on the risk assessment, consideration should be given to using a higher level of respiratory protection such as an elastomeric full-facepiece respirator or a PAPR (Supplement 4).

E.8 Autopsy suites and embalming rooms

Autopsies and embalming procedures can be performed on corpses with diagnosed or undiagnosed TB disease. These procedures can pose a high risk for transmission of *M. tuberculosis*, particularly during the performance of aerosol-generating procedures (e.g., median sternotomy). Persons who handle corpses postmortem may be at risk for transmission of *M. tuberculosis* (69;70;154-159). Because some procedures performed as part of an autopsy or embalming may generate infectious aerosols, special AII measures are required.

- E.8.1** Autopsies should not be performed on persons with suspected or confirmed TB disease without adequate protection for those performing the autopsy or embalming procedures.
- E.8.2** Settings where autopsies and embalming are performed should meet or exceed the requirements of an AII room if possible (Supplement 3) and Drawing VS-99-07 (160). Air should be exhausted to the outside of the building. Air-cleaning technologies, such as HEPA filtration or UVGI may be used to increase the number of equivalent ACH (Supplement 3).
- E.8.3** As an added administrative measure, when performing autopsies on persons with suspected or confirmed TB disease, coordination between attending physician(s) and pathologists for proper infection control and specimen collection should be ensured.
- E.8.4** The use of local exhaust ventilation should be considered to reduce exposures to infectious aerosols (e.g., when using a saw, including Striker saw) and vapors from embalming fluids.
- E.8.5** For HCWs performing an autopsy on a corpse with suspected or confirmed TB disease at the time of death, at least N95 disposable respirators should be worn (Supplement 4). Based on the risk assessment, consider using a higher level of respiratory protection than an N95 disposable respirator such as an elastomeric full-facepiece respirator or a PAPR (Supplement 4).
- E.8.6** After an autopsy is performed on a corpse with suspected or confirmed TB disease, allow adequate time to elapse to ensure removal of *M. tuberculosis*-contaminated room air before performing another procedure in the same room (Table S3-1, Supplement 2). If time delay is not feasible, the autopsy staff should continue to wear respirators while in the room.

Outpatient settings

Outpatient settings may include TB treatment facilities, medical settings in correctional facilities, dental-care settings, medical offices, ambulatory-care settings and dialysis units.

E.9 TB treatment facilities

TB treatment facilities may include TB clinics, infectious disease clinics, or pulmonary clinics. TB clinics and other settings where patients with TB disease and LTBI are seen on a regular basis require special attention.

- E.9.1** The same principles of triage used in emergency departments and ambulatory-care settings (Section E.12) should be applied to TB treatment facilities. These include prompt identification,

evaluation, and AII of patients with suspected or confirmed infectious TB disease.

- E.9.2** Clinics that provide care for patients with suspected or confirmed infectious TB disease should have at least one AII room. Base the need for additional AII rooms on the risk assessment for the setting.
- E.9.3** Persons with suspected or confirmed infectious TB disease should be promptly placed in an AII room to minimize exposure in the waiting room and other areas of the clinic, and they should be instructed to observe strict respiratory hygiene and cough etiquette procedures.
- E.9.4** When patients with suspected or confirmed infectious TB disease are in the TB clinic and not in an AII room, they should wear a surgical mask.
- E.9.5** Patients with suspected or confirmed infectious TB disease should be physically separated from all patients, but especially from those with HIV infection and other immunocompromising conditions that increase the likelihood of development of TB disease if exposed.
- E.9.6** Immunosuppressed patients with suspected or confirmed infectious TB disease need to be physically separated from others to protect both the patient and others. Schedule appointments to avoid exposing HIV-infected or otherwise severely immunocompromised persons to *M. tuberculosis*. Designate certain times of the day for appointments for patients with infectious TB disease, or treat them in areas where immunocompromised persons are not treated.
- E.9.7** All cough-inducing and aerosol-generating procedures should be performed using environmental controls (e.g., in a booth or an AII room) (Supplement 3). Keep patients in the booth or AII room until coughing subsides. Do not allow another patient or HCW to enter the booth or AII room until sufficient time has elapsed for adequate removal of *M. tuberculosis*-contaminated air (Table S3-1, Supplement 2).
- E.9.8** Screen all TB clinic staff for *M. tuberculosis* infection, including outreach workers (Table 2).
- E.9.9** Implement a respiratory protection program for all HCWs working in the TB clinic who enter AII rooms, visit areas where persons with suspected or confirmed TB disease are located, or transport patients with suspected or confirmed TB disease in vehicles. When the risk assessment indicates the need to wear respirators, at least an N95 disposable respirator should be worn.

E.10 Medical settings in correctional facilities

TB is a substantial health concern in correctional facilities; employees and inmates are at high risk (94;161-168). TB outbreaks in correctional facilities can lead to transmission in surrounding communities (166). ACET recommends that all correctional facilities have a written TB infection-control plan (161).

The higher risk for *M. tuberculosis* transmission in health-care settings in correctional facilities (including jails and prisons) is due to the disproportionate number of inmates with risk factors for exposure to the organism or if infected, for development of TB disease (168;169).

Compared with the general population, inmates have higher TB prevalence, associated with their higher prevalence of HIV infection, increased illicit substance use, and lower socioeconomic status (166).

Guidelines have been published about controlling the transmission of *M. tuberculosis* in correctional settings (94;161).

E.10.1 Follow the recommendations for inpatient and outpatient settings.

E.10.2 Collaborate with the state or local health department on decisions about TB contact investigations and discharge planning (94).

E.10.3 Collaborate with the state or local health department to provide TB training and education to inmates and employees (161). Corrections staff should be educated about signs and symptoms of TB disease and encouraged to facilitate prompt evaluation of inmates with suspected infectious TB disease(170).

E.10.3 Develop a TB infection-control plan that is setting-specific, even if the institution is part of a multi-facility system (161;171).

E.10.4 Correctional facilities should be classified as at least medium risk, therefore, all correctional facility health-care personnel and other staff including correctional officers who may come into contact with a person with TB disease should be screened for TB at least annually (166;168).

E.10.5 Collect sputum samples in AII rooms or sputum induction booths, not in inmates' cells. Sputum collection may also be performed safely outside, away from other people, windows and ventilation intakes.

E.10.6 Ensure the availability of at least one AII room. Any inmate with suspected or confirmed infectious TB disease should be placed in an AII room immediately, or transferred to a facility with an AII room. Base the number of additional AII rooms needed on the risk assessment for the setting.

E.10.7 Inmates with suspected or confirmed infectious TB disease who must be transported outside an AII room for medically essential procedures should wear a surgical mask during transport, if possible. Medical or security staff who transport infectious TB patients in a vehicle or who must enter AII rooms should wear respiratory protection (at least N95 disposable respirators). Implement a respiratory protection program, including training, education, and fit-testing in the correctional facility's TB infection-control program.

E.10.8 When transporting a patient with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from the rest of the vehicle, have the patient sit in the back seat, and open the windows.

E.10.9 Correctional facilities should maintain a tracking system for inmate TB screening and treatment and establish a mechanism

for sharing this information with state and local health departments and other correctional facilities (161;166).

- E.10.10** Ensure the confidentiality of inmates during screening for signs or symptoms of TB disease and risk factors.

E.11 Dental-care settings

The generation of droplet nuclei containing *M. tuberculosis* due to dental procedures has not been demonstrated (172). Nevertheless, oral manipulations during dental procedures could stimulate coughing and dispersal of infectious particles. Patients and dental HCWs share the same air space for varying periods of time which contributes to the potential for transmission of *M. tuberculosis* in dental settings (173). For example, during relatively low-risk procedures in a dental setting, MDR TB may have been transmitted to two HIV-infected dentists (174).

The following recommendations should be followed (175;176):

- E.11.1** Develop infection-control policies for each dental health-care setting based on the community TB risk assessment (Section B), and periodically review the risk assessment. The policies should include appropriate screening for LTBI and TB disease for dental HCWs, education on the risk for transmission for the dental HCWs, and provisions for detection and management of patients who have suspected or confirmed TB disease.
- E.11.2** Dental HCWs should routinely document whether the patient has a history of TB exposure or signs or symptoms of TB disease when taking a patient's initial medical history and at periodic updates.
- E.11.3** During clinical assessment and evaluation, a patient with suspected or confirmed TB disease should be instructed to observe strict respiratory hygiene and cough etiquette procedures (105) and wear a surgical mask whenever possible. Postpone non-urgent dental treatment, and promptly refer these persons to an appropriate medical facility for evaluation of possible infectiousness. Keep these patients in the dental health-care setting no longer than required to arrange a referral.
- E.11.4** If urgent dental care must be provided for a patient who has suspected or confirmed infectious TB disease, provide the dental care in a setting that meets the requirements for an AII room (Supplement 3). Use respiratory protection (at least N95 disposable respirator) while performing procedures on such patients.
- E.11.5** In dental health-care settings that routinely provide care to populations at high risk for TB disease, it may be beneficial to use engineering controls (e.g., portable HEPA units) similar to those used in waiting rooms or clinic areas of health-care settings with a comparable community-risk profile.

E.12 Medical offices and ambulatory care settings

In general, the symptoms of TB disease are symptoms for which patients might seek treatment in a medical office. Thus, it is possible that

infectious TB disease could be encountered in some medical offices and ambulatory care settings.

E.12.1 Due to the potential for *M. tuberculosis* transmission, follow the general recommendations for management of patients with suspected or confirmed TB disease as well as the specific recommendations for emergency departments (Section E.2)

E.12.2 Use the risk assessment to determine the need for or selection of environmental controls and the frequency of testing HCWs for *M. tuberculosis* infection.

E.13 Dialysis units

Some patients with TB disease need chronic dialysis for treatment of end-stage renal disease (ESRD) (177-179). The incidence of TB disease and infection in patients with ESRD may be higher than in the general population (179-181) and may be compounded by the overlapping risks of ESRD and TB disease among patients with diabetes mellitus (29). Also, some dialysis patients or patients who are otherwise immunocompromised (e.g, patients with organ transplants) may be on immunosuppressive medications (146;146;181).

E.13.1 Patients with ESRD who need chronic dialysis should have at least one baseline test for *M. tuberculosis* infection to screen for LTBI and determine the need for treatment of LTBI. Annual re-screening is indicated if ongoing exposure of ESRD patients to *M. tuberculosis* is likely. Cutaneous anergy in patients with ESRD can limit the sensitivity of TSTs (178;182) and result in a false-negative TST result.

E.13.2 Perform hemodialysis procedures on hospitalized patients with suspected or confirmed TB disease in an AII room. Dialysis staff should use recommended respiratory protection, at least an N95 disposable respirator. Patients with suspected or confirmed TB disease who need chronic hemodialysis may need referral to a hospital or other facility with the ability to perform dialysis procedures in an AII room until the patient is no longer infectious or another diagnosis is made. Some anti-TB medications are dosed differently for hemodialysis patients (23).

Non-traditional facility-based settings

Non-traditional facility- based settings include emergency medical services (EMS), home-based health-care and outreach settings, long-term care settings (e.g, hospices, skilled nursing facilities), and homeless shelters.

TB is more common in the homeless than in the general population (183-185). Since persons who visit homeless shelters often share exposure and risk characteristics of TB patients who are treated in outpatient clinics, homeless shelters with clinics should observe the same TB infection-control measures as outpatient clinics. ACET has developed recommendations to assist health-care

providers, health departments, shelter operators and workers, social service agencies, and homeless persons prevent and control TB in this population (183).

E.14 Emergency Medical Services (EMS)

Although the overall risk is low (186), documented transmission of *M. tuberculosis* has occurred in Emergency Medical Services (EMS) occupational settings (187), and approaches to reduce this risk have been described (186;188).

E.14.1 When transporting a patient with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from the rest of the emergency vehicle, have the patient sit in the back seat, and open the windows. Set the vehicle's ventilation system to non-recirculating mode to provide as much outside air as possible through the unit. Airflow should be from the cab, across the patient, and out of the vehicle. Ideally, the vehicle should have a rear exhaust fan that should be used during transport. If the vehicle is equipped with a supplemental recirculating ventilation unit that passes air through HEPA filters before returning it to the vehicle, use this unit to increase effective ACH (187).

E.14.2 When transporting a patient with suspected or confirmed infectious TB disease in a vehicle, the patient should wear a surgical mask, if possible.

E.14.3 When transporting a patient with suspected or confirmed TB disease, EMS personnel should use respiratory protection. At least N95 disposable respirators should be worn. Administrative and environmental controls cannot be ensured during emergency transport situations.

E.14.4 Include EMS personnel in a comprehensive screening program to test for *M. tuberculosis* infection and provide baseline screening and follow-up testing as indicated by the setting's risk classification. Some personnel transport patients to a variety of settings with different levels of risk; base the risk classification on the type of risk encountered most frequently.

E.14.5 Include EMS personnel in the follow-up contact investigations of patients with infectious TB. The Ryan White Comprehensive AIDS Resource Emergency Act of 1990 (PL 101-381) mandates notification of EMS personnel after they have been exposed to infectious pulmonary TB disease (42 U.S.C. 1994).

E.15 Home-based health-care and outreach settings

Transmission of *M. tuberculosis* has been documented in staff who work in home-based health-care and outreach settings (189;190).

E.15.1 The setting's infection-control plan should include training that reminds HCWs who provide medical services in the homes of patients or other outreach settings of the importance of early evaluation of signs or symptoms of TB disease to facilitate early detection and treatment of TB disease. Training should also include the role of the HCW in educating patients about the

importance of reporting signs or symptoms of TB disease, and the importance of reporting any adverse effects to treatment for LTBI or TB disease.

- E.15.2** HCWs who provide medical services in the homes of patients with suspected or confirmed TB disease can help prevent transmission of *M. tuberculosis* by: a) educating patients and other household members about the importance of taking medications as prescribed, b) facilitating medical evaluation of signs or symptoms of TB disease, and c) administering DOT, including DOT for treatment of LTBI whenever feasible.
- E.15.3** HCWs who provide medical services in the homes of patients with suspected or confirmed infectious TB disease should instruct TB patients to observe strict respiratory hygiene and cough etiquette procedures. Until such patients are no longer infectious (Supplement 1), HCWs should wear respiratory protection (at least N95 disposable respirators) when entering TB patients' homes or when transporting patients (Supplement 4).
- E.15.4** HCWs who provide medical services in the homes of patients should not perform cough-inducing procedures on patients with suspected or confirmed infectious TB disease because recommended infection controls are not likely to be in place. Sputum collection should be performed outdoors, away from other people, windows and ventilation intakes.
- E.15.5** Include HCWs who provide medical services in patients' homes in comprehensive, employer-sponsored TB training, education, and screening programs, based on the risk classifications of the site(s).
- E.15.6** When transporting a patient with suspected or confirmed infectious TB disease in a vehicle, if possible, physically isolate the cab (the front seat) from the rest of the vehicle, have the patient sit in the back seat, and open the windows.

E.16 Long-term care facilities (e.g. hospices, skilled nursing facilities)

Infection with *M. tuberculosis* poses a health risk to patients, HCWs, visitors and volunteers in these settings. Transmission of *M. tuberculosis* has occurred in long-term care facilities (191-194), and pulmonary TB disease has been documented in HIV-infected patients and other immunocompromised persons residing in hospices (192;195;196). New residents to these settings should receive a symptom screen and possibly a test for *M. tuberculosis* infection to exclude a diagnosis of TB disease. A symptom screen is a procedure used during a clinical evaluation in which the patient is asked if they have experienced any signs or symptoms of TB disease.

- E.16.1** Long-term care facilities must have adequate administrative and environmental controls including AII and a respiratory protection program to accept patients with suspected or confirmed infectious TB disease.
- E.16.2** The setting should have a written protocol for the early identification of patients with signs or symptoms of TB disease and procedures for referring these patients to a setting where they can be evaluated and managed.

- E.16.3** Patients with suspected or confirmed infectious TB disease should not stay in long-term care facilities unless adequate administrative and environmental controls and a respiratory protection program are in place.
- E.16.4** Persons with TB disease who are determined to be noninfectious may remain in the long-term care facility and do not need to be in AII.

F. Training and Education of HCWs

HCW training and education about infection with *M. tuberculosis* and TB disease is an essential part of administrative controls in a TB screening program. HCW training and education can increase adherence to TB infection-control measures. Training and education should emphasize the increased risks posed by an undiagnosed person with TB disease in a health-care setting and the specific measures to reduce this risk. HCWs receive many different types of training, and therefore it may be preferable to combine training for TB infection control with other related trainings.

F.1 Initial TB training and education

- F.1.1** The setting should document that all HCWs, including physicians, have received initial TB training relevant to their work setting and additional occupation-specific education. The level and detail of baseline training will vary according to the responsibilities of the HCW and the risk classification of the setting.

Educational materials on TB training are available from a variety of sources at no cost in hard copy, on videotape (197), on compact discs and on-line. The state or local health department should have additional access to materials and resources, and may be able to help develop a setting-specific TB education program. Suggested components of a baseline TB training program for HCWs are provided in Table 6. CDC's TB website provides access to training and education materials (at www.cdc.gov/tb, under Education/Training Materials). Additional training and education materials may be found on the TB Education and Training Resources Website (www.findtbresources.org). Supplement 7 of this document lists other TB-related websites and resources.

- F.1.2** Physicians, trainees, students, and other HCWs who work in a health-care setting but do not receive payment from that setting should receive baseline training in TB infection-control policies and practices, the TB screening program, and reporting procedures for a *M. tuberculosis* infection test conversion or diagnosis of TB disease.
- F.1.3** Initial TB training should be provided prior to the HCW starting duties.

F.2 Follow-up TB training and education

- F.2.1** The Occupational Safety and Health Administration (OSHA) requires annual respiratory protection training for HCWs who use respiratory devices (Supplement 4). HCWs in settings with a classification of *potential ongoing transmission* should receive

additional training and education on: a) signs and symptoms of TB disease, b) *M. tuberculosis* transmission, c) infection-control policies, d) importance of TB screening for HCWs, and e) responsibilities of employers and employees regarding *M. tuberculosis* infection test conversion and diagnosis of TB disease.

F.2.2 All settings should conduct an annual evaluation of the need for follow-up training and education for HCWs based on the number of untrained and new HCWs, changes in the organization and services of the setting, and availability of new TB infection-control information.

F.2.3 If a potential or known exposure to *M. tuberculosis* occurs in the setting, prevention and control measures should include retraining of HCWs in the infection-control procedures established to prevent the recurrence of exposure.

F.2.4 If a potential or known exposure results in a newly recognized positive TST or QFT result, test conversion, or diagnosis of TB disease, education might include information on a) transmission of *M. tuberculosis*, b) noninfectiousness of HCWs with LTBI, and c) potential infectiousness of HCWs with TB disease. HCWs may return to work when they a) have had three negative AFB sputum smear results (108-111) collected 8–24 hours apart with at least one being an early morning specimen (because respiratory secretions pool overnight), b) have responded to anti-TB treatment that is likely to be effective based on susceptibility results, **and** c) the HCW is determined to be noninfectious. Consideration should also be given to the type of setting and the potential risk to patients (e.g., general medical office versus HIV clinic) (Supplements 1 and 2).

Table 6. Suggested components of an initial TB training and education program for health-care workers (HCWs)

Clinical information

- Basic concepts of *M. tuberculosis* transmission, pathogenesis, and diagnosis, including the difference between LTBI and TB disease and the possibility of reinfection after previous infection with *M. tuberculosis* or TB disease
- Signs and symptoms of TB disease and the importance of a high index of suspicion for patients or HCWs with these symptoms
- Indications for initiation of AII of inpatients with suspected or confirmed TB disease
- Policies and indications for discontinuing AII precautions
- Principles of treatment for LTBI and for TB disease (indications, use, effectiveness, potential adverse effects)

Epidemiology of TB

- Epidemiology of TB in the local community, in the United States, and worldwide
- Risk factors for TB disease

*Infection-control practices to prevent and detect *M. tuberculosis* transmission in health-care settings*

- Overview of the TB infection-control program
- Potential for occupational exposure to infectious TB disease in health-care settings
- Principles and practices of infection control to reduce the risk for transmission of *M. tuberculosis*, including the hierarchy of TB infection-control measures, written policies and procedures, monitoring, and control measures for HCWs at increased risk for exposure to *M. tuberculosis*

- Rationale for infection-control measures and documentation evaluating the effect of these measures in reducing occupational TB risk exposure and *M. tuberculosis* transmission
- Reasons for testing for *M. tuberculosis* infection, significance of a positive test for *M. tuberculosis* infection, importance of participation in a TB screening program, and importance of retaining documentation of previous test for *M. tuberculosis* infection, chest radiograph results and treatment for LTBI and TB disease
- Efficacy and safety of BCG vaccination and principles of screening for *M. tuberculosis* infection and interpretation in BCG recipients
- Procedures for investigating a *M. tuberculosis* infection test conversion or TB disease occurring in the workplace
- Joint responsibility of HCWs and employers to ensure prompt medical evaluation after *M. tuberculosis* test conversion or development of signs or symptoms of TB disease in HCWs
- Role of HCW in preventing transmission of *M. tuberculosis*
- Responsibility of HCWs to promptly report a diagnosis of TB disease to the setting's administration and infection-control program
- Responsibility of clinicians and the infection-control program to report a suspected case of TB disease in a patient (including autopsy findings) or HCW to the state or local health department
- Responsibilities and policies of the setting, the local health department, and the state health department to ensure confidentiality for HCWs with TB disease or LTBI
- Responsibility of the setting to inform EMS staff who transported a patient with suspected or confirmed TB disease
- Responsibilities and policies of the setting to ensure that an HCW with TB disease is noninfectious before returning to duty
- Importance of completing therapy for LTBI or TB disease to protect the HCW's health and to reduce the risk to others
- Proper implementation and monitoring of environmental controls (Supplement 3)
- Training for safe collection, management, and disposal of clinical specimens
- OSHA required record-keeping on HCW *M. tuberculosis* infection test conversions
- Record-keeping and surveillance of TB cases among patients in the setting
- Proper use of respiratory protection (Supplement 4) and the need to inform the infection-control program of factors that might affect the efficacy of respiratory protection as required by OSHA
- Success of adherence to infection-control practices in decreasing the risk for transmission of *M. tuberculosis* in health-care settings

TB and immunocompromising conditions

- Relationship between infection with *M. tuberculosis* and medical conditions and treatments that can lead to impaired immunity
- Available tests and counseling and referral locations for HIV infection, diabetes, and other immunocompromising conditions associated with an increased risk for progression to TB disease
- Procedures for informing employee health or infection-control personnel of medical conditions associated with immunosuppression
- Policies on voluntary work reassignment options for immunocompromised HCWs
- Applicable confidentiality safeguards of the health-care setting, locality, and state

TB and public health

- Role of the state and local health department's TB control program in screening for LTBI and TB disease, providing treatment, conducting contact investigations and outbreak investigations, and providing education, counseling, and responses to public inquiries
- Roles of CDC, including the National Institute for Occupational Safety and Health (NIOSH) and of OSHA
- Availability of information, advice, and counseling from community sources, including universities, local experts, and hotlines
- Responsibility of the setting's clinicians and infection-control program to promptly report a case of suspected TB disease or a cluster of TST conversions to the state or local health department

- Responsibility of the setting's clinicians and infection-control program to promptly report to the state or local health department a person with suspected or confirmed TB disease who leaves the setting against medical advice
-

G. HCW screening programs for TB support surveillance and clinical care

TB screening programs provide information that is important in caring for individual HCWs and information that facilitates detection of *M. tuberculosis* transmission. The screening program consists of four main components, 1) baseline testing for *M. tuberculosis* infection, 2) serial testing for *M. tuberculosis* infection, 3) serial screening for signs or symptoms of TB disease, and 4) TB training and education.

Surveillance data from HCWs can protect both HCWs and patients. Screening can prevent future transmission by identifying lapses in infection control and expediting treatment for persons with LTBI or TB disease. Tests to screen for *M. tuberculosis* infection should be administered, interpreted, and recorded according to the procedures detailed in Supplement 2. Protection of privacy and maintenance of confidentiality of HCW test results should be ensured. Methods to screen for infection with *M. tuberculosis* are available: e.g., TST and Quanti-FERON test (QFT).

G.1 Baseline testing for *M. tuberculosis* infection: TST or QFT

Baseline testing for *M. tuberculosis* infection is recommended for all newly hired HCWs who might have contact with persons with suspected or confirmed infectious TB disease, regardless of the risk classification of the setting. In a small number of settings, there may be a choice not to perform baseline TB screening or serial TB screening for HCWs who will **never** be in contact with, or have shared air space with patients who have TB disease (e.g., telephone operators who work in a separate building from patients), or who will never be in contact with clinical specimens that may contain *M. tuberculosis*. Baseline test results provide a basis for comparison in the event of a potential or known exposure to *M. tuberculosis* and facilitate the detection and treatment of LTBI or TB disease in an HCW before employment begins and reduces the risk to patients and other HCWs. Baseline testing can be conducted with either the TST or the QFT.

G.1.1 If TST is used and if the baseline first-step TST result is positive, TB disease should be excluded, and if excluded, then the HCW should be evaluated for treatment of LTBI. Two-step testing is recommended for HCWs whose initial TST result is negative (e.g., < 10 mm for most HCWs). If the first step TST result is negative, the second step TST should be administered 1–3 weeks after the first TST was administered. A second TST is needed at baseline because injection of PPD for the initial TST may “boost” responses to subsequent tests. If the second TST result is also negative, the person is classified as negative.

A positive result to the second step of a two-step TST is likely due to boosting as opposed to recent infection with *M. tuberculosis*. These responses may result from remote infections with *M. tuberculosis*, infection or exposure to nontuberculous mycobacteria (NTM), also

known as mycobacteria other than TB (MOTT), or previous BCG vaccination. Two-step testing will minimize the possibility that boosting will lead to an unwarranted suspicion of transmission of *M. tuberculosis* in the setting during a later contact investigation. A second TST is not needed if the HCW has a documented TST result from any time during the previous 12 months (G.2).

G.1.1.1 Perform and document the baseline two-step TST results before the employee begins work (preferably) or within ten days of beginning work.

G.1.1.2 If the second test of a two-step TST result is not read within 48–72 hours, administer a third test as soon as possible (even if many months have passed) and ensure that the result is read within 48–72 hours (29). A positive TST reaction may still be measurable up to seven days after testing (198). However, if a patient fails to return in 72 hours and has a negative test result, the TST should be repeated (30).

G.1.1.3 A previous TST is not a contraindication to a subsequent TST unless the test was associated with severe ulceration or anaphylactic shock, which are very rare adverse events (22;199;200). Multiple TSTs are safe and do not increase the risk for a false-positive result or a TST conversion in persons without exposure to mycobacteria (29).

G.1.2 TST reactivity due to the administration of BCG at birth or in early childhood wanes over the course of 10–15 years. Thus, many HCWs with previous BCG vaccination will have a negative test result for *M. tuberculosis* infection (66;201-206). Because HCWs with a history of BCG are often from high TB-prevalence countries, positive test results for *M. tuberculosis* infection in HCWs with previous BCG vaccination should be interpreted as representing infection with *M. tuberculosis* (66;201-206). Although BCG reduces the occurrence of severe forms of TB disease in children and overall may reduce the risk for progression from LTBI to TB disease (207;208), BCG does not prevent *M. tuberculosis* infection(209). Test results for *M. tuberculosis* infection for HCWs **with** a history of BCG should be interpreted using the same diagnostic cut points used for HCWs **without** a history of BCG vaccination.

G.1.3 If using the QFT for baseline testing of HCWs, including those in low-risk settings, one negative QFT result is sufficient to demonstrate that the HCW is not infected with *M. tuberculosis*. Perform and document the baseline QFT result, preferably prior to the HCW starting duties. HCWs with *conditionally positive* and *positive* baseline QFT results should be evaluated for LTBI and TB disease. This evaluation should include a TST if no other risks of *M. tuberculosis* infection are identified (100).

G.2 Baseline testing for *M. tuberculosis* infection after TST within the past 12 months

G.2.1 A second TST is not needed if the HCW has a documented TST result from any time during the previous 12 months. If a newly employed HCW has had a documented negative TST result within the past 12 months, a single TST may be administered in the new setting (Table S2-4). This additional TST represents the

second stage of two-step testing. The second test decreases the possibility that boosting on later testing will lead to incorrect suspicion of transmission of *M. tuberculosis* in the setting.

G.2.2 A recent TST (<1 year) is not a contraindication to a subsequent TST unless the test was associated with severe ulceration or anaphylactic shock, which are very rare adverse events (22;199;200).

G.2.3 A recent TST (<1 year) may boost subsequent QFT responses. As with the two-step TST, a positive QFT result after a recent TST should be interpreted with caution. A negative QFT result is sufficient evidence that the HCW is not infected with *M. tuberculosis*.

G.3 Baseline documentation of a history of TB disease, a previously positive test result for *M. tuberculosis* infection, or completion of treatment for LTBI or TB disease

G.3.1 It is not necessary to perform additional tests for *M. tuberculosis* infection on HCWs with a **documented** history of TB disease, **documented** previously positive test result for *M. tuberculosis* infection, or **documented** completion of treatment for LTBI or TB disease. Documentation of a previously positive test result for *M. tuberculosis* infection may substitute for a baseline test if the documentation includes a recorded TST result in mm, or if a percent human response QFT result is recorded.

G.3.2 All other HCWs should undergo baseline testing for *M. tuberculosis* infection to ensure that the test result on record in the setting has been performed and measured using the procedures detailed in Supplement 2.

G.3.3 A recent TST (<1 year) is not a contraindication to the administration of an additional test unless the TST was associated with severe ulceration or anaphylactic shock, which are very rare adverse events (22;199;200). However, the recent test may complicate interpretation of subsequent test results due to the possibility of boosting. QFT should be used in instances where the TST has resulted in a severe adverse reaction.

G.4 Serial follow-up of TB screening and testing for *M. tuberculosis* infection

G.4.1 The need for serial follow-up screening for groups of HCWs with negative test results for *M. tuberculosis* infection is an institutional decision that is based on the setting's risk classification. This decision and changes over time based on updated risk assessments should be official and documented.

G.4.2 HCWs with a documented previously positive test result for *M. tuberculosis* infection should have symptom screening annually instead of participating in serial skin testing. HCWs with a baseline positive or newly positive TST result should receive one chest radiograph to exclude a diagnosis of TB disease. After this baseline chest radiograph is performed and the result is documented, repeat radiographs are not needed unless signs or symptoms of TB disease develop, or a clinician recommends a

repeat chest radiograph (29;101) or as part of a contact investigation.

G.4.3 If a serial follow-up screening program is required, the risk assessment for the setting (Section II.B) will determine which HCWs should be included in the program and the frequency of screening. Two-step TST testing should not be performed for follow-up testing.

G.4.4 If possible, stagger follow-up screening (rather than testing all HCWs at the same time each year) so that all HCWs who work in the same area or profession are not tested in the same month. Staggered screening of HCWs (e.g., on the anniversary of their employment or on their birthdays) increases opportunities for early recognition of infection-control problems that can lead to conversions in test results for *M. tuberculosis* infection.

G.5 **HCWs with a newly recognized positive test for *M. tuberculosis* infection or signs or symptoms of TB disease**

G.5.1 Clinical evaluation

G.5.1a Exclude a diagnosis of TB disease in any HCW with a newly recognized positive test for *M. tuberculosis* infection result or test conversion and in any HCW with signs or symptoms of TB disease. Arrange with employee health, the state or local health department, or a personal physician for evaluation of HCWs with suspected TB disease. Any physicians who evaluate HCWs with suspected TB disease should be familiar with current diagnostic and therapeutic guidelines for LTBI and TB disease (23;29).

G.5.1b Promptly evaluate any HCW with a newly recognized positive test result for *M. tuberculosis* infection or test conversion. The definitions for positive test results for *M. tuberculosis* infection and test conversion in HCWs are found in Supplement 2. Symptoms of disease in the lung, pleura, or airways including larynx include coughing ≥ 3 weeks, loss of appetite, unexplained weight loss, night sweats, bloody sputum or hemoptysis, hoarseness, fever, fatigue, or chest pain. The evaluation should include a clinical examination and symptom screen (a procedure used during a clinical evaluation in which the patient is asked if they have experienced any signs or symptoms of TB disease), a chest radiograph, and collection of sputum specimens.

G.5.1c If TB disease is diagnosed, begin anti-TB therapy immediately according to published guidelines (23). The diagnosing clinician (who may or not be a physician with the institution's infection-control program) should notify the state or local health department in accordance with disease reporting laws, which generally specify a 24-hour time limit.

- G.5.1d** If TB disease is excluded, offer the HCW treatment for LTBI in accordance with published guidelines (29;210) (See Supplement 2). If the HCW has already completed treatment for LTBI and is part of a TB screening program, a symptom review should be performed instead of testing for LTBI.
- G.5.1e** Providers who medically evaluate HCWs with baseline two-step test results who are at otherwise at low risk for LTBI may choose a 15 mm induration cut point in interpreting a positive TST result; however, HCWs who have an increase of ≥ 10 mm induration on follow-up testing, given a previously negative baseline or follow up test result, even who are at low risk, probably have acquired *M. tuberculosis* infection and should be evaluated for TB disease, and when disease is excluded, treated for LTBI unless medically contraindicated (29;210).

G.5.2 Chest radiography

- G.5.2a** For newly hired HCWs with documentation of a history of TB disease, a previously positive test for *M. tuberculosis* infection, or completion of treatment for LTBI or TB disease, infection-control physicians may recommend performing a baseline chest radiograph to document the history of disease or confirm the current inactive status. The baseline chest radiograph may be useful for comparison with later films.
- G.5.2b** HCWs with a baseline positive or newly positive TST result should receive one chest radiograph to exclude a diagnosis of TB disease. After this baseline chest radiograph is performed and the result is documented, repeat radiographs are not needed unless signs or symptoms of TB disease develop, or a clinician recommends a repeat chest radiograph (29;101) or as part of a contact investigation. Instead of participating in serial skin testing, HCWs with a positive test result for *M. tuberculosis* infection should receive a symptom screen. The frequency of this symptom screen should be determined by the risk classification for the facility.
- G.5.2c** Serial follow-up chest radiographs are not recommended for HCWs with documentation of a previously positive test result for *M. tuberculosis* infection, treatment for LTBI, or treatment for TB disease, or for asymptomatic HCWs with negative test results for *M. tuberculosis* infection.
- G.5.2d** HCWs who have a previously positive test result for *M. tuberculosis* infection and who change jobs should carry documentation of a baseline chest radiograph result (and the positive test result for *M. tuberculosis* infection) to their new employers.

G.5.3 Workplace restrictions

- G.5.3a** HCWs with a newly recognized positive test result for *M. tuberculosis* infection should be evaluated by a physician as soon as possible. Standing orders for chest radiographs in the case of a newly recognized positive test result for *M. tuberculosis* infection and standard procedures for prompt communication with the state or local health department can facilitate prompt evaluation. Keep symptomatic HCWs away from the workplace until a diagnosis of TB disease is excluded. If TB disease is diagnosed, the HCWs with TB disease should be allowed to return to work when they 1) have had three negative AFB sputum smear results (108-111) collected 8–24 hours apart with at least one being an early morning specimen (because respiratory secretions pool overnight), 2) have responded to anti-TB treatment that is likely to be effective based on susceptibility results, **and** 3) the HCW is determined to be noninfectious (Supplements 1 and 2).
- G.5.3b** Asymptomatic HCWs do not need to be excluded from the workplace but should be completely evaluated within ten days of starting employment.
- G.5.3c** HCWs with suspected or confirmed infectious pulmonary, laryngeal, endobroncheal or tracheal TB disease or a draining tuberculous skin lesion pose a risk to patients, HCWs and other persons, and should be excluded from the workplace until they are documented to be noninfectious (Supplements 1 and 2).
- G.5.3d** HCWs with TB disease in sites other than those listed above (extrapulmonary TB disease) usually do not need to be excluded from the workplace. They may be confirmed as noninfectious and may continue to work based on evidence that concurrent pulmonary TB disease has been excluded.
- G.5.3e** Once TB disease is excluded, no risk for transmission of *M. tuberculosis* to other HCWs or patients exists, and the HCW may return to work with no restrictions. HCWs receiving treatment for LTBI may return to work immediately.
- G.5.3f** HCWs with LTBI who cannot take or do not accept or complete a full course of treatment for LTBI should not be excluded from the workplace. They should be counseled about the risk for developing TB disease and instructed to seek prompt evaluation if signs or symptoms of TB disease develop. If serial follow-up screening is required in the setting (if the setting is classified as *medium risk*), these HCWs should receive a symptom screen annually and should be offered treatment for LTBI again unless medically

contraindicated(29). HCWs with signs or symptoms of TB disease should be referred for further medical evaluation.

G.5.3g HCWs who have a documented positive TST result and who leave employment should be counseled about the risk for developing TB disease and instructed to seek prompt evaluation if symptoms of TB disease develop. This information should be recorded in the HCWs employee health record when they leave employment.

G.5.4 Identification of source cases and recording of drug-susceptibility patterns

G.5.4a If an HCW has a conversion in a test result for *M. tuberculosis* infection, evaluate the HCW for a history of suspected or known exposure to *M. tuberculosis* to determine the potential source.

G.5.4b When the source case is known, identify the drug-susceptibility pattern of the *M. tuberculosis* isolate from the source. Record the drug-susceptibility pattern in the HCW's medical or employee health record to guide the treatment of LTBI or TB disease, if indicated.

G.6 HCWs with medical conditions associated with increased risk for progression to TB disease

HIV infection is the highest risk factor for progression from LTBI to TB disease (29). Other immunocompromising conditions, including diabetes mellitus, some cancers, and some drug treatments, also increase the risk for rapid progression from LTBI to TB disease. TB disease can also adversely affect the clinical course of HIV infection and AIDS, and can complicate HIV treatment (23;29;40). HCWs who are severely immunocompromised require special precautions.

G.6.1 Serial TB screening beyond that indicated by the risk classification for the setting is not indicated for persons with medical conditions that suppress the immune system or otherwise increase the risk for infection with *M. tuberculosis* progressing to TB disease. All HCWs should, however, be encouraged during their initial TB training to learn if they have a medical condition and should be aware that receiving medical treatment can impair cell-mediated immunity. HCWs should be informed about the availability of counseling, testing and referral for immunocompromising conditions(37;38).

G.6.2 HCWs should know whether they are immunocompromised, and they should be aware of the risks from exposure to *M. tuberculosis* (1). In some cases, reassignment to areas where exposure is minimized or nonexistent may be medically advisable or desirable. Immunocompromised HCWs should have the option of an assignment in an area or activity that has a low risk for exposure to *M. tuberculosis*. This choice is a personal

decision for the immunocompromised HCW (211) (<http://www.eeoc.gov/laws/ada.html>). Health-care facilities should provide education and follow infection-control recommendations (62).

- G.6.3** Information provided by HCWs on their immune status and requests for voluntary work assignments should be treated confidentially, according to written procedures on the confidential handling of such information. All HCWs should be aware of these procedures at the time of employment and during initial TB training and education.

H. Problem Evaluation

Contact investigations may be initiated in response to a) conversions in test results in HCWs for *M. tuberculosis* infection, b) diagnosis of TB disease in an HCW, c) suspected person-to-person transmission of *M. tuberculosis*, d) lapses in TB infection-control practices that expose HCWs and patients to *M. tuberculosis*, or e) possible TB outbreaks identified using automated laboratory systems (212).

In these situations, the objectives of a contact investigation may be to a) determine the likelihood that transmission of *M. tuberculosis* has occurred, b) determine the extent of *M. tuberculosis* transmission, c) identify persons who were exposed and, if possible, the source(s) of potential transmission, d) identify factors that could have contributed to transmission, including failure of environmental infection-control measures, failure to follow infection-control procedures, or inadequacy of current measures or procedures, e) implement recommended interventions, f) evaluate the effectiveness of the interventions, and g) ensure that exposure to *M. tuberculosis* has been terminated and that the conditions leading to exposure have been eliminated.

Earlier recognition of a setting in which *M. tuberculosis* transmission has occurred could be facilitated through innovative approaches to TB contact investigations such as network analysis and through genetic typing of isolates. Network analysis makes use of information such as shared locations within a facility that may not be collected in traditional TB contact investigations (34). This type of information may be useful during contact investigations involving hospitals or correctional settings, to identify any shared wards, hospital rooms, or cells. Genotyping of isolates is universally available in the United States and is a useful adjunct in the investigation of *M. tuberculosis* transmission (33). Because the situations prompting an investigation are likely to vary, investigations should be tailored to the individual circumstances. The following recommendations provide general guidance for conducting contact investigations.

H.1 General recommendations for investigating conversions in test results for *M. tuberculosis* infection in HCWs

- H.1.1** Problem evaluation during contact investigations should be accomplished through cooperation between infection-control personnel, occupational health, and the state or local TB control program.
- H.1.2** If a test conversion in an HCW is detected as a result of serial screening and the source is not apparent, conduct a contact

investigation to determine the probable source and the likelihood that transmission occurred in the health-care setting (99).

H.1.3 Identify and correct lapses in TB infection control that may have contributed to the transmission of *M. tuberculosis*.

H.1.4 Record and report *M. tuberculosis* infection test conversions and TB disease among HCWs according to OSHA requirements (www.osha.gov/recordkeeping). Consult OSHA standard 29 Code of Federal Regulations (CFR) 1904, *Recording and Reporting Occupational Injuries and Illness*, to determine recording and reporting requirements (213).

H.2 Investigating an *M. tuberculosis* infection test conversion with a probable source outside the health-care setting

H.2.1 If an *M. tuberculosis* infection test conversion in an HCW is detected, and exposure *outside* the health-care setting has been documented by the corresponding state or local health department, terminate the investigation within the health-care setting.

H.3 Investigating an *M. tuberculosis* infection test conversion with a known source in the health-care setting

H.3.1 An *M. tuberculosis* infection test conversion should be reported to the state or local health department and investigation of the conversion should be done in collaboration with the state or local health department. If an *M. tuberculosis* infection test conversion in an HCW is detected and the HCW's history does not suggest exposure outside the health-care setting but does identify a probable source in the setting

H.3.1a Identify and evaluate close contacts of the suspected source case. Contacts may include other patients and visitors.

H.3.1b Determine possible reasons for the exposure.

H.3.1c Implement interventions to correct the lapse(s) in infection control.

H.3.1d Immediately screen HCWs and patients if they were close contacts to the source case.

For exposed HCWs and patients in a setting which has chosen to use screen for infection with *M. tuberculosis* using the TST

- Administer a symptom screen
- Administer a TST to those who had previously negative TST results. (A two-step baseline TST should **not** be performed in contact investigations.)
- If the initial TST result is negative, repeat the TST and symptom screen 8–10 weeks after the end of exposure.

- If the symptom screen or the initial or 8–10 week follow-up TST result is positive, the exposed person should be promptly evaluated for TB disease, including a chest radiograph.
- If TB disease is excluded, further medical and diagnostic evaluation for LTBI is needed, which includes a judgment about the extent of exposure.

For exposed HCWs and patients in a setting which has chosen to use screen for infection with *M. tuberculosis* using the QFT

- Administer a symptom screen
- Administer a QFT
- Although QFT is not currently recommended for detecting *M. tuberculosis* infection when TB disease is suspected, a QFT conversion is most likely indicative of recent *M. tuberculosis* infection, and therefore, TB disease must be excluded.
- TST may be needed in those who have negative QFT results to further screen for TB disease.
- If the symptom screen or the QFT result is positive, the exposed person should be promptly evaluated for TB disease, including a chest radiograph.
- If TB disease is excluded, further medical and diagnostic evaluation for LTBI is needed, which includes a judgment about the extent of exposure.
- A TST may contribute to this medical evaluation in persons who are otherwise at low risk for LTBI. If the first TST result after the exposure is negative, repeating the TST and symptom screen 8–10 weeks after the end of exposure may be helpful..

H.3.1e If no additional conversions in the test results for *M. tuberculosis* are detected on follow-up testing, terminate the investigation.

H.3.2 If additional conversions in the tests for *M. tuberculosis* are detected on follow-up testing, implement a classification of *potential ongoing transmission* for that specific setting or group of HCWs. Transmission might still be occurring and additional actions are needed:

H.3.2a Promptly report the initial cluster of test conversions to the state or local health department.

H.3.2b Reassess possible reasons for exposure and transmission.

H.3.2c Evaluate the degree of adherence to the interventions implemented.

H.3.2d Repeat testing for *M. tuberculosis* infection 8–10 weeks after the end of exposure for HCW contacts who previously had negative test results.

H.3.2e Expand the circle of contacts to include others who may have been exposed.

H.3.2f If no additional TST conversions are detected on the second round of follow-up testing, terminate the investigation.

H.3.3 If additional TST conversions are detected on the second round of follow-up testing, maintain a classification of *potential ongoing transmission* and consult the state or local health department or other persons with expertise in TB infection control for assistance.

H.3.4 **The classification of *potential ongoing transmission* should be used as a temporary classification only.** It warrants immediate investigation and corrective steps; after it has been determined that ongoing transmission has ceased, the setting should be reclassified as *medium risk*. It is recommended to maintain the classification of *medium risk* for at least one year.

H.4 Investigating an *M. tuberculosis* infection test conversion in an HCW with an unknown exposure

H.4.1 If an *M. tuberculosis* infection test conversion in an HCW is detected and the HCW's history does not suggest exposure outside the health-care setting and does not identify a probable source of exposure in the setting, further investigation to identify a probable source in the health-care setting is warranted.

H.4.2 If no source case is identified, estimate the interval during which the HCW may have been infected. Generally, this is 8–10 weeks before the most recent negative *M. tuberculosis* infection test result through two weeks before the first positive *M. tuberculosis* infection test result (i.e., a conversion in *M. tuberculosis* infection test).

H.4.3 Review laboratory and infection-control records to identify all patients (and any HCWs) who have or had suspected or confirmed infectious TB disease and who may have transmitted *M. tuberculosis* to the HCW.

H.4.4 If the investigation identifies a likely source:

H.4.4a Identify and evaluate contacts of the suspected source. Close contacts are the highest priority for screening.

For presumed exposed HCWs and patients in a setting which has chosen to use screen for infection with *M. tuberculosis* using the TST

- Administer a symptom screen
- Administer a TST to those who had previously negative TST results. (A two-step baseline TST should **not** be performed in contact investigations.)

- If the initial TST result is negative, repeat the TST and symptom screen 8–10 weeks after the end of exposure.
- If the symptom screen or the initial or 8–10 week follow-up TST result is positive, the presumed exposed person should be promptly evaluated for TB disease, including a chest radiograph.
- If TB disease is excluded, further medical and diagnostic evaluation for LTBI is needed, which includes a judgment about the extent of exposure.

For presumed exposed HCWs and patients in a setting which has chosen to use screen for infection with *M. tuberculosis* using the QFT

- Administer a symptom screen
- Administer a QFT
- Although QFT is not currently recommended for detecting *M. tuberculosis* infection when TB disease is suspected, a QFT conversion is most likely indicative of recent *M. tuberculosis* infection, and therefore, TB disease must be excluded.
- TST may be needed in those who have negative QFT results to further screen for TB disease.
- If the symptom screen or the QFT result is positive, the presumed exposed person should be promptly evaluated for TB disease, including a chest radiograph.
- If TB disease is excluded, further medical and diagnostic evaluation for LTBI is needed, which includes a judgment about the extent of exposure.
- A TST may contribute to this medical evaluation in persons who are otherwise at low risk for LTBI. If the first TST result after the exposure is negative, repeating the TST and symptom screen 8–10 weeks after the end of exposure may be helpful.

H.4.4b Determine possible reasons for the exposure and transmission.

H.4.4c Implement interventions to correct the lapse(s).

H.4.5 If the investigation does not identify a likely source

H.4.5a If serial TB screening is performed in the setting, review the results of screening of other HCWs in the same area of the health-care setting or same occupational group.

H.4.5b If serial TB screening is not performed in the setting or if insufficient numbers of recent results are available,

conduct additional TB screening of other HCWs in the same area or occupational group.

- H.4.6** If the review and screening yield no additional conversions, then no evidence to indicate health-care–associated transmission exists and the investigation should be terminated. Whether HCW conversions resulted from exposure in the setting or elsewhere or whether true infection with *M. tuberculosis* has even occurred is uncertain. However, the absence of other data implicating health-care–associated transmission suggests that the conversion could have resulted from a) unrecognized exposure to *M. tuberculosis* outside the health-care setting, b) cross-reactivity with another antigen such as BCG or nontuberculous mycobacteria (NTM; also known as MOTT) or c) errors in applying, reading, or interpreting the test result for *M. tuberculosis* infection.
- H.4.7** If the review and screening identify additional TST conversions, health-care–associated transmission is more likely.
 - H.4.7a** Evaluate the patient identification process, TB infection-control policies and practices, and environmental controls to identify lapses that could have led to exposure and transmission.
 - H.4.7b** If no problems are identified, implement a classification of *potential ongoing transmission*, and consult the state or local health department or other persons with expertise in TB infection control for assistance.
 - H.4.7c** If problems are identified, implement recommended interventions and repeat testing for *M. tuberculosis* infection 8–10 weeks after the end of exposure for HCWs with negative test results.
 - H.4.7d** If no additional test conversions are detected on follow-up testing, terminate the investigation.
- H.4.8** If additional conversions in test results for *M. tuberculosis* infection are detected on follow-up testing:
 - H.4.8a** Maintain a classification of *potential ongoing transmission*.
 - H.4.8b** Reassess possible reasons for exposure and transmission.
 - H.4.8c** Evaluate the appropriateness of and degree of adherence to the interventions implemented.
 - H.4.8d** Repeat testing for *M. tuberculosis* infection 8–10 weeks after the end of exposure for HCWs with negative test results.
 - H.4.8e** Consult the state or local health department or other persons with expertise in TB infection control.
 - H.4.8f** If no additional conversions are detected on this second round of follow-up testing, terminate the investigation.
 - H.4.8g** If additional conversions are detected, continue a classification of *potential ongoing transmission* and consult the state or local health department or other persons with expertise in TB infection control.
 - H.4.8h** **The classification of *potential ongoing transmission* should be used as a temporary classification only.** It warrants immediate investigation and corrective steps;

after it has been determined that ongoing transmission has ceased, the setting should be reclassified as *medium risk*. It is recommended to maintain the classification of *medium risk* for at least one year.

H.5 Investigating a case of TB disease in an HCW

- H.5.1** When confidentiality laws prevent the state or local health department from communicating information regarding a patient's identity, staff at the hospital should work with its legal counsel and the HCW to determine how the hospital may be notified without breaching confidentiality.
- H.5.2** Occupational health services and other physicians in the setting should have procedures for immediately notifying the local administrators or infection-control personnel if an HCW is diagnosed with TB disease so that a problem evaluation can be initiated.
- H.5.3** If an HCW is diagnosed with TB disease and does not have a previously documented positive test for *M. tuberculosis* infection, conduct an investigation to identify the probable sources and circumstances for transmission (Recommendations, H1).
- H.5.4** If an HCW is diagnosed with TB disease, regardless of previous test status, an additional investigation must be conducted to ascertain whether *M. tuberculosis* was transmitted from this HCW to others, including other HCWs, patients and visitors.
 - H.5.4a** Determine the potential infectiousness of the HCW and, if potentially infectious, the likely period of infectiousness (Recommendations, H.7.2d).
 - H.5.4b** Conduct an investigation that includes: 1) identification of contacts (e.g., other HCWs, patients, visitors), 2) evaluation of contacts for LTBI and TB disease, and 3) notification of the state or local health department for consultation and investigation of community contacts who were exposed outside the health-care setting.
- H.5.5** *M. tuberculosis* genotyping may be performed such that the results are promptly available and they are useful adjuncts to epidemiologically based public health investigations of contacts and possible source cases, especially in sorting out the role of laboratory contamination. Most data support the role of genotyping (50;150;214-228).

H.6 Investigating possible patient-to-patient transmission of *M. tuberculosis*

- H.6.1** Routinely record information about TB cases among patients in the setting for risk classification and risk assessment purposes. Documented information by location and date should include results of sputum smear, chest radiograph, culture, drug-susceptibility testing, and adequacy of infection-control measures.

- H.6.2** Each and every case of TB that transits through a health care-associated setting (not just those diagnosed) should prompt an assessment by the infection-control team, while the patient is still in the setting or, if the discovery is made after discharge, shortly thereafter. The assessment should focus on 1) a determination of infectiousness of the patient, 2) confirmation of compliance with local public health reporting requirements (including the prompt reporting of a person with suspected TB disease as required), and 3) assessment of the adequacy of infection control.

A contact investigation should be initiated in situations where infection control is deemed to be inadequate and the patient is infectious. Patients with AFB sputum smear-positive results are more infectious than patients with AFB sputum smear-negative results, but patients with AFB sputum smear-negative results can be infectious (229). Patients with sputum AFB sputum smear-negative results, but who undergo high risk procedures (including bronchoscopy) without inadequate infection control measures represent a potentially high risk of exposure, and a contact investigation should be initiated. All investigations should be conducted in consultation with local public health department.

- H.6.3** If serial surveillance of these cases reveals one of the following conditions, patient-to-patient transmission may have occurred and a contact investigation should be initiated if:

- High proportion of patients with TB disease were admitted to or seen in the setting during the year preceding onset of their TB disease, especially when TB disease is seen in patients who were otherwise unlikely to be exposed to *M. tuberculosis*
- Increase in the number of TB patients diagnosed with drug-resistant TB compared to the previous year
- Isolates from multiple patients have identical and characteristic drug-susceptibility or DNA fingerprint patterns

- H.6.4** If surveillance of TB cases in patients suggests the possibility of patient-to-patient transmission of *M. tuberculosis*:

H.6.4a Collaborate with the state or local health department to conduct an investigation.

H.6.4b For settings where HCW are serially tested for *M. tuberculosis* infection, review HCW records for an increase in the number of conversions in test results for *M. tuberculosis* infection.

H.6.4c Review patient surveillance data and medical records for additional cases of TB disease.

H.6.4d Look for possible exposures from patients with newly diagnosed TB disease to other patients with TB disease during previous or current admissions. Determine if the patients were admitted to the same room or area, or if

they received the same procedure or went to the same treatment area on the same day.

H.6.5 If the investigation suggests that transmission has occurred:

H.6.5a Evaluate possible causes of transmission of *M. tuberculosis* (e.g., delayed diagnosis of TB disease, institutional barriers to implementing timely and correct AII practices, inadequate environmental controls).

H.6.5b Determine if other patients or HCWs may have been exposed. If so, evaluate these persons for LTBI and TB disease (i.e., test for *M. tuberculosis* infection, and administer a symptom screen).

H.6.5c If the state or local health department was not previously contacted, notify the health department so that a community contact investigation can be initiated, if necessary.

H.6.5d Consider the possibility of laboratory errors in diagnosis, or the contamination of bronchoscopes (153) or other equipment.

H.7 Contact investigations

H.7.1 The main goal of contact investigations is to identify secondary cases of TB disease and LTBI among contacts so that they can begin therapy for TB disease or LTBI(230-232). Contact investigations should be accomplished through cooperation between infection-control personnel and the local TB control program. Initiate a contact investigation if

- a person with TB disease was seen in a health-care setting and TB disease was not diagnosed and reported quickly, resulting in failure to apply recommended TB infection controls,
- environmental controls or other infection-control measures were found to be malfunctioning while a person with TB disease was in the setting, or
- an HCW develops TB disease and exposes other persons in the setting.

H.7.2 As soon as TB disease is diagnosed or a problem is recognized, standard public health practice prioritizes the identification of other patients, HCWs and visitors who may have been exposed to the index or source case before TB infection-control measures were correctly applied (39). Consider that visitors to the patient may also be contacts, or may possibly be the source case.

Depending on the circumstance, the following activities should be done in collaboration with or by the state or local health department [<http://www.cdc.gov/mmwr/preview/mmwrhtml/00038823.htm>] (233).

H.7.2a Interview the index case and all HCWs who may have been exposed.

H.7.2b Review the index case's medical records.

H.7.2c Determine the **exposure site(s)**, (i.e., where the index case lived, worked, visited, or was hospitalized before being placed in AII).

H.7.2d Determine the **infectious period of the index case**.
The infectious period is the time period during which a person with TB disease is considered infectious and is presumed capable of transmitting *M. tuberculosis* to persons who share the same air space. The infectious period is an important part of determining if epidemiologic links exist between TB patients because it describes when a TB patient was most probably capable of transmitting TB to others.

For patients with positive AFB sputum smear results: the infectious period begins three months before the collection date of the first positive smear result or the symptom onset date (whichever is earlier), and ends two weeks after the start date of anti-TB treatment or when the patient is placed into AII or the date of the first negative smear result that is followed by consistently negative smear results.

For patients with negative AFB sputum smear results: the infectious period begins one month before the symptom onset date (if they had symptoms) and ends when the patient is placed into AII.

H.7.2e Determine the **exposure period** for each contact. The exposure period is the time during which a person shared the same air space with a person with TB disease and is likely to have been infected with *M. tuberculosis*.

H.7.3 Determine if transmission occurred from the index case to persons with whom the index had intense contact. Determine the intensity of the exposure based on proximity, overlap with the infectious period of the index case, duration of exposure, presence or absence of infection-control measures, infectiousness of the index case, and performance of procedures that could increase the risk for transmission during contact (e.g., sputum induction, bronchoscopy, airway suction). Determine the exposed cohort of contacts for TB screening.

The following activities (H.7.4 to H.7.7) should be accomplished through cooperation between infection-control personnel and the local TB control program.

H.7.4 The most intensely exposed HCWs and patients should be screened as soon as possible after exposure to *M. tuberculosis* occurred. Identify and evaluate contacts of the suspected source. Close contacts are the highest priority for screening.

For presumed exposed HCWs and patients in a setting which has chosen to use screen for infection with *M. tuberculosis* using the TST

- Administer a symptom screen
- Administer a TST to those who had previously negative TST results. (A two-step baseline TST should **not** be performed in contact investigations.)
- If the initial TST result is negative, repeat the TST and symptom screen 8–10 weeks after the end of exposure.
- If the symptom screen or the initial or 8–10 week follow-up TST result is positive, the HCW should be promptly evaluated for TB disease, including a chest radiograph.
- If TB disease is excluded, further medical and diagnostic evaluation for LTBI is needed, which includes a judgment about the extent of exposure.

For presumed exposed HCWs and patients in a setting which has chosen to use screen for infection with *M. tuberculosis* using the QFT

- Administer a symptom screen
- Administer a QFT
- Although QFT is not currently recommended for detecting *M. tuberculosis* infection when TB disease is suspected, a QFT conversion is most likely indicative of recent *M. tuberculosis* infection, and therefore, TB disease must be excluded.
- TST may be needed in those who have negative QFT results to further screen for TB disease.
- If the symptom screen or the QFT result is positive, the HCW should be promptly evaluated for TB disease, including a chest radiograph.
- If TB disease is excluded, further medical and diagnostic evaluation for LTBI is needed, which includes a judgment about the extent of exposure.
- A TST may contribute to this medical evaluation in persons who are otherwise at low risk for LTBI. If the first TST result after the exposure is negative, repeating the TST and symptom screen 8–10 weeks after the end of exposure may be helpful.

H.7.5 If the most intensely exposed persons have a positive test result for *M. tuberculosis* infection, or a test conversion in the absence

of a previous history of a positive test result or TB disease, evaluate persons with whom the index patient had less contact. If the evaluation of the intensely exposed contacts yields no evidence of transmission, it is not necessary to expand testing to others.

- H.7.6** Exposed persons with documented previously positive test results for *M. tuberculosis* infection do not require either repeat testing or a chest radiograph (unless they are immunocompromised or at a high risk for TB disease) but they should be questioned about signs or symptoms of TB disease at the time of screening. If the person has signs or symptoms of TB disease a) record the symptoms in the HCW's medical or employee health record, b) perform a chest radiograph, c) perform a full medical evaluation, and d) obtain sputum samples for smear and culture, if indicated.
- H.7.7** Determine why a TB disease diagnosis or AII was delayed or procedures failed, which led to transmission of *M. tuberculosis* in the setting. Record the reasons and corrective actions taken, including changes in policies, procedures, and TB training and education practices.

I. Collaboration with the State or Local Health Department

- I.1 Establish communication with staff at the state or local health department's TB control program before a problem arises. Coordinate with the local TB control program for assistance with the planning and implementation of TB control activities in the health-care setting and for names of experts to help with policies, procedures, and program evaluation.**
- I.2 By law, the state or local health department must be notified when TB disease is suspected or confirmed in a patient or HCW so that follow-up can be arranged and a community contact investigation can be conducted. Notify the state or local health department as early as possible before patient discharge to facilitate follow-up, continuation of therapy, and arrangements for DOT (23).**
- I.3 For inpatient facilities, coordinate a discharge plan with the patient (including a patient who is an HCW with TB disease) and the TB control program of the state or local health department.**
- I.4 In accordance with state and local laws and regulations, laboratories should report (by telephone, fax, or e-mail) positive AFB smear results from any specimens within 24 hours of collection and positive culture results within 24 hours of the notation of the positive culture result (124;125). Report all drug-susceptibility test results on *M. tuberculosis* isolates to the state or local health department as soon as these results are available.**
- I.5 Develop procedures to ensure that the state or local health department notifies the health-care setting if a HCW is suspected of having or is diagnosed with TB disease by a physician outside the setting.**
- I.6 HCW and patient confidentiality should be ensured.**

J. Environmental Controls

Environmental controls are the second line of defense in the TB infection-control program, after administrative controls. Environmental controls include technologies for the removal or inactivation of airborne *M. tuberculosis*. These technologies include local exhaust ventilation, general ventilation, high-efficiency particulate air (HEPA) filtration, and ultraviolet germicidal irradiation (UVGI). These controls help to prevent the spread and reduce the concentration of infectious droplet nuclei in the air. A summary of environmental controls and their use in prevention of transmission of *M. tuberculosis* is provided below. Supplement 3 contains detailed information on the application of environmental controls.

J.1 Local exhaust ventilation

Local exhaust ventilation is a source-control technique used for capturing airborne contaminants, such as infectious droplet nuclei or other infectious particles, before they are dispersed into the general environment. Local exhaust ventilation methods utilize external hoods, enclosing booths, and tents.

- J.1.1** Use local exhaust ventilation for cough-inducing and aerosol-generating procedures.
- J.1.2** If local exhaust ventilation is not feasible, perform cough-inducing and aerosol-generating procedures using environmental controls (e.g., booth) or in a room that meets the requirements for an AII room.

J.2 General ventilation

General ventilation systems dilute and remove contaminated air and control airflow patterns in a room or facility.

- J.2.1** Include an engineer or other professional with expertise in ventilation as part of the health-care setting's staff, or hire a consultant with expertise in ventilation engineering specific to health-care settings.
- J.2.2** Design ventilation systems to meet all applicable federal, state, and local requirements.
- J.2.3** A single-pass ventilation system is the preferred choice in areas where infectious airborne droplet nuclei are probably present (e.g., AII rooms). Use HEPA filtration if recirculation of air is necessary.
- J.2.4** AII rooms in existing health-care settings should have an airflow of ≥ 6 air changes per hour (ACH). When feasible, the airflow should be increased to 12 ACH by a) adjusting or modifying the ventilation system, or b) using air-cleaning methods such as room-air recirculation units containing HEPA filters or UVGI systems that increase the equivalent ACH (Supplement 3). New construction or renovation of health-care settings should be designed so that AII rooms achieve an airflow of ≥ 12 ACH. Table S3-2 provides ventilation rates for other areas in health-care settings.

- J.2.5** If using a variable air volume (VAV) ventilation system in an AII room, design the system to maintain the room under negative pressure at all times. The VAV system minimum set point must be adequate to maintain the recommended total and outdoor ACH and a negative pressure ≥ 0.01 inches of water gauge relative to adjacent areas.
- J.2.6** Determine the required number of AII rooms, other negative-pressure rooms, and local exhaust devices based on the risk assessment of the setting. The location of these rooms and devices will depend, in part, on where recommended ventilation conditions can be achieved. Grouping AII rooms in one area may facilitate the care of patients with TB disease and the installation and maintenance of optimal environmental controls.
- J.2.7** Check AII rooms for negative pressure using smoke tubes or other devices before occupancy, and daily when occupied by a patient with suspected or confirmed TB disease.
- J.2.8** Where negative pressure is recommended, the pressure differential should be ≥ 0.01 inches of water gauge (Supplement 3).
- J.2.9** Design, construct, and maintain general ventilation systems so that air flows from clean to less clean (more contaminated) areas.
- J.2.10** Design general ventilation systems to provide optimal airflow patterns within rooms and to prevent air stagnation or short-circuiting of air from the supply area to the exhaust area.
- J.2.11** Health-care settings serving populations with a high prevalence of TB disease may need to improve the existing general ventilation system or use air-cleaning technologies in general-use areas such as waiting rooms, emergency medical service areas, and radiology suites. Applicable approaches include: a) single-pass, non-recirculating systems that exhaust air to the outside, b) recirculation systems that pass air through HEPA filters before recirculating it to the general ventilation system, and c) room-air recirculation units with HEPA filters and UVGI systems.

J.3 Air-cleaning methods

J.3.1 High-efficiency particulate air (HEPA) filters

- J.3.1a** HEPA filters **must be used**: a) when discharging air from local exhaust ventilation booths or enclosures directly into the surrounding room or area, and b) when discharging air from an AII room (or other negative-pressure room) into the general ventilation system (e.g., in settings in which the ventilation system or building configuration makes venting the exhaust to the outside impossible).
- J.3.1b** HEPA filters **can be used** to remove infectious droplet nuclei from air that is recirculated in a setting or exhausted directly to the outside.

- J.3.1c** HEPA filters can also be used as an added safety measure in exhaust ducts to remove droplet nuclei from air being discharged to the outside.
- J.3.1d** Air can be recirculated through HEPA filters in areas in which: a) no general ventilation system is present, b) an existing system is incapable of providing sufficient ACH, or c) air cleaning (particulate removal) without affecting the fresh-air supply or negative-pressure system is desired. Such uses can increase the number of equivalent ACH in the room or area.
- J.3.1e** Recirculation of HEPA-filtered air can be achieved by a) exhausting air from the room into a duct, passing it through a HEPA filter installed in the duct, and returning it to the room or the general ventilation system, b) filtering air through HEPA recirculation systems installed on the wall or ceiling of the room, or c) filtering air through portable room-air recirculation units.
- J.3.1f** To ensure adequate functioning, install HEPA filters carefully and maintain the filters per manufacturers' instructions. Maintain written records of all HEPA maintenance and monitoring (98).
- J.3.1g** Manufacturers of room-air recirculation units should provide documentation of the filtration efficiency and of the overall efficiency of the unit in removing airborne particles from a space of a given size, and installation instructions.

J.3.2 Ultraviolet germicidal irradiation (UVGI)

UVGI is an air-cleaning technology that can be used in a room or corridor to irradiate the air in the upper portion of the room (upper-air irradiation), installed in a duct to irradiate air passing through the duct (duct irradiation), or incorporated into room air-recirculation units.

- J.3.2a** UVGI can be used in ducts that recirculate air back into the same room or in ducts that exhaust air directly to the outside. However, UVGI should **not** be used **in place of** HEPA filters when discharging air from isolation booths or enclosures directly into the surrounding room or area or when discharging air from an AII room into the general ventilation system.
- J.3.2b** For each system, follow design guidelines to maximize UVGI effectiveness, which can be expressed in terms of equivalent ACH. Because air velocity, air mixing, relative humidity, UVGI intensity, and lamp position all affect the efficacy of UVGI systems, consult an UVGI system designer before purchasing and installing an UVGI system. Experts who might be consulted include industrial hygienists, engineers, and health physicists.
- J.3.2c** To function properly and minimize potential hazards to HCWs and other room occupants, upper-air UVGI systems should be properly installed, maintained, and

labeled. A person knowledgeable in the use of UV radiometers and/or actinometers should monitor UV irradiance levels to ensure that exposures in the work area are within safe exposure levels. UV irradiance levels in the upper-air, where the air disinfection is occurring, should also be monitored to determine that irradiance levels are within the desired effectiveness range.

- J.3.2d** Change and clean UVGI tubes according to the manufacturer's instructions or when irradiance measurements indicate that output is reduced below effective levels.
- J.3.2e** In settings that use UVGI systems, education of HCWs (and patients and visitors) should include: a) basic principles of UVGI systems (mechanism and limitations), b) potential hazardous effects of UVGI if overexposure occurs, c) potential for photosensitivity associated with certain medical conditions or use of some medications, and d) importance of maintenance procedures and record keeping.

J.4 Program issues

- J.4.1** Personnel from engineering, maintenance, infection control, and environmental health should collaborate to ensure the optimal selection, installation, operation, and maintenance of environmental controls.
- J.4.2** Develop a written maintenance plan that outlines the responsibility and authority for maintenance of the environmental controls and addresses HCW training needs. Standard operating procedures should include the notification of infection-control personnel before performing maintenance on ventilation systems servicing TB patient-care areas.
- J.4.3** Schedule routine preventive maintenance for all components of the ventilation systems (e.g., fans, filters, ducts, supply diffusers, exhaust grills) and air-cleaning devices.
- J.4.4** Conduct quality control (QC) to verify that environmental controls are operating as designed and that records are current.
- J.4.5** Make provisions for emergency electrical power so that the performance of essential environmental controls is not interrupted during a power failure.

K. Respiratory protection

The first two levels of the infection-control hierarchy, administrative and environmental controls, minimize the number of areas where exposure to *M. tuberculosis* may occur. They also reduce, but do not eliminate, the risk in the few areas where exposures can still occur (e.g., AII rooms, and rooms where cough-inducing or aerosol-generating procedures are performed). Because persons entering these areas may be exposed to airborne *M. tuberculosis*, the third level of the hierarchy is the use of respiratory protective equipment in situations that pose a high risk for exposure (Supplement 4).

On October 17, 1997, OSHA published a proposed standard for occupational exposure to *M. tuberculosis* (234). On December 31, 2003, OSHA announced the termination of rulemaking for a TB standard (235). Prior OSHA policy permitted the use of any Part 84 particulate filter respirator for protection against TB disease (236). Respirator usage for TB had been regulated by OSHA under CFR Title 29, Part 1910.139 (29CFR1910.139) (237) and compliance policy directive (CPL) 2.106 (*Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis*). Respirator usage for TB is now regulated under the general industry standard for respiratory protection (29CFR1910.134) (238). General information on respiratory protection for aerosols, including *M. tuberculosis*, has been published (239-241).

K.1 Indications for use

K.1.1 Respiratory protection should be used by:

- All persons, including HCWs and visitors, entering rooms in which patients with suspected or confirmed infectious TB disease are being isolated.
- Persons present during cough-inducing or aerosol-generating procedures performed on patients with suspected or confirmed infectious TB disease.
- Persons in other settings where administrative and environmental controls are not likely to protect them from inhaling infectious airborne droplet nuclei. This includes persons who transport patients with suspected or confirmed infectious TB disease in EMS vehicles and persons who provide urgent surgical or dental care to patients with suspected or confirmed infectious TB disease (Supplement 1).

K.1.2 Laboratorians conducting aerosol-producing procedures may require respiratory protection. A decision concerning use of respiratory protection in laboratories should be made on an individual basis depending on the type of ventilation in use for the laboratory procedure and the likelihood of aerosolization of viable mycobacteria which may result from the laboratory procedure.

K.2 Respiratory protection program

OSHA requires health-care settings where HCWs use respiratory protection to prevent the inhalation of infectious droplet nuclei to develop, implement, and maintain a respiratory protection program. All HCWs who use respiratory protection should be included in the program (Supplement 4). The two most critical elements of a respiratory protection program are: 1) training of HCWs and 2) selection of recommended, well-fitting respirators.

K.2.1 Training of HCWs

K.2.1a Provide HCWs with annual training on:

- Nature, extent, and hazards of TB disease in the health-care setting; this training may be done in

conjunction with other related training on infectious disease associated with airborne transmission such as SARS-Corona Virus (CoV) and measles

- The risk assessment process and its relationship to the respirator program
- Signs and symbols used to show that respirators are required in an area
- Reasons for using respirators
- Environmental controls used to prevent the spread and reduce the concentration of infectious droplet nuclei
- Reasons for selecting a particular respirator for a given hazard (Recommendations, K.2.2)
- Operation, capabilities, and limitations of respirators
- Cautions about facial hair and respirator use
- OSHA regulations regarding respirators including assessment of employees' knowledge

K.2.1b Provide opportunities for trainees to handle and wear a respirator until proficient (Recommendations, K.2.3)

K.2.1c Provide trainees with copies or summaries of lecture materials for use as references.

K.2.1d Provide instructions to refer all respirator problems immediately to the respirator program administrator.

K.2.2 Selection of respirators

Respiratory protective devices used in health-care settings for protection against *M. tuberculosis* should meet the following criteria (242;243)

K.2.2a Any of the particulate filter respirators certified by CDC/NIOSH (N-, R-, or P-95, 99, or 100), including disposable respirators, or PAPRs with high efficiency filters. CDC/NIOSH has certified N95 respirators that also meet Federal Drug Administration (FDA) requirements for surgical masks, and can be used for protection against bloodborne pathogens (244).

K.2.2b Ability to adequately fit respirator wearers (e.g., a fit factor of ≥ 100 for disposable and half-mask respirators) who are included in a respiratory protection program.

K.2.2c Ability to fit the different facial sizes and characteristics of HCWs. This can usually be met by making respirators available in different sizes.

K.2.2d In selecting respirator models, give preference to models shown by to have inherently well-fitting characteristics (i.e., provide appropriate protection factors to 95% of a panel of test subjects with a distribution of face sizes and shapes that approximates that of the general population or the target population) (245-247).

K.2.3 Fit testing

A fit test is used to determine which respirator fits the user adequately and to ensure that the user knows when the respirator fits properly. A fit test can help identify the 5% of persons who may not consistently achieve a good fit (248).

Perform fit testing during the initial respiratory protection program training and periodically thereafter (based on the risk assessment for the setting), and in accordance with applicable regulations. As of 01 January 2004, current OSHA regulations require initial and annual fit testing for all respirator use (238) (see <http://www.osha.gov/SLTC/respiratoryprotection/index.html>).

There are insufficient evidence-based data to make a recommendation on the periodicity of fit testing. The need for subsequent fit testing is based on several issues. Periodic fit testing for respirators used in TB environments can serve as an effective training tool in conjunction with the content included in employee training and retraining. Fit testing provides an objective means to demonstrate and evaluate skills such as the ability to wear and remove a respirator. Fit testing in conjunction with training is critical in determining which respirator model and size fits the wearer best and in confirming that the wearer can don the respirator properly to achieve a good fit. The frequency of fit testing should also be guided by a change in a) risk of transmission of *M. tuberculosis*, b) facial features of the wearer, c) medical condition that would affect respiratory function, d) physical characteristics of respirator (despite the same model number), or d) model or size of the assigned respirator (249).

K.3 Respirator options: general recommendations

- K.3.1** In situations requiring respiratory protection, the minimum respiratory protection device is a filtering facepiece (nonpowered, air-purifying, half-facepiece) respirator, such as an N95 disposable respirator. This CDC/NIOSH-certified respirator meets the minimum filtration performance for respiratory protection in areas where patients with suspected or confirmed TB disease may be present.
- K.3.2** For situations in which the risk for exposure to *M. tuberculosis* is especially high due to cough-inducing and aerosol-generating procedures, more protective respirators may be needed (Section K.4).

K.4 Respirator options: special circumstances

- K.4.1** Visitors to AII rooms and other areas with patients who have suspected or confirmed infectious TB disease should wear respirators. Visitors may wear N95 disposable respirators and should be instructed by HCWs on the use of the respirator prior to entering an AII room (See Fit check in Glossary).
- K.4.2** Because particulate respirators vary widely by model, and fit testing is usually not available to visitors, preference should be

given to models shown by the manufacturer to have inherently well-fitting characteristics (245;250;251). Employers should request fitting characteristics of the respirators from the manufacturers (10). This voluntary use of respirators by visitors might provide some level of protection. A recent study showed decreased rates of pulmonary aspergillosis in neutropenic patients with hematologic malignancy who were required to wear non-certified respirators when leaving their rooms (252).

K.4.3 The risk assessment for the setting may identify a limited number of circumstances (e.g., bronchoscopy on patients suspected of having TB disease, autopsy on persons suspected of having TB disease at the time of death, selected laboratory procedures) for which HCWs may require a level of respiratory protection that exceeds the minimum level provided by an N95 disposable respirator. In such circumstances, provide HCWs with a level of respiratory protection that both exceeds the minimum criteria and is compatible with patient-care delivery. Such protection may include more protective powered respirators such as PAPRs or pressure-demand airline respirators (i.e., positive pressure) (Supplement 4). Detailed information on these and other respirators has been published (239;240;243;253).

K.4.4 In some settings HCWs may be at risk for both inhalation exposure to *M. tuberculosis* and mucous membrane exposure to bloodborne pathogens. In these situations, the HCW may wear a non-fluid resistant respirator with a full face shield to achieve both respiratory protection and fluid protection. Alternatively, the HCW may use the combination product surgical mask/N95 disposable respirator certified by CDC/NIOSH and cleared by FDA that provides both respiratory protection and bloodborne pathogen protection.

K.4.5 When surgical procedures (or other procedures requiring a sterile field) are performed on persons with suspected or confirmed infectious TB disease, respiratory protection worn by HCWs protects both a) the surgical field, and therefore the patient, from the HCW's respiratory secretions, and b) the HCW from infectious droplet nuclei that may be expelled by the patient or generated by the procedure. Respirators with exhalation valves, PAPRs, and most positive-pressure airline respirators do **not** protect the sterile field.

K.4.6 Settings that do not provide care for persons with suspected or confirmed TB disease do not need a respiratory protection program for exposure to *M. tuberculosis*. However, these settings should have written protocols for the early identification of persons with signs or symptoms of TB disease and procedures for referring these patients to a setting where they can be evaluated and managed. Filtering facepiece respirators should also be available for emergency use by HCWs who may be exposed to persons with suspected or confirmed TB disease before transfer. In addition, respirators and the associated respiratory protection program may be needed to protect HCWs

from other infectious diseases or exposures to harmful vapors and gases.

- K.4.7** Surgical masks are designed to prevent respiratory secretions of the wearer from entering the air. To reduce the expulsion of droplet nuclei into the air, persons with suspected or confirmed TB disease should be instructed to observe respiratory hygiene and cough etiquette procedures (105) and should wear surgical masks when not in AII rooms. These patients do not need to wear particulate respirators, which are designed to filter the air before it is inhaled by the person wearing the respirator.
- K.4.8** Patients with suspected or confirmed TB disease should **never** wear any kind of respiratory protection that has an exhalation valve. This type of respirator does not prevent droplet nuclei from being expelled into the air.

L. Cough-Inducing and Aerosol-Generating Procedures

L.1 General recommendations

Procedures that involve instrumentation of the lower respiratory tract or induction of sputum can increase the likelihood that droplet nuclei will be expelled into the air. These cough-inducing procedures include: endotracheal intubation, suctioning, diagnostic sputum induction, aerosol treatments (e.g., pentamidine therapy, nebulized treatments), and bronchoscopy, and also include laryngoscopy, gastric aspiration, and nasogastric tube placement. Other procedures that can generate aerosols include: irrigating tuberculous abscesses, homogenizing or lyophilizing tissue, performing autopsies on cadavers with untreated TB disease, and other processing of tissue that may contain tubercle bacilli and TB laboratory procedures.

- L.1.1** Do not perform cough-inducing or other aerosol-generating procedures on patients with suspected or confirmed infectious TB disease unless the procedure is necessary and can be performed with recommended precautions.
- L.1.2** When a cough-inducing procedure must be performed on a patient with suspected or confirmed infectious TB disease, use a local exhaust ventilation device (e.g., booth or special enclosure). If this is not feasible, perform the procedure in a room that meets the ventilation requirements for an AII room.
- L.1.3** When in rooms or enclosures in which cough-inducing or other aerosol-generating procedures are being performed, wear respiratory protection.
- L.1.4** After completion of cough-inducing procedures, keep patients in the AII room or enclosure until coughing subsides. Give the patients tissues, and instruct them to cover the mouth and nose with tissues when coughing. Dispose of tissues in accordance with your infection control plan.
- L.1.5** For postoperative recovery, do not place the patient in a recovery room with other patients. Rather, place the patient in a room that meets the ventilation requirements for an AII room. If the room does not meet the ventilation requirements for an AII room, air-cleaning technologies (e.g., HEPA filtration, UVGI) can be used to increase the number of equivalent ACH (Supplement 3).

- L.1.6** Before the booth, enclosure, or room is used for another patient, allow enough time for the removal of at least 99% of airborne contaminants. This interval will vary based on the efficiency of the ventilation or filtration system (Table S3-1, Supplement 2).
- L.1.7** Perform all manipulations of *M. tuberculosis* specimens that may generate aerosols in a biological safety cabinet.

L.2 Special considerations for bronchoscopy

- L.2.1** Whenever possible, perform bronchoscopy in a room that meets the ventilation requirements for an AII room (Supplement 3). Air-cleaning technologies can be used to increase equivalent ACH.
- L.2.2** If a bronchoscopy must be performed in a positive-pressure room (e.g., operating room), exclude TB disease before performing the procedure. Examine three spontaneous or induced sputum specimens for AFB (if possible) to exclude a diagnosis of TB disease before bronchoscopy is considered as a diagnostic procedure (110;254).
- L.2.3** In a patient who is intubated and mechanically-ventilated, minimize the opening of circuitry.
- L.2.4** For HCWs present during bronchoscopic procedures on patients with suspected or confirmed TB disease, a respirator with a level of protection of an N95 disposable respirator or higher (e.g., full-facepiece elastomeric respirator or PAPR) should be worn.

L.3 Special considerations for administration of aerosolized pentamidine and other medications

Patients receiving aerosolized pentamidine (or other aerosolized medications) who are immunocompromised and have a confirmed or suspected pulmonary infection (i.e., PCP or pneumonia caused by *Pneumocystis jirovecii*, previously called *Pneumocystis carinii* pneumonia) are also at risk for TB disease. Patients receiving other aerosolized medications may have an immunocompromising condition that puts them at greater risk for TB disease.

- L.3.1** Screen patients for TB disease before initiating prophylaxis with aerosolized pentamidine. Include a medical history, test for infection with *M. tuberculosis*, and chest radiograph.
- L.3.2** Before each subsequent treatment with aerosolized pentamidine, screen patients for signs or symptoms of TB disease. If signs or symptoms are present, evaluate the patient for TB disease.
- L.3.3** Give patients with suspected or confirmed TB disease oral prophylaxis for *P. jirovecii* (formerly *P. carinii*), if clinically practical.
- L.3.4** Patients receiving other aerosolized medication may have immunocompromising conditions, therefore if warranted, should be similarly screened, evaluated, and treated with oral medications if practical.

SUPPLEMENT 1: ESTIMATING THE INFECTIOUSNESS OF A TB PATIENT

I. General Principles

Transmission of *M. tuberculosis* is most likely to result from exposure to persons who have a) unsuspected pulmonary TB disease and are not receiving anti-TB treatment, b) diagnosed TB disease and are receiving inadequate therapy, or c) diagnosed TB disease and are early in the course of effective therapy. Administration of effective anti-TB treatment has been associated with decreased infectiousness among persons who have TB disease (255). Effective treatment reduces coughing, the amount of sputum produced, the number of organisms in the sputum, and the viability of the organisms in the sputum. However, the duration of therapy required to decrease or eliminate infectiousness varies (256). Some TB patients are never infectious, whereas those with unrecognized or inadequately treated drug-resistant TB disease may remain infectious for weeks or months (2;3;78;83;146;257-260). In one study, 17% of transmission occurred from persons with negative AFB smear results (229). Rapid laboratory methods, including PCR-based techniques, can decrease diagnostic delay and reduce the duration of infectiousness (261).

The infectiousness of patients with TB correlates with the number of organisms they expel into the air (262). The number of organisms expelled are related to several factors: a) presence of cough lasting ≥ 3 weeks, b) cavitation on chest radiograph, c) positive AFB sputum smear result, d) respiratory tract disease with involvement of the lung or airways including larynx, e) failure to cover the mouth and nose when coughing, f) lack of, incorrect, or short duration of anti-TB treatment (263), or g) undergoing cough-inducing or aerosol-generating procedures (e.g., sputum induction, bronchoscopy, airway suction). Closed and effectively filtered ventilatory circuitry and minimizing opening of such circuitry in intubated and mechanically-ventilated patients may minimize exposure (Recommendations, E.3.2).

Persons with extrapulmonary TB disease are generally not infectious unless they have concomitant pulmonary disease, nonpulmonary disease located in the oral cavity or the larynx, or extrapulmonary disease that includes an open abscess or lesion in which the concentration of organisms is high, especially if drainage from the abscess or lesion is extensive or if aerosolization of drainage fluid is performed (61;64;69;74;264). Persons with tuberculous pleural effusions may have concurrent unsuspected pulmonary or laryngeal TB disease. These patients should be considered infectious until TB disease is excluded. Patients with suspected tuberculous pleural effusions or extrapulmonary TB disease should be considered pulmonary TB suspects until concomitant pulmonary disease is excluded.

Although children with TB disease are generally less likely than adults to be infectious, transmission from young children can occur (120;122). Therefore, children and adolescents with TB disease should be evaluated for infectiousness using most of the same criteria as for adults (i.e., presence of cough lasting ≥ 3 weeks; cavitation on chest radiograph; respiratory tract disease with involvement of lungs, airways, or larynx; lack of, incorrect, or short duration of anti-TB treatment (263), undergoing cough-inducing or aerosol-generating procedures (e.g., sputum induction, bronchoscopy, airway suction). Although gastric lavage is useful in the diagnosis of pediatric TB disease, the grade of the positive AFB smear result does not correlate with infectiousness. Pediatric patients who might be infectious include those who are not on anti-TB treatment, have just been started on treatment or are on inadequate treatment, **and** who have extensive pulmonary or laryngeal involvement, coughing ≥ 3 weeks, cavitary TB disease, positive AFB sputum smear results, or who are undergoing cough-inducing or aerosol-generating procedures. Children who have typical primary TB lesions on chest radiograph and do not have any of these indicators of infectiousness may not need to be placed in AII.

Transmission of *M. tuberculosis* has not been shown to be associated with the collection of gastric aspirate specimens (265). Children who do not have predictors for infectiousness do not need to have gastric aspirates obtained in an AII room or other special enclosure; however, the procedure should not be performed in an area where a person or persons infected with HIV may be exposed. Because the source case for pediatric TB patients may be a member of the infected child's family, parents and other visitors of all hospitalized pediatric TB patients should be screened for TB disease as soon as possible to ensure that they do not become sources of health-care-associated transmission of *M. tuberculosis* (265-268).

In general, patients who have suspected or confirmed TB disease and who are not on anti-TB treatment should be considered infectious if characteristics include

- Presence of cough
- Cavitation on chest radiograph
- Positive acid-fast bacilli (AFB) sputum smear result
- Respiratory tract disease with involvement of the lung, or airways including larynx
- Failure to cover the mouth and nose when coughing
- Undergoing cough-inducing or aerosol-generating procedures (e.g., sputum induction, bronchoscopy, airway suction)

If a patients with one or more of these characteristics is on standard multi-drug therapy with documented clinical improvement, usually in connection of smear conversion over several weeks, the risk of infectiousness is reduced.

II. Suspected TB disease

For patients placed in AII due to suspected infectious TB disease of the lungs, airway, or larynx, AII can be discontinued when the likelihood of infectious TB disease is considered unlikely **and** either 1) another diagnosis is made that explains the clinical syndrome **or** 2) the patient has three negative AFB sputum smear results (108-111). The three sputum specimens should be collected 8–24 hours apart (112), and at least one should be an early morning specimen (because respiratory secretions pool overnight). Generally, this will allow patients with negative sputum smear results to be released from AII in two days.

Hospitalized patients in whom the suspicion of TB disease remains after the collection of three negative AFB sputum smear results should not be released from AII until they are on standard multidrug anti-TB treatment **and** are clinically improving. Thus, a patient who is suspected of having TB disease of the lung, airway, or larynx, is symptomatic with cough and not responding clinically to anti-TB treatment, should not be released from AII into a non-AII room and additional sputum specimens should be collected for AFB examination until three negative AFB sputum smear results are obtained (22;23). Further diagnostic approaches may need to be considered such as sputum induction and, after sufficient time on treatment, bronchoscopy.

Because patients with TB disease who have negative AFB sputum smear results can still be infectious (229), patients with suspected disease who meet the above criteria for release from AII should not be released to an area where other patients with immunocompromising conditions are housed.

III. Confirmed TB disease

A patient who has drug-susceptible TB of the lung, airway, or larynx, who is on standard multidrug anti-TB treatment and who has had a significant clinical and bacteriologic response to therapy (i.e., reduction in cough, resolution of fever, and progressively decreasing quantity of AFB on smear result) is probably no longer infectious. However, because culture and drug-susceptibility results are not usually known when the decision to discontinue AII is made, **all patients with confirmed TB disease should remain in AII while hospitalized until they**

- have had three consecutive negative AFB sputum smear results collected 8–24 hours apart, with at least one being an early morning specimen,
- have received standard multidrug anti-TB treatment, **and**
- have demonstrated clinical improvement.

IV. Discharge to home of patients with suspected or confirmed TB disease

If a hospitalized patient who has suspected or confirmed TB disease is deemed medically stable, (including patients with positive AFB sputum smear results indicating pulmonary TB disease) **the patient may be discharged from the hospital before converting the positive AFB sputum smear results to negative AFB sputum smear results if**

- a specific plan exists for follow-up care with the local TB control program,
- the patient has been started on a standard multidrug anti-TB treatment regimen and DOT has been arranged
- no children or persons with immunocompromising conditions are present in the household,
- all immunocompetent household members have been previously exposed to the patient, and
- the patient is willing to not travel outside of the home except for health care associated visits until the patient has negative sputum smear results.

V. Release setting

Patients with suspected or confirmed TB disease should not be released to health-care settings or homes where the patient can expose others who are at high risk for progressing to TB disease if infected, such as persons infected with HIV or young children.

VI. Drug-Resistant TB disease

Because the consequences of transmission of MDR TB are severe, some infection-control practitioners may choose to keep persons with suspected or confirmed MDR TB disease in AII during the entire hospitalization, regardless of sputum smear results.

The role of drug resistance in transmission is complex. Transmission of drug-resistant organisms to persons with and without HIV infection is well documented (44;269;270). In some cases, transmission from patients with TB disease caused by drug-resistant organisms may be extensive due to prolonged infectiousness due to delays in diagnosis and delays in initiation of effective therapy (43;78;80;83;218;271;272).

Although many TB outbreaks among HIV-infected persons have been reported (41;42;81), the risk for transmission does not appear to be increased from patients with TB disease and HIV infection compared to TB patients without HIV infection (44;273-276). It is not clear whether persons infected with HIV are more likely to be infected with *M. tuberculosis* if exposed.

DRAFT

DRAFT

DRAFT

However, once infected with *M. tuberculosis*, the risk for progression to TB disease in persons infected with HIV is high (277). Progression to TB disease can be rapid, with emergence as soon as one month after exposure (41;43;44;83).

SUPPLEMENT 2: DIAGNOSIS AND TREATMENT OF LATENT TB INFECTION (LTBI) AND TB DISEASE**I. Procedures to diagnose Latent Tuberculosis Infection (LTBI) and TB disease**

Latent tuberculosis infection (LTBI) is a condition following exposure to a person with infectious TB disease and subsequent infection with *M. tuberculosis* where the bacilli are alive but inactive in the body. People who have LTBI but who do not have TB disease are asymptomatic (have no symptoms), do not feel sick, and cannot spread TB to other people. LTBI can be diagnosed by the tuberculin skin test (TST) or the Quantiferon-TB test (QFT). The TST (previously referred to as “PPD” test) consists of a small dose of PPD-tuberculin injected just beneath the surface of the skin by the Mantoux method. The QFT is an in vitro cytokine assay that assesses the cell-mediated immune response to *M. tuberculosis* in whole blood(100).

TB disease should be considered for any patient who has signs or symptoms of disease, including coughing for ≥ 3 weeks, loss of appetite, unexplained weight loss, night sweats, bloody sputum or hemoptysis, hoarseness, fever, fatigue, or chest pain. The index of suspicion for TB disease will vary by individual risk factors, geographic area, and prevalence of TB disease in the population served by the health-care setting. Persons exposed to patients with infectious TB disease may acquire LTBI depending on host immunity and the degree and duration of exposure. Diagnostic tests for TB disease include chest radiography and laboratory tests of sputum (examination for AFB and culture). The treatment of persons with TB disease involves important aspects of TB control by stopping transmission of *M. tuberculosis* and preventing persons with LTBI from developing infectious TB disease (26).

In most U.S. populations, targeted testing for LTBI and TB disease is performed to identify persons with LTBI and TB disease who would benefit from treatment. Therefore, all testing activities should be accompanied by a plan for follow-up care of persons with LTBI or TB disease. A decision to test for infection with *M. tuberculosis* should be based on a commitment to treat LTBI (29). Health-care agencies or other facilities should consult with the state or local health department before starting a program to test HCWs for infection with *M. tuberculosis* to ensure that adequate provisions are in place for the evaluation and treatment of persons whose test results are positive, including the medical supervision of the course of treatment for those who are treated for LTBI or TB disease.

Groups that are not at high risk for LTBI or TB disease should not be tested routinely, because testing in low-risk populations diverts resources from other priority activities. In addition, TB screening of low-risk persons is discouraged because a substantial proportion of persons from low-risk populations who have positive TST results may actually have false-positive TST results and may not represent infection with *M. tuberculosis* (29;278). Testing for infection with *M. tuberculosis* should be performed for well-defined, high-risk groups. These groups can be divided into two categories (Introduction B.1 , B.2):

- Persons at higher risk for exposure to and infection with *M. tuberculosis*
- Persons at higher risk for progression from LTBI to TB disease

Flexibility is needed in defining high-priority groups for TB screening. The changing epidemiology of TB indicates that the risk for TB among groups currently considered high priority may decrease over time, and groups currently not identified originally as being at high risk may be considered as high priority.

A. Tuberculin skin test (TST)

The TST is a method for diagnosing LTBI in persons for whom TB disease has been excluded. Although currently available preparations of PPD used in TSTs are less than 100% sensitive and specific for the detection of LTBI, the TST is currently the most widely used diagnostic test in the United States. The TST is less sensitive in patients who have TB disease.

As with all medical tests, the TST is subject to variability, and variability in reading TST results has been documented (66;202;279). Many of the variations in administering and reading TST results can be avoided by training and attention to details (280). Detailed information on the use of TSTs for diagnosing LTBI has been published (29), and details of TST administration and TST result reading procedures are described below.

A.1 Adherence to TST and Treatment of LTBI

Operational policies, procedures, and practices at health-care facilities can enhance HCW adherence to serial TST and treatment for LTBI. A recent focus group study identified both potential barriers and facilitators to adherence (281). HCWs identified structural factors such as inconvenient TST screening schedules and locations, long waiting times, the cost of LTBI medication, and the failure of private physicians to recommend treatment for LTBI as factors that negatively impacted adherence. Facilitators that help HCWs adhere to having TSTs placed included active follow-up by supervisors and occupational health staff, work-site visits for TST screening, and provision of counseling to address informational and emotional needs. Misinformation and stigma about TB also emerged in the discussions, suggesting the need for additional training and education for HCWs. The findings also suggest that the establishment of TST policies and procedures that address these issues may improve HCWs' adherence to serial skin testing and treatment of LTBI (281).

A.2 Administering the TST

For each patient, conduct a risk assessment that takes into consideration recent exposure to *M. tuberculosis*, clinical conditions that increase risk for TB disease if infected, and the program's capacity to deliver treatment for LTBI to determine if the TST should be administered. A decision to test for infection with *M. tuberculosis* should be based on a commitment to treat LTBI (29).

The recommended method for tuberculin skin testing is the Mantoux method, which is an intradermal administration of a measured amount of tuberculin (197;280;282-284). Mantoux TST training materials supporting the guidance in this document are available free of charge from CDC at www.cdc.gov/tb (197;280;282-284). Multi-puncture tests (tine tests) are not as reliable as the Mantoux method of skin testing and should not be used as a diagnostic test in the United States (22). Contact the state and local health department for TST resources.

Before administering TSTs or performing any other procedure involving patient contact, HCWs should wash their hands using an appropriate hand-washing technique (285). In certain field settings it may be necessary to use additional

hand-hygiene techniques. State or local regulations should determine what additional standard precautions should be followed (i.e., whether or not gloves should be worn while placing TSTs and the procedures for the disposal of supplies).

See Table S2-3 for recommended quality control procedural observation checklists for administering and reading TST results. Details of TST administration procedures are described below.

- A.2.1 Locate and clean the injection site. Select an area ≥ 2 inches away from the elbow (29). The area should be free of any barriers (e.g., muscle margins, heavy hair, veins, sores, or scars) to placing the TST and reading the TST result.
- A.2.2 Prepare the syringe. Check the expiration date on the vial, and fill the syringe with 0.1 ml of tuberculin. Use a ¼- to ½-inch 27-gauge needle and disposable tuberculin syringe.
 - A.2.2a Pre-filling of syringes is not recommended. Tuberculin is adsorbed in varying amounts by glass and plastics. To minimize reduction in potency by adsorption, tuberculin should be given as soon after the syringe has been filled as possible. Following these procedures will also help avoid contamination: test doses should always be removed from the vial under strictly aseptic conditions, and the remaining solution should remain refrigerated (not frozen) (29).
 - A.2.2b Tuberculin should be stored in the dark as much as possible and exposure to strong light should be avoided (29).
- A.2.3 Inject tuberculin just beneath the surface of the skin (intradermally)(199;200). Hold the needle bevel up, and insert the needle slowly at a 5-15 degree angle. Inject 5 TU of PPD antigen into the volar surface of the forearm (palm-side up).
- A.2.4 Check the skin test. A tense, pale elevation of the skin (a wheal) 6 -10 mm in diameter (286) should be produced as the TST is administered. Explain to the patient that the wheal is absorbed naturally in approximately ten minutes.
 - A.2.4a If the TST was administered incorrectly, (i.e., too deeply or too shallow), repeat the TST immediately ≥ 2 inches from the original injection site (29).
 - A.2.4b Caution the patient to avoid pressure on the wheal (blot the injection site lightly with a gauze pad if a drop of blood appears), and to avoid covering the skin with anything that may interfere with reading the TST result (e.g., adhesive bandages, cream, ointment, lotion, liquids, medication). Also, advise the patient not to scratch the site, which may interfere with reading the TST result (286).
- A.2.5 Record all the information required for documentation by the facility (e.g., date and time of TST administration, who placed the TST, injection site location, lot number of tuberculin).

- A.2.6 Syringe and needle technologies continue to evolve to help prevent needle stick injuries (<http://www.cdc.gov/nip/dev/jetinject.htm>). Institutional policy should determine which skin test device has been evaluated and approved for use by your facility (287).

A.3 Reading the TST result

Reading the TST result consists of first determining the presence or absence of induration (hard, dense, raised formation), and if induration is present, measuring the diameter of induration transverse (perpendicular) to the long axis of the forearm (29;280). Erythema, or redness of the skin, should not be considered when reading a TST result.

The TST result should be read by a designated, trained HCW 48–72 hours after the TST is placed (29;29;286). A person who does not return within 72 hours for reading should receive another TST as soon as possible. Patients and HCWs should never be allowed to read their own TST results. Experience has shown that HCWs do not measure their own TST results reliably (31).

See Table S2-3 for a recommended quality control procedural observation checklist for reading TST results. Detailed procedures for reading TST results are described below.

- A.3.1 Visually inspect the TST site under good light. Determine the presence or absence of induration (hard, dense, raised formation). Do not measure erythema (abnormal redness of the skin) as part of the TST result.
- A.3.2 If induration is present, palpate the induration. Use fingertips to find margins of the induration.
- A.3.3 Mark the induration by placing small dots on both sides of the induration with a ballpoint pen or fine-tipped eyeliner pencil. An eyeliner pencil is useful for TST training and for blinded independent duplicate readings (BIDRs) (see Glossary) because the dots are easy to remove. Alternative TST result reading methods have been described (282-284;288). Use fingertip as a guide for marking the widest edges of the induration (not erythema) with dots transverse to the long axis of the forearm.
- A.3.4 Measure the induration with a TST ruler. Place the “0” ruler line inside the edge of the left dot. Read the ruler line inside right dot edge (use lower measurement if between two gradations on mm scale).



The TST result in this picture should be recorded as 12 mm. The “0” ruler line is inside the edge of the left dot.

- A.3.5 Record all TST results in mm, even those classified as negative. Do not record only as “positive” or “negative.” Record the absence of induration as “0 mm” (286).
- A.3.6 In very rare instances, the immediate reaction may be severe (vesiculation, ulceration, or necrosis of the skin). Report severe adverse events to the FDA MedWatch Adverse Events Reporting System (AERS): 1-800-FDA-1088 (telephone); 1-800-FDA-0178 (fax); Report Form 3500 in the *Physicians’ Desk Reference*; www.fda.gov/medwatch.

A.4 Interpreting the TST result and its positive-predictive value

The positive-predictive value of a TST is the probability that a person with a positive TST result is actually infected with *M. tuberculosis*. The positive predictive value is dependent on the prevalence of infection with *M. tuberculosis* in the population being tested and the specificity of the test (202;289;290).

- A.4.1 In populations with a low prevalence of infection with *M. tuberculosis*, the probability that a positive TST result represents true infection with *M. tuberculosis* can be very low, especially if the cut point is set too low, (i.e., the test is not adequately specific and there is a low prevalence in the population).
- A.4.2 In populations with a high prevalence of infection with *M. tuberculosis* and inadequate test specificity, the probability that a positive TST result using the same cut point represents true infection with *M. tuberculosis* is much higher.

A.5 Interpreting the TST result in HCWs

TST result interpretation depends on two factors: 1) measured TST induration in mm, and 2) the person's risk of being infected with *M. tuberculosis* and risk of progression to TB disease if infected.

The three cut points on Table S2-2 should be used to determine whether the TST result should be classified as positive or negative. A TST result with no induration (0 mm) or a measured induration below the defined cut point for each category is considered to signify absence of infection with *M. tuberculosis*.

In the context of TST screening as part of a TB infection-control program, the interpretation of TST results occurs in two distinct parts: 1) interpretation by standard criteria, without regard to personal risk factors or setting specific factors, of the TST results for infection control, surveillance, and referral purposes, and 2) interpretation by individualized criteria to determine need for treatment of LTBI.

Determining the need for treatment of LTBI is a subsequent and separate task. For infection-control and surveillance purposes, TST results are interpreted and recorded under strict criteria, without considering setting-based or personal risk factors (Table S2-1). Any HCW with a positive TST result from serial TB screening should be referred to a medical provider for an evaluation and to determine the need for treatment of LTBI based on individual risk (Table S2-2).

A.5.1 Interpreting the TST result for infection control and surveillance

On baseline TST testing, a TST result of ≥ 10 mm is considered positive for most HCWs, and a TST result of ≥ 5 mm is considered positive for HCWs who are infected with HIV or who have other immunocompromising conditions (Table S2-2). All HCWs with positive baseline TST results should be referred for medical and diagnostic evaluation, and further skin testing does not need to be performed for these HCWs.

On serial screening for the purposes of infection-control surveillance, TST results showing an increase of ≥ 10 mm within two years should be interpreted and recorded as a TST conversion. For the purposes of assessment and monitoring of infection control, TST conversion rates should be regularly determined. Health-care settings with a large number of HCWs to be tested may have systems in place that can accurately determine the TST conversion rate every month (e.g., from among a group of HCWs tested annually), while smaller settings may have imprecise estimates of their TST conversion rate even with annual assessments.

The precision of the facility's TST conversion rate and any analysis assessing change from baseline TST results will depend on the number and frequency of HCWs tested. This should be considered when establishing a regular interval for TB screening for HCWs.

After a known exposure in a health-care setting, close HCW contacts who have TST results of ≥ 5 mm should be considered to have a positive

TST result, and interpreted as a new infection only in HCWs whose prior TST result is 0 mm. However, HCWs with a baseline or follow-up TST result of >0 mm but <10 mm with a health care–associated exposure to *M. tuberculosis*, who then have an increase of ≥ 10 mm should be considered to have a TST conversion due to a new infection (Table S2-1).

In a contact investigation, a follow-up TST should be administered 8–10 weeks after the end of exposure (rather than 1–3 weeks later, as in two-step testing). In this circumstance, a change from a negative TST result to a positive TST result should **not** be interpreted as a boosted reaction. The change in the TST result indicates a TST conversion and suggests recent exposure, transmission, and infection.

All HCWs who are immunocompromised should be referred for a medical and diagnostic evaluation for any TST result of ≥ 5 mm on baseline or follow-up screening. Because infection-control staff will usually not know the immune status of the HCWs being tested, HCWs who have TST results of 5–9 mm should be advised that such results can be an indication for referral for medical evaluation for HCWs who have HIV infection or other causes of severe immunosuppression.

Once a HCW has met criteria for a positive TST result and has documentation to support this, repeat TSTs do not need to be performed because their results would not provide any additional information (22). This includes HCWs who have positive TST results but who will not receive treatment for LTBI after medical evaluation. For future TB screening, instead of participating in serial skin testing, the HCW should receive a medical evaluation and a symptom screen annually.

A.5.2 Interpreting the TST result for medical and diagnostic referral and evaluation

HCWs who have a positive TST result and who meet the criteria for referral should have a medical and diagnostic evaluation. During that evaluation, it is possible that for HCWs who are at low risk, such as those from low-incidence settings, a baseline result of ≥ 15 mm of induration (instead of ≥ 10 mm) may be the cut point. Table S2-2 presents the criteria used to determine the need for treatment of LTBI.

Setting-based risk factors, such as the prevalence of TB disease and personal risk factors, such as having an immunocompromising condition or known contact with a TB case, should be assessed when choosing the cut point for a positive TST result in making decisions for the diagnosis and treatment of LTBI. The medical evaluation can occur in different settings, including an occupational health clinic, state or local health department, or private medical clinic.

Table S2-1. Criteria for obtaining medical and diagnostic evaluation for HCWs

Purpose of testing	TST results	QFT results
1. Baseline	1. ≥ 10 mm is positive (either first or second step)	1. Conditionally positive or positive
2. Serial testing (without known exposure)	2. Increase of ≥ 10 mm is positive	2. A change from <ul style="list-style-type: none"> - negative to conditionally positive, - negative to positive, or - conditionally positive to positive
3. Known exposure (close contact)	3a. ≥ 5 mm is positive in persons who have a baseline TST result of 0 mm 3b. Increase of ≥ 10 mm is positive in those with baseline or previous follow-up screening TST result ≤ 10 mm	

For HCWs who are otherwise at low risk for LTBI and are tested at the start of employment, a baseline TST result of ≥ 15 mm from two-step testing (instead of ≥ 10 mm) induration may be considered the cut point for a positive TST result for clinical purposes. When 15 mm is used as the cut point, TST results of 10–14 mm may be considered clinically negative; these HCWs should not have repeat TSTs, and the referring physician may not recommend treatment for LTBI. This may be especially true in areas of the country where the prevalence of infection with nontuberculous mycobacteria (NTM) (also known as MOTT) (see Glossary) is high.

HCWs who have TST results of 5–9 mm on baseline testing should be advised that such results may be an indication for treatment of LTBI if the HCW is a contact of a person with infectious TB disease, has HIV infection, or has other causes of severe immunosuppression (e.g., organ transplant, receipt of the equivalent of ≥ 15 mg/day of prednisone for ≥ 1 month). The risk for TB disease in persons treated with corticosteroids increases with higher dose and longer duration of corticosteroid use.

HCWs with negative two-step baseline TST results who are referred for medical evaluation for an increase of ≥ 10 mm induration on follow up TST screening, even who are otherwise at low risk for TB disease, probably acquired *M. tuberculosis* infection since receiving the previous TST and should be evaluated for TB disease. If disease is excluded, the HCW should be offered treatment for LTBI if they have no contraindication to treatment.

Table S2-2. Factors affecting treatment decisions during the medical and diagnostic evaluation, by TST result

TST result ≥ 5 mm is positive in:	TST result ≥ 10 mm is positive in:	TST result ≥ 15 mm is positive in ¹ :
<ul style="list-style-type: none"> • Persons infected with HIV • Recent contacts of a person with TB disease • Persons with fibrotic changes on chest radiograph consistent with prior TB disease • Organ transplant recipients and other immunosuppressed persons (e.g., persons receiving ≥ 15 mg/day of prednisone for ≥ 1 month)³ • TB suspects⁴ 	<ul style="list-style-type: none"> • Recent immigrants (i.e., within the last five years) from countries with a high incidence of TB disease • Persons who inject illicit drugs • Residents and employees (including HCWs)² of the following high-risk congregate settings: <ul style="list-style-type: none"> - hospitals and other health-care facilities - long-term care facilities (e.g., hospices, skilled nursing facilities) - residential facilities for patients with AIDS or other immunocompromising conditions - correctional facilities - homeless shelters • Mycobacteriology laboratory personnel • Persons with any of the following clinical conditions or immunocompromising conditions that place them at high risk for TB disease: <ul style="list-style-type: none"> - silicosis - diabetes mellitus - chronic renal failure - some hematologic disorders (e.g., leukemias and lymphomas) - other specific malignancies (e.g., carcinoma of the head, neck, or lung) - unexplained weight loss of $\geq 10\%$ of ideal body weight - gastrectomy - jejunioileal bypass • Persons living in areas with high incidence of TB disease • Children ≤ 5 years of age • Infants, children, and adolescents exposed to adults at high-risk for developing TB disease 	<ul style="list-style-type: none"> • Persons with no known risk factors for TB disease • HCWs who are otherwise at low-risk for TB disease and who received baseline testing at the start of employment as part of a TB screening program²

¹ TST results ≥ 15 mm is positive in anyone. These persons should receive a symptom screen and do not need be tested again. They should be evaluated for TB disease, and if disease is excluded, they should be offered treatment for LTBI if they have no contraindication to treatment.

² For HCWs who are otherwise at low risk for LTBI and progression to TB disease if infected, and who received baseline testing at the start of employment as part of a TB infection control screening program, a TST result of ≥ 15 mm (instead of 10 mm) is considered to be positive. Although a result of ≥ 10 mm is considered a positive result for HCWs for the purposes of referral for medical and diagnostic evaluation, if the TST result is 10–14 mm, the referring clinician may not recommend treatment of LTBI.

³ The risk for TB disease in persons treated with corticosteroids increases with higher dose and longer duration of corticosteroid use.

⁴ Persons considered to be TB suspects may be treated on the basis of the medical and diagnostic evaluation, regardless of the TST results.

A.6 Quality Control (QC) Program for techniques of TST administration and reading TST results

Random variation (i.e., differences in procedural techniques) in TST administration and reading TST results can cause poor quality TST results, including false-positive or false-negative TST results. Many of the variations in administering TSTs and reading TST results can be avoided by training and attention to details. HCWs who are responsible for TST procedures should be trained to reduce variation by following standardized operational procedures, and should be observed by an expert TST trainer. All TST procedures (administering, reading and recording the results) should be supervised and controlled to detect and correct variation. Corrective actions may include coaching and demonstration by the TST trainer. Annual re-training is recommended for HCWs responsible for administering TSTs and reading TST results.

One strategy to identify TST procedure variation is to use a quality control tool (Table S2-3). The expert TST trainer should observe the procedures and indicate procedural variation on the observation checklists.

A.6.1. QC for administering TSTs by the Mantoux method

The TST trainer should participate in QC TST administrations with other TST trainers to maintain TST trainer certification. State regulations specify who is qualified to administer the test by injection. The TST trainer should first ensure antigen stability by maintaining the manufacturer's recommended cold chain (i.e., controlling antigen exposure to heat and light from the time it is out of refrigeration until the time it is placed back into refrigeration or until the vial is empty or expired). The TST trainer should prevent infection during an injection by preventing contamination of solution, needle, syringe, and by preparing the skin.

The TST trainer should prevent antigen administration errors by controlling the five rights of administration: 1) the right antigen, 2) the right dose, 3) the right patient, 4) the right route, 5) the right time for TST administration, reading, and clinical evaluation (291). Finally, the TST trainer should observe and coach the HCW in training in administering multiple intradermal injections by the Mantoux method. The TST trainer should record procedural variation on the observation checklist (Table S2-3). TST training and coaching should continue until ≥ 10 correct skin test placements (i.e., ≥ 6 mm wheal) are achieved (Table S2-3).

For training purposes, normal saline for injection may be used instead of PPD for intradermal injections. Volunteers are usually other HCWs who agree to be tested. Try to recruit volunteers who have known positive TST results so the trainees can practice reading positive TST results. A previous TST is not a contraindication to a subsequent TST unless the test was associated with severe ulceration or anaphylactic shock, which are very rare adverse events (22;199;200).

Initial training for a TST *placer* consists of

- Three hours of introductory lecture and demonstration by an expert TST placer or trainer. An expert TST trainer is a qualified HCW who has received training on administering multiple TSTs and reading multiple TST results.
- Nine hours of supervised practical work using procedural checklists observed and coached by the expert TST trainer (Table S2-3).
- Administering ≥ 10 total skin tests on volunteers, using injectable saline, and producing ≥ 10 wheals that measure 6-10 mm.

TST training should include supervised TST administration, which is a procedure in which an expert TST trainer supervises a TST trainee during all steps on the procedural observation checklist for TST administration (Table S2-3). Wheal size should be checked for all supervised TST administrations, and skin tests should be repeated if wheal size is inadequate (i.e., if < 6 mm). TST training and coaching should continue until ≥ 10 correct skin test placements (i.e., ≥ 6 mm wheal) are achieved (Table S2-3).

A.6.2 QC for reading TST results by the palpation method

The TST trainer should participate in QC readings with other TST trainers to maintain TST trainer certification. When training HCWs to read TST results, it is helpful to provide measurable TST responses, (i.e., try to recruit volunteers who have known positive TST results so the trainees can practice reading positive TST results).

TST readers should correctly read both measurable (> 0 mm) and non-measurable responses (0 mm) (e.g., ≥ 20 TST results: ≥ 10 measurable and ≥ 10 non-measurable). The TST trainer should observe and coach the HCW in reading multiple TST results by the palpation method and should record procedure variation on the observation checklist (Table S2-3).

The TST trainer should conduct BIDRs for comparison with the HCW's reading. BIDRs are performed when two or more consecutive TST readers immediately measure the same TST result by standard procedures without consulting or observing one

another's readings and record results independently (may use recommended procedural observation checklist; Table S2-3).

Initial training for a TST reader consists of:

- Six hours of introductory lecture and demonstration by an expert TST reader. Training materials are available from CDC (197;280) and should also be available at the state or local health department.
- Four sessions (16 hours total) of supervised practical work using procedural checklists (observed and coached by an expert TST reader).
- Performing ≥ 80 BIDR readings. TST trainers should attempt to organize the sessions so that at least 50% of the TST results read have a result >0 mm according to the expert TST reader.
- On the last day of TST training, performing ≥ 30 BIDR readings (out of the total 80 readings). TST trainers should attempt to ensure that at least 25% of those tested have a TST result >0 mm according to the expert TST reader.
- Missing no more than two items on the procedural observation checklist (Table S3-2) for three random observations by an expert TST reader.
- Performing all procedures on the checklist correctly during the final observation.

TST training and coaching should continue until the HCW is able to perform all procedures correctly and a satisfactory measurement is achieved (i.e., the trainer and the trainee read the TST results within 2 mm of each other). For example, if the trainer reads the TST result as 11 mm (this may be considered the “gold standard” reading), the trainee’s reading should be between 9-13 mm to be considered correct. Only a single mm measured induration should be recorded (not “11 mm x 11 mm” or “11 mm x 15 mm”).

The following *Quality control (QC) Procedural Observation Checklist* (Table S2-3) is recommended by CDC as a tool for use during TST training.

Table S2-3. Quality control (QC) procedural observation checklist for placing tuberculin skin tests (TSTs)

Placing a TST, Mantoux method

Date _____

Trainer (QC by) _____

Trainee (TST administered by) _____

Scoring: ✓ or Y = yes; N = No; NA = not applicable

I. Preliminary

- _____ Utilizes appropriate hand hygiene methods before starting
- _____ Screens patient for contraindications (severe adverse reactions to prior TST)¹
- _____ Uses well-lit area

II. Syringe filled with exactly 0.1 ml of 5 tuberculin units (TU) PPD antigen

- _____ Removes antigen vial from refrigeration and confirms that it is 5 TU PPD antigen
- _____ Checks label and expiration date on vial
- _____ Marks opening date on multidose vial
- _____ Fills immediately after vial removed from refrigeration
- _____ Cleans vial stopper with antiseptic swab
- _____ Twists needle onto syringe to ensure tight fit
- _____ Removes needle guard
- _____ Inserts needle into the vial
- _____ Draws slightly over 0.1 ml of 5 TU PPD into syringe
- _____ Removes needle from vial
- _____ Removes excess volume or air bubbles to exactly 0.1 ml of 5 TU PPD
- _____ Returns antigen vial to the refrigerator immediately after filling²

III. TST administration site selected and cleaned

- _____ Selects upper third of forearm with palm up³
- _____ Selects site ≥ 2 inches from elbow, wrist, or other injection site
- _____ Selects site free from veins, lesions, heavy hair, bruises, scars, muscle ridge
- _____ Cleans arm site with antiseptic swab using circular motion from center to outside
- _____ Allows site to dry thoroughly before administering antigen

IV. Needle inserted properly to administer antigen

- _____ Rests arm on firm, well-lit surface
- _____ Stretches skin slightly
- _____ Holds needle bevel-up and tip at 5E-15E angle to skin
- _____ Inserts needle in first layer of skin with tip visible beneath skin
- _____ Advances needle until entire bevel is under the first layer of skin
- _____ Releases stretched skin
- _____ Injects entire dose slowly
- _____ Forms wheal, as liquid is injected
- _____ Removes needle without pressing area
- _____ Places used needle and syringe immediately in puncture-resistant container without recapping needle
- _____ Immediately measures wheal to ensure 6-10 mm in diameter
- _____ Actual wheal measurement : _____ mm
- _____ If blood or fluid present, blots site lightly with gauze or cotton ball
- _____ Discards used gauze or cotton ball according to local standard precautions
- _____ Re-injects ≥ 2 inches from original site if inadequate wheal (i.e., < 6 mm)
- _____ Washes hands after TST administration

V. *Explanation to the client regarding care instructions for the injection site:*

- _____ The wheal (bump) is normal and will remain about ten minutes
- _____ Do not touch wheal; avoid scratching
- _____ Avoid pressure or bandage on injection site
- _____ Rare local discomfort and irritation does not require treatment
- _____ May wash with soap and water (without pressure) after one hour
- _____ No lotions or liquids on site, except for light washing, as above
- _____ Keep appointment for reading!

¹ Severe adverse reactions to the TST are very rare, but include ulceration, necrosis, vesiculation, or bullae at the test site, or anaphalactic shock, and are the only contraindications to having a TST administered.

² Prefilling of syringes is not recommended. Skin tests should be given as soon after the syringe has been filled as possible (22).

³ If neither arm is available, the back of the shoulder is a good alternate TST administration site (292).

Table S2-3. Quality control (QC) procedural observation checklist for reading tuberculin skin test (TST) results

Reading a TST result, palpation method

Date _____

Trainer (QC by) _____

Trainee (TST result read by) _____

Scoring: √ or Y = yes; N = no; NA = not applicable

I. Preliminary

- _____ Utilizes appropriate hand hygiene methods before starting
- _____ Keeps fingernails shorter than fingertips to avoid misreading TST result
- _____ Keeps TST reading materials at hand (eyeliner pencil or ballpoint pen¹, ruler)
- _____ Uses well-lit area

II. Inspect for site

- _____ Inspects for the site of the injection

III. Palpate: finding margin ridges (if any)

- _____ Palpates with arm bent at elbow 90°
- _____ Lightly sweeps two inches diameter from injection site in four directions
- _____ Uses zigzag feather-like touch
- _____ Repeats palpation with arm bent at elbow at a 45° angle to determine presence or absence of induration.

If induration is present, continue with these steps.²

V. Mark: placing marks

- _____ Holds palm over injection site
- _____ Moves finger pad toward injection site
- _____ Drops fingernail on skin at indurated margin before marking with marker
- _____ Places single dot with marker on skin at fingernail, left
- _____ Places single dot with marker on skin at fingernail, right
- _____ Inspects dots, repeats finger movements towards indurated margin, adjusts dots if needed
- _____ Dots are transverse (perpendicular) to long axis of forearm

V. Measure: placing and reading ruler

- _____ Places zero ruler line inside left dot edge
- _____ Reads ruler line inside right dot edge
- _____ Reads lower mark when between scale divisions

VI. Documenting results

- _____ Correctly records results in mm; only a single measured induration in mm should be recorded
- Trainee's measurement: _____ mm
- Trainer's ("gold standard") measurement: _____ mm
- Trainee's result within 2 mm of gold standard reading?³ _____ (yes/no)

¹ A fine-tipped eyeliner pencil or ballpoint pen may be used as a marker. An eyeliner pencil is useful for TST training and for blinded independent duplicate readings (BIDRs) because marks are easily removed. Alternative TST result reading methods have been described (282-284;288).

² If induration is not present, record the TST result as 0 mm and go to the end of this form (VI).

³ If the TST trainer reads the TST result as 11 mm (the "gold standard" reading), the trainee's TST result should be between 9 and 13 mm to be considered correct. Only a single measured induration in mm should be recorded.

A.7 Special considerations in tuberculin skin testing

A.7.1 Anergy

The absence of a reaction to a TST does not exclude a diagnosis of TB disease or infection with *M. tuberculosis*. In immunocompromised persons, delayed-type hypersensitivity (DTH) responses such as tuberculin reactions can decrease or disappear more rapidly; and a few otherwise healthy persons apparently are incapable of reacting to tuberculin even after diagnosed infection with *M. tuberculosis*. This condition, called anergy, can be caused by many factors, such as advanced HIV infection, measles infection, sarcoidosis, poor nutrition, certain medications, vaccinations, TB disease itself, and other factors (182;269;293-296).

Anergy testing is not routinely recommended for anyone infected with HIV or who are otherwise immunocompromised because TST results alone, positive or negative, are not sensitive or specific enough to guide clinical decision making (182).

A.7.2 Reconstitution of DTH in HIV-infected persons taking antiretroviral therapy

In one prospective study (297), TB patients who initially had negative TST results had positive TST results after initiation of highly active antiretroviral therapy (HAART). HCWs must be aware of the potential public health and clinical implications of restored TST reactivity among persons who have not been diagnosed with TB disease but who may have LTBI. Repeat testing for infection *M. tuberculosis* is recommended in HIV-infected persons previously known to have negative TST results after the initiation of HAART. Recommendations on the prevention and treatment of TB in HIV-infected persons have been published (29;40;210).

A.7.3 Pregnancy

Tens of thousands of pregnant women have received TSTs since the test was developed, and no documented episodes of TST-related fetal harm have been reported (298). Pregnant HCWs should be included in serial skin testing as part of an infection-control program or a contact investigation since no contraindication for skin testing exists.

A.7.4 Booster phenomenon and two-step testing

All newly employed HCWs who are screened with TSTs should receive baseline two-step TSTs upon hire unless they have documentation of a positive TST or QFT result, or documentation of treatment for LTBI or TB disease. If an initial TST result is classified as negative, the second step of a two-step TST should be administered 1–3 weeks after the first TST was administered. In HCWs with one documented negative TST result during the 12 months proceeding the time of employment, only

one additional TST is needed for baseline testing. Screening programs that use QFT eliminate the need for two-step testing.

In some persons with LTBI, the DTH responsible for TST reactions wanes over time. Repeated TST can elicit a reaction called “boosting” whereupon an initial TST result in a person with LTBI is negative, but a subsequent TST result is positive. For example, a skin test administered years after infection with *M. tuberculosis*, can result in a false-negative result. This initial skin test may then stimulate (or “boost”) their ability to react to tuberculin, resulting in a positive result to a subsequent test (including the second step of a two-step procedure) (26;66;279;299;300). With serial testing, a boosted reaction on a subsequent TST result might be misinterpreted as a newly acquired infection relative to the false-negative result from the initial TST. Misinterpretation of a boosted reaction as a new infection with *M. tuberculosis* or TST conversion could prompt unnecessary investigations to find the source case, unnecessary treatment for the person tested, and unnecessary testing of other HCWs.

The booster phenomenon can occur in anyone, but it is most likely to occur in older persons. Boosted TST results can occur in persons with remote infection with *M. tuberculosis* (i.e., infected many years ago), persons infected with NTM (also known as MOTT), and persons with prior BCG vaccination (29;201;206;301;302).

To estimate the frequency of boosting in a particular setting, a four-appointment schedule of TST administration and reading of TST results (i.e., appointments for TST administration and reading of both steps in the two-step test) is preferred, rather than the three-appointment schedule practiced in some settings (i.e., appointments for the administration of both tests of the two-step test, with reading of the second-step TST result only) (161).

Use of a three-appointment schedule can result in the loss of diagnostic information especially relevant to a subsequent medical evaluation for possible LTBI but may be acceptable in some settings (198;301;303). Given that any setting may have HCWs who are at risk of boosting, and that a rate of boosting even as low as 1% can result in unnecessary investigation of transmission, baseline two-step testing should be performed on **all** newly hired HCWs.

Boosted TST reactions could lead to a false classification of *potential ongoing transmission* for the setting if the HCW’s follow-up TST result is positive and occurred during routine TB screening rather than at baseline with the two-step TST. This is especially important for settings that are classified as *low risk* where testing is indicated only upon exposure and a reliable baseline test is necessary to detect health-care-associated transmission of *M. tuberculosis*.

In programs that use TST to detect infection with *M. tuberculosis*, two-step testing is recommended for baseline testing of all persons who will routinely receive TSTs (i.e., HCWs and residents of long-term care

facilities) to reduce the likelihood of mistaking a boosted reaction for a new infection and to establish a reliable baseline TST result. Guidance for baseline TST for HCWs is provided in Table S2-4.

If the result of the baseline first step of a two-step TST meets the criteria for medical and diagnostic evaluation (Table S2-1), further skin testing is not necessary (even if the medical and diagnostic evaluation do not result in the diagnosis of LTBI).

If an initial TST result is classified as negative, the second step of a two-step TST should be administered 1–3 weeks after the first TST was administered. A positive result to the second step of a two-step TST, where the result of the baseline first step of the two-step TST was negative, most probably represents boosting. On the basis of the second-step TST result and the criteria in Table S2-1, the HCW should be referred for medical and diagnostic evaluation. **The boosted reaction should not be considered a TST conversion.** If the second test result does not meet the criteria for referral for medical and diagnostic evaluation, the HCW should be classified as uninfected and retested as needed. A reaction on any subsequent TST that meets the criteria for a positive test in Table S2-1 most probably represents new infection with *M. tuberculosis* (29).

Two-step testing should be used only for baseline screening for newly hired HCWs (and other persons who will routinely receive TSTs) and should not be used for a contact investigation.

In a contact investigation, a follow-up TST should be administered 8–10 weeks after the end of exposure for those with negative results on the first TST (rather than 1–3 weeks later, as in a two-step TST). In this circumstance, a change from a negative to a positive TST result should **not** be interpreted as a boosted reaction. The change in the TST result indicates a TST conversion and suggests recent exposure, transmission, and infection.

After a known exposure in a health care–associated setting (close contact to a patient with infectious TB disease or perhaps to another HCW with infectious TB disease), TST results of ≥ 5 mm should be considered positive and interpreted as a new infection only in HCWs whose prior TST result is 0 mm. However, HCWs with a baseline or follow-up TST result >0 mm but <10 mm with a health-care–associated exposure to *M. tuberculosis* who have an increase ≥ 10 mm should be interpreted as a TST conversion due to a new infection.

Table S2-4. Indications for two-step TSTs

Situation	Recommended testing
No previous TST result	Two-step baseline TSTs
Previous negative TST result (documented or not) >12 months prior to new employment	Two-step baseline TSTs
Previous documented negative TST result ≤12 months prior to new employment	Single TST needed for baseline testing (this will be the second-step)
Two or more previous documented negative TSTs, but most recent TST >12 months prior to new employment	Single TST; two-step testing is not necessary
Previous documented positive TST result	No TST
Previous undocumented positive TST result ¹	Two-step baseline TST(s)
Previous BCG vaccination	Two-step baseline TST(s)
Programs that use serial QFT	Two-step testing is not necessary if QFT will be continued

¹ For newly hired HCWs and other persons who will be tested on a routine basis (such as residents of long-term care facilities), a previous TST is not a contraindication to a subsequent TST unless the test was associated with severe ulceration or anaphylactic shock, which are very rare adverse events (199;200;304). If the previous positive TST result is not documented, administer two-step TSTs.

A.7.5 BCG vaccination

In the United States, vaccination with BCG is not recommended routinely for anyone, including HCWs or children (201). Prior BCG vaccination is not a contraindication to having a TST administered, or two-step skin testing. HCWs with prior BCG vaccination should receive baseline skin testing in the same way as those without BCG vaccination (Table S2-4).

Prior BCG vaccination can lead to boosting in baseline two-step testing in some persons (66;205;301;302;305). It is not possible to distinguish a boosted TST reaction resulting from BCG vaccination (a false-positive TST result) and a TST result due to prior infection with *M. tuberculosis* (true positive TST result) (29). Infection-control programs should refer HCWs with positive TST results for medical evaluation as soon as possible (Table S2.2).

Prior BCG vaccination increases the probability of a boosted reaction that is likely to be uncovered on initial two-step skin testing. For an HCW with a negative baseline two-step TST result who is a known contact of a patient who has suspected or confirmed infectious TB

disease, treatment for LTBI should be considered if the TST result is ≥ 5 mm, regardless of BCG vaccination status.

A.7.6 PPD preparations for diagnosing infection with *M. tuberculosis*

Two PPD preparations are currently available in the United States: Tubersol[®] (Pasteur Merieux-Connaught) (199) and Aplisol[®] (Parkdale Pharmaceuticals) (200). When compared with the US reference PPD, there was no difference in TST interpretation between the two (306); however, when Tubersol[®] and Aplisol[®] were compared to each other, there was a slight difference in reactivity, Aplisol producing slightly larger reactions than Tubersol[®], but this difference did not reach statistical significance (306). The difference in specificity, 98% versus 99%, was likewise small. However when applied in large institutional settings, which test thousands of workers annually who are at low risk for infection with *M. tuberculosis*, this difference in specificity may affect the PPD.

TB screening programs should use one antigen consistently and realize that changes in products might make serial changes in TST result size difficult to interpret. In one report, systematic changes in product use resulted in a cluster of pseudo-conversions that were believed erroneously to indicate a health-care-associated outbreak (307). Persons responsible for making decisions about the choice of pharmacy products should seek advice from the state or local health department's TB infection-control program before switching PPD preparations and should inform program staff of any changes.

A.7.7 HCWs who refuse testing for *M. tuberculosis* infection

If an HCW refuses testing for *M. tuberculosis* infection, educate them on the importance of serial screening of HCWs for LTBI and TB disease. If the HCW refuses to have a TST administered, offer to test them with the QFT and vice versa.

B. The QuantiFERON-TB test (QFT) and other cytokine-based assays

The whole-blood interferon gamma assay, QuantiFERON-TB (QFT), is an FDA-approved in vitro cytokine-based assay for cell-mediated immune reactivity to *M. tuberculosis*. Unlike a TST, the QFT requires a single patient visit, assesses response to both *M. tuberculosis* and NTM (also known as MOTT) simultaneously, and does not boost anamnestic immune responses. Interpretation of the QFT result is less subjective than interpretation of the TST result, and the QFT result may be affected less by prior BCG vaccination and reactivity to NTM than the TST (204). The QFT may be used for screening HCWs for infection with *M. tuberculosis* and may be more efficient and cost effective than TSTs (100). Other cytokine-based immunoassays are under development and may be demonstrated to be useful in the diagnosis of *M. tuberculosis* infection. Future FDA licensed products in combination with CDC-issued recommendations may provide additional diagnostic alternatives.

B.1 Performing the QFT

The QFT should be performed as described in the product insert provided with the QFT kit available from the manufacturer's website (www.cellestis.com). An abbreviated test procedure is described below.

- B.1.1 Blood collection:** A blood sample (minimum of 5 mL) is collected into sterile evacuated blood tubes containing heparin as anticoagulant (green caps – 7 or 10 mL tubes recommended to ensure sufficient blood is collected). The solutions in the tubes should be well mixed after filling, the tubes clearly labeled, and stored at room temperature. Blood samples should be transported to the laboratory performing the test as soon as possible to allow sufficient time for the laboratory to process the blood samples within 12 hours of collection.
- B.1.2 Laboratory step 1: Incubation of blood samples with tuberculin and control antigens.** Within 12 hours of collection, laboratory staff must dispense 4 x 1 mL aliquots of blood into 4 wells of a 24-well culture plate and add tuberculin PPD, *M. avium* PPD, Mitogen positive control, or Saline negative control separately to the respective wells. The solutions on the plate should be mixed and incubated at 37°C for 16-24 hours.
- B.1.3 Laboratory step 2: Measurement of interferon-gamma levels in plasma samples.** Plasma is collected from above the settled blood cells in each incubation well and the concentration of interferon-gamma present in each sample is determined by an enzyme-linked immunosorbent assay (ELISA). Data is interpreted with the aid of software supplied by the manufacturer and results reported.

B.2 Interpreting the QFT result

Interpretation of QFT data is performed electronically using the QFT software supplied by the manufacturer. Table S2-5 indicates the approved interpretation method that is automatically performed by the software. A complete description of the test's interpretation is included in the product insert.

Table S2-5: QFT Results and Interpretation

M – N¹ (IU/mL)	T – N² (IU/mL)	% Tuberculin Response³	% Avian Difference	Report and Laboratory Interpretation	Clinical Interpretation
≥1.5	≥1.5	≥30%	≤10%	QFT % Tuberculin Response is ≥30%	Positive QFT result, <i>M. tuberculosis</i> infection likely
≥1.5	≥1.5	≥15% but <30%	≤10%	QFT % Tuberculin Response is 15-30%	Conditionally Positive QFT result, <i>M. tuberculosis</i> infection likely if risk identified but not likely for Low-risk individuals
≥1.5	All other response profiles			QFT % Tuberculin Response is <15% or not significant	Negative QFT result, <i>M. tuberculosis</i> infection NOT likely
≤1.5	All other response profiles			QFT IFN-γ response to mitogen is inadequate.	Indeterminate QFT result

¹“M-N” is the IFN-γ response to mitogen minus the IFN-γ response to nil antigen.

²“T-N” is the IFN-γ response to PPD from *M. tuberculosis* minus the IFN-γ response to nil antigen, and this must be ≥1.5 IU/mL for a person to be considered to have a positive QFT result for *M. tuberculosis* infection. If T-N <1.5 IU/mL the individual is deemed negative for *M. tuberculosis* infection regardless of their % Human Response and % Avian Difference results.

³ A % **Tuberculin Response** cut point of 15% is used for people with identified risk for infection with *M. tuberculosis* while a cut point of 30% is used for people with no identified risk factors.

Table S2-6. Factors affecting treatment decisions during the medical and diagnostic evaluation, by QFT result

QFT is performed as part of serial TB screening program and result is <i>conditionally positive</i> or <i>positive</i> in those at increased risk for progression to TB disease ¹	QFT result is <i>conditionally positive</i> or <i>positive</i> in those at increased risk for LTBI	QFT result is positive in those who have no identified risk for exposure to <i>M. tuberculosis</i> or progression to TB disease
<ul style="list-style-type: none"> • Persons infected with HIV • Recent contacts of a person with TB disease • Persons with fibrotic changes on chest radiograph consistent with prior TB disease • Organ transplant recipients and other immunosuppressed persons (e.g., persons receiving ≥ 15 mg/day of prednisone for ≥ 1 month)³ • TB suspects⁴ 	<ul style="list-style-type: none"> • Recent immigrants (i.e., within the last five years) from countries with a high incidence of TB disease • Persons who inject illicit drugs • Residents and employees (including HCWs)² of the following high-risk congregate settings: <ul style="list-style-type: none"> - correctional facilities - long-term care facilities (e.g., hospices, skilled nursing facilities) - hospitals and other health-care facilities - residential facilities for patients with AIDS or other immunocompromising conditions - homeless shelters • Mycobacteriology laboratory personnel • Persons with any of the following clinical conditions or immunocompromising conditions that place them at high risk for TB disease: <ul style="list-style-type: none"> - silicosis - diabetes mellitus - chronic renal failure - some hematologic disorders (e.g., leukemias and lymphomas) - other specific malignancies (e.g., carcinoma of the head, neck, or lung) - unexplained weight loss of $\geq 10\%$ of ideal body weight - gastrectomy - jejunioileal bypass • Persons living in areas with high incidence of TB disease • Children ≤ 5 years of age • Infants, children, and adolescents exposed to adults at high-risk for developing TB disease 	<ul style="list-style-type: none"> • A positive confirmatory TST

- ¹ In routine medical practice, outside of TB screening programs for HCWs, QFT is not currently recommended for persons who are at increased risk for progression to TB disease if infected. However, in the course of serial TB screening programs for HCWs, persons discovered to have *conditionally positive* or *positive* QFT results should be evaluated for TB disease and if disease is excluded, they should be considered for treatment of LTBI if they have no contraindication to treatment(29)
- ² For HCWs who are otherwise at low risk for LTBI and progression TB disease if infected and are tested at the start of employment, although a QFT result of *conditionally positive* or *positive* is considered positive for the purposes of referral for medical and diagnostic evaluation, the referring clinician may not recommend treatment for LTBI.
- ³ The risk for TB disease in persons treated with corticosteroids increases with higher dose and longer duration of corticosteroid use.
- ⁴ Persons considered to be TB suspects may be treated on the basis of the medical and diagnostic evaluation, regardless of the QFT results.

B.3 Interpreting QFT results in HCWs

B.3.1 Interpreting the QFT result for infection control, surveillance and referral

For all HCWs, a *positive* or a *conditionally positive* QFT result is considered a positive baseline result for the purposes of infection control surveillance. Persons with a *positive* QFT result should be referred for a medical and diagnostic evaluation but do not need to be tested further for surveillance.

Persons with a *conditionally positive* QFT result should also be referred for medical and diagnostic evaluation. Serially testing with QFT should be continued as part of TB screening but these persons should not be included in the cohort of HCWs with negative baseline QFT results for surveillance purposes and calculation of QFT conversion rates (see Table S2-6).

A person with QFT results **changing from *conditionally positive* to *positive*** should also be referred for medical and diagnostic evaluation; however, the result should not be included in the calculation of the setting's QFT conversion rate.

On subsequent serial testing, a person with QFT results **changing from *negative* to *positive*** should be referred for medical and diagnostic evaluation and considered to be a QFT converter for infection-control surveillance purposes.

QFT conversion rates should be determined regularly. The precision of the QFT conversion rate and any analysis assessing a change from baseline will depend on the number and frequency of HCWs tested, and should be considered when establishing a regular interval for evaluation and monitoring of HCWs with QFTs. Health-care settings with a large number of HCWs to be tested may have systems in place that can accurately determine the QFT conversion rate every month (e.g., from among a group of HCWs tested annually). However, QFT conversion rates are more difficult to calculate in settings with a small number of HCWs even with annual assessments.

B.3.2 Interpreting the QFT result during medical and diagnostic evaluation

HCWs who meet the criteria for referral should have a medical and diagnostic evaluation. Table S2-6 presents the factors affecting treatment decisions during medical and diagnostic evaluation by risk for infection with *M. tuberculosis*. Setting-based risk factors, such as the prevalence of TB disease in the setting and personal risk factors, such as immunocompromising conditions or known contact with a person with TB disease, should be assessed when making decisions for the diagnosis and treatment of LTBI. Medical evaluations can occur in different settings, including an occupational health clinic, state or local health department, or private medical clinic.

B.4 Quality control (QC) program for the QFT

The two parts of the QFT are blood stimulation and ELISA testing. The manufacturer (Cellestis) describes positive and negative "controls" for the blood stimulation, however these are used for calculation of results so that they do not necessarily improve accuracy. The QFT needs to meet strict performance parameters for a valid test result to be recorded. QC is an on-going laboratory matter; a separate QC program is not required by the infection-control team.

The laboratory performing the QFT will be required to validate their performance of the test prior to processing clinical samples. State and federal laboratory requirements regulate laboratory testing procedures.

B.5 Special considerations in performing QFT

B.5.1 Anergy

The mitogen positive control used in the QFT serves as both a measure of the viability of the lymphocytes in a blood sample, and the immune status of the donor. If a person's mitogen-stimulated blood sample does not produce ≥ 1.5 IU/mL of interferon- γ above that found for the nil control, the result is expressed as *indeterminate*. An indeterminate result does not mean that the QFT has failed, it indicates the test subject has inadequate immune response for the test to be performed, which may be due to anergy or immunosuppression. Alternatively, the blood samples may have been incorrectly treated. For people in whom an *indeterminate* result is reported, the person should be retested using the QFT and they should be advised that their result could be suggestive of immunosuppression.

B.5.2 QFT use with HIV-infected persons taking antiretroviral therapy

To date, the effect of HIV infection and the effect of antiretroviral therapy (ART) on the performance of the QFT has not been fully evaluated.

B.5.3 Persons aged <17 years or Pregnant

The use of the QFT has not been adequately evaluated among pregnant women and persons aged <17 years, and is not recommended for such populations (100).

B.5.4 Booster phenomenon and performing QFT

The QFT does not involve the injection of any substance into the individuals being tested and is not affected by the booster phenomenon. The QFT may be repeated as often as required without any possibility of boosting.

B.5.5 BCG vaccination

In the United States, vaccination with BCG is not recommended routinely (201). Prior BCG vaccination is not a contraindication to having a QFT performed. HCWs with prior BCG vaccination should receive a baseline QFT in the same way as those without BCG vaccination.

C. Chest radiography

Chest radiography is used to look for abnormalities suggestive of pulmonary TB disease. HCWs who have positive test results for *M. tuberculosis* infection or signs or symptoms of TB disease regardless of test results for *M. tuberculosis* infection should have a chest radiograph performed to exclude a diagnosis of TB disease. However, a chest radiograph is not a substitute for TST or QFT in a serial TB screening program for HCWs.

Persons who have LTBI or cured TB disease should **not** have repeat chest radiographs performed routinely (101). Repeat radiographs are not needed unless signs or symptoms of TB disease develop, or a clinician recommends a repeat chest radiograph (29;101), or as part of a contact investigation.

Radiographic abnormalities that strongly suggest pulmonary TB disease include upper-lobe infiltration, cavitation, and effusion. Infiltrates can be patchy or nodular and seen in the apical or subapical posterior upper lobes or superior segment of the lower lobes in the lungs. If radiographic or clinical findings are consistent with TB disease, further studies (e.g., medical evaluation, bacteriologic examinations, comparison of current and prior chest radiographs) should be performed (23).

A chest radiograph is indicated for all persons being considered for treatment of LTBI to exclude pulmonary TB disease. If chest radiographs do not indicate pulmonary TB **and** if no signs or symptoms of TB disease are present, persons with a positive test result for infection with *M. tuberculosis* may be candidates for treatment of LTBI. In persons with LTBI, the chest radiograph is usually normal, although it may show abnormalities suggestive of prior TB disease or other pulmonary conditions. In patients with signs or

symptoms of TB disease, pulmonary infiltrates may only be apparent on CT-scan. Previous, healed TB disease can produce radiographic findings that usually differ from those associated with current TB disease. These findings include nodules, fibrotic scars, calcified granulomas, or basal pleural thickening. Nodules and fibrotic scars might contain slowly multiplying tubercle bacilli and pose a high risk for progression to TB disease. Calcified nodular lesions (calcified granulomas) and apical pleural thickening pose a lower risk for progression to TB disease (23).

C.1 Chest radiography and pregnancy

Because TB disease is dangerous to both mother and fetus, pregnant women who have a positive TST result or who are suspected of having TB disease as indicated by symptoms or other concerns, should receive chest radiographs (with shielding consistent with safety guidelines) as soon as feasible, even during the first trimester of pregnancy (23;29;298).

C.2 Chest radiography and HIV-infected persons

The radiographic presentation of pulmonary TB in persons infected with HIV might be apical (in the top part of the lungs). However, apical cavitary disease is less common among such patients. More common chest radiograph findings for persons infected with HIV are infiltrates in any lung zone, mediastinal or hilar adenopathy, or, in rare cases, a normal chest radiograph (23;83;126;308-313).

D. Evaluation of sputum samples

Sputum examination is a crucial diagnostic procedure for pulmonary TB disease (22) and is indicated for:

- Persons suspected of having pulmonary TB disease due to chest radiograph findings consistent with TB disease, especially those with any symptoms of infection in the lung, pleura, or airways including larynx
- Persons with chest radiographic findings suggestive of prior, healed TB disease
- HIV-infected persons with any respiratory signs or symptoms regardless of chest radiograph findings
- Persons suspected of having pulmonary TB disease for whom bronchoscopy is planned

D.1 Sputum specimen collection

Persons requiring sputum examination should have at least three sputum specimens collected 8–24 hours apart (112), with at least one being an early morning specimen, examined by smear and culture (314). Specimens should be collected in a sputum induction booth or in an AII room. In resource-limited settings without environmental containment, or when an AII room is not available, sputum collection may be performed safely outdoors, away from other people, windows and ventilation intakes. Patients should be instructed on how to produce an adequate sputum specimen (containing little saliva), and should be supervised and observed by a HCW during the collection of sputum, if possible (22). However, if the patient's specimen is judged to be inadequate it should still

be sent for bacteriologic testing. The HCW should wear an N95 disposable respirator during sputum collection.

D.2 Sputum induction

For patients who are unable to produce an adequate sputum specimen, expectoration may be induced by inhalation of an aerosol of warm, hypertonic saline. As sputum induction is a cough-inducing procedure, pre-treatment with a bronchodilator should be considered in patients with a history of asthma or other chronic obstructive airway diseases. Bronchodilator medication should be available during any sputum induction in the event of induced bronchospasm.

The patient should be seated in a small, well-ventilated sputum induction booth or in an AII room (Supplement 3). For best results, an ultrasonic nebulizer that generates an aerosol of approximately 5 ml/minute should be used. Three percent hypertonic saline is commercially available, and its safety has been demonstrated. At least 30 ml of 3% hypertonic saline should be administered; administration of smaller volumes will have a lower yield. Higher concentrations may be used with an adjustment in the dose and closer monitoring for adverse effects.

Patients should be instructed to breathe deeply and cough intermittently. Sputum induction should be continued for up to 15 minutes or until an adequate specimen (containing little saliva) is produced. Induced sputum will often be clear and watery. Any expectoration produced should be accepted, labeled as expectorated sputum, and sent to the laboratory.

D.3 Laboratory examination

Detection of AFB in stained smears by microscopy can provide the first bacteriologic indication of TB disease. Laboratories should report positive smear results within 24 hours of collection and positive culture results within 24 hours of the notation of the positive culture. A positive result for AFB in a sputum smear is predictive of increased infectiousness. Smears allow identification of mycobacteria, but definitive identification, strain typing, and drug-susceptibility testing of *M. tuberculosis* require that a culture be performed (22). Negative AFB sputum smear results do not exclude a diagnosis of TB disease if clinical suspicion of disease is high. In the United States, 63% of patients with reported positive sputum culture results have positive AFB sputum smear results (104).

A culture of sputum or other clinical specimen that contains *M. tuberculosis* provides a definitive diagnosis of TB disease. In most cases, identification of *M. tuberculosis* and drug-susceptibility results are available within 28 days (or 4-6 weeks) using recommended rapid methods such as liquid culture and DNA probes. A negative culture result is obtained in approximately 14% of patients with confirmed pulmonary TB disease (4;5). Testing sputum with techniques such as NAA facilitates the rapid detection and identification of *M. tuberculosis* but should not replace culture and drug-susceptibility testing in patients with suspected TB disease (22;113;315). Mixed mycobacterial infection can obscure the identification of *M. tuberculosis* during the laboratory evaluation (e.g., due to cross contamination or dual infections) and can be distinguished by the use of

mycobacterial species-specific DNA probes (316). Examination of colony morphology on solid culture media can also be useful.

Drug-susceptibility tests should be performed on initial isolates from all patients to assist in the identification of an effective anti-TB treatment regimen. Drug-susceptibility tests should be repeated if sputum specimens continue to be culture-positive after three months of anti-TB treatment or if culture results become positive for *M. tuberculosis* after a period of negative culture results (22;23).

E. Bronchoscopy

If possible, bronchoscopy should be avoided in patients with a clinical syndrome consistent with pulmonary or laryngeal TB disease because bronchoscopy increases the risk for transmission either through an airborne route (55;72;73;146;317) or endoscope contamination (72;147-153). In a patient who is intubated and mechanically-ventilated, closed circuitry may reduce the risk of exposure.

If the suspicion for pulmonary TB disease is high or if the patient is seriously ill with a disorder, either pulmonary or extrapulmonary, that is thought to be TB disease, multidrug anti-TB treatment using one of the recommended regimens should be initiated promptly, often before AFB smear results are known (23). Microscopic examination of three sputum specimens, obtained 8–24 hours apart (112), with at least one obtained in the early morning, is recommended. Obtaining three sputum samples is safer than performing bronchoscopy for patients and HCWs. Three sputum samples have superior yield for AFB smear results and *M. tuberculosis* culture results and should be pursued prior to bronchoscopy (108;318-320). Furthermore, a single sputum induction has a higher yield for a positive AFB smear result and culture result (110;321). Sputum induction is well tolerated (108;119;321-323), even in children (319).

In circumstances where a person who is suspected of having TB disease is not on a standard anti-TB treatment regimen, and the sputum smear results (possibly including induced specimens), are negative yet a reasonably high suspicion for TB disease remains, further consideration to initiate treatment for TB disease should be given. If the etiology of a radiographic abnormality remains unknown, further evaluation with bronchoscopy may be indicated; however, in cases where TB disease remains a diagnostic possibility, initiation of a standard anti-TB treatment regimen for a period of time prior to bronchoscopy may reduce the risk for transmission. Bronchoscopy may be valuable in establishing the diagnosis; in addition, a positive culture result can be both of clinical and public health importance in order to obtain drug-susceptibility results. Bronchoscopy in patients with suspected or confirmed TB disease should not be undertaken until after consideration of the risks of transmission of *M. tuberculosis* (22;55;73;146;317). If bronchoscopy is performed, because it is a cough-inducing procedure, additional sputum samples for AFB smear and culture should be collected after the procedure to increase the diagnostic yield.

II. Treatment for Latent TB Infection (LTBI)

Treatment for LTBI is essential to controlling and eliminating TB disease in the United States as it substantially reduces the risk that infection with *M. tuberculosis* will progress to TB disease (10;324). Certain groups of people are at very high risk of developing TB disease once infected,

and every effort should be made to begin treatment for LTBI and to ensure those persons complete the entire course of treatment (Table S2-2). Before beginning treatment of LTBI, a diagnosis of TB disease should be excluded by history, medical examination, chest radiography, and when indicated, bacteriologic studies.

A. Candidates for Treatment of LTBI

Persons in the following high-risk groups should be given treatment for LTBI if their TST result is ≥ 5 mm, regardless of age (23;29):

- Persons infected with HIV
- Recent contacts of a person with TB disease
- Persons with fibrotic changes on chest radiograph consistent with prior TB disease
- Organ transplant recipients and other immunosuppressed persons (e.g., persons receiving ≥ 15 mg/day of prednisone for ≥ 1 month)

Persons in the following high-risk groups should be considered for treatment of LTBI if their TST result is ≥ 10 mm:

- Recent immigrants (i.e., within the last five years) from countries with a high-incidence of TB disease
- Persons who inject illicit drugs
- Residents and employees (including HCWs) in the following high-risk congregate settings:
 - correctional facilities
 - long-term care facilities (e.g., hospices, skilled nursing facilities)
 - hospitals and other health-care facilities
 - residential facilities for persons with HIV/AIDS or other immunocompromising conditions
 - homeless shelters
- Mycobacteriology laboratory personnel
- Persons with any of the following clinical conditions or other immunocompromising conditions that place them at high risk for TB disease:
 - silicosis
 - diabetes mellitus
 - chronic renal failure
 - some hematologic disorders (e.g., leukemias and lymphomas)
 - other specific malignancies (e.g., carcinoma of the head, neck, or lung)
 - unexplained weight loss of $\geq 10\%$ of ideal body weight
 - gastrectomy
 - jejunioileal bypass
- Persons living in areas with high incidence of TB disease
- Children ≤ 5 years of age
- Infants, children, and adolescents exposed to adults at high-risk for developing TB disease

Persons with no known risk factors for TB disease may be considered for treatment of LTBI if their TST result is ≥ 15 mm. However, programs to screen HCWs for infection

with *M. tuberculosis* should only be conducted among high-risk groups. All testing activities should be accompanied by a plan for follow-up care for persons with LTBI or if it is found, TB disease. A decision to test for infection with *M. tuberculosis* should be based on a commitment to treat LTBI (29).

For persons who have prior positive TST results, and who completed treatment for LTBI in the past (meaning they took at least six months of INH, four months of rifampin, or two months of rifampin and pyrazinamide [RZ]), it is not necessary for them to be treated again, unless reinfection occurs. Documentation of completed therapy for LTBI (or TB disease) is ideal. Instead of participating in serial skin testing, the HCW should receive a medical evaluation and a symptom screen annually. A symptom screen is a procedure used during a clinical evaluation in which the patient is asked if they have experienced any signs or symptoms of TB disease.

Persons who may **not** be good candidates for treatment of LTBI include those with a previous history of liver injury or a history of excessive alcohol consumption. Active hepatitis and end-stage liver disease are relative contraindications to the use of isoniazid for treatment of LTBI (29;210). If the decision is made to treat such patients, baseline and follow-up monitoring of serum aminotransaminases should be considered.

Screening HCWs for infection with *M. tuberculosis* is an important administrative measure for the control of TB transmission in health-care settings. TB screening can detect ongoing transmission of *M. tuberculosis* and prevent future transmission by identifying lapses in infection control and identifying infected with *M. tuberculosis* and TB disease. Most individual HCWs, however, do not have the risk factors for progression to disease that serve as the basis for the current recommendations for targeted testing and treatment of LTBI. Most HCWs in the United States do not provide care in high TB-prevalence areas. Therefore, HCWs should be tested as determined by risk classification for the health-care setting, and may be categorized as having a positive TST result or TST conversion as part of the TB infection-control program for the purposes of surveillance and referral, but may not necessarily be a candidate for treatment of LTBI.

In the context of TST screening as part of an infection-control program, the interpretation of TST results in HCWs occurs in these steps:

- A.1 HCWs should receive baseline TST testing, following the indications for two-step testing (Table S2-3).
- A.2 HCWs should receive serial TST screening as determined by the health-care setting's risk classification (Table 2 and Section G).
- A.3 For infection-control purposes, the results of the TSTs should be recorded and interpreted as part of the TB infection-control program as either a 1) negative TST result, 2) previously documented positive TST result, or 3) TST conversion. All recordings should also document the size of the induration in mm, not simply "negative" or "positive."
- A.4 To determine whether treatment for LTBI should be indicated, HCWs should be referred for medical and diagnostic evaluation according to the TST result criteria in Table S2-1.
- A.5 In conjunction with a medical and diagnostic evaluation, HCWs with positive TST results should be considered for treatment of LTBI according to the criteria in Table S2-2.

- A.6 HCWs cannot be compelled to take treatment for LTBI, but should be encouraged to do so if eligible for treatment.

It is important to note that HCWs' TST results might be considered positive or a TST conversion as part of the TB infection-control program for the purposes of surveillance and referral, but some of these HCWs may not be considered candidates for treatment of LTBI according to the individual medical and diagnostic evaluation. Once an HCW has been classified as having a positive TST result or as a TST converter, further skin testing is not necessary.

B. Treatment regimens for LTBI

For persons suspected of having LTBI, treatment of LTBI should not begin until TB disease has been excluded. Persons highly suspected of having TB disease should receive the standard multidrug anti-TB treatment regimen for treatment of TB disease until the diagnosis is confirmed or excluded.

Standard regimens for the treatment of LTBI are shown in Table S2-7. Although regimens are broadly applicable, modifications that should be considered under special circumstances include HIV infection, suspected drug resistance, pregnancy (325).

Reports of severe liver injury and death associated with the combination of RZ for treatment of LTBI (326-328) prompted the American Thoracic Society (ATS) and CDC to revise previous recommendations (29;40) to indicate that RZ should generally **not** be offered for the treatment of LTBI (210). If the potential benefits significantly outweigh the demonstrated risk for severe liver injury and death associated with this regimen and the patient has no contraindications, a physician with experience treating LTBI and TB disease should be consulted prior to the use of this regimen (210). Clinicians should continue the appropriate use of rifampin and pyrazinamide in standard multidrug anti-TB treatment regimens for the treatment of TB disease (23).

For all regimens for treatment of LTBI, non-adherence to intermittent dosing (i.e., once- or twice-weekly) results in a larger proportion of total doses missed than daily dosing. DOT should be used for all doses during the course of treatment of LTBI whenever feasible, however, **all** patients on intermittent treatment for LTBI (or TB disease) should receive DOT. Collaborate with the state or local health department on decisions about DOT arrangements (23).

Table 7. Common drug regimens for treatment of LTBI

Drugs	Months of Duration	Interval	Minimum Doses
Isoniazid (INH)	9* (preferred)	Daily	270
		Twice weekly	76
INH	6	Daily	180
		Twice weekly	52
Rifampin	4	Daily	120
Rifampin/Pyrazinamide (RZ)	Generally should not be offered for treatment of LTBI		

* Nine months of INH is preferred, but six months of INH or four months of rifampin are acceptable alternatives.

B.1 Contacts of patients with drug-susceptible TB disease

Persons with a previously negative TST result who are contacts of patients with drug-susceptible TB disease and who subsequently have a positive TST result (≥ 5 mm) should be evaluated for treatment of LTBI, regardless of age. Most persons who are infected with *M. tuberculosis* will have a positive TST result within 6 weeks of exposure (66;202;329-332). Therefore, contacts of patients with drug-susceptible TB disease with negative TST results should be retested 8–10 weeks after the end of exposure to a patient with suspected or confirmed TB disease. Persons infected with *M. tuberculosis* should be advised that it is possible that they can be reinfected with *M. tuberculosis* if re-exposed (48-52). Persons infected with HIV persons receiving immunosuppressive therapy, regardless of TST result, and persons with a prior positive TST result who are close contacts of a person with suspected or confirmed TB disease, should be considered for treatment of LTBI.

The interpretation of TST results is more complicated in a contact investigation among HCWs who have negative baseline TST results from two-step testing, but where there was induration >0 mm on the baseline TST or subsequent serial testing. Differences in the TST results between the contact investigation and previous baseline and serial TST could be due to a) inter-test variability in reaction size (TST readers measuring the TST results differently), b) intervening exposure to NTM (also known as MOTT), BCG or *M. tuberculosis*, and c) reversion.¹ In practice, only inter-test variability and exposure to or infection with NTM or *M. tuberculosis* are likely.

Treatment of LTBI should not be started until a diagnosis of TB disease has been excluded. If uncertain about the presence of TB disease due to an ambiguous chest radiograph, a standard multidrug anti-TB treatment regimen may be started and adjusted as necessary based on the results of sputum cultures and the patient's clinical response (23). If cultures are obtained without initiating therapy,

¹ Reversion is defined as a subsequent TST result which is appreciably smaller than a previous test; reversion has been observed to be more likely when the intervening time between TSTs increases.

treatment for LTBI should not be initiated until all culture results are reported as negative.

B.2 Contacts of patients with drug-resistant TB disease

Treatment for LTBI caused by drug-resistant or MDR TB disease is complex and should be done in consultation with the state or local health department's infection-control program and experts in the medical management of drug-resistant TB. Sometimes this will require waiting for results of susceptibility testing. Treatment should be guided by susceptibility test results from the isolate to which the patient was exposed and is presumed infected (23;333;334).

C. Pretreatment evaluation and monitoring of treatment

The pretreatment evaluation of persons who are targeted for treatment of LTBI provides an opportunity for health-care providers to a) establish rapport with patients, b) discuss details of the patient's risk for progression from LTBI to TB disease, c) explain the benefits of treatment and the importance of adhering to the drug regimen, d) review possible adverse effects of the regimen, including interactions with other medications, and e) establish an optimal follow-up plan.

Monitoring for adverse effects of anti-TB medications must be individualized. Persons on treatment for LTBI should be specifically instructed to look for symptoms associated with the most common reactions to the medications they are taking (250). Laboratory testing should be performed to evaluate possible adverse effects (23;29). Routine laboratory monitoring during treatment of LTBI is indicated for patients with abnormal baseline test results, and for persons with a risk for hepatic disease.

Baseline laboratory testing is indicated for persons infected with HIV, pregnant women, women in the immediate postpartum period (usually within three months of delivery), persons with a history of liver disease, persons who use alcohol regularly, and those who have or who are at risk for chronic liver disease.

All patients being treated for LTBI should have clinical monitoring at least monthly, including a brief clinical assessment in the person's primary language for signs of hepatitis (nausea, vomiting, abdominal pain, jaundice, and yellow or brown urine). Patients on treatment for LTBI should be told about the adverse effects of the drug(s) and the need for prompt cessation of treatment and clinical evaluation if adverse effects occur.

Due to the risk for serious hepatic toxicity and death, the use of the combination of RZ for the treatment for LTBI should not generally be offered. If it is used, a physician with experience treating LTBI and TB disease should be consulted prior to the use of this regimen, and more extensive biochemical and clinical monitoring is recommended (210).

III. Treatment for TB Disease

Suspected or confirmed TB cases must be reported to the state or local health department in accordance with laws and regulations. Case management for TB disease should be coordinated with officials of the state or local health department. Regimens for treatment of TB disease must contain multiple drugs to which the organisms are susceptible. For persons with TB disease, treatment with a single drug can lead to the development of bacterial resistance to that drug.

Likewise, adding a single drug to a failing anti-TB treatment regimen can lead to resistance to the added drug (23).

For most patients, the preferred regimen for treating TB disease consists of an initiation two-month phase of four drugs--isoniazid, rifampin, pyrazinamide, and ethambutol--followed by a continuation phase of isoniazid and rifampin of at least four months, for a minimum total treatment of six months. Completion of therapy is based on the number of doses taken within a maximal period of time, and not simply six months (23). Persons with cavitary pulmonary TB disease and positive culture results of sputum specimens at the completion of two months of therapy should receive a longer seven-month continuation phase due to the significantly higher rate of relapse (23).

TB treatment regimens may need to be altered for persons infected with HIV who are on ART. Whenever possible, the care of persons with both TB disease and HIV infection should be provided by or in consultation with experts in the management of both TB and HIV-related disease (23). To prevent the emergence of rifampin-resistant organisms, persons with TB disease, HIV infection, and with CD4 cell counts <100 cells/mm³ should **not** be treated with highly intermittent (i.e., once- or twice-weekly) regimens. These patients should receive daily treatment during the intensive phase by DOT (if feasible) and daily or three times weekly by DOT during the continuation phase (335). Detailed information on TB treatment for persons infected with HIV has been posted and updated (www.dhfs.state.wi.us/AIDS-HIV/Resources/Overviews/AIDS_HIV.htm, www.hiv-druginteractions.org and http://www.cdc.gov/nchstp/tb/TB_HIV_Drugs/TOC.htm) and published (23;40).

Drug-susceptibility testing should be performed on all initial isolates from patients with TB disease (or from patients with LTBI if isolates were obtained). When results from drug-susceptibility tests become available, the anti-TB treatment regimen should be reassessed and the drugs used in combination should be adjusted accordingly (333;334;336-338). If drug resistance is present, clinicians who are not experts in the management of patients with drug-resistant TB disease should seek expert consultation (23), and collaborate with the state or local health department for treatment decisions.

The major determinant of the outcome of treatment is patient adherence to the drug regimen. Thus, careful attention should be paid to measures designed to enable and foster adherence (23;281;339). DOT is an adherence-enhancing strategy in which a trained HCW or other specially trained person watches a patient swallow each dose of medication and records the dates that the DOT was observed. DOT is the standard of care for all patients with TB disease and should be used for all doses during the course of therapy for TB disease and for LTBI whenever feasible. Plans for DOT should be coordinated with the state or local health department (23).

IV. Reporting of Serious Adverse Events

HCWs should report very serious adverse events associated with the administration of tuberculin antigen or treatment of LTBI or TB disease to the FDA MedWatch AERS: 1-800-FDA-1088 (telephone); 1-800-FDA-0178 (fax); Report Form 3500 in the *Physicians' Desk Reference*; www.fda.gov/medwatch. Specific instructions for the types of adverse events that should be reported are included in MedWatch report forms.

SUPPLEMENT 3: ENVIRONMENTAL CONTROLS

I. Overview

Environmental controls include the following technologies to remove or inactivate *M. tuberculosis*: local exhaust ventilation, general ventilation, high-efficiency particulate air (HEPA) filtration, and ultraviolet germicidal irradiation (UVGI). These controls help to prevent the spread and reduce the concentration of airborne infectious droplet nuclei. Environmental controls are the second line of defense in the TB infection-control program, and they work in harmony with administrative controls.

The reduction of occupational exposures to *M. tuberculosis* can be facilitated through the effective use of environmental controls at the source of exposure (e.g., coughing patient or laboratory specimen), or in the general workplace environment. Source control is amenable to situations where the source has been identified and the generation of the contaminant is localized. Source-control techniques can prevent or reduce the spread of infectious droplet nuclei into the air by collecting infectious particles as they are released. These techniques are especially important during procedures that are likely to generate infectious aerosols (e.g., bronchoscopy, sputum induction, endotracheal intubation, suctioning, irrigating tuberculous abscesses, aerosol treatments, autopsies on cadavers with untreated TB disease, and some laboratory specimen manipulations) and when patients with infectious TB disease are coughing or sneezing.

Unsuspected and undiagnosed cases of infectious TB disease are currently believed to represent a significantly large proportion of the current risk to health-care workers (HCWs) (10;76). In such situations, source control is not a feasible option. Instead, general ventilation and air cleaning must be relied upon for control. General ventilation can be used to dilute the air and remove air contaminants as well as to control airflow patterns in rooms or in a health-care setting. Air-cleaning technologies include high-efficiency particulate air (HEPA) filtration to reduce the concentration of *M. tuberculosis* droplet nuclei, and UVGI to kill or inactivate the microorganisms so they no longer pose a risk for infection.

Ventilation systems for health-care settings should be designed, and modified when necessary, by ventilation engineers in collaboration with infection-control practitioners and occupational health staff. Recommendations for designing and operating ventilation systems have been published (102;160;340). The many types and conditions for use of ventilation systems in health-care settings and the individual needs of these settings preclude the provision of extensive guidance in this document.

The information provided below is conceptual in nature and intended to educate HCWs about environmental controls and how these controls may be used in the TB infection-control program. This information should not be used in place of consultation with experts who can advise on ventilation system design, selection, installation, and maintenance. Because environmental controls will fail if they are not properly operated and maintained, routine training and education of staff are key components to a successful TB infection-control program.

This section does not specifically address mechanical ventilators (Recommendations, E.3.2.).

II. Local exhaust ventilation

Local exhaust ventilation captures airborne contaminants at or near their source and removes the contaminants without exposing persons in the area to infectious agents. It is considered the most efficient way to remove airborne contaminants because it captures them before they can disperse. Local exhaust devices typically use hoods. Two types of hoods are: 1) enclosing devices, in which the hood either partially or fully encloses the infectious source, and 2) exterior devices, in

which the infectious source is near but outside the hood. Fully enclosed hoods, booths, or tents are always preferable to exterior devices due to their superior ability to prevent contaminants from escaping into the HCW's breathing space. Descriptions of both enclosing and exterior devices have been published (160).

A. Enclosing devices

Enclosing devices for local exhaust ventilation include: 1) booths for sputum induction or administration of aerosolized medications (Figure S3-1), 2) tents or hoods for enclosing and isolating a patient, and 3) biological safety cabinets (BSCs), which are relevant to the United States and are consistent with other guidelines) (142). These devices are available in various configurations. The simplest device is a tent placed over the patient; the tent has an exhaust connection to the room-discharge exhaust system. The most complex device is an enclosure with a sophisticated self-contained airflow and recirculation system (Figure S3-1).




Figure S3-1. An enclosing booth designed to sweep air past a patient with TB disease and collect the infectious droplet nuclei on a HEPA filter.

Tents and booths should have sufficient airflow to remove at least 99% of airborne particles during the interval between the departure of one patient and the arrival of the next (Table S3-1). The time required to remove a given percentage of airborne particles from an enclosed space depends on: 1) the number of ACH, which is determined by the number of cubic feet of air in the room or booth and the rate at which air is entering the room or booth at the intake source; 2) the location of the ventilation inlet and outlet; and 3) the configuration of the room or booth. The surfaces of tents and booths should be

periodically cleaned in accordance with manufacturers' recommendations and the guidance provided in Supplement 5.

Table S3-1. Air changes per hour (ACH) and time required for removal efficiencies of 99% and 99.9% of airborne contaminants¹

ACH	<u>Minutes required for removal efficiency of:</u> ²	
	99%	99.9%
2	138	207
4	69	104
6	46	69
12	23	35
15	18	28
20	7	14
50	3	6

¹ This table was adapted from the formula for the rate of purging airborne contaminants (*1;341*). The values apply to a room or enclosure in which the generation of aerosols has ceased (e.g., the patient is no longer present in the room or the aerosol procedure has been completed and the room or booth is no longer occupied). The times provided assume perfect mixing of the air in the space; removal times will be longer in rooms or areas with imperfect mixing or air stagnation. Caution should be exercised in applying the table to such situations.

² Minutes required for removal of airborne contaminants from the time that generation of infectious droplet nuclei has ceased.

B. Exterior devices

Exterior devices for local exhaust ventilation are usually hoods that are very near to, but not enclosing, an infectious patient. The airflow produced by these devices should be sufficient to prevent cross-currents of air near the patient's face from allowing droplet nuclei to escape. Whenever possible, the patient should face directly into the opening of the hood to direct any coughing or sneezing into the hood. The device should maintain an air velocity of 200 feet per minute (fpm) at the patient's breathing zone to ensure the capture of droplet nuclei. Smoke tubes should be used to verify that the control velocity at the typical location of the patient's breathing zone is adequate to provide capture for the condition of highest expected cross-drafts, and then the patient's breathing zone should be maintained at this location for the duration of the treatment.

C. Discharge of exhaust from booths, tents, and hoods

Air from booths, tents, and hoods is either discharged into the room in which the device is located or to the outside. If the exhaust air is discharged into the room, a HEPA filter should be incorporated at the discharge duct or vent of the device. The exhaust fan should be located on the discharge side of the HEPA filter to ensure that the air pressure in the

filter housing and booth is negative with respect to adjacent areas. Uncontaminated air from the room will flow into the booth through all openings, thus preventing infectious droplet nuclei in the booth from escaping into the room. Section IV of this Supplement contains additional information on the installation, maintenance, and monitoring of HEPA filters.

Most commercially available booths, tents, and hoods are fitted with HEPA filters; additional HEPA filtration is not needed with these devices. If a device does not incorporate a HEPA filter, the air from the device should be exhausted directly to the outside and away from air-intake vents, persons, and animals, in accordance with applicable federal, state, and local regulations on environmental discharges.

III. General Ventilation

General ventilation is used to: 1) dilute and remove contaminated air, 2) control the direction of airflow in a health-care setting, and 3) control airflow patterns in rooms.

A. Dilution and removal of contaminated air

General ventilation maintains air quality by both air dilution and removal of airborne contaminants. Uncontaminated supply air mixes with contaminated room air (dilution), and air is subsequently removed from the room by the exhaust system (removal). These processes reduce the concentration of droplet nuclei in the room air.

A.1 Ventilation systems for air dilution and removal

Two types of general ventilation systems are used to dilute and remove contaminated air: single-pass air systems and recirculating air systems.

In a **single-pass air system**, the supply air is either outside air that has been heated or cooled, or air that is uncontaminated from a central system that supplies several areas. After air passes through the room or area, 100% of the air is exhausted to the outside. A single-pass system is the preferred choice for an AII room because it prevents contaminated air from being recirculated to other areas of the health-care setting.

In a **recirculating air system**, a small portion of the exhaust air is discharged directly to the outside and replaced with fresh outside air, which mixes with the portion of exhaust air that was not discharged. If not treated, the resulting air mixture can contain a large proportion of contaminated air when it is recirculated to areas serviced by the system. This air mixture can be recirculated into the general ventilation, and infectious particles can be carried from contaminated areas to uncontaminated areas. Alternatively, the air mixture could be recirculated in a specific room or area so that other areas are not affected. The use of air-cleaning technologies for removing or inactivating infectious particles in recirculated air systems is discussed in Section IV of this Supplement.

A.2 Delivery of general ventilation

General ventilation is delivered by either constant air-volume (CAV) systems or variable air-volume (VAV) systems. In general, CAV systems are best for AII

rooms and other negative-pressure rooms because the negative-pressure differential is easier to maintain. VAV systems are acceptable if provisions are made to maintain the minimum total and outside ACH and a negative pressure ≥ 0.01 inches of water gauge relative to adjacent areas at all times.

A.3 Ventilation rates

Recommended ventilation rates for health-care settings are usually expressed in numbers of ACH, which is the ratio of the volume of air entering the room per hour to the room volume. It equals the exhaust airflow (Q cfm) divided by the room volume (V cubic feet) multiplied by 60:

$$\text{ACH} = (Q \div V) \times 60$$

Table S3-2 provides ventilation recommendations for selected areas in new or renovated health-care settings. These recommendations have been adapted from those published by the American Institute of Architects (102). The feasibility of achieving a specific ventilation rate depends on the construction and operational requirements of the ventilation system and might differ for retrofitted and newly constructed facilities. The expense and effort of achieving a high ventilation rate may be reasonable for new construction but less so when retrofitting an existing setting.

In existing settings, air-cleaning technologies such as fixed or portable room-air recirculation units (also called portable air cleaners) or UVGI may be used to increase the equivalent ACH. This “equivalent ventilation” concept has been used to compare microbial inactivation by UVGI with particle removal by mechanical ventilation (342;343) and to compare particle removal by HEPA filtration of recirculated air with particle removal by mechanical ventilation. The equivalent ventilation approach does not, however, negate the requirement to provide sufficient fresh outside air for occupant comfort (Table S3-2).

To dilute the concentration of normal room-air contaminants and minimize odors, a portion of the supply air should come from the outdoors (Table S3-2). Health-care settings should consult ASHRAE Standard 62, *Ventilation for Acceptable Indoor Air Quality*, for outside air recommendations in areas not listed in Table S3-2 (344;345).

Table S3-2. Ventilation recommendations for selected areas in new or renovated health-care settings

Area	Minimum total ACH	Minimum outdoor ACH ¹	Air movement relative to adjacent areas	All air exhausted directly outdoors ²
Microbiology laboratory	6	—	In	Yes
Anteroom to AII room	10	—	In/out	Yes
AII room ^{3,4}	12	2	In	Yes
Autopsy suite	12	—	In	Yes
Bronchoscopy room	12	2	In	Yes
Emergency department and radiology waiting rooms	12	2	In	Yes
Operating room or surgical room	15	3	Out	—

Adapted from (1;102).

¹ ANSI/ASHRAE Standard 62, *Ventilation for Acceptable Indoor Air Quality*, should be consulted for outside air recommendations in areas that are not specified here (340;344;345).

² If it is not possible to exhaust all the air to the outdoors, the air may be recirculated after passing through HEPA filtration. In AII rooms, such recirculation is acceptable only if the air is recirculated back to the same room and not to other areas of the setting.

³ AII rooms in **existing** settings should have an airflow of ≥ 6 total ACH; air-cleaning devices may be used to increase the equivalent ACH.

⁴ Patients requiring a protective environment (PE) room (e.g., severely immunocompromised patients) who also have TB disease require protection from common airborne infectious microorganisms.

B. Control of airflow direction in a health-care setting

Airflow direction is controlled in health-care settings to contain contaminated air and prevent its spread to uncontaminated areas.

B.1 Directional airflow

The general ventilation system should be designed and balanced so that air flows from less contaminated (more clean) to more contaminated (less clean) areas (102;340). For example, air should flow from corridors (cleaner areas) into AII rooms (less clean areas) to prevent the spread of contaminants. In some rooms in which surgical and invasive procedures are performed and in protective environment (PE) rooms, the direction of airflow should be from the room to the hallway. Environmental control recommendations for situations involving the care and treatment of patients with TB disease in operating rooms and PE rooms are provided in Section III, Part F of this supplement. Cough-inducing or

aerosol-generating procedures should not be performed on patients with suspected or confirmed TB disease in rooms where air flows from the room to the hallway.

B.2 Negative pressure for achieving directional airflow

The direction of airflow is controlled by creating a lower (negative) pressure in the area into which the flow of air is desired. Negative pressure is the relative air-pressure difference between two areas in a health-care setting. For air to flow from one area to another, the air pressure in the two areas must be different. Air will flow from a higher pressure area to a lower pressure area. A room that is under negative pressure has a lower pressure than adjacent areas, which keeps air flowing from the adjacent rooms or areas into the room. Negative pressure is achieved by exhausting air at a higher volumetric rate than the rate that the air is being supplied.

C. Control of airflow patterns in rooms

General ventilation systems should be designed to provide controlled patterns of airflow in rooms and to prevent air stagnation or short-circuiting of air from the supply to the exhaust, (i.e., passage of air directly from the air supply to the exhaust). To provide controlled airflow patterns, the air supply and exhaust should be located so that clean air flows first to parts of the room where HCWs are likely to work and then across the infectious source and into the exhaust. In this way, HCWs are not positioned between the infectious source and the exhaust. This configuration is not always possible but should be used whenever feasible.

One way to achieve a controlled airflow pattern is to supply air at the side of the room opposite the patient and exhaust it from the side where the patient is located (Figure S3-2A). Another method, which is most effective when the supply air is cooler than the room air, is to supply air near the ceiling and exhaust it near the floor (Figure S3-2B). Care must be taken to ensure that furniture or moveable equipment do not block the low exhausts. Airflow patterns are affected by air temperature differentials, location of the supply diffusers and exhaust grilles, location of furniture, movement of HCWs and patients, and the configuration of the space.

DRAFT

DRAFT

DRAFT




Figure S3-2A and S3-2B. Room airflow patterns designed to provide mixing of air and prevent short-circuiting (passage of air directly from the air supply to the exhaust)

If the room ventilation is not designed for a “plug-flow” type of airflow pattern (described in the figures above), then adequate mixing must be maintained to minimize air stagnation. Most rooms with properly installed supply diffusers and exhaust grilles will have adequate mixing. A qualitative measure of mixing is the visualization of air movement with smoke tubes at several locations in the room. Smoke movement in all areas of the room indicates good mixing. More sophisticated studies can be conducted using a tracer gas to quantify air-mixing and air-exchange rates.

If areas of air stagnation are present, air mixing can be improved by adding a circulating fan or repositioning the supply and exhaust vents. Room-air recirculation units positioned in the room or installed above the ceiling can also improve air mixing. If supply or exhaust vents, circulating fans or room-air recirculation units are placed incorrectly, HCWs may not be adequately protected.

D. Achieving negative pressure in rooms

Negative pressure is needed to control the direction of airflow between selected rooms in a health-care setting and their adjacent spaces to prevent contaminated air from escaping from the room into other areas (102) (Table S3-3). Control of a room's differential airflow and total leakage area is critical to achieving and maintaining negative pressure. Differential airflow, differential pressure, and leakage area are inter-related. This relationship is shown in Figure S3-3 and is expressed in the empirical equation below (346).

$$A_E = 0.01138 * (\Delta Q^{1.170} / \Delta P^{0.602})$$

In the equation, A_E is the leakage area in square inches, ΔQ is the differential airflow rate in cfm, and ΔP is the differential pressure drop in inches of water gauge. This empirical equation was used to develop Figure S3-3. Figure S3-3 shows that changing one parameter will influence one or both of the other parameters.




Figure S3-3. Empirical relationship between differential airflow differential pressure and leakage areas.

For example, the control of differential pressure can frequently be improved by increasing the air tightness or seal of a room, maintaining the HVAC system, and ensuring continuous monitoring. In a room that is already very tight (e.g., with 10 square inches of leakage), however, a small change in differential pressure will have a large affect on differential airflow. Similarly, a room with a larger leakage area (e.g., 300 square inches of leakage) requires a higher differential airflow rate to achieve a pressure differential of 0.01 inches of water gauge. As shown in Figure S3-3, reducing the leakage in a room with 300 square inches of leakage can help achieve a pressure differential of 0.01 inches of water gauge. If the leakage area is reduced to approximately 40 square

inches, a pressure differential of 0.01 inches of water gauge can be achieved by exhausting approximately 100 cubic feet per minute (cfm) more air from the room than is supplied to the room.

Room leakage can occur through cracks or spaces near doors, windows, ceiling, and utility connections. Measures should be taken to minimize these leaks. Changes in the performance of the HVAC system will affect the pressure differential in a room and can potentially cause a negative-pressure room to become positive-pressure. Each of these parameters therefore requires close monitoring to ensure that minor changes in the performance of the HVAC system do not adversely affect the entire system (347;348).

D.1 Pressure differential

To achieve negative pressure in a room that has a normally functioning ventilation system, first measure and balance the supply and exhaust airflows to achieve an exhaust flow greater than the supply flow. Next, measure the pressure differential across the closed door. Although the minimum pressure difference needed for airflow into a room is quite small (about 0.001 inches of water gauge), a pressure differential of ≥ 0.01 inches of water gauge (2.5 Pascals [Pa]) is now recommended. This higher pressure differential is easier to measure and offers a margin of safety for maintaining negative pressure as the pressure in surrounding areas changes due to the opening and closing of doors, operation of elevators, stack effect (rising of warm air, similar to a chimney), ventilation system fluctuations, and other factors. The higher pressurization value is consistent with the most recent AIA recommendations for isolation applications in health-care settings (102) and is the generally accepted level of negative pressurization for microbiological and biomedical laboratories (349).

Opening of doors and windows can drastically affect the negative pressure in an AII room. Infection control requires AII room windows and doors to remain closed, except when doors must be opened for people to enter or leave the room. It may also be necessary to keep certain doors in the corridor outside the AII rooms closed to maintain the negative-pressure differential between an AII room and the corridor. Pressurization cannot be maintained in rooms or spaces that are not enclosed.

If ≥ 0.01 inches of water gauge is not achieved and cannot be achieved by increasing the flow differential (within the limits of the ventilation system), the room should be inspected for leakage. Figure S3-4 can be used to estimate the total room leakage area based on the previously measured pressure and air flow differentials. If the room leakage is too large, for example 300 square inches, it may be difficult to maintain a negative-pressure differential as high as 0.01 inches of water gauge. A lower value is acceptable if air-pressure monitoring shows that negative pressure is always maintained (or airflow indicators consistently show airflow in the desired direction). If negative pressure cannot be maintained, the leakage area may need to be reduced by sealing cracks around windows or replacing porous suspended ceiling panels with gasketed or sealed solid panels.

Since negative pressure in an AII room can be affected by even minor changes in the operation of the ventilation system, negative pressure can be difficult to

maintain with a VAV ventilation system. To maintain negative pressure, a VAV supply system should be coupled with a compensating exhaust system that increases when the supply flow rate increases. Alternatively, the exhaust can be set at a fixed rate that ensures negative pressure throughout the VAV supply cycle. The VAV minimum flow rate must also be adequate to maintain the recommended minimum total and outdoor ACH (Table S3-2).

D.2 Alternate methods for achieving negative pressure

Although not a substitute for negative pressure in an AII room, an anteroom can reduce the escape of droplet nuclei during the opening and closing of the door to an AII room and can buffer an AII room from pressure fluctuations in the corridor. To function properly, an anteroom must have more air exhausted from the room than supplied in order to remove *M. tuberculosis* that can enter from the AII room. An anteroom can also have its own supply diffuser, if needed, to balance the pressure with the corridor. If an anteroom is unventilated or not properly ventilated, it will function only as a lesser contaminated vestibule between the AII room and the corridor and may not prevent the escape of droplet nuclei into the corridor. To adjust airflow and pressure differentials, health-care settings should consult a ventilation engineer who is knowledgeable about all applicable regulations, including building fire codes.

If the desired negative pressure cannot be achieved because a room lacks a separate ventilation system or the room's system cannot provide the proper airflow, steps should be taken to provide a way to discharge air from an AII room. One way to achieve negative pressure in a room is to add a **supplemental exhaust unit**. If an AII room has a window or an outside wall, a small exhaust fan can be used. An engineer should be consulted to evaluate the potential for negative effects on surrounding areas (e.g., disruption of exhaust airflow in adjoining bathrooms) and to ensure the provision of the recommended amounts of outdoor air. The exhaust must not be discharged where it can immediately re-enter the building or pose a hazard to persons outside.

Fixed room-air recirculation systems, (i.e. systems that recirculate the air in an entire AII room), can be designed to achieve negative pressure by discharging air to the outside. Some portable room-air recirculation units are also designed to discharge air to the outside to achieve negative pressure. These air cleaners must be designed specifically for this purpose.


D.3 Monitoring negative pressure

Negative pressure must be monitored to ensure that air is always flowing from the corridor (or surrounding area) into the AII room. Negative pressure can be monitored either continuously or periodically. Monitoring methods include: chemical aerosols (e.g., smoke tube), differential pressure-sensing devices (e.g., manometer), and physical indicators (e.g., flutter strips).

A chemical aerosol resembling smoke can be used to observe airflow between a room and the surrounding area, or within a room. Devices called smoke tubes generate smoke, which follows the local air currents wherever it is released. To check the negative pressure in a room, hold a smoke tube approximately two

inches in front of the base of the AII room's closed door or in front of the air transfer grille, if the door has such a feature. Hold the smoke tube parallel to the door, and a small amount of smoke will be generated slowly to ensure that the velocity of smoke emanating from the tube does not overpower the air velocity (Figure S3-4). If the room is under negative pressure, the smoke will travel into the room (from higher to lower pressure). If the room is not under negative pressure, the smoke will be blown outward or stay in front of the door. Any room air cleaners in the room should be operating. Persons using smoke tubes should avoid inhaling the "smoke" because direct inhalation of high concentrations of the smoke can be irritating (350).

Figure S3-4. Smoke tube testing and anemometer placement to determine the direction of airflow into and out of a room.



If an anemometer is used, it should be placed with the sensor in the airflow path at the base of the door. Differential pressure-sensing devices can also be used to monitor negative pressure. They provide either non-continuous (periodic) pressure measurements or continuous pressure monitoring. A continuous monitoring indicator can simply be a visible or audible warning signal indicating that air pressure is positive. Both periodic and continuous pressure detectors generate a digital or analog signal that can be recorded for later verification or used to adjust the room's ventilation control system automatically.


Physical indicators such as flutter strips are sometimes used to provide a continuous visual sign that a room is under negative pressure. These simple and inexpensive devices are placed directly in the door and can be useful in identifying a pressure differential problem.

Pressure-measuring devices should sense the pressure just inside the airflow path into the AII room (e.g., at the base of the door). Unusual airflow patterns can cause pressure variations. For example, the air can be under negative pressure at

the middle of a door and under positive pressure at the base of the same door. Figure S3-5 shows the ideal location of a pressure-measuring device. If the pressure-sensing ports of the device cannot be located directly across the airflow path, it will be necessary to validate that the negative pressure at the sensing point is and remains the same as the negative pressure across the flow path.

Pressure-sensing devices should incorporate an audible warning with a time delay to indicate an open door. When a door is open, the negative pressure cannot be maintained, but this should not generate an alarm unless the door is left open. Therefore, the time delay should allow adequate time for persons to enter or leave an AII room without activating the alarm.

Figure S3-5. Cross-sectional view of a room showing the location of negative pressure measurement



The pressure differentials used to achieve low negative pressure (<0.005 inches) require the use of very sensitive mechanical devices, electronic devices, or pressure gauges to ensure accurate measurements. Pressure measuring and monitoring devices can give false readings if the calibration has drifted. For example, a sensor may indicate that the room pressure is slightly negative with respect to the corridor, but, due to air current momentum effects or “drift” of the electrical signal, air may actually be flowing out of the AII room through the opening at the base of the door. In one study, of 38 AII rooms with electrical or mechanical devices to continuously monitor air pressurization, half had airflow at the door in the opposite direction of that indicated by the continuous monitors (351). The investigators attributed this problem to instrument limitations and device malfunction. A negative pressure differential of ≥ 0.01 inches of water gauge (compared with the previously recommended 0.001 inches of water gauge) may help to minimize this problem.

Periodic checks are required to maintain the desired negative pressure and the optimal operation of monitoring devices:

- All rooms should be checked for negative pressure before occupancy.
- When occupied by a patient, an AII room should be checked daily with smoke tubes or other visual checks for negative pressure.
- If pressure-sensing devices are used in AII rooms occupied by patients with suspected or confirmed TB disease, negative pressure should be checked daily by use of smoke tubes.
- If these AII rooms are not being used for patients who have suspected or confirmed TB disease but potentially could be used for such patients, the negative pressure should be checked monthly.
- Laboratories should be checked daily for negative pressure.

E. AII rooms and other negative pressure rooms

AII rooms are used to: 1) separate patients who are likely to have infectious TB from other persons, 2) provide an environment in which environmental factors are controlled to reduce the concentration of droplet nuclei, and 3) prevent the escape of droplet nuclei from such rooms into adjacent areas using directional airflow. Other negative-pressure rooms include bronchoscopy suites, sputum induction rooms, selected examination and treatment rooms, autopsy suites, and clinical laboratories.

E.1 Preventing the escape of droplet nuclei

AII rooms used for TB isolation should be single-patient rooms with negative pressure relative to the corridor or other areas connected to the room. Opening of doors and windows can drastically affect the negative pressure in an AII room. Infection control requires AII room windows and doors to remain closed, except when doors must be opened for people to enter or leave the room. It may also be necessary to keep certain doors in the corridor outside the AII rooms closed to maintain the negative-pressure differential between an AII room and the corridor. The use of self-closing doors is recommended. The room's openings (e.g., windows, electrical and plumbing entries) should be sealed as much as possible, with the exception of a small gap (1/8-1/2 inch) at the base of the door to provide a controlled airflow path. Proper use of negative pressure will prevent contaminated air from escaping the room (352;353).

E.2 Reducing the concentration of droplet nuclei

AII rooms in existing health-care settings should have an airflow of ≥ 6 total ACH. Whenever feasible, this airflow rate should be increased to ≥ 12 equivalent ACH by adjusting or modifying the ventilation system or by using air-cleaning technologies such as fixed or portable room-air recirculation systems or UVGI systems. New construction or renovation of existing health-care settings should be designed so that AII rooms achieve an airflow of ≥ 12 total ACH. These recommendations are consistent with guidelines by ASHRAE and AIA. ASHRAE guidelines recommend an airflow of ≥ 6 total ACH for AII rooms and treatment rooms, based primarily on comfort and odor-control considerations, but they advocate increased air-change rates for isolation of patients with respiratory diseases such as TB disease (340). AIA guidelines for new construction

recommend ≥ 12 total ACH for AII rooms (102). Table S3-2 provides ventilation recommendations for other negative-pressure rooms in new or renovated health-care settings.

To dilute the concentration of normal room air contaminants and minimize odors, a portion of the supply air should come from the outdoors. A minimum of 2 ACH of outdoor air should be provided to AII rooms and other negative-pressure rooms (102;340).

E.3 Exhaust from AII rooms and other negative-pressure rooms

Air from AII rooms and other negative-pressure rooms for patients with suspected or confirmed TB disease should be exhausted directly to the outside and away from air-intake vents, persons, and animals, in accordance with applicable Federal, state, and local regulations on environmental discharges. Exhaust ducts should be located away from areas such as sidewalks or windows that can be opened. Ventilation system exhaust discharges and inlets should be designed to prevent the re-entry of exhausted air. Wind blowing over a building creates a highly turbulent recirculation zone that can cause exhausted air to re-enter the building. Exhaust flow should be discharged above this zone. Design guidelines for proper placement of exhaust ducts have been published (354). If recirculation of air from such rooms into the general ventilation system is unavoidable, the air should be passed through a HEPA filter before recirculation.

E.4 Alternatives to negative-pressure rooms

AII can also be achieved by the use of negative-pressure enclosures (e.g., tents or booths). These can provide patient isolation in emergency departments and medical testing and treatment areas and can supplement AII in designated negative-pressure rooms.

F. Other selected settings

Operating rooms, autopsy suites, sputum induction rooms, and aerosolized treatment rooms pose potential hazards from infectious aerosols generated during procedures on patients with TB disease (64;355-357). Table 5 summarizes recommended administrative, environmental and respiratory protection controls for these and other selected settings, and Section II.E of the main document describes additional or specialized TB infection controls that are applicable to special circumstances and types of health-care delivery settings. Table S3-2 provides ventilation recommendations for these settings in new or renovated health-care facilities. Existing facilities may need to augment the current ventilation system or use the air-cleaning methods described below to increase the number of equivalent ACH.

Patients with TB disease who also require a protective environment (PE) room (e.g., severely immunocompromised patients) are a special case. These patients require protection from common airborne infectious microorganisms and must be placed in a room that has HEPA-filtered supply air and is under positive pressure relative to its surroundings (102). If an anteroom is not present, the use of other air-cleaning methods should be considered to increase the equivalent ACH. The air-cleaning systems can be placed in the room and in surrounding areas to minimize contamination of the

surroundings. Similar controls can be utilized in operating rooms that are used for patients with TB disease since these rooms must be maintained under positive pressure relative to their surroundings to maintain a sterile field.

IV. Air-Cleaning Methods

A. High-efficiency particulate air (HEPA) filtration

HEPA filtration can be used to supplement other recommended ventilation measures by providing a minimum removal efficiency of 99.97% of particles $\geq 0.3 \mu\text{m}$ in diameter. This air-cleaning method is considered an adjunct to other ventilation measures. Used alone, it neither provides outside air for occupant comfort nor satisfies other recommended ventilation measures, such as using source control whenever possible and minimizing the spread of contaminants in a setting through control of airflow patterns and pressure differentials.

HEPA filters have been shown to reduce the concentration of *Aspergillus* spores (which range in size from $1.5 \mu\text{m}$ to $6 \mu\text{m}$) to below measurable levels (358-360). Because droplet nuclei generated by TB patients are believed to range from $1 \mu\text{m}$ - $5 \mu\text{m}$ in diameter (263) (as large as *Aspergillus* spores) (361), HEPA filters will remove *M. tuberculosis*-containing infectious droplet nuclei from contaminated air. HEPA filters can be used to clean air before it is: 1) exhausted to the outside, 2) recirculated to other areas of a health-care setting, or 3) recirculated in an AII room. Because electrostatic filters can degrade over time with exposure to humid environments and ambient aerosols (362), their use in systems that recirculate air back into the general ventilation system from AII rooms and treatment rooms should be avoided. If used, the filter manufacturer should be consulted regarding the performance of the filter to ensure that it maintains its desired filtration efficiency over time and with loading.

A.1 Use of HEPA filtration when exhausting air to the outside

HEPA filters can be used as an added safety measure to clean air from AII rooms and local exhaust devices (e.g., booths, tents, hoods) before exhausting it to the outside. This added measure is not necessary, however, if the exhaust air cannot re-enter the ventilation system supply and does not pose a risk to persons and animals where it is exhausted.

In many instances, exhaust air is not discharged directly to the outside. Rather, the air is directed through heat-recovery devices (e.g., heat wheels, or radiator-like devices). Heat wheels are often used to reduce the costs of operating ventilation systems (363). As the wheel rotates, energy is transferred into or removed from the supply inlet air stream. If a heat wheel is used with a system, a HEPA filter should also be used. The HEPA filter should be placed upstream from the heat wheel due to the potential for leakage across the seals separating the inlet and exhaust chambers and the theoretical possibility that droplet nuclei could be impacted on the wheel by the exhaust air and subsequently stripped off into the supply air.

A.2 Recirculation of HEPA-filtered air

Air from All rooms and other negative-pressure rooms should be exhausted directly to the outside. In some instances, however, recirculation of air into the general ventilation system from such rooms is unavoidable (e.g., in settings in which the ventilation system or building configuration makes venting the exhaust to the outside impossible). In such cases, HEPA filters should be installed in the exhaust duct exiting the room to remove infectious organisms from the air before it is returned to the general ventilation system.

Individual room-air recirculation can be used in areas where no general ventilation system exists, where an existing system is incapable of providing sufficient ACH, or where air cleaning (particulate removal) is desired without affecting the fresh air supply or negative-pressure system. Recirculation of HEPA-filtered air in a room can be achieved by: 1) exhausting air from the room into a duct, passing it through a HEPA filter installed in the duct, and returning it to the room (Figure S3-6); 2) filtering air through HEPA recirculation systems installed on the wall or ceiling of the room (Figure S3-7); or 3) filtering air through portable HEPA recirculation systems. In this document, the first two approaches are referred to as fixed room-air recirculation systems because the HEPA filters are not easily movable.

Figure S3-6. Fixed, ducted room-air recirculation system using a HEPA filter inside an air duct





Figure S3-7. Fixed, ceiling-mounted room-air recirculation system using a HEPA filter



A.1.1 Fixed room-air recirculation systems

The preferred method of recirculating HEPA-filtered air is by use of a built-in system in which air is exhausted from the room into a duct, filtered through a HEPA filter, and returned to the room (Figure S3-6). This technique can add equivalent ACH in areas in which the recommended minimum ACH is difficult to meet with general ventilation. This “equivalent ventilation” concept compares particle removal by HEPA filtration of the recirculated air with particle clearance from exhaust ventilation. Because the air does not have to be conditioned, this permits higher airflow rates than the general ventilation system can usually achieve. An alternative is to install HEPA filtration units on the wall or ceiling (Figure S3-7).

Fixed recirculation systems are preferred to portable (free-standing) units because they can be installed with a greater degree of reliability. In addition, many fixed systems have a higher airflow capacity than portable systems, and the potential for short circuiting of air is reduced as the distance between the air intake and exhaust is increased.

A.1.2. Portable room-air recirculation systems

Portable room-air recirculation units with HEPA filters (also called portable air cleaners) may be considered when: 1) a room has no general ventilation system, 2) the system cannot provide adequate ACH, or 3) increased effectiveness in airflow is needed. Effectiveness depends on the ability to circulate as much of the air in the room as possible through

the HEPA filter. Effectiveness can vary depending on the room's configuration, the furniture and persons in the room, and the placement of the HEPA filtration unit relative to the supply diffusers and exhaust grilles.

Portable room-air recirculation units have been shown to be effective in removing bioaerosols and aerosolized particles from room air (364-368;368;369). Findings show that many commercially available units are useful in reducing the concentration of airborne particles and are therefore helpful in reducing airborne disease transmission. The performance of 14 units was evaluated for volumetric airflow, airborne particle reduction, noise level, and other parameters (365). Volumetric airflow rates ranged from 110 cfm to 1,152 cfm, and equivalent ACH ranged from an average of 8-22 in a standard-size, single patient room. Recommendations were provided to make subsequent models safer, more effective, quieter, and easier to use and service. Purchasers should be aware that several of the manufacturers' specifications indicated flow rates of "free-wheeling" fans and not the fan under the load of a filter.

Portable HEPA filtration units should be designed to: 1) achieve ≥ 12 equivalent ACH, 2) ensure adequate air mixing in all areas of the rooms, and 3) be compatible with the ventilation system. An estimate of the unit's ability to circulate the air in a room can be made by visualizing airflow patterns as described previously for estimating room air mixing (Supplement 3, Section III.D.3). If the air movement is adequate in all areas of the room, the unit should be effective.

If portable devices are used, units with relatively high volumetric airflow rates that provide maximum flow through the HEPA filter are preferred. Placement should be selected to optimize the recirculation of AII room air through the HEPA filter. Careful consideration must be given to obstacles (e.g., furnishings, medical equipment, walls) that could disrupt airflow and to system specifications (e.g., physical dimensions, airflow capacity, locations of air inlet and exhaust, noise) to maximize performance of the units, minimize short-circuiting of air, and reduce the likelihood that the units will be switched off by room occupants.

A.3 Installing, maintaining, and monitoring HEPA filters

The performance of HEPA filters depends on proper installation, testing, and meticulous maintenance (370), especially if the system recirculates air to other parts of the health-care setting. Improper design, installation, or maintenance could allow infectious particles to circumvent filtration and escape into the general ventilation system (340). These failures also could impede proper ventilation performance.

HEPA filters should be installed to prevent leakage between filter segments and between the filter bed and its frame. A regularly scheduled maintenance program is required to monitor filters for possible leakage and filter loading. A quantitative filter performance test such as the dioctyl phthalate (DOP)

penetration test (371;372) should be performed at the initial installation and every time the filter is changed. Records should be maintained for all filter changes and testing. A leakage test using a particle counter or photometer should be performed every 6-12 months for filters in general-use areas and in areas with systems likely to be contaminated with *M. tuberculosis* (e.g., AII rooms).

A manometer or other pressure-sensing device should be installed in the filter system to provide an accurate and objective means of determining the need for filter replacement. Pressure drop characteristics of the filter are supplied by the manufacturer. Installation of the filter should allow for maintenance that will not contaminate the delivery system or the area served. For general infection control purposes, special care should be taken to avoid jarring or dropping the filter element during or after removal.

The scheduled maintenance program should include procedures for installation, removal, and disposal of filter elements. HEPA filter maintenance should be performed only by adequately trained personnel and only while the ventilation system or room-air recirculation unit is not being operated.

Laboratory studies indicate that re-aerosolization of viable mycobacteria from filter material (HEPA filters and N95 disposable respirator filter media) is unlikely under normal conditions (373-375). Although these studies indicate that it is unlikely that *M. tuberculosis* would become an airborne hazard once removed by a HEPA filter (or other high-efficiency filter material), the risks associated with handling loaded HEPA filters in ventilation systems under field-use conditions have not been evaluated. For this reason, persons performing maintenance and replacing filters on any ventilation system that is likely to be contaminated with *M. tuberculosis* should wear a respirator (Supplement 4) and gloves. When feasible, HEPA filters may be disinfected in 10% bleach solution or other appropriate mycobacteriacide before removal(376). In addition, filter housing and ducts leading to the housing should be labeled clearly with the words "TB-Contaminated Air" or other similar warning. Disposal of filters and other potentially contaminated materials should be in accordance with applicable state or local regulations.

One or more lower efficiency disposable pre-filters installed upstream can extend the life of a HEPA filter by at least 25%. If the disposable filter is followed by a 90% extended surface filter, the life of the HEPA filter can be extended by almost 900% (160). Pre-filters should be handled and disposed of in the same manner as the HEPA filter.

B. Ultraviolet germicidal irradiation (UVGI)

Ultraviolet (UV) radiation is a form of electromagnetic radiation with wavelengths between the blue region of the visible spectrum and the x-ray region. For convenience of classification, the International Commission on Illumination has divided the wavelengths between 100 nanometers (nm) and 400 nm into three wavelength bands: UV-A (long wavelengths, range: 315-400 nm), UV-B (midrange wavelengths, range: 280-315 nm), and UV-C (short wavelengths, range: 100-280 nm). These spectral band designations are used to define approximate spectral regions and may vary among sources (377). UV-C

radiation can be produced by a number of artificial sources (e.g., arc lamps, metal halide lamps). Most commercially available UV lamps used for germicidal purposes are low-pressure mercury vapor lamps that emit radiant energy in the UV-C range, predominantly at a wavelength of 253.7 nm (378).

Research has demonstrated that UVGI is effective in killing or inactivating *M. tuberculosis* under experimental conditions (255;343;379-383) and in reducing transmission of other infectious agents in hospitals (384), military housing (385), and classrooms (386-388). Due to the results of numerous studies (342;389-392) and the experiences of clinicians and mycobacteriologists during the past several decades, UVGI has been recommended as a supplement or adjunct to other TB infection-control and ventilation measures in settings where the need to kill or inactivate *M. tuberculosis* is important (6;7;161;393;394). UVGI alone does not provide outside air or circulate interior air.

B.1 Applications of UVGI

UVGI is considered a method of air cleaning because it can kill or inactivate microorganisms so that they are no longer able to replicate and form colonies. UVGI is not a substitute for HEPA filtration prior to exhausting the air from AII rooms back into the general circulation. UVGI lamps can be placed in ducts, in fixed or portable room air-recirculation units, or in upper-air irradiation systems. The use of this air-cleaning technique has increased in recent years, particularly in large open areas where unsuspected or undiagnosed patients with TB disease might be present (e.g., emergency department waiting rooms, shelters, correctional facilities) and the costs of conditioning large volumes of outdoor air are prohibitive.

For each UVGI system, guidelines should be followed to maximize effectiveness. Effectiveness can be expressed in terms of an equivalent air change rate (387;395-397), comparing the ability of UVGI to inactivate organisms with removal via general ventilation. Initially, it is important to understand and characterize the application for which UVGI will be used. Because the effectiveness of UVGI systems will vary, the use of UVGI must be carefully evaluated and the level of efficacy clearly defined and monitored.

The number of persons who are properly trained in the design and installation of UVGI systems is limited. It is strongly recommended that health-care facility managers consult an UVGI system designer to address safety and efficacy considerations before such a system is procured and installed. Experts who might be consulted include industrial hygienists, engineers, and health physicists.

B.1.1 Duct irradiation

Duct irradiation is designed to kill or inactivate *M. tuberculosis* without exposing persons to UVGI. In duct irradiation systems, UVGI lamps are placed inside ducts to disinfect the exhaust air from AII rooms or other areas where *M. tuberculosis* may be present before it is recirculated to the same room (desirable) or to other areas served by the system (less desirable). When UVGI duct systems are properly designed, installed, and maintained, high levels of UVGI can be produced in the duct that

can potentially cause high UVGI exposures during maintenance operations.

Duct-irradiation systems depend on the circulation of as much of the room air as possible through the duct. Velocity profiles and mixing are important factors in determining the UVGI dose received by airborne particles. Design velocity for a typical UVGI unit is approximately 400 fpm (398). The particle residence time must be sufficient for inactivation of the microorganisms. When used in ducts, UVGI lamps should be placed at right angles to the direction of airflow at the center of the longest run.

Duct irradiation may be used in:

- Ventilation systems serving AII rooms to recirculate air from the room, through a duct containing UV lamps, and back into the same room. UVGI duct systems should not be used either in place of HEPA filters if air from AII rooms must be recirculated to other areas of a facility or as a substitute for HEPA filtration of air from booths, tents, or hoods used for cough-inducing procedures.
- Return air ducts serving patient rooms, waiting rooms, emergency departments, and general-use areas where patients with undiagnosed TB disease could potentially contaminate the recirculated air
- Recirculating ventilation systems serving rooms or areas where ceiling heights are too low for the safe and effective use of upper-air UVGI.

B.1.2 Upper-air irradiation

In upper-air irradiation, UVGI lamp fixtures are suspended from the ceiling and installed on walls. The base of the lamps are shielded to direct the radiation upward and outward to create an intense zone of UVGI in the upper air while minimizing the levels of UVGI in the lower part of the room where the occupants are located. The system depends on air mixing to move the air from the lower part of the room to the upper part where microbial-contaminated air can be irradiated.

An important consideration is the placement of UVGI fixtures to achieve sufficient irradiance of the upper-air space. The ceiling should be high enough (≥ 8 feet) for a large volume of upper air to be irradiated without overexposing occupants in the lower part of the room to UVGI. System designers must consider the mechanical ventilation system, room geometry, and emission characteristics of the entire fixture.

Upper-air UVGI may be used in

- AII rooms and rooms where high-risk procedures (e.g., bronchoscopy, sputum induction, administration of aerosolized medications) are performed.

- Patient rooms, waiting rooms, emergency departments, corridors, central areas, and other large areas where patients with undiagnosed TB disease could potentially contaminate the air.
- Operating rooms and adjacent corridors where procedures are performed on patients with TB disease.
- Medical settings in correctional facilities.

B.1.3. UVGI-containing portable room air cleaners

In portable room air-recirculation units containing UVGI, a fan moves a volume of room air across UVGI lamps to disinfect the air before it is recirculated back to the room. Some portable units contain both a HEPA filter (or other high-efficiency filter) as well as UVGI lamps.

In addition to the guidelines described above for the use of portable room air recirculation systems containing HEPA filtration, consideration must be given to the volume of room air that passes through the unit, the UVGI levels, particle residence time, and particulate filter efficiency (if present). One study in which a bioaerosol chamber was used showed that portable room air cleaners with UVGI lamps as the primary air-cleaning mechanism are effective (> 99%) in inactivating or killing airborne vegetative bacteria (399). Additional studies need to be performed in rooms with portable air cleaners that rely on UVGI for air cleaning.

Portable room air cleaners with UVGI may be used in

- All rooms as an adjunct method of air cleaning.
- Waiting rooms, emergency departments, corridors, central areas, or other large areas where patients with undiagnosed TB disease could potentially contaminate the air.

B.2 Effectiveness of UVGI

Air mixing, air velocity, relative humidity, UVGI intensity, and lamp configuration affect the efficacy of UVGI systems. For upper-air systems, airborne microorganisms in the lower, occupied areas of the room must move to the upper part of the room to be killed or inactivated by upper-air UVGI. Air mixing can occur through convection caused by temperature differences, fans, location of supply and exhaust ducts, or movement of people.

B.2.1 Air mixing

UVGI has been shown to be effective in killing bacteria in the upper-air applications under conditions in which air mixing was accomplished mainly by convection. In one early study, aerosolization of *M. bovis* BCG (a surrogate for *M. tuberculosis*) in a room without mechanical ventilation that relied primarily on convection and infiltration resulted in 10-25 equivalent ACH, depending on the number of UVGI fixtures used (342). Other early studies examined the effect of air mixing on UVGI efficacy (400;401). These studies indicated that the efficacy of UVGI was greatly increased if cold supply air relative to the lower portion of

the room entered through diffusers in the ceiling. The authors concluded that large temperature gradients between the upper and lower portions of the room favored (cold air in the upper portion of the room) or inhibited (hot air in the upper portion of the room) vertical mixing of air between the two zones. When large-bladed ceiling fans were used to promote mixing in the experimental room, the ability of UVGI to inactivate *Serratia marcescens*, an organism known to be highly sensitive to UVGI, was doubled (402;403).

Recent studies conducted with louvered UVGI fixtures have reported similar effects. One study documented an increase in UVGI effectiveness of 16% at two ACH and 33% at six ACH when a mixing fan was used (404). Another study conducted in a simulated health-care room found that: 1) at zero ACH, a high degree of efficacy of upper-air UVGI was achieved in the absence or presence of mixing fans when no temperature gradient was created, and 2) at six ACH, bringing in warm air at the ceiling resulted in a temperature gradient with cooler room air near the floor and a UVGI efficacy of only 9%. Turning on box fans under these winter conditions increased UVGI efficacy nearly ten-fold (to 89%) (382;405).

To reduce variability in upper-air UVGI efficacy due to temperature gradients in the room, a fan should be routinely used to continually mix the air, unless the room has been shown to be well mixed under various conditions of operation. Use of a fan would also reduce or remove the suggested winter versus summer variable ACH requirements for optimal upper-air UVGI efficacy (406).

B.2.2 Relative humidity

In studies conducted in bioaerosol chambers, the ability of UVGI to kill or inactivate microorganisms declined sharply when the relative humidity exceeded 60% (407-410). In room studies, declines in the ability of upper-air UVGI to kill or inactivate microorganisms at high relative humidity (65%, 75% and 100%) (342) (382) have also been reported. The exact mechanism responsible for the reduced effectiveness of UVGI at these higher levels of relative humidity is unknown but does not appear to be related to changes in UV irradiance levels. Relative humidity changes from 55-90% resulted in no corresponding changes in UVGI levels (397). In another study, an increase in relative humidity from 25-67% did not reduce UVGI levels (382). Bacteria have been shown to absorb significant amounts of water from the air as the relative humidity increases. It has been suggested that at high humidity, the UV irradiance levels required to inactivate the bacteria may be approaching levels determined for liquid suspensions of bacteria (408). The ability of bacteria to repair UVGI damage to their DNA via photoreactivation has also been reported to increase as relative humidity increases (382;408).

For optimal efficacy of upper-air UVGI, relative humidity should be maintained at $\leq 60\%$, a level that is consistent with current recommendations for providing acceptable indoor air quality and

minimizing environmental microbial contamination in indoor environments (344;345;411;412).

B.2.3 Ventilation rates

The relationship between ventilation and UVGI has also been evaluated. Some predicted inactivation rates have been calculated and published for varying flow rates, UV intensity, and distances from the lamp based on radiative heat transfer theory (398). In room studies, ventilation rates (zero ACH, three ACH and six ACH) were combined with various irradiation levels of upper-air UVGI. All experiments were conducted at 50% relative humidity and 70°F. In general, using *M. parafortuitum* as a surrogate for *M. tuberculosis*, ventilation rates had no adverse effect on the efficiency of upper-air UVGI. The combined effect of both environmental controls was mostly additive, with perhaps a small loss of upper-air UVGI efficiency at six ACH (382). Thus, it is possible to use ventilation rates of up to six ACH and to achieve ≥ 12 ACH (ACH + equivalent ACH) by combining these rates with the appropriate level of upper-air irradiation (382). It has been suggested that higher ventilation rates (>6 ACH) may, however, decrease the time the air is irradiated and thus decrease the killing of bacteria (389;413).

Ventilation rates up to six ACH do not appear to adversely affect the performance of upper-air UVGI. Further studies are needed to examine the combined effects of mechanical ventilation and UVGI at higher room-air exchange rates.

B.2.4 UVGI intensity

UVGI intensity field plays a primary role in the performance of upper-air UVGI systems. The UVGI dose received by microorganisms is a function of UVGI times duration of exposure. Intensity is influenced by the lamp wattage, distance from the lamp, surface area, and presence of reflective surfaces. The number of lamps, location, and UVGI level needed in a room depends on the room's geometry, area, and volume, and the location of supply air diffusers (382;396). UVGI fixtures should be spaced to reduce overlap while maintaining an even irradiance zone in the upper air.

The emission profile of a fixture is an important determinant of UVGI effectiveness. Information on total UVGI output for a given fixture (lamp plus housing and louvers) should be requested from the manufacturer and used for comparison when selecting UVGI systems. Information on only the UVGI output of the lamp is inadequate; the lamp output will be greater than the output for the fixture due to losses from reflectors and nonreflecting surfaces and the presence of louvers and other obstructions (396;397). In addition, information provided by the manufacturer reflects ideal laboratory conditions; damage to fixtures or improper installation will affect UV output. Because old or dust-covered UVGI lamps are less effective, routine maintenance and cleaning of UVGI lamps and fixtures is important. UVGI system designers should consider room geometry,

fixture output, room ventilation, and the desired level of equivalent ACH in determining the types, numbers, and placement of UVGI fixtures in a room to achieve target irradiance levels in the upper air.

B.3 Health and safety issues

Short-term overexposure to UV radiation can cause erythema (abnormal redness of the skin), photokeratitis (inflammation of the cornea), and conjunctivitis (inflammation of the conjunctiva) (414). Keratoconjunctivitis is a reversible condition, but it can be debilitating while it runs its course. Because the health effects of UVGI are generally not evident until after exposure has ended (typically 6-12 hours later), HCWs may not recognize them as occupational injuries. Symptoms include a feeling of sand in the eyes, tearing, and sensitivity to light.

In 1992, UV-C radiation was classified by the International Agency for Research on Cancer as “probably carcinogenic to humans (Group 2A)” (415). This classification was based on studies suggesting that UV-C radiation can induce skin cancers in animals, DNA damage, chromosomal aberrations, and sister chromatid exchange and transformation in human cells in vitro; and DNA damage in mammalian skin cells in vivo. In the animal studies, a contribution of UV-C to the tumor effects could not be excluded, but the effects were greater than expected for UV-B alone (415). Some studies have demonstrated that UV radiation can activate HIV gene promoters (i.e., genes in HIV that prompt replication of the virus) in laboratory samples of human cells (416-421). The potential for UV-C to cause cancer and promote HIV in humans is unknown, but skin penetration may be an important factor. It has been reported that only 20% of incident 250-nm UV penetrates the stratum corneum, compared to approximately 30-60% of 300-nm UV (422).

In upper-air UVGI systems, fixtures must be designed and installed to ensure that UVGI exposures to occupants are below current safe exposure levels. Health-hazard evaluations have identified potential problems at some facilities using UVGI systems. These include overexposure of HCWs to UVGI and inadequate maintenance, training, labeling, and use of personal protective equipment (PPE) (355;423;424). An improperly maintained (unshielded) germicidal lamp was believed to be the cause of dermatosis or photokeratitis in five HCWs in an emergency department (425) and three HCWs who were inadvertently exposed to an unshielded UVGI lamp in a room that had been converted from a sputum induction room to an office (426). These case reports highlight the importance of posting warning signs to identify the presence of UVGI and suggest shielding to minimize UVGI exposures to occupants in the lower room. In most applications, properly designed, installed, and maintained UVGI fixtures provide protection from most, if not all, of the direct UVGI in the lower room. However, radiation reflected from glass, polished metal, and high-gloss ceramic paints can be harmful to persons in the room, particularly if more than one UVGI fixture is in use. Surfaces in irradiated rooms that can reflect UVGI into occupied areas of the room should be covered with non-UV-reflecting material.

Although more study is needed, lightweight clothing made of tightly woven fabric and UV-absorbing sunscreens with solar-protection factors (SPFs) of 15 or

higher may help protect photosensitive persons. Plastic eyewear containing an UV inhibitor that prevents the transmission of $\geq 95\%$ of UV radiation in the 210-405-nm range is commercially available. HCWs should be advised that any eye or skin irritation that develops after UVGI exposure should be evaluated by an occupational health professional.

B.4 Exposure criteria

In 1972, CDC/NIOSH published a recommended exposure limit (REL) for occupational exposure to UV radiation (414). The REL is intended to protect HCWs from the acute effects of UV exposure. Photosensitive persons and those exposed concomitantly to photoactive chemicals may not be protected by the recommended standard.

The CDC/NIOSH REL for UV radiation is wavelength dependent because different wavelengths have different adverse effects on the skin and eyes (414). At 254 nm, the predominant wavelength for germicidal UV lamps, the CDC/NIOSH REL is 0.006 joules per square centimeter (J/cm^2) for a daily eight-hour work shift. The American Conference of Governmental Industrial Hygienists (ACGIH®) has a Threshold Limit Value® for UV radiation that is identical to the REL in this spectral region (427). To protect HCWs who are exposed to UVGI for eight hours per workday, the measured irradiance should be $\leq 0.2 \mu\text{W}/\text{cm}^2$ per eight-hour exposure. However, many HCWs move around considerably in the course of their work and are not exposed to a single irradiance level for eight hours. Permissible exposure times (PET) for HCWs with unprotected eyes and skin can be calculated for various irradiance levels as follows:

$$\text{PET (seconds)} = \frac{0.006 \text{ J}/\text{cm}^2 \text{ (the CDC/NIOSH REL at 254 nm)}}{\text{Measured irradiance level (at 254 nm) in W}/\text{cm}^2}$$

Exposures exceeding the CDC/NIOSH REL require the use of PPE to protect the skin and eyes.

B.5 Labeling, maintenance, and monitoring

B.5.1 Labeling and posting

Health-care settings should post warning signs on UV lamps and wherever high-intensity (i.e., UVGI exposure greater than the REL) UVGI irradiation is present to alert maintenance staff, HCWs, and the general public of the hazard. The warning signs should be written in the languages of the affected persons. Some examples are shown below:

Wall sign for upper-air UVGI:

CAUTION
ULTRAVIOLET ENERGY:
SWITCH OFF LAMPS BEFORE
ENTERING ROOM

General warning posted near UVGI lamps:

CAUTION
ULTRAVIOLET ENERGY:
PROTECT EYES and SKIN

Warning posted on the door of air handlers where UVGI is present in ductwork:

CAUTION
ULTRAVIOLET ENERGY IN DUCT:
DO **NOT** SWITCH OFF SAFETY BUTTON
OR ACTIVATE LAMPS WITH DOOR OPEN

B.5.2 Maintenance

Because the UVGI output of the lamps decline with age, a schedule for replacing the lamps should be developed in accordance with manufacturers' recommendations. The schedule can be determined from a time-use log, a system based on cumulative time, or routinely (e.g., at least annually). UVGI lamps should be checked monthly for dust build-up, which lessens radiation output. A dirty UVGI lamp should be allowed to cool and then should be cleaned in accordance with the manufacturer's recommendations so that no residue remains.

UVGI lamps should be replaced if they stop glowing, if they flicker, or if the measured irradiance (Section B.5.3) drops below the performance criteria or minimum design criterion set forth by the design engineers. Maintenance personnel must switch off all UVGI lamps before entering the upper part of the room or before accessing ducts for any purpose. Only a few seconds of direct exposure to the intense UVGI in the upper-air space or in ducts can cause dermatosis or photokeratitis. Protective clothing and equipment (e.g., gloves, goggles, face shield, sunscreen) should be worn if exposure greater than the recommended levels is possible or UVGI radiation levels are unknown.

Banks of UVGI lamps can be installed in ventilation system ducts. Safety devices and lock-out or tag-out protocols should be used on access doors to eliminate exposures of maintenance personnel. For duct irradiation systems, the access door for servicing the lamps should have an inspection window through which the lamps are checked periodically for dust build-up and to ensure they are functioning properly. The access door should have a warning sign written in appropriate languages to alert maintenance personnel to the health hazard of looking directly at bare UV lamps. The lock for this door should have an automatic electric switch or other device that turns off the lamps when the door is opened.

Types of fixtures used in upper-air irradiation include wall-mounted, corner-mounted, and ceiling-mounted fixtures that have louvers or baffles to block downward radiation and ceiling-mounted fixtures that have baffles to block radiation below the horizontal plane of the fixtures. If possible, light switches that can be locked should be used to prevent injury to persons who might unintentionally turn the lamps on during maintenance procedures. Because lamps must be discarded after use,

consideration should be given to selecting germicidal lamps that are manufactured with relatively low amounts (i.e., ≤ 5 mg) of mercury. UVGI products should be UL (Underwriters Laboratories) or ETL (Electrical Testing Laboratories) listed for their specific application and installed in accordance with the National Electric Code.

B.5.3 Monitoring

UVGI intensity should be measured by an industrial hygienist or other person knowledgeable in the use of UV radiometers with a detector designed to be most sensitive at 254 nm. Equipment used to measure UVGI should be maintained and calibrated on a regular schedule, as recommended by the manufacturer.

UVGI should be measured in the lower room to ensure that exposures to occupants are below levels that could result in acute skin and eye effects. The monitoring should consider typical duties and locations of the HCWs and should be done at eye level. At a minimum, UVGI levels should be measured at the time of initial installation and whenever fixtures are moved or other changes are made to the system that could affect UVGI. This could include changes to the room that may result in higher exposures to occupants (e.g., addition of UV-reflecting materials, or painting of walls and ceiling). UVGI monitoring information, lamp maintenance, meter calibration, and lamp and fixture change-outs should be recorded.

UVGI measurements should also be made in the upper air to define the area that is being irradiated and determine if target irradiance levels are met (428). Measurements can be made using UVGI radiometers or other techniques such as spherical actinometry, which measures the UVGI in an omnidirectional manner to estimate the energy to which microorganisms would be exposed (429). Because high levels of UVGI can be measured in the upper air, persons making the measurements should use adequate skin and eye protection. UVGI radiation levels close to the fixture source can have permissible exposure times on the order of seconds or minutes for HCWs with unprotected eyes and skin. Thus, overexposures can occur with very brief UVGI exposures in the upper air (or in ventilation system ducts where banks of unshielded UV lamps are placed) in HCWs who are not adequately protected.

B.6 Upper-Air UVGI Systems and Portable Room-Air Recirculation Units

A recent study examined the relationship between three portable room-air recirculation units with different capture or inactivation mechanisms and an upper-air UVGI system in a simulated health-care room (368). The study determined that the equivalent ACH produced by the recirculation units and that produced by the upper-air UVGI system were approximately additive. For example, one test using aerosolized *M. parafortuitum* provided an equivalent ACH for UVGI of 17 and an equivalent ACH for the recirculation unit of 11; the total experimentally measured equivalent ACH for the two systems was 27. Thus,

the use of portable room-air recirculation units in conjunction with upper-air UVGI systems may increase the overall removal of *M. tuberculosis* droplet nuclei from room air.

V. Environmental Controls: Program Issues

To be most effective, environmental controls must be installed, operated, and maintained correctly. Ongoing maintenance is a critical part of infection control that should be addressed in the written TB infection-control plan. The plan should outline the responsibility and authority for maintenance and address staff training needs. At one hospital, improperly functioning ventilation controls were believed to be an important factor in the transmission of MDR TB disease to three patients and a correctional officer, three of whom died (430). In three other multi-hospital studies evaluating the performance of AII rooms, failure to routinely monitor air-pressure differentials, or a failure of the continuous monitoring devices installed in the AII rooms, resulted in a significant percentage of the rooms being under positive pressure (44;351;431;432).

Routine preventive maintenance should be scheduled and should include all components of the ventilation systems (e.g., fans, filters, ducts, supply diffusers, exhaust grilles) and any air-cleaning devices in use. Performance monitoring should be conducted to verify that environmental controls are operating as designed. Performance monitoring may include 1) directional airflow assessments using smoke tubes and use of pressure monitoring devices that are sensitive to pressures at 0.001 inches of water gauge, and 2) measurement of supply and exhaust airflows to compare with recommended air change rates for the respective areas of the facility. Records should be kept to document all preventive maintenance and repairs.

Standard procedures should be established to ensure that maintenance staff notify infection-control personnel before performing maintenance on ventilation systems servicing patient-care areas. Likewise, infection-control staff should request assistance from maintenance personnel in checking the operational status of AII rooms and local exhaust devices (e.g., booths, hoods, tents) before use. A protocol that is well-written and followed will help to prevent unnecessary exposures of HCWs and patients to infectious aerosols. Proper labeling of ventilation system components (e.g., ducts, fans, filters) will help identify air-flow paths. Clearly labeling which fan services a given area will help prevent accidental shutdowns (433).

In addition, provisions should be made for emergency power to avoid interruptions in the performance of essential environmental controls during a power failure.

SUPPLEMENT 4: RESPIRATORY PROTECTION

I. Considerations for Selection of Respirators

The overall effectiveness of respiratory protection is affected by 1) the level of respiratory protection selected (e.g., the assigned protection factor), 2) the fit characteristics of the respirator model, 3) the care in donning the respirator, and 4) the accuracy of the fit-testing program. Although data on the effectiveness of respiratory protection from many hazardous airborne materials have been collected, the precise level of effectiveness in protecting HCWs from *M. tuberculosis* transmission in health-care settings has not been determined.

Information on the transmission parameters of *M. tuberculosis* is also incomplete. Neither the smallest infectious dose of *M. tuberculosis* nor the highest level of exposure to *M. tuberculosis* at which transmission will not occur has been defined conclusively (143;434;435). Furthermore, the size distribution of droplet nuclei and the number of particles containing viable *M. tuberculosis* organisms that are expelled by patients with infectious TB disease have not been adequately defined, and accurate methods of measuring the concentration of infectious droplet nuclei in a room have not been developed. Nevertheless, in certain settings (e.g., AII rooms, ambulances during the transport of infectious TB patients), administrative and environmental controls alone may not adequately protect HCWs from infectious airborne droplet nuclei.

On October 17, 1997, OSHA published a proposed standard for occupational exposure to TB (234). On December 31, 2003, OSHA announced the termination of rulemaking for a tuberculosis standard (235). Prior OSHA policy permits the use of any Part 84 particulate filter respirator for protection against TB disease (236). Respirators usage for TB had been regulated by OSHA under CFR Title 29, Part 1910.139 (29CFR1910.139) (237) and compliance policy directive CPL 2.106 (*Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis*). OSHA also revoked 29CFR1910.139. Hence, respirator usage for TB is now regulated under the general industry standard for respiratory protection (29CFR1910.134) (238). General information on respiratory protection for aerosols, including *M. tuberculosis*, has been published (239-241).

A. Performance criteria for respirators

Performance criteria for respirators are derived from data on 1) effectiveness of respiratory protection against noninfectious hazardous materials in workplaces other than health-care settings and an interpretation of how these data may be applied to respiratory protection against *M. tuberculosis*, 2) efficiency of respirator filters in filtering biological aerosols, 3) face-seal leakage, and 4) characteristics of respirators used in conjunction with administrative and environmental controls in outbreak settings where transmission of *M. tuberculosis* to HCWs and patients was stopped. Respiratory protective devices used in health-care settings for protection against *M. tuberculosis* should meet the following criteria:

- A.1** Any of the particulate filter respirators certified by CDC/NIOSH (N-, R-, or P-95, 99, or 100), including disposable respirators, or PAPRs with high efficiency filters.
- A.2** Ability to adequately fit HCWs who are included in a formal respiratory protection program with well-fitting respirators such as those with a fit factor (see Glossary) of ≥ 100 for disposable and other half-mask respirators.
- A.3** Ability to fit the different facial sizes and characteristics of HCWs. This can usually be met by making respirators available in different sizes.

The most important attribute of a respirator is the ability to fit the different facial sizes and characteristics of HCWs. However, studies have shown that fitting characteristics vary widely from model to model and that currently available fit-testing methods are not sufficiently accurate to compensate for respirators with poor fitting characteristics. Thus, in selecting respirator models, preference should be given to models shown by the manufacturer to have inherently well-fitting characteristics, (i.e., provide protection factors of ≥ 10 to 95% of the general population). Although more study is needed, a fit

test can help identify the 5% of persons who may not consistently achieve a good fit (245;248;250;436;437). Data have shown that fit characteristics are not related to the physical design of the respirator (i.e., duck-bill versus molded) (250).

B. Types of respiratory protection for TB

Respirators encompass a range of devices that vary in complexity from flexible masks covering only the nose and mouth, to units that cover the user's head, and have independent air supplies (e.g., PAPRs). Respirators must be selected from those approved by CDC/NIOSH under the provisions of 42 CFR, Part 84 (438).

B.1 Nonpowered air-purifying respirators

All nine classes of nonpowered, air-purifying, particulate-filter respirators are certified under 42 CFR 84. These include N-, R-, and P-series respirators of 95%, 99%, and 100% (99.7%) efficiency (Table S4-1). All of these respirators meet or exceed CDC's filtration efficiency performance criteria during the service-life of the filter (1;239;240).

Nonpowered air-purifying respirators work by drawing ambient air through the filter during inhalation. Inhalation causes negative pressure to develop in the tight-fitting facepiece and allows air to enter while the particles are captured on the filter. Air leaves the facepiece during exhalation because positive pressure develops in the facepiece and forces air out of the mask through the filter (disposable) or through an exhalation valve (replaceable and some disposable).

The classes of certified nonpowered air-purifying respirators include both filtering facepiece (disposable) respirators and elastomeric (rubber-like) respirators with filter cartridges. The certification test for filtering facepieces and filter cartridges consists only of a filter performance test. It does **not** ensure adequate fitting characteristics. Although all N-, R-, and P-series respirators are recommended for protection against *M. tuberculosis* in health-care settings and other workplaces that are generally free of oil aerosols that could degrade filter efficiency, well-fitting N-series respirators are usually less expensive than R- and P-series respirators and have been shown to provide adequate protection (239;240). All respirators should be replaced as needed based on hygiene considerations and respirator damage.

B.2 Powered air-purifying respirators (PAPRs)

A PAPR uses a blower that draws air through the filters into the facepiece. PAPRs can be equipped with a tight-fitting facepiece or a loose-fitting helmet or hood. PAPR filters are classified as "high efficiency" and are different from those described in Table S4-1. PAPR high efficiency filters meet the N100, R100, and P100 criteria at the beginning of their service life. No loading tests using 0.3- μ m particles are conducted as part of certification. PAPRs may be useful for persons with facial hair(439).

B.3 Atmosphere-supplying respirators

Positive-pressure airline (supplied-air) respirators are provided with air from a stationary source (compressor) or an air tank.

Table S4-1. Nonpowered air-purifying respirator filter classes certified under 42 CFR 8

Resistance to Filter Efficiency Degradation	Filter Efficiencies		
	95 (95%) ¹	99 (99%) ¹	100 (99.97%) ¹
N (Not resistant to Oil)	N95	N99	N100
R (Resistant to oil)	R95	R99	R100
P (Oil Proof)	P95	P99	P100

¹The number in parenthesis is the allowable penetration value.

C. Effectiveness of respiratory protection devices

Data on the effectiveness of respiratory protection against hazardous airborne materials are based on experience in the industrial setting; data on protection against transmission of *M. tuberculosis* in health-care settings are not available. The parameters used to determine the effectiveness of a respiratory protective device are face-seal efficacy and filter efficiency.

C.1 Face-seal efficacy

Face-seal leakage is the weak link that limits a respirator's protective ability. Face-seal leakage compromises the ability of particulate respirators to protect HCWs from airborne materials (440). A proper seal between the respirator's sealing surface and the face of the person wearing the respirator is essential for the effective and reliable performance of any tight-fitting, negative-pressure respirator. The face seal is less critical, but still important, for more complex PAPRs and positive-pressure respirators.

For tight-fitting, negative-pressure respirators (e.g., N95 disposable respirators), the amount of face-seal leakage is determined by 1) the fit characteristics of the respirator, 2) the care in donning the respirator, and 3) the accuracy of the fit-testing program. Studies have found that a respirator's fit characteristics can be more important than the accuracy of the fit test (246;250;437;441). Increased face-seal leakage can result from additional factors, including incorrect facepiece size, failure to follow the manufacturer's instructions at each use, beard growth, perspiration or facial oils that can cause facepiece slippage, improper maintenance, and respirator damage.

Face-seal leakage is inherent in tight-fitting negative-pressure respirators. Every time a person wearing a nonpowered particulate respirator inhales, negative pressure (relative to the workplace air) is created inside the facepiece. Due to this negative pressure, air containing contaminants can leak into the respirator through openings at the face-seal interface and avoid the higher-resistance filter material. An N95 disposable respirator should have <10% leakage. Full

facepiece, nonpowered respirators have the same leakage (<2%) as PAPRs with tight-fitting facepieces.

The more complex PAPRs and positive-pressure airline respirators reduce or eliminate this negative facepiece pressure and thus reduce leakage into the respirator and enhance protection. A PAPR is equipped with a blower that forcibly draws ambient air through high-efficiency filters and then delivers the filtered air to the facepiece. This air is blown into the facepiece at flow rates that generally exceed the expected inhalation flow rates. The pressure inside the facepiece reduces face-seal leakage to low levels, particularly during the relatively low inhalation rates expected in health-care settings. PAPRs with a tight-fitting facepiece have <2% face-seal leakage under routine conditions (243). Powered-air respirators with loose-fitting facepieces, hoods, or helmets have <4% inward leakage under routine conditions (243). Thus, a PAPR may offer lower levels of face-seal leakage than nonpowered, half-mask respirators.

C.2 Filter leakage

Aerosol leakage through respirator filters depends on at least five independent variables: 1) filtration characteristics for each type of filter, 2) size distribution of the droplets in the aerosol, 3) linear velocity through the filtering material, 4) filter loading (i.e., amount of contaminant deposited on the filter), and 5) electrostatic charges on the filter and on the droplets in the aerosol (436).

When 95-series filters are used in particulate air-purifying respirators, filter efficiency may approach 5% (50% of the allowable leakage of 10% for an N95 disposable respirator). When high efficiency or 100-series filters are used in particulate air-purifying respirators, filter efficiency is so high (effectively 100%) that filter leakage is not a consideration. Therefore, for all high-efficiency or 100-series filter respirators, virtually all inward leakage of droplet nuclei occurs at the respirator's faceseal or exhalation valve.

D. Training and periodic fit testing

Training is the most critical element in any respiratory protection program. One component of training is fit testing. Fit testing is part of the respiratory protection program required by OSHA for all respiratory protective devices used in the workplace. Fit testing should be performed during the initial respiratory protection training and periodically thereafter.

Perform fit testing during the initial respiratory protection program training and periodically thereafter (based on the risk assessment for the setting), and in accordance with applicable regulations. As of 01 January 2004, current OSHA regulations require initial and annual fit testing for all respirator use (238) (see <http://www.osha.gov/SLTC/respiratoryprotection/index.html>). A fit test is used to determine which respirator fits the user adequately and to ensure that the user knows when the respirator fits properly. Fit testing can help identify the 5% of persons who do not consistently achieve a good fit (248).

A fit test may also help ensure that a respirator adequately fits a particular HCW. The HCW may need to be fit tested with several respirators to determine which offers the best

fit. However, fit tests can detect only the leakage that occurs at the time of the test and does not account for the variation in fit that occurs in day-to-day use. Thus, fit testing should not be relied upon to compensate for respirator models with inherently poor-fitting characteristics.

Fit testing can involve either a qualitative or quantitative test (243). A qualitative test relies on the subjective response of the HCW being fit tested. A quantitative test uses detectors to measure inward leakage.

E. Maintenance and reuse of respirators

Respirator maintenance should be an integral part of an overall respirator program. Maintenance applies both to respirators with replaceable filters and to respirators that are classified as disposable but that are reused. Manufacturers' instructions for inspecting, cleaning, maintaining, and use (or reuse) of respirators should be followed to ensure that the respirator continues to function properly (243).

When respirators are used for protection against noninfectious aerosols (e.g., wood dust) that might be present in the air in heavy concentrations, the filter can become obstructed with airborne material. This obstruction in the filter material can result in increased resistance, making breathing uncomfortable. In health-care settings where respirators are used for protection against biological aerosols, the concentration of infectious particles in the air is probably low. Thus, the filter in a respirator is very unlikely to become obstructed with airborne material. In addition, no evidence exists to indicate that particles impacting on the filter material in a respirator are reaerosolized easily. For these reasons, the filter material used in respirators in health-care settings should remain functional for weeks. However, because electrostatic filter media efficiency can be degraded, the manufacturer should be contacted for the product's established service life to confirm filter performance.

Respirators with replaceable filters are reusable, and a respirator classified as disposable may be reused by the same HCW as long as it remains functional and is used in accordance with local infection-control procedures. Respirators with replaceable filters and filtering facepiece respirators may be reused by HCWs as long as they have been inspected before each use and are within the manufacturer's service life. If the filter material is physically damaged or soiled or if the manufacturer's service life criterion has been exceeded, the filter (in respirators with replaceable filters) should be changed or the disposable respirator should be discarded according to local regulations. Infection-control personnel should develop standard procedures for storing, reusing, and disposing of respirators that have been designated for disposal.

II. Implementing a Respiratory Protection Program

If respirators are used in a health-care setting, OSHA requires the development, implementation, administration, and periodic reevaluation of a respiratory protection program (238;242;243). The most important elements of a respiratory protection program include a) assignment of responsibility, b) training, and c) fit testing (1). All HCWs who use respirators for protection against infection with *M. tuberculosis* should be included in the respiratory protection program. Visitors to patients with TB disease should be given respirators to wear while in AII rooms and should be instructed on the importance of user seal-checking (formerly called "fit checking") to

ensure adequate respiratory protection. The health-care facility should develop a policy on use of respirators by visitors.

The number of HCWs included in the respiratory protection program will vary depending on 1) the number of persons with suspected or confirmed TB disease seen in a facility, 2) the number of rooms or areas in which patients with suspected or confirmed infectious TB disease stay or are encountered, and 3) the number of HCWs needed to staff these rooms or areas. In facilities where respiratory protection programs are required, enough HCWs should be included to provide adequate care for a patient with suspected or confirmed TB disease. However, administrative measures should be used to limit the number of HCWs exposed to *M. tuberculosis* (Introduction D.1).

Information on the development and management of a respiratory protection program is available in technical training courses that cover the basics of respiratory protection. Such courses are offered by OSHA, American Industrial Hygiene Association, universities, manufacturers, and private contractors. To be effective and reliable, respiratory protection programs must include at least the following elements (241-243):

A. Assignment of responsibility

One person (the program administrator) must be in charge of the respiratory protection program and be given the authority and responsibility to manage all aspects of the program. The administrator must have sufficient knowledge (obtained by training or experience) to develop and implement a respiratory protection program. Preferably, the administrator should have a background in industrial hygiene, safety, health care, or engineering. The administrator should report to the highest official possible (e.g., manager of the safety department, supervisor of nurses, HCWs' health manager, infection-control manager) and should be allocated sufficient time to administer the respiratory protection program in addition to other assigned duties.

B. Standard operating procedures

The effectiveness of a respiratory protection program requires the development of written standard procedures. These procedures should include information and guidance for the proper selection, use, and care of respirators (241).

C. Screening

HCWs should not be assigned a task requiring use of respirators unless they are physically able to perform job duties while wearing the respirator. HCWs who might need to use a respirator should be screened by a physician for pertinent medical conditions at the time they are hired and then re-screened annually (241). The screening process should begin with a screening questionnaire for pertinent medical conditions, the results of which should be used to identify HCWs who need further evaluation (Table S4-2). Unless prescribed by the screening physician, serial physical examination or testing with chest radiographs or spirometry is neither necessary nor required (248).

D. Training

HCWs who wear respirators and the persons who supervise them should be informed about the need for respirators and the potential risks associated with not using a respirator when needed. Training should be repeated annually and include at least the following components:

D.1 Description of

- D.1.1 Nature, extent, and hazards of transmission of *M. tuberculosis* in the health-care setting
- D.1.2 Risk assessment and its relationship to the respiratory protection program. The risk assessment should define areas requiring the use of respirators and the level of protection needed. For example: normal operations may require only N95 disposable respirators. Higher-risk areas, such as sputum induction or bronchoscopy rooms or autopsy suites, require a higher level of protection. Consideration should be given to full-face piece non-powered respirators, or PAPRs.
- D.1.3 Signs and symbols used to show that respirators are required in an area
- D.1.4 Environmental controls used to prevent the spread and reduce the concentration of infectious droplet nuclei. Examples are mechanical ventilation controls (e.g., in AII rooms) and BSCs. Because environmental controls may not entirely eliminate the risk for transmission of *M. tuberculosis*, the respirator wearer must be trained to know when to wear a respirator.
- D.1.5 Reasons for selecting a particular respirator for a given hazard
- D.1.6 Operation, capabilities, and limitations of respirators
- D.1.7 Respirator care. Trainees should be instructed in how to store disposable respirators and how to clean, maintain, and store replaceable filter respirators (unless a central maintenance facility that provides this service is available).
- D.1.8 OSHA respirator standard 29 CFR 1910.134. All HCWs who wear respirators should know the respiratory protection regulations.
- D.2 Opportunities for trainees to handle and wear a respirator until proficient. Trainees should be given a copy of the manufacturer's instructions for use and told to follow these instructions.
- D.3 Cautions about facial hair. Trainees should be told that facial hair between the wearer's skin and the sealing surfaces of a tight-fitting respirator will prevent a good seal. A respirator that permits negative-air pressure inside the facepiece during inhalation can allow leakage and, in the case of positive pressure devices, will either reduce service time or waste breathing air. Use of a loose-fitting PAPR avoids most limitations of facial hair. Employers may implement policy that prohibits facial hair in settings where use of a tight-fitting respirator is required and PAPRs are not available.
- D.4 Copies or summaries of lecture materials for use as quick reference materials.
- D.5 OSHA regulations regarding respirators including assessment of employees' knowledge
- D.6 Instructions to refer all respirator problems immediately to the program administrator.

E. Selection

Respirators must be selected from those approved by CDC/NIOSH under the provisions of 42 CFR 84 [www.cdc.gov/niosh/celintro.html]. A listing of CDC/NIOSH-Approved Disposable Particulate Respirators (Filtering Facepieces) may be found at www.cdc.gov/niosh/npptl/respirators/disp_part/particlist.html. If a health-care setting

uses respirators for protection against other regulated hazards (e.g., formaldehyde, ethylene oxide), then these potential exposures should be specifically addressed in the program. Combination product surgical mask/N95 disposable respirators (respirator portion certified by CDC/NIOSH and surgical mask portion listed by FDA) are available that provide both respiratory protection and bloodborne pathogen protection.

F. Fit testing

Well-designed respirators are likely to achieve desired fit without having to rely on fit testing (181;188;233). However, HCWs should undergo initial and periodic fit testing to identify a respirator with an adequate fit. HCWs should receive fitting instructions that include demonstrations of and practice in how the respirator should be worn and adjusted and how to determine if it fits properly. Performing a user seal-check (formerly called “fit checking”) after redonning the respirator each time is important to ensure adequate respiratory protection. The overall protection factors are improved with the use of individual fit testing.

To check positive pressure, the surface of the respirator should be covered (by the wearer’s hands or by a piece of household plastic film) and the wearer should gently exhale. If air is felt escaping around the facepiece, the respirator should be repositioned and the user seal-check should be performed again. If the wearer does not feel air escaping around the facepiece, the positive pressure user seal-check was successful.

To check negative pressure, the respirator should be covered again, and the wearer should gently inhale. This should create a vacuum, causing the respirator to be drawn in slightly toward the face. If the respirator is not drawn in toward the face, it should be removed and examined for any defect such as a small hole. If none is found, the respirator should be repositioned and a second attempt at negative pressure user seal-checking should be made. If the respirator draws in toward the face while the wearer covers the surface and inhales, the negative pressure user seal-check was a success.

G. Inspection and maintenance

Respirator inspection and maintenance must be an integral part of the respirator program. Disposable respirators must be discarded if they are soiled or damaged (e.g., creased or torn). Non-disposable respirators must be regularly cleaned and disinfected. If a replaceable filter respirator is used by more than one person (i.e., not assigned to one person permanently), it must be cleaned and disinfected after each use. Respirators must be stored in a convenient and sanitary location that provides protection from dust, harmful chemicals, sunlight, moisture, and excessive heat or cold. Respirators that are used routinely must be inspected during cleaning; damaged or deteriorated parts must be replaced.

H. Evaluation

The respirator program must be evaluated periodically to ensure its continued effectiveness.

DRAFT

DRAFT

DRAFT

Table S4-2. Model Framework for Medical Questionnaire for Respirator Users

Today's date: _____

Employee: _____

Job title: _____

SS# or other ID: _____ Date of birth: _____

Employer: _____

Employer phone number: _____

Age: _____ Height: _____ Weight: _____

Have you worn a respirator before?

Yes No

If yes, describe any difficulties noted with respirator use: _____

Will you be wearing any other personal protective equipment that might touch or interfere with the respirator (e.g., glasses, hat, headband, splash shield)?

Yes No

If yes, please describe: _____

Have you ever had or do you currently have any of the following conditions:

1. Lung Disease	Yes	No
2. Persistent Cough	Yes	No
3. Heart Trouble	Yes	No
4. Shortness of Breath	Yes	No
5. History of Fainting/Seizures	Yes	No
6. High Blood Pressure	Yes	No
7. Diabetes	Yes	No
8. Feelings of Claustrophobia	Yes	No
9. Skin Problems/Abnormalities	Yes	No
10. Heat Exhaustion/Heat Stroke	Yes	No
11. Defective Vision	Yes	No
12. Defective Hearing	Yes	No
13. Asthma	Yes	No
14. Anemia	Yes	No
15. Epilepsy	Yes	No
16. Back Problems	Yes	No
17. Any other condition which might interfere with respirator use	Yes	No

Please explain YES answers (use back of form if necessary) _____

Are you currently taking any medications?

Yes No

If yes, please list: _____

Do you now or have you ever smoked?

Yes No

At what age did you start smoking? _____

How long ago did you quit smoking? _____

How many packs per day did or do you smoke? _____

EMPLOYEE'S SIGNATURE

DATE

For physician use:

Is there documentation of previous medical screening for respirator use? Yes No

If yes, date: _____

Changes from last screening: _____

DRAFT

DRAFT

DRAFT

Further evaluation needed based on questionnaire:

PHYSICIAN'S SIGNATURE

DATE

Note: Additional information may be found in 29CFR1910.134 , Appendix C (<http://www.osha.gov/pls/oshaweb/>).

DRAFT

DRAFT

DRAFT

Table S4-3. Model Request for Medical Clearance for Respirator Use
(To be completed by Employee)

Today's date: _____

Employee: _____

Job title: _____

SS#: _____ Date of birth: _____

Employer: _____

Employer phone number: _____

Age: _____ Height: _____ Weight: _____

Describe the job or work assignment for which respiratory protection will be used:

What hazardous environment will respiratory protection be used for? _____

Circle type(s) of respirator(s) to be used?

Powered-air purifying (PAPR)

Supplied-air (pressure demand)

Air-purifying (non-powered)

Other

Circle extent of use:

Full shift (daily)

Task dependent (occasionally)

Rarely

Emergency use only

Length of time respiratory protection will be required (hours per day): _____

Will there be elevated temperatures? Yes No

Supervisor _____ Date _____

Physician's Evaluation

Employee name _____

May _____ May not _____ Wear the above noted respirator(s) _____

The restrictions for respirator use by this employee are: _____

EXAMING PHYSICIAN'S SIGNATURE _____ DATE _____

SUPPLEMENT 5: CLEANING, DISINFECTING, AND STERILIZING PATIENT-CARE EQUIPMENT AND ROOMS

I. General

Medical instruments and equipment used on patients who have TB disease are usually not involved in the transmission of *M. tuberculosis*. However, transmission of *M. tuberculosis* and pseudo-outbreaks (e.g., contamination of clinical specimens) have been linked to inadequately disinfected bronchoscopes contaminated with *M. tuberculosis* (72;73;144;147;148;150). Guidelines for cleaning, disinfecting, and sterilizing flexible endoscopic instruments have been published (442-446).

The rationale for cleaning, disinfecting, or sterilizing patient-care instruments and equipment can be understood more readily if medical devices, equipment, and surgical materials are divided into three general categories (447). These categories--critical, semicritical, and noncritical--are based on the potential risk for infection if an item remains contaminated at the time of use.

A. Critical medical instruments

Instruments that are introduced directly into the bloodstream or other normally sterile areas of the body (e.g., needles, surgical instruments, cardiac catheters, implants) are critical medical instruments. These items should be sterile at the time of use.

B. Semicritical medical instruments

Instruments that may come into contact with mucous membranes but do not ordinarily penetrate body surfaces (e.g., noninvasive flexible and rigid fiberoptic endoscopes or bronchoscopes, endotracheal tubes, anesthesia breathing circuits) are semicritical medical instruments. Although sterilization is preferred for these instruments, high-level disinfection that destroys vegetative microorganisms, most fungal spores, mycobacteria (including tubercle bacilli), and small nonlipid viruses may be used. Meticulous cleaning of such items before sterilization or high-level disinfection is essential (442). When an automated washer is used to clean endoscopes and bronchoscopes, the washer must be compatible with the instruments to be cleaned (442;448). High-level disinfection can be accomplished with either manual procedures alone or use of an automated endoscope reprocessor with manual cleaning (72;442). In all cases manual cleaning is an essential first step in the process to remove debris from the instrument.

C. Noncritical medical instruments or devices

Instruments or devices that either do not ordinarily touch the patient or touch only the patient's intact skin (e.g., crutches, bed boards, blood pressure cuffs) are noncritical medical instruments. These items are not associated with transmission of *M. tuberculosis*. When non-critical instruments or equipment are contaminated with blood or body substances, they should be cleaned and then disinfected with a hospital-grade, Environmental Protection Agency (EPA)-registered germicide disinfectant with a label claim for tuberculocidal activity (i.e., an intermediate-level disinfectant). Tuberculocidal activity is not necessary for cleaning agents or low-level disinfectants that are used to clean or disinfect minimally soiled noncritical items and environmental surfaces (e.g., floors, walls, table tops, surfaces with minimal hand contact).

II. Disinfection

The rationale for use of a disinfectant with tuberculocidal activity is to ensure the killing of other potential pathogens with less intrinsic resistance than that of mycobacteria. A common misconception in the use of surface disinfectants in health care relates to the underlying purpose of products labeled as tuberculocidal germicides. Such products will not interrupt and prevent transmission of *M. tuberculosis* in health-care settings because TB is not acquired from environmental surfaces. The tuberculocidal claim is used as a benchmark by which to measure germicidal potency. Since mycobacteria have the highest intrinsic level of resistance among the vegetative bacteria, viruses, and fungi, any germicide with a tuberculocidal claim on the label (i.e., an intermediate-level disinfectant) is considered capable of inactivating a broad spectrum of pathogens, including much less resistant organisms, such as the bloodborne pathogens (e.g., hepatitis B virus, hepatitis C virus, and HIV). It is this broad spectrum capability, rather than the product's specific potency against mycobacteria, that is the basis for protocols and regulations indicating the appropriateness of tuberculocidal chemicals for surface disinfection.

Policies of health-care settings should specify whether cleaning, disinfecting, or sterilizing an item is necessary to decrease the risk for infection. Decisions about decontamination processes should be based on the intended use of the item, not on the diagnosis of the patient for whom the item is used. Selection of chemical disinfectants depends on the intended use, the level of disinfection required, and the structure and material of the item to be disinfected.

The same cleaning procedures used in other rooms in the health-care setting should be used to clean AII rooms. However, personnel should follow AII practices while cleaning these rooms when the rooms are still in use. Personal protective equipment is not necessary during the final cleaning of an AII room after a patient has been discharged if the room has been ventilated for the appropriate amount of time (Table S3-1, Supplement 2).

SUPPLEMENT 6: FREQUENTLY ASKED QUESTIONS (FAQs)

- I. Tuberculin skin testing**
- II. Risk Assessment**
- III. Environmental controls**
- IV. Respiratory protection**
- V. Other**

I. Tuberculin Skin Testing (TST)***Is there any risk in having a TST administered more than once a year?***

No, having multiple TSTs administered does not increase the risk for a false-positive TST result, nor does it cause a TST conversion in persons without exposure to mycobacteria(29). HCWs may safely receive TSTs several times a year if an exposure to *M. tuberculosis* is suspected or if the HCW transfers to a workplace that requires a new baseline two-step TST.

Can repeated TSTs by themselves cause TST results to convert from negative to positive?

No, in the absence of an infection with a species of mycobacterium or BCG vaccination, repeated TSTs alone will not cause a conversion.

If someone does not return for a TST reading within 48–72 hours, when can a TST be administered to them again?

A TST may be administered again as soon as possible. If the second test of a two-step TST is not read within 48–72 hours, administer a third test as soon as possible (even if many months have passed) and ensure that the result is read within 48–72 hours.

What defines a negative TST result?

A TST result of zero mm or anything below the defined cut point for each criteria category is considered a negative TST result (Table S2-2, Supplement 2).

What defines a positive TST result?

A TST result of any mm reading above or at the defined cut point for each criteria category is considered a positive TST result (Table S2-2). This cut point may vary according to the purpose of the test (i.e., infection control surveillance versus medical and diagnostic evaluation).

What is a false-negative result?

A false-negative TST or QuantiFERON-TB test (QFT) result is one that is interpreted as negative for a particular purpose (i.e., infection control surveillance or medical and diagnostic evaluation) in a person who is actually infected with *M. tuberculosis*. A false-negative TST result may be due to incorrect TST administration (too deeply, or too shallow), incorrect reading of the TST result, or if the person tested is anergic (i.e., unable to respond to the TST due to an immunocompromising condition).

What is a false-positive result?

A false-positive TST or QFT result is one that is interpreted as positive for a particular purpose (i.e., infection control surveillance or medical and diagnostic evaluation) in a person who is actually **not** infected with *M. tuberculosis*. This is more likely to occur in persons who have been vaccinated with BCG or who are infected with nontuberculous mycobacteria (NTM) (also known as MOTT). A false-positive TST result may be due to incorrect TST administration (too deeply, or too shallow), or incorrect reading of the TST result.

What is the earliest age that a TST can be administered?

There is no minimum age that a TST can be administered. TSTs are safe for infants and children. Infants <6 months of age are more likely to be anergic (so the possibility of a false-negative TST result is possible) and the TST should be repeated after the age of 6 months.

A pregnant HCW in our setting is reluctant to get a TST. Should we encourage her to have the test done?

Yes, the HCW should be educated that pregnancy is not a contraindication to having a TST and that skin testing does not affect the fetus or results of the tests (325). Tens of thousands of pregnant women have received TSTs since the test was developed, and no documented episodes of TST-related fetal harm have been reported. The importance of the facility's infection control program should be emphasized to the HCW. In the event of an investigation of a potential or known exposure to *M. tuberculosis*, the TST should never be postponed due to pregnancy; for the protection of both the woman and the fetus, the TST should be performed immediately so that infection with *M. tuberculosis* can be detected and prompt referral for medical evaluation can be made, if necessary. Guidelines issued by the American College of Obstetricians and Gynecologists (ACOG) emphasize that postponement of the diagnosis of infection with *M. tuberculosis* during pregnancy is unacceptable(449).

A pregnant HCW in our setting has a positive TST result and is reluctant to get a chest radiograph. Should we encourage her to have the chest radiograph done?

Yes. The positive TST result could be associated with TB disease, which is dangerous to both mother and fetus. Pregnant women who have a positive TST result or who are suspected of having TB disease as indicated by symptoms or other concerns, should receive a chest radiograph (with abdominal shielding consistent with safety guidelines) as soon as possible, even during the first trimester of pregnancy.

Can HCWs who have an allergy to latex receive TSTs?

Yes, persons with a latex allergy can receive TSTs if latex-free products are used. If a person with a latex allergy does have a TST performed using products or equipment that contain latex, interpretation of the TST results can be difficult because the TST reaction might be the result of the latex allergy, reaction to PPD, or a combination of both. Repeat skin testing using latex-free products may help clarify this.

Are routine chest radiographs recommended for HCWs (or patients or institutional residents) with positive TST results?

No, persons who have a positive TST result should **not** have repeat chest radiographs performed routinely (29;101). HCWs (or patients or institutional residents) with a baseline positive or newly positive TST result should receive one chest radiograph to exclude a diagnosis of TB disease. Afterwards, repeat radiographs are not needed unless signs or symptoms of TB disease develop, or a clinician recommends a repeat chest radiograph (29;101), or after exposure to *M. tuberculosis*. Instead of participating in serial skin testing, the HCW should receive a medical evaluation and a symptom screen, which is a procedure used during a clinical evaluation in which the patient is asked if they have experienced any signs or symptoms of TB disease. The frequency of this medical evaluation should be determined by the risk assessment for the facility. HCWs who have a previously positive TST result and who change jobs should carry the results of their chest radiograph (and documentation of treatment history for LTBI, if applicable) to their new employers.

Our setting conducts TSTs annually on the anniversary of each HCW's employment. Last year, several TST conversions occurred in April, so we performed a contact investigation for all exposed HCWs that month. Do we have to test all HCWs annually in April from now on?

No, skin testing HCWs on the anniversary of their employment or on their birthday (rather than testing all HCWs at the same time each year) is preferable since it increases the opportunity for early recognition of infection-control problems that can lead to TST conversions. Therefore, revert to testing HCWs on their employment anniversaries, even though some HCWs may end up being tested twice or more in the 12 months following a contact investigation. This will ensure that no HCW has an interval of more than one year between TSTs, which is particularly important in a setting in which TST conversions have occurred.

Should HCWs who report upon hire that they have had a positive TST result or previously treated LTBI or TB disease receive a new baseline TST before starting work at a new health-care setting?

Yes, all newly hired HCWs should receive two-step TSTs, preferably prior to starting duties, **unless** the HCW has documentation of a positive TST result or previously treated LTBI or TB disease. If documentation is available of a positive TST result, that may be accepted as the baseline TST for the HCW at the new employment setting, and an additional TST is not needed. If no documentation is available of a positive TST result or of previously treated LTBI or TB disease, the HCW should receive two-step TSTs, consisting of an initial TST and, if that result is negative, a second TST administered 1–3 weeks after the first TST was administered to detect boosting, and the results should be documented at the new setting.

Is a baseline test for infection with *M. tuberculosis* needed for HCWs who begin a job that involves little contact with patients (e.g., medical records staff)?

Yes, all newly hired HCWs should receive two-step TSTs, preferably prior to starting duties, **unless** the HCW has documentation of a positive TST result or previously treated LTBI or TB disease. However, in a small number of settings, there may be a choice not to perform baseline TB screening (at the beginning of the HCW's employment) or serial TB screening for HCWs who will **never** be in contact with, or have shared air space with patients who have TB disease (e.g., telephone operators who work in a separate building from patients), or who will never be in contact with clinical specimens that may contain *M. tuberculosis*. Baseline testing for infection with *M. tuberculosis* protects other HCWs and patients by facilitating the diagnosis and treatment of TB disease or LTBI acquired prior to the current job and is helpful in the event of a possible exposure to *M. tuberculosis*.

What procedure should be followed for a new HCW who received a TST three months ago?

If a HCW has documentation of recent TST (≤ 12 months), that result can be the baseline. Having multiple TSTs administered does not increase the risk for a positive TST result, nor does it cause a TST conversion in persons without exposure to mycobacteria (29).

We are hiring an HCW from a country in which BCG is routinely given. She states that since she was vaccinated with BCG, her TST result will be positive and she should not receive a baseline TST. Should this HCW be exempted from a baseline TST?

No, all HCWs, including those who have been vaccinated with BCG, should be required to have a baseline two-step TST and follow-up serial TSTs, if indicated, unless the HCW has documentation of a positive TST result or previously treated LTBI or TB disease, she should receive baseline two-step TSTs. Many persons who received BCG never have a positive TST result. For many others, the positive reaction wanes after a few years. Thus, many HCWs who received BCG will have a negative baseline TST result and will be able to participate in serial TST screening. Those with a positive TST result require evaluation for TB disease. Since BCG

does not protect against acquiring infection with *M. tuberculosis* if exposed, U.S. guidelines state that a positive TST result in a person who received BCG should be interpreted as indicating LTBI. The HCW in this example should receive baseline two-step TSTs (or one QFT).

Are there any health-care settings or areas of the country in which initial two-step testing for newly hired HCWs is not needed?

No, all newly hired HCWs should receive baseline two-step testing to avoid false-negative interpretations of the initial TST result. Even in an area of the country where little boosting is present, an HCW might have lived elsewhere and have a boosted response due to prior exposure. If the potential for boosting exists among even 1% of HCWs, a setting could be falsely reclassified as having *potential ongoing transmission* if two-step testing was omitted, and a later contact investigation detected TST conversions in HCWs with a boosted response when the TST results were actually false-positive results. This is especially important for settings classified as *low-risk* since follow-up skin testing is indicated only upon exposure to *M. tuberculosis* for HCWs with negative TST results.

We hire workers to provide healthcare in homes. Two-step skin testing is difficult due to the requirement to return for testing and reading several times. May we omit the two-step TST?

No, all HCWs should receive two-step baseline skin testing unless they have documentation of a previously positive result for infection with *M. tuberculosis* or treated LTBI or TB disease. Baseline skin testing will ensure that TB disease or LTBI that could reactivate and put clients at risk is detected before work begins and ensures that treatment for LTBI or TB disease can be given promptly, if indicated. Documentation of a two-step baseline TST result will prevent a boosted reaction from being incorrectly interpreted as a TST conversion if a subsequent TST is administered to evaluate an exposure to *M. tuberculosis* (contact investigation). Two-step testing can also avert an unnecessary contact investigation for a source case if a TST conversion is detected during serial TST screening.

An HCW at our hospital has not had a TST in 18 months because she was on maternity leave and missed her anniversary date for her annual TST. She has been employed at the hospital for the past five years. Is a two-step TST needed on her next skin test date?

No, two-step TSTs are needed only for newly hired HCWs (or for persons who will receive serial TSTs, such as residents of long-term care facilities), to establish a baseline for a specific setting. Once a baseline TST result has been established in an HCW, any change of TST result from negative to positive should be interpreted as potential health-care–associated transmission. An HCW who misses the anniversary date for an annual TST should have a single TST upon returning to work. After that, the HCW should resume a regular testing schedule with a single TST on the next TST anniversary date.

Should two-step testing be performed during a contact investigation for HCWs who have not had a TST within the past 12 months?

No, two-step testing should **only** be used for baseline TST screening and has **no** role in a contact investigation. If the initial TST result in a contact investigation is classified as negative, a follow-up TST should be administered 8–10 weeks after the end of exposure. When an HCW has been exposed to a person with TB disease, a change in a TST result from negative to positive should be interpreted as *potential ongoing transmission* and **not** a boosted reaction.

If an HCW has a baseline first-step TST result that is between 0 and 10 mm, does a second step need to be administered?

Yes, for any baseline first-step TST result that is <10 mm, (which is the positive cut point for most HCWs), a second-step TST should be applied 1–3 weeks after the first TST was

administered to detect boosting and establish a reliable baseline. If the first step of the baseline TST result is ≥ 10 mm, the HCW is considered to have LTBI and a second TST is not necessary.

An HCW who had a baseline (first- or second-step) TST result of 8 mm is retested a year later for serial TB screening and found to have a TST result of 16 mm. There was no known exposure to *M. tuberculosis*. Although the TST result is now ≥ 10 mm, there was not a ≥ 10 mm increase in the TST result to meet the criteria for a TST conversion. How should this be interpreted?

Determining whether a TST result is positive or negative depends on two criteria, 1) absolute measured induration (i.e., 5, 10 or 15 mm induration depending on the level of risk) and 2) change in the size of the TST result. Usually, these two criteria agree. Occasionally, there can be discrepancy, as in this example. When this occurs, expert advice may be sought from the state or local health department. The interpretation of the TST result in this example should take into account the change in TST result size, time frame of the change, risk for exposure, if any, and the occurrence of other documented TST conversions in the healthcare setting. For HCWs at low risk for LTBI, TST results of 10-14 mm may be considered clinically negative, but these HCWs should not have repeat TSTs because additional increase in induration >10 mm will not be useful in determining likelihood of LTBI. This may be especially true in areas where the prevalence of nontuberculous mycobacteria (NTM) (also known as MOTT) is high. This HCW should be considered to have a positive TST result based on the 16 mm result (but not a TST conversion), and should receive a symptom screen annually.

If an HCW is at low risk for TB disease and they have a TST result of 13 mm, what should the infection-control program do, and should the HCW be treated?

Several aspects are involved in the answer to this question. The first is the administrative responsibility of the infection control program. If this TST is part of serial testing in an established (not newly hired) HCW with a 0 mm baseline two-step TST result, the 13 mm result represents an increase by ≥ 10 mm and this should be considered a TST conversion for the purposes of surveillance, **and** the employee should be referred for medical evaluation to exclude TB disease. Caution is needed for non-zero baseline measurements in determining action. For example, if the baseline TST result for this HCW is 7 mm, then a follow up TST result of 13 mm is not a TST conversion for surveillance purposes and does not meet with criteria to refer the HCW for medical evaluation. If however, the baseline TST result was 3 mm and a follow up test result was 7 mm, it also does not meet the criteria for TST conversion (i.e., not an increase of ≥ 10 mm since the last TST) but is suspicious for LTBI and the HCW might be referred for medical evaluation. If an HCW has a TST result of 13 mm and the TST was given as part of baseline testing for a new HCW, the HCW should be referred for medical evaluation and this HCW would remain part of infection control screening but would not receive further TST.

The second aspect of this question is the medical decision making after referral by the infection-control program; note that this referral could be housed in the same unit or delivered by the same person(s). In all cases, TB disease needs to be excluded. If a HCW had a TST result of 13 mm as part of baseline testing and was at otherwise low risk for LTBI or progression to TB disease if infected, treatment for LTBI may not be recommended. If however, the HCW had a TST result of 13 mm as part of a serial screening and had a history of a 0 mm TST result at baseline two steps and follow up testing, then this increase of 13 mm induration in the intervening one year likely represents exposure and infection with *M. tuberculosis*, and treatment for LTBI is recommended. Recommendations for other scenarios (e.g., baseline 3 mm, follow up 7 mm, and presents on referral with 13 mm) are not established and require consultation with experts in the diagnosis and treatment of LTBI.

If the longitudinal reading of the induration of the TST result is 12 mm and the horizontal reading is 8 mm, what should be recorded?

The correct TST reading should be recorded as 8 mm (not 12 mm or 8x12 mm). For purposes of standardization, only record the mm of induration that is measured transverse, or perpendicular to the long axis of the forearm. Erythema (abnormal redness of the skin) around the TST site might develop but should not be read as part of the TST result. Consideration should be given to retesting if the selected area for placing on the arm was on or near a muscle margin, scar, heavy hair, veins, or sores, which could be barriers to reading.

Where can our setting obtain self-reading TST cards that allow HCWs to report their own results?

HCWs should not read their own TST results, therefore, self-reading cards for reporting TST results are not recommended. Experience has shown that HCWs do not measure their own TST results reliably (31). All TST results should be read and recorded by a trained TST reader other than the person on whom the TST was administered.

Where can our setting obtain materials for educating HCWs about TB?

Supplement 7 of this document is a list of TB websites and resources. Your state or local health department should have additional materials and access to resources, and should be able to help develop a setting-specific TB education program.

Should gloves be worn when placing TSTs?

Local areas should determine what standard precautions should be followed at their facility. Glove use is part of universal precautions. Glove use specifically for TST administration is not addressed in CDC guidelines.

Is TST quality control (QC) important?

Yes, performing QC for HCWs during training and retraining of administering TSTs and reading TST results is important in order to avoid false-negative and false-positive TST results. TST QC ensures that HCWs continue to administer and read TST results correctly.

What is “boosting?”

Boosting is an occurrence in which some persons who are skin tested many years after infection with *M. tuberculosis* have a negative TST result, followed by a positive result. The positive TST result is caused by a boosted immune response of the prior sensitivity rather than by a new infection. The boosted reaction should not be considered a TST conversion.

Why is a two-step TST important for the baseline?

The two-step TST at baseline finds those persons whose first TST result is negative but the second-step TST result exceeds the criteria for referral for medical evaluation. Hence, performing a two-step TST at baseline (at the beginning of an HCW’s employment) is critically important and minimizes the possibility that boosting will incorrectly lead to suspicion of transmission of *M. tuberculosis* in the setting, being interpreted as a conversion during a later routine screening or a contact investigation.

When can a TST be administered if you’re also administering vaccines (measles, varicella, yellow fever, smallpox)?

A TST should be administered either on the same day as vaccination with live virus or 4-6 weeks later. Live-attenuated vaccines that may cause false-negative TST result are BCG, measles, mumps, rubella, oral polio, varicella, yellow fever, oral typhoid (296) and influenza virus

vaccines. HCWs scheduled to receive an annual TST should not receive the TST until ≥ 1 month after smallpox vaccination (450) or MMR (296) to prevent possible false-negative TST results.

If a newly hired HCW requires both a measles, mumps and rubella (MMR) vaccination and a two-step TST, should the MMR and first-step TST be given on the same day?

Yes, the MMR vaccine and first-step TST may be given on the same day, however, it would be advisable to administer the second-step TST ≥ 4 weeks after MMR vaccination (instead of 1–3 weeks after the first-step TST result is read) to decrease the probability of false-negative result on the second TST. There are no specific CDC guidelines that address concurrent live vaccine (such as like MMR or Varivax) and the placement of the first-step TST. The measles vaccine (and possibly mumps, rubella, and varicella vaccines) may transiently suppress the response to PPD in a person infected with *M. tuberculosis*. Simultaneously administering PPD and the measles-containing vaccine does not interfere with reading the TST result at 48–72 hours and ensures that the person has received measles vaccine. TST screening may be performed and read before administering the MMR, however, this option is the least favored because it will delay receipt of the MMR vaccine(296).

Is it safe to administer a TST on a nursing mother?

Yes, it is safe to administer a TST on a nursing mother.

Should my private home health-care service perform TSTs on employees?

Yes, all newly hired HCWs who do not have documentation of a positive TST result or previously treated LTBI or TB disease should receive two-step baseline skin testing to minimize the possibility that boosting will later lead to suspicion of transmission of *M. tuberculosis* in the setting during a contact investigation. Once a baseline is established, further TB screening would be recommended if the risk assessment classifies the facility as medium-risk or potential ongoing transmission. The frequency of screening should be determined by the risk assessment.

When performing two-step skin testing, what should be done if the second test is not performed in 1–3 weeks?

Perform the TST as soon as possible. Interpretation of the TST result is increasingly difficult as the interval between TSTs becomes longer than 3 weeks because interpretation of the TST result rests on the assumption that there is no intervening exposure to *M. tuberculosis*.

May we accept a TST result reading of 10 mm after 13 days?

No, 13 days later is too late to read a TST result. If the TST result was not read between 48–72 hours, even if there seems to be a reaction after 72 hours, another TST should be administered as soon as possible and read within 48–72 hours.

Where can I get mm rulers to measure TST results?

CDC has a TST training kit, which includes a TST training video, facilitator's guide, and a TST mm ruler. This and other TB education and training materials are available at CDC's website: https://www2.cdc.gov/nchstp_od/PIWeb/TBorderform.asp. Also check with your state or local health department.

Where can I obtain PPD?

Your state and local health departments may provide antigen for tuberculin skin testing without charge to selected targeted testing and treatment programs.

How frequently should people in the general public receive TSTs?

Testing for LTBI in the general public is not necessary unless the person is at risk for infection with *M. tuberculosis*, such as persons infected with HIV, HCWs, or someone who was exposed to a person with TB disease (i.e., if they are involved in a contact investigation).

May we use a multiple puncture Tine® test to administer a TST?

No. In the United States, multiple puncture or Tine® tests should not be used to determine whether a person is infected with *M. tuberculosis*. The Mantoux method of skin testing is the preferred method because it is more accurate.

Can we put band-aids on TSTs?

No, it is not recommended to put bandages or any covering on TSTs because it may interfere with the reading (e.g., adhesive bandages, cream, ointment, lotion, liquids, medication).

What should we do if an HCW has a baseline TST result of 16 mm, then one year later the TST result was read as 0 mm?

One reason for the different results could be that the subsequent TST was administered incorrectly (too deeply, or too shallow) or the results may have been read incorrectly, leading to false-positive or false-negative results. In this particular case of a 16 mm result at baseline, it was not necessary for the HCW to receive another TST. If the baseline result had been negative but greater than zero mm induration and insufficient for medical evaluation (e.g., 8 mm in an HIV-negative HCW) and the second result was thought to be administered or read incorrectly, then the test should be repeated. If the test was thought to be administered and read correctly and there was no known history of exposure, repeat testing should resume on the next scheduled testing date.

What if the TST is given intra-muscularly instead of intradermally?

There is no known harm for a TST administered intra-muscularly; however, CDC has no official guidance regarding this. But if this occurs, the TST result will be invalid, therefore, the TST should be placed again intradermally ≥ 2 inches from the original injection site or on the other arm. This can be done immediately. If the local reaction is severe and does not resolve within a few days, the person should consult a medical provider. Quality control (QC) of administering TSTs is important (Supplement 2, A.6; Table S2-3).

How are HCW TST conversion rates calculated?

TST conversion rates are a simple way of comparing the number of HCWs who have converted their TST since the prior year and the HCWs with negative TST results who did not convert over the same time period. The numerator includes only HCWs who had a negative TST result at the facility in the prior year, **and** have a positive TST result this year. The denominator includes only HCWs who had a negative TST result at the facility in the prior year.

Where can I get a list of safer injection devices for placing a TST?

The Needlestick Safety and Prevention Act, 2001, requires employers to identify and use effective, safer injection devices or document evaluated devices. OSHA revised the Bloodborne Pathogens standard to include these requirements. A resource document that lists safer injection devices reported to meet design criteria for TST accuracy has been developed and is available from the National TB Controller's Association, <http://www.ntca-tb.org/>. CDC's National Immunization Program also provides needle-free injection information at this web site: <http://www.cdc.gov/nip/dev/jetinject.htm>.

II. Risk Assessment

Our setting is a hospital with 160 beds. Three HCWs have had TST conversions over a two-month period. This is usually the number of TST conversions we detect in one year in our hospital. Do we need to start testing all of our HCWs every three months due to potential ongoing transmission?

Yes, unless it can be proven otherwise, there appears to be evidence of ongoing transmission in this setting. If the HCWs with TST conversions can be linked together in some way, either through a type or location of work, or DNA fingerprinting, then the classification of *potential ongoing transmission* should apply only to that subset of HCWs. Otherwise, the classification of *potential ongoing transmission* may be applied to the entire setting. In either case, a problem evaluation should be undertaken to ascertain the reason for the TST conversions (Section H. Problem Evaluation). Reasons for the TST conversions could be an undiagnosed case of TB in the setting or incorrect reading of TST results (false-positive results). Early consultation with the state or local health department and an expert in TB infection control may be helpful in identifying and resolving the problem.

If a health-care setting has a risk classification of potential ongoing transmission, how long should that classification be applied?

The classification of *potential ongoing transmission* should be used as a temporary classification only. It warrants immediate investigation and corrective steps; after it has been determined that ongoing transmission has ceased, the setting should be reclassified as *medium risk*. It is recommended to maintain the classification of *medium risk* for at least one year.

In some health-care settings, it is very difficult to know how many patients with TB disease were seen in one year. How should the risk classification be assigned?

In some situations, such as in outpatient clinics or emergency medical settings where patients may be seen before hospitalization during which TB disease is diagnosed, it can be difficult to accurately estimate the number of TB patients seen in one year. These situations underscore the importance of an accurate medical history and complete contact investigation for all persons with suspected or confirmed TB disease. This is accomplished through cooperation between infection-control personnel and the state or local health department's TB control program.

III. Treatment for latent TB infection (LTBI)

Who should be treated for LTBI?

Persons infected with LTBI should be considered eligible and medically evaluated (including assessment of contraindications) for treatment of LTBI. The following groups of persons are recommended to be treated for LTBI because they are at higher risk of developing TB disease once infected: persons infected with HIV, persons recently infected with LTBI (<2 years), persons who have immigrated from areas of the world with high rates of TB disease, children, especially those ≤ 5 years of age, persons who inject illicit drugs (especially if they are coinfecting with HIV), persons with pulmonary fibrotic lesions on chest radiograph presumed to be from prior, untreated TB disease, and persons who have body weight <10% of ideal weight.

What are contraindications to treatment of LTBI?

Active hepatitis and end-stage liver disease (ESRD) are relative contraindications to the use of isoniazid or pyrazinamide for treatment of LTBI. Due to the numerous and complex drug-drug interactions between the rifamycins and HIV protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs), clinicians are strongly encouraged to seek expert advice from the state or local health departments if the concurrent use of these drugs is being considered. In persons infected with HIV who are taking HIV PIs or NNRTIs, the use of rifampin is usually

contraindicated because drug interactions between rifampin and these agents can lead to increased rifampin levels and decreased levels of PI, resulting in increased risk for rifampin toxicity and decreased PI efficacy. The latest information regarding use of these drugs can be obtained at http://www.cdc.gov/nchstp/tb/tb_hiv_drugs/toc.htm.

Is there an age restriction for being eligible for treatment of LTBI?

No, there is no age restriction for eligibility of treatment for LTBI. Targeted tuberculin testing programs should be conducted for high risk persons, and is discouraged for persons or settings considered to be low-risk. Infected persons who are considered to be at high risk for developing TB disease should be offered treatment of LTBI, regardless of age. However, infection control programs conduct active screening and include HCWs who are often at low risk and therefore proper medical evaluation needs to be conducted when an HCW with a positive TST result is discovered. In this context, age may be a factor in the decision to treat. Older persons are at increased risk for hepatic toxicity to INH.

Why is the two-month regimen of combined rifampin and pyrazinamide (RZ) generally not recommended for treatment of LTBI any more?

Although the two-month regimen of combined rifampin and pyrazinamide (RZ) was previously recommended as an option for the treatment of LTBI, reports of severe liver injury and death associated with its use prompted the American Thoracic Society (ATS) and CDC to revise recommendations to indicate that this regimen should generally **not** be offered for treatment of LTBI.

What is the preferred regimen for treatment of LTBI?

Nine months of isoniazid (INH) is the preferred treatment regimen for patients who have LTBI and who are eligible for treatment. The 6-month regimen of INH or the 4-month regimen of rifampin are also acceptable alternatives (Supplement 2, II).

IV. Environmental Controls

Is an airborne infection isolation (AII) room the same as a negative-pressure isolation room?

Yes, AII rooms are special negative-pressure rooms for the specific purpose of isolating persons with suspected or confirmed TB disease from other persons in the setting. Not all negative-pressure rooms are AII rooms because they might not have the required air flow or differential pressure of an AII room. “AII room” is an accepted term and is used in the guidelines of American Institutes of Architects (AIA) that describe the purpose for and details of ventilation of AII rooms.

From previous experience, during the winter months at our hospital we worry that we might not have enough AII rooms for all of our patients with suspected (or confirmed) infectious TB disease. Can we obtain just two negative sputum smears for acid-fast bacilli (AFB) before releasing patients from AII?

No, the criterion for the release of a patient with suspected infectious TB disease from AII is having three consecutive negative sputum smear results. These specimens should be obtained 8–24 hours apart (Recommendations, D.3) and at least one should be an early morning specimen. Generally, this will allow patients with negative sputum smear results to be released from AII in two days. Consider adding or renovating one or more AII room(s). Before undertaking this expense, however, ensure that the criteria being used to place patients in AII are correct and that the available rooms are not being used for patients in whom you do **not** suspect infectious TB disease. In addition, the following intervals should be reviewed to identify any delays that could be corrected and decrease AII time for patients: time between hospital admission and ordering of

sputum specimens for AFB examination; time between ordering and collecting specimens; time between collection of specimens and receipt of results from the laboratory.

How many AII rooms are required in a 120-bed hospital?

No systematic studies have been conducted that provide a useful predictive model to quantitatively address this question. The risk assessment for the setting will help determine how many AII rooms each facility needs, depending on the number of TB patients seen (Table 2). At least one AII room is needed for facilities where TB patients stay while they are being treated, and experts suggest one additional AII room for every 200 patient-days of cases of suspected or confirmed TB disease. Additional AII rooms may be considered if options are limited for transferring patients with suspected or confirmed TB disease to other settings with AII rooms. A hospital with 120 beds needs a minimum of one AII room, possibly more, depending on how many TB cases are seen in one year.

Who is responsible for ensuring that negative pressure is achieved in AII rooms?

Infection-control staff at each health-care facility are responsible for ensuring negative pressure is achieved in AII rooms (this responsibility may be delegated to engineering, maintenance, or other appropriate staff to perform the actual negative-pressure tests). AII rooms should be checked for negative pressure before occupancy. When occupied by a patient, AII rooms should be checked daily with smoke tubes or other visual checks for negative pressure.

Can AII be discontinued for a patient with suspected TB disease who has positive AFB sputum smear results but has a negative nucleic acid amplification (NAA) test result for *M. tuberculosis*?

Yes, if the presence of inhibitors in the specimen for the NAA test is negative, and dual infection with *M. tuberculosis* and another Mycobacterial species is not clinically suspected, the patient may be released from AII. An NAA test, when performed properly on a patient who has positive sputum smear results, is highly sensitive and specific for the identification of *M. tuberculosis*.

What is the difference between engineering controls and environmental controls?

Environmental controls is a more inclusive category than engineering controls. Examples of environmental controls are ultraviolet germicidal irradiation (UVGI) and portable air cleaners. Examples of engineering controls are heating and air-conditioning units, directional airflow, and room air changes.

What is the difference between VAV and CAV? How do I know what my facility has?

VAV is variable air volume, and CAV is constant air volume, and the terms refer to how the ventilation system is designed to deliver air to and maintain temperature and relative humidity control within a room. General ventilation is delivered by either CAV systems or VAV systems. In general, CAV systems are best for AII rooms and other negative-pressure rooms because the negative-pressure differential is easier to maintain. VAV systems are acceptable if provisions are made to maintain the minimum total and outside ACH and negative pressure ≥ 0.01 inches of water gauge relative to adjacent areas at all times. If uncertain what type of heating, ventilation, and air conditioning (HVAC) system exists at your facility, ask your setting's engineer or building manager.

Why was the differential pressure requirement for an AII room increased from 0.001 to 0.01 inch of water gauge?

In an ideal, controlled environment, 0.001 inch of water gauge has been shown to achieve negative pressure in an AII room. However, AIA and others have demonstrated that a minimum

of 0.01 inch of water gauge is needed in some installations to ensure that negative pressure is achieved.

Our TB clinic only treats persons with LTBI. Do we need an AII room and a respiratory protection program?

Ideally, yes. Given the characteristics of patients who are encountered in TB clinics, this setting poses a potentially high risk for transmission of *M. tuberculosis*. In general, TB clinics should have at least one AII room and a respiratory protection program. An AII room and a respiratory protection program may not be needed if 1) every person treated in the clinic will be adequately screened before admission and determined not to have TB disease, 2) no cough-inducing procedures will ever be performed in the clinic, **and** 3) a system is in place to promptly detect and triage persons who enter the clinic and have signs or symptoms of TB disease.

How can a portable HEPA filter unit help control transmission of *M. tuberculosis*?

HEPA filters help dilute infectious particles and can essentially remove all particles in the size range of droplet nuclei from the air that passes through them.

V. Respiratory protection

What is the difference between a CDC/NIOSH-certified respirator and a surgical mask?

Respirators are designed to help reduce the wearer's exposure to airborne particles (for HCWs). The primary purpose of a surgical mask is to help prevent biological particles from being expelled by the wearer into the environment (for patients). Surgical masks are designed to be fluid resistant and not necessarily for filtration efficiency.

What kind of respiratory protection should HCWs use when providing care to persons with suspected or confirmed infectious TB disease in the home?

The recommended respiratory protection for HCWs who provide care in the homes of patients with suspected or confirmed infectious TB disease is at least an N95 disposable respirator.

What kind of respiratory protection should HCWs use when transporting patients in a vehicle with suspected or confirmed TB disease?

For HCWs who transport patients with suspected or confirmed TB disease, the recommended respiratory protection is at least an N95 disposable respirator. If the patient has suspected or confirmed **infectious** TB disease, physically isolate the cab (the front of the vehicle) from the rest of vehicle when possible, have the patient sit in the back seat, and open the windows. In all situations, when isolated patients leave the AII room, they should be instructed to wear a surgical mask. Surgical masks (**not** respirators) should be worn by the patient, to keep the person who is wearing it from spreading germs. Patients who cannot tolerate masks due to medical conditions should observe strict respiratory hygiene and cough etiquette procedures (see Glossary) (105).

What kind of respiratory protection should be used in the operating room (OR) by HCWs with facial hair or other factors that preclude proper fitting of an N95 disposable respirator? Will wearing a surgical mask underneath a powered air-purifying respirator (PAPR) solve this problem?

In the OR, HCWs with facial hair who are caring for a person with suspected or confirmed TB disease should wear a loose-fitting PAPR-like device. The PAPR has not been certified to be worn with a surgical mask. All respiratory protection equipment should be used in accordance with the manufacturer's instructions.

Should bacterial filters be used routinely on the breathing circuits of all ventilators and anesthesia equipment on patients with suspected or confirmed TB disease?

Yes, bacterial filters should be used routinely on the breathing circuits of patients with suspected or confirmed TB disease to prevent exhaled air containing infectious droplet nuclei from contaminating the room air. Filters should be used on mechanical ventilators and also on hand-held ventilating bags (i.e., manual resuscitators, such as ambu-bags®). The bacterial filter should be shown by the manufacturer to filter particles 0.3 µm in size in both the unloaded and the loaded states with a filter efficiency of >95% (i.e., filter leakage of <5%), at the maximum design flow rates of the ventilator (Recommendations, E.3.2.).

Who should not wear an N95 disposable respirator?

Any HCW who is restricted from using a respirator due to medical reasons should not wear one. Visitors may be permitted to wear N95 disposable respirators but do not need to undergo respirator training or fit-testing. HCWs should receive training in the proper use of respiratory protection (Supplement 4). Well-designed respirators are likely to achieve desired fit without having to rely on fit-testing (181;188;233).

How important is the fit of the respirator?

Fit of the respirator is very important. If a respirator does not fit tightly to the face, airborne hazards can penetrate or enter underneath the facepiece seal and into the breathing zone. It is important to perform a user seal-check before entering an AII room or a potentially contaminated environment (<http://www.cdc.gov/niosh/topics/respirators>).

Is it necessary to fit check or user seal check a respirator before each use?

The term “user seal-checking” has replaced the term “fit checking.” Although more study is needed, the user seal check (required by current OSHA regulations) may be important to minimize contaminant leakage into the facepiece. Each respirator manufacturer has a recommended user seal-checking procedure that should be followed by the user each time the respirator is worn.

How do I perform a respirator fit test?

Respiratory fit test used to be called “fit check.” First, it is important to choose the best respirator. Select a respirator that is comfortable on the face. Then the wearer should perform a user seal-check to ensure that the respirator is sealing against the face; this should be done each time the respirator is worn. The two types of user seal-checks are positive-pressure and negative-pressure.

To check positive pressure, after donning the respirator, the wearer should cover the surface of the respirator with their hands or with a piece of household plastic film and exhale gently. If air is felt escaping around the facepiece, the respirator should be repositioned and the user seal-check should be performed again. If the wearer does not feel air escaping around the facepiece, the positive pressure user seal-check was successful.

To check negative pressure, after donning the respirator, the wearer should cover the surface of the respirator again, and the wearer should gently inhale. This should create a vacuum, causing the respirator to be drawn in slightly toward the face. If the respirator is not drawn in toward the face, it should be removed and examined for any defect such as a small hole. If none are found, the respirator should be repositioned and a second attempt at negative pressure user seal-check should be made. If the respirator draws in toward the face while the wearer covers the surface and inhales, the negative pressure user seal-check was successful.

How long may I use my respirator for TB exposures before I discard it?

Respirators may be functional for weeks to months; reuse is only limited by considerations of hygiene, damage and breathing resistance. Disposable respirators may be reused by the same HCW as long as it remains functional. Each respirator manufacturer has a recommended user seal-checking procedure that should be followed by the user each time the respirator is worn.

Where can I find a good medical evaluation for fit-testing? Appendix C of the OSHA respirator standard is the mandatory OSHA respirator medical evaluation questionnaire, 29 CFR 1910.134. It can be accessed by going to www.osha.gov, click on the "R" on the alphabetical index at the top, click on "Respiratory Protection," click on "What OSHA standards and enforcement information apply?" and lastly on "1910.134 App C." The standard requires a "follow-up medical exam" if an employee answers yes to any question in Part A Section 2 Questions 1-8 or if the initial medical exam demonstrates a need for follow-up [see 1910.134(e)(3)(i)]. The "Questions & Answer on the Respiratory Protection Standard" document clarifies that the physician or licensed health care professional (PLHCP) determines the scope of the medical evaluation and that on occasion, all that may be needed would be a clarification of an issue by telephone (see pg 18 of this document at www.osha.gov/qna.pdf).

Should persons who perform maintenance on and replace filters on any ventilation system that is likely to be contaminated with *M. tuberculosis* wear a respirator?

Yes. Laboratory studies indicate that re-aerosolization of viable mycobacteria from HEPA filters and N95 disposable respirator filter media is unlikely under normal conditions, however, the risks associated with handling loaded HEPA filters in ventilation systems under field-use conditions have not been evaluated. For this reason, persons performing maintenance and replacing filters on any ventilation system that is likely to be contaminated with *M. tuberculosis* should wear at least an N95 disposable respirator (Supplement 4).

When does an infectious case becomes non-infectious?

Previously, many healthcare professionals believed that the effect of chemotherapy to eliminate infectiousness is virtually immediate; older texts state simply that patients on chemotherapy are not infectious. However, no ideal test is available to diagnose the infective potential of a TB patient on treatment, and it is unlikely that infectivity disappears near the moment when anti-TB therapy is initiated.

Quantitative bacteriological studies indicate that the concentration of viable *M. tuberculosis* in sputum of persons with cavitary, positive AFB sputum smear results indicating pulmonary TB at the time of diagnosis, which averages 10^6 - 10^7 organisms/ml, decreases by more than 90% (10-fold) during the first two days of treatment, an effect attributable mainly to isoniazid (41), and by more than 99% (100-fold) by day 14-21, the latter effect attributable mainly to rifampin and pyrazinamide (42). Thus, if no factor other than the elimination of viable *M. tuberculosis* from sputum were to account for the loss of infectivity during treatment, it could be surmised that most patients, at least those with infection due to isolates susceptible to isoniazid, who have received treatment for a few days with the standard regimen of isoniazid, rifampin, ethambutol, and pyrazinamide, have an infective potential that averages 10% of that at the time of diagnosis. After 2-3 weeks of treatment, infectiousness averages less than 1% of the pretreatment level.

VI. Other***Can sputum smear results for AFB be used for two days to exclude a diagnosis of TB disease?***

Yes, three consecutive sputum smear results for AFB for two days may be used to exclude TB disease if they are obtained at least 8 hours apart, and at least one is an early morning specimen, in conjunction with other criteria, such as establishing an alternative diagnosis. Generally, this will allow patients with negative sputum smear results to be released from AII in two days.

Should we perform a bronchoscopy on a patient with TB disease?

If possible, bronchoscopy should be avoided in patients with a clinical syndrome consistent with pulmonary or laryngeal TB disease because bronchoscopy increases the risk for transmission either through an airborne route (55;72;73;146;317) or endoscope contamination (72;147-153). Microscopic examination of three sputum specimens obtained 8–24 hours apart (112), with at least one obtained in the early morning, is first recommended. Obtaining three sputum samples is safer than performing bronchoscopy for patients and HCWs, three samples have superior yield for AFB smear results and *M. tuberculosis* culture results, and should be pursued prior to bronchoscopy (108;318-320). Patients who are intubated and mechanically ventilated with machines with a closed and effectively filtered ventilator circuit may represent less potential for exposure during bronchoscopy provided measures are pursued to minimize opening the circuit (Recommendations, E.3.2).

SUPPLEMENT 7: TB WEBSITE LINKS

Centers for Disease Control and Prevention (CDC)

<http://www.cdc.gov>

- Division of Tuberculosis Elimination (DTBE)
<http://www.cdc.gov/tb>
 - Major TB Guidelines
http://www.cdc.gov/nchstp/tb/pubs/mmwrhtml/maj_guide.htm
 - State TB Program Contact Information
<http://www.cdc.gov/nchstp/tb/pubs/tboffices.htm>
 - TB Education and Training Resources Web Site
<http://www.findtbresources.org>
 - TB Program Web sites
<http://www.cdc.gov/nchstp/tb/tbwebsites.htm>
- Division of AIDS, STD, and TB Laboratory Research
<http://www.cdc.gov/ncidid/dastlr/TB/default.htm>
- National Center for Infectious Diseases (NCID)
<http://www.cdc.gov/ncid>
- National Institute for Occupational Safety and Health (NIOSH)
<http://www.cdc.gov/niosh/homepage.html>
 - Respirator information
<http://www.cdc.gov/niosh/topics/respirators/>

CDC/NIOSH Certified Equipment List (CEL)

www.cdc.gov/niosh/celintro.html

CDC/NIOSH-Approved Disposable Particulate Respirators (Filtering Facepieces)

www.cdc.gov/niosh/npptl/respirators/disp_part/particlist.html

- Division of Healthcare Quality Promotion
<http://www.cdc.gov/ncidod/hip/enviro/guide.htm>
- Emergency Preparedness and Response
<http://www.bt.cdc.gov>

Other U.S. Federal Government Web sites

- National Institutes of Health (NIH)
<http://www.nih.gov>
- National Heart, Lung, and Blood Institute
<http://www.nhlbi.nih.gov/funding/training/tbaa/index.htm>
- National Institute of Allergy and Infectious Diseases (NIAID)
<http://www.niaid.nih.gov/dmid/tuberculosis/>
- AIDSinfo
<http://www.aidsinfo.nih.gov/guidelines/>
- Occupational Safety and Health Administration (OSHA)
<http://www.osha.gov>; www.osha.gov/qna.pdf
 - Tuberculosis (OSHA)
www.osha.gov/SLTC/tuberculosis/index.html
 - Recordkeeping (OSHA)
<http://www.osha.gov/recordkeeping>
- Ryan White Care Act/Wisconsin HIV/AIDS Program
http://www.dhfs.state.wi.us/AIDS-HIV/Resources/Overviews/AIDS_HIV.htm
- U.S. Food and Drug Administration (FDA)
<http://www.fda.gov>
- Safety Information and Adverse Event Reporting System (FDA-AERS)
<http://www.fda.gov/medwatch>
- FDA and CDC Public Health Advisory: Infections from Endoscopes Inadequately Reprocessed by an Automated Endoscope Reprocessing System
<http://www.fda.gov/cdrh/safety/endoreprocess.html>

National Tuberculosis Model Centers

- Charles P. Felton National Tuberculosis Center, New York, New York
<http://harlemtbcenter.org>
- Francis J. Curry National Tuberculosis Center, San Francisco, California
<http://www.nationaltbcenter.edu/index.cfm>
- New Jersey Medical School National Tuberculosis Center, Newark, New Jersey
<http://www.umdnj.edu/ntbcweb/tbsplash.html>

Organizations

- American Lung Association (ALA)
<http://www.lungusa.org/diseases/lungtb.html>
- American Thoracic Society (ATS)
<http://www.thoracic.org>
- Association for Professionals in Infection Control and Epidemiology, Inc. (APIC)
<http://www.apic.org>
- HIV Drug Interactions Organization
<http://www.hiv-druginteractions.org>
- Infectious Disease Society of America/Bioterrorism and Information Resources (IDSA)
<http://www.idsociety.org/bt/toc/htm>
- National Prevention Information Network (NPIN)
<http://www.cdcnpin.org/scripts/index.asp>
- National TB Controllers Association (NTCA)
<http://www.ntca-tb.org>
- PharmWeb: Rapid Screening of Tuberculosis Pharmaceuticals
<http://www.pharmweb.net/pwmirror/library/pharmwebvlib.html>

International Organizations

- International Union Against Tuberculosis and Lung Disease (IUATLD)
http://www.iuatld.org/full_picture/en/frameset/frameset.phtml
- Stop TB Initiative
<http://www.stoptb.org>
- Tuberculosis Research Center, India
<http://www.trc-chennai.org>
- World Health Organization (WHO) Global TB Program

<http://www.who.int/gtb/>

State HIV and TB websites

AL	http://www.adph.org
AK	http://www.epi.alaska.gov
AZ	http://www.hs.state.az.us/phs/oids/tuberculosis/index.htm
CA	http://www.dhs.ca.gov/ps/dcdc/TBCB/tubindex.htm
CO	http://www.cdphe.state.co.us/dc/tb/tbhome.asp
CT	http://www.dph.state.ct.us/
DE	http://www.state.de.us/dhss/dph/dpc/tuberculosis.html
FL	http://www.doh.state.fl.us/disease_ctrl/tb/WorldTBDay/2004/WT2004main.html
GA	http://www.health.state.ga.us/epi/
HI	http://www.hawaii.gov/doh/resource/comm_dis/tb/index.htm
IA	http://www.idph.state.ia.us/ch/tb_control.asp
IN	http://www.in.gov/isdh/programs/tb
KS	http://www.kdhe.state.ks.us/tb/index.html
KY	http://www.chs.state.ky.us/publichealth/TB.htm
LA	http://www.opd.dhh.state.la.us/tuberculosis/index.html
MA	http://www.state.ma.us/dph/cdc/tb/
MD	http://www.edcp.org/tb/index.html
ME	http://www.maine.gov/dhs/boh/ddc/tuberculosis.htm
MI	http://www.michigantb.org
MN	http://www.health.state.mn.us/tb
MT	http://www.dphhs.state.mt.us
NC	http://www.schs.state.nc.us/epi/tb
ND	http://www.ndmtb.com
NE	http://www.hhs.state.ne.us/cod/Tuberculosis/tbindex.htm
NH	http://www.dhhs.state.nh.us/DHHS/DHHS_SITE/default.htm
NV	http://www.health2k.state.nv.us
NYC	http://www.nyc.gov/html/doh/html/tb/tb.html
OH	http://www.odh.state.oh.us/
OK	http://www.health.state.ok.us
OR	http://www.dhs.state.or.us/publichealth/tb
PA	http://www.dsf.health.state.pa.us
RI	http://www.health.ri.gov/disease/communicable/tb_data.htm
SC	http://www.scdhec.net/hs/diseasecont/tb/html/
SD	http://www.state.sd.us/doh/tb
TN	http://www2.state.tn.us/health/CEDS/index.htm
TX	http://www.tdh.state.tx.us/tb
UT	http://health.utah.gov/els/hiv aids/tb/tbrefugee.html
VA	http://www.vdh.virginia.gov/epi/tb
WA	http://www.doh.wa.gov/cfh/tb
WI	http://www.dhfs.wisconsin.gov/dph_bcd/tb/index.htm
WY	http://www.wdh.state.wy.us/tb
Puerto Rico	http://www.salud.gov.pr

SUPPLEMENT 8: GLOSSARY

Acid-fast-bacilli (AFB): A laboratory test that involves microscopic examination of a stained smear (usually of sputum) to determine if mycobacteria are present. A presumptive diagnosis of pulmonary TB can be made with a positive AFB sputum smear result; however about half the patients with TB disease of the lungs have negative AFB sputum smear results. The diagnosis of TB disease is usually not confirmed until *M. tuberculosis* is identified in culture. A positive nucleic acid amplification (NAA) test is useful as a confirmatory test.

Aerosol: Droplet nuclei expelled by a person with an infectious disease (e.g., by coughing, sneezing, or singing). The droplet nuclei can remain suspended in the air and can transmit *M. tuberculosis* to other persons.

ACH: Air changes per hour: See Air changes.

Adhere: To follow instructions regarding a treatment regimen (adhere to treatment).

Administrative controls: Managerial measures that reduce the risk for exposure to persons who may have TB disease. Examples include coordinating efforts with the state or local health department, conducting a TB risk assessment of the setting, developing and instituting a written TB infection-control plan to ensure prompt detection, airborne infection isolation (AII), and treatment of persons with suspected or confirmed TB disease, and screening and evaluating HCWs who are at risk for TB disease or who might be exposed to *M. tuberculosis* (Section D.1, Introduction).

Air changes: Ratio of the volume of air flowing through a space in a certain period of time (airflow rate) to the volume of that space (room volume). This ratio is usually expressed as the number of room air changes per hour (ACH).

Airborne infection isolation (AII): AII refers to the isolation of patients infected with organisms spread via airborne droplet nuclei $<5\ \mu\text{m}$ in diameter. This isolation area receives numerous ACH (≥ 12 ACH for new construction as of 2001; ≥ 6 ACH for construction before 2001), and is under negative pressure, such that the direction of the air flow is from the outside adjacent space (e.g., the corridor) into the room. The air in an AII room is preferably exhausted to the outside, but may be recirculated provided that the return air is filtered through a high-efficiency particulate air (HEPA) filter.

Airborne infection isolation room (AII room): Formerly called negative pressure isolation room, an AII room is a single-occupancy patient-care room used to isolate persons with suspected or confirmed infectious TB disease. Environmental factors are controlled in AII rooms to minimize the transmission of infectious agents that are usually spread from person to person by droplet nuclei associated with coughing or aerosolization of contaminated fluids. AII rooms should provide negative pressure in the room (so that air flows under the door gap into the room); **and** an air flow rate of 6-12 ACH; **and** direct exhaust of air from the room to the outside of the building or recirculation of air through a HEPA filter.

American Institute of Architects (AIA): Professional organization that develops standards for building ventilation.

American Society of Heating, Refrigerating, and Air-Conditioning Engineers, Inc. (ASHRAE): Professional organization that develops guidelines for building ventilation.

Aminotransferases: Also termed transaminases. Used to assess for hepatotoxicity in persons taking anti-TB medications and include aspartate aminotransferase (AST) serum glutamic-oxalacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT).

Anemometer: An instrument used to measure the velocity (speed) of air.

Anergy: Condition in which a person has a diminished ability to react to antigens due to a condition or situation resulting in immunosuppression; the person is considered to be anergic. Traditionally, this has been encountered in tuberculin skin testing (TST). Anergy skin testing has poor predictive value and is not routinely recommended.

Anteroom: Small room leading from a corridor into an AII room. It is separated from both the AII room and the corridor by doors. An anteroom can act as an airlock, preventing the escape of contaminants from the AII room into the corridor

Apical: Relating to or located at the tip (an apex).

Assigned Protection Factor (APF): The minimum anticipated protection provided by a properly functioning respirator or class of respirators to a given percentage of properly fitted and trained users.

Asymptomatic: Neither causing nor exhibiting signs or symptoms of disease.

Bacille Calmette-Guérin (BCG): An attenuated strain of *Mycobacterium bovis* that is used in many parts of the world as a TB vaccine, named after the French scientists Calmette and Guérin. BCG has limited efficacy in preventing disease and is rarely used in the United States. The vaccine is effective in preventing disseminated and meningeal TB disease in infants and young children and is appropriately used in many other countries where TB disease is endemic.

Baseline TST or baseline QFT: The TST or QFT given to newly hired HCWs who have potential for exposure to *M. tuberculosis* and will participate in an ongoing serial TB screening program. If the TST method is used, for HCWs who have not had a documented negative test for *M. tuberculosis* during the preceding 12 months, the baseline TST result should be obtained by using the two-step method. (See Two-step skin testing.) QFT baseline testing does not need a two-step method.

Biological safety cabinet (BSC): A ventilated box that provides HCWs with a degree of protection against hazardous aerosols that are generated within it. A BSC is the principal device used to contain infectious splashes or aerosols generated by many microbiological processes. It provides physical barriers and directional airflow to carry hazards away from the HCW. Maintenance is an important part of ensuring of BCS function.

Biosafety in Microbiological and Biomedical Laboratories (BMBL): A publication of the U.S. Public Health Service that describes the combinations of standard and special microbiological practices, safety equipment, and facilities constituting Biosafety Levels (BSL) 1-4, which are recommended for work with a variety of infectious agents in laboratory settings. The recommendations are advisory and intended to provide a voluntary guide or code of practice.

Biosafety levels (BSL): Four biosafety levels (BSLs) are described in Section III of Biosafety in Microbiological and Biomedical Laboratories (BMBL), which consist of combinations of laboratory practices and techniques, safety equipment, and laboratory facilities. Each combination is specifically appropriate for the operations performed, the documented or suspected routes of transmission of the infectious agents, and the laboratory function or activity.

Blinded independent duplicate reading (BIDR): Two or more TST readers immediately measure the same TST result by standard procedures (may use suggested procedural observation checklist; See section XX) without consulting or observing one another's readings and record results independently. BIDRs help ensure TST readers continue to read TST results correctly.

Boosting: A phenomenon in which some persons who receive a TST many years after acquiring LTBI have a negative result to an initial TST, followed by a positive result to a subsequent TST. The second (i.e., positive) result is caused by a boosted immune response of the prior sensitivity rather than by a new infection. Two-step testing is used to distinguish new infections from boosted reactions in TB infection-control screening programs that utilize TST for detecting *M. tuberculosis* (see Two-step skin testing). Because QFT is an in vitro method, it is not complicated by boosting.

Bronchoscopy: Procedure for examining the respiratory tract that requires inserting an instrument (bronchoscope), either flexible or rigid, through the mouth or nose and into the respiratory tree. Bronchoscopy can be used to obtain diagnostic specimens and creates an risk for transmission for exposed HCWs when performed on a patient with pulmonary or laryngeal TB disease.

BSL: Biosafety levels. See Biosafety in Microbiological and Biomedical Laboratories (BMBL).

CAV: See Constant air volume.

Cavity: A hole in the lung parenchyma, not usually involving the pleural space, resulting from the destruction of pulmonary tissue by an interaction of *M. tuberculosis* infection and the host response seen in TB disease (or other pulmonary infections). TB patients with cavitory disease indicated by a chest radiograph are often more infectious than TB patients without cavitory disease.

Chest x-ray: See Radiography.

Clinical examination: An in-person evaluation of the clinical status of a patient by a physician or equivalent practitioner.

Close contact (TB): A person who has shared the same air space in a household or other enclosed environment for a prolonged period of time (days or weeks, not minutes or hours) with a person with suspected or confirmed TB disease. Close contacts have also been referred to as "high-priority contacts" since they have the highest risk for infection with *M. tuberculosis*.

Cluster (TB): A group of patients with TB disease that are linked by epidemiologic, location, or genotyping data. Two or more TST conversions within a short period of time can be a cluster, and may suggest transmission within the facility. A genotyping cluster is two or more cases whose isolates have an identical genotyping pattern.

Combination product surgical mask/N95 disposable respirator: Product certified by CDC/NIOSH and cleared by FDA that provides both respiratory protection and bloodborne pathogen protection.

Comply: To agree to have a procedure performed (comply to give blood).

Conditionally positive QFT result: *M. tuberculosis* infection likely if risk identified but not likely for low-risk individuals.

Constant air volume (CAV): As the name implies, a CAV system supplies and exhausts air at a constant flow rate. The flow rate does not change over time based on temperature load or other parameters.

Contact (TB): A person who has shared the same air space with a person who has infectious TB disease. Although sputum smear results, the grade of the sputum smear result if positive, and sputum culture results influence the likelihood of infectiousness, other factors such as exposure time, environmental conditions, and site of disease are also important.

Contact investigation: Procedures that occur when a case of infectious TB is identified, including elicitation of people (contacts) exposed to the case, testing and evaluation of contacts to identify LTBI or TB disease, and treatment of these individuals.

Contagious: Refers to a disease that can be transmitted from one living being to another through direct contact (such measles) or indirect contact (such as TB or cholera). The agent responsible for the contagious character of a disease is described as being *infectious*, the usual culprits being microorganisms, like *M. tuberculosis*, or macroorganisms (such as parasitic worms).

Contraindication: Any condition, especially any condition of disease, which renders some particular line of treatment improper or undesirable.

Conversion: See TST conversion.

Conversion rate: The percentage of a population with a converted test result (TST or QFT) for *M. tuberculosis* within a specified time period. This is calculated by dividing the number of conversions among eligible HCWs in the setting in a specified period of time (numerator) by the number of HCWs who received tests in the setting over the same period of time (denominator) multiplied by 100.

Culture: Growth of microorganisms in the laboratory performed for detection and identification in sputum or other body fluids. This test usually takes 2-4 weeks for mycobacteria (2-4 days for most other bacteria).

Cough etiquette: See respiratory hygiene.

Cross contamination: When bacteria from one sample are introduced into another sample causing a false-positive result.

Delayed-type hypersensitivity (DTH): Cell-mediated inflammatory reaction to an antigen previously seen by the immune system. The reaction is initiated by direct cellular mechanisms through mononuclear leukocytes rather than by an antibody (or humoral) response and typically occurs 48–72 hours after exposure to an antigen. A DTH reaction to an intradermal challenge (i.e.,

as is done with the TST using the Mantoux method) results in migration of inflammatory cells to the site and causes the skin induration.

Differential pressure: A measurable difference in air pressure that creates a directional airflow between adjacent compartmentalized spaces.

Directly observed therapy (DOT): Adherence-enhancing strategy in which a trained HCW or other specially trained person watches a patient swallow each dose of medication and records the dates that the DOT was observed. DOT is the standard of care for all patients with TB disease and should be used for all doses during the course of treatment for TB disease and for LTBI whenever feasible. **All** patients on intermittent (i.e., once- or twice-weekly) treatment for TB disease or LTBI should receive DOT. Plans for DOT should be coordinated with the state or local health department (23). Rates of relapse and development of drug-resistance are decreased when DOT is used.

Disposable respirator: A respirator that is meant to be used and then discarded, also known as a single-use respirator. Respirators should be discarded after excessive resistance, sorbent exhaustion, or physical damage.

DNA fingerprinting: Deoxyribonucleic acid (DNA) fingerprinting is a clinical laboratory technique used by public health officials during a TB outbreak to distinguish between different strains of *M. tuberculosis* and to help assess the likelihood of TB transmission.

Droplet nuclei: Microscopic particles produced when a person coughs, sneezes, shouts, or sings. These particles can remain suspended in the air for prolonged periods of time, and can be carried on normal air currents in the room and beyond, to adjacent spaces or areas receiving exhaust air.

Drug-susceptibility test: Laboratory test that determines whether the *M. tuberculosis* bacteria cultured from a patient's isolate are susceptible or resistant to various first-line or second-line anti-TB drugs.

Effusion: See Pleural effusion.

Enabler: An item or service that helps to remove barriers for willing (but unable) clients to adhere to anti-TB therapy (e.g., transportation, bus tokens, stable housing, driver's license, service programs).

Environmental control measures: Physical or mechanical measures (as opposed to administrative control measures) used to reduce the risk for transmission of *M. tuberculosis*. Examples include ventilation, filtration, ultraviolet lamps, airborne infection isolation rooms (AIIRs), and local exhaust ventilation devices (Section D.2, Introduction).

Epidemiologic cluster: Closely grouped series of cases in time or place.

Erythema: Abnormal redness of the skin. Erythema may develop around a tuberculin skin test (TST) site, but should not be read as part of the TST result.

Etiology: The branch of medicine that deals with the causes or origins of disease.

Expert TST trainer: A qualified HCW who has received training on placing and reading multiple TST results.

Exposed cohorts: Groups of people (e.g., family members, co-workers, friends, club, team or choir members, people in correctional facilities, or homeless shelter residents) who shared the same air space with the suspected case patient with TB disease during the infectious period. A person in the exposed cohort is a contact. See Contact and Close contact.

Exposure: The condition of being subjected to something (e.g., an infectious agent) that could have a harmful effect. A person exposed to *M. tuberculosis* does not necessarily become infected (See Transmission).

Exposure period: The overlapping time period of a) the time the contact shared the same air space with the TB index case, and b) the infectious period.

Exposure site: Location where the person with TB disease frequented during the infectious period, e.g., hospital ward, school, work site, homeless shelter, correctional facilities, bar, airplane.

Extrapulmonary TB: Disease in any part of the body other than the lungs (e.g., the kidney, spine, or lymph nodes.) The presence of extrapulmonary disease does not exclude pulmonary TB disease.

False negative TST or QFT result: A TST or QFT result that is interpreted as negative (for a particular purpose, i.e., infection control surveillance or medical and diagnostic evaluation) in a person who is actually infected with *M. tuberculosis*.

False positive TST or QFT result: A TST or QFT result that is interpreted as positive (for a particular purpose, i.e., infection control surveillance or medical and diagnostic evaluation) in a person who is not actually infected with *M. tuberculosis*. This is more likely to occur in persons who have been vaccinated with BCG or who are infected with nontuberculous mycobacteria (NTM).

Facility: A physical building or set of buildings.

Filtering facepiece respirator: A type of air purifying respirator which uses a filter as an integral part of the facepiece or with the entire facepiece composed of the filtering medium.

Fit check: See User seal-check.

Fit factor: A quantitative estimate of the fit of a particular respirator to a specific individual, and typically estimates the ratio of the concentration of a substance in ambient air to its concentration inside the respirator when worn.

Flutter strips: Physical indicators used to provide a continuous visual sign that a room is under negative pressure. These simple and inexpensive devices are placed directly in the door and can be useful in identifying a pressure differential problem.

Health-care-associated: Acquired in a hospital or health-care setting. The term “health care-associated” is used instead of “nosocomial” in this text.

Health-care setting: Any relationship (physical or organizational) where the potential for exposure to *M. tuberculosis* through air space shared with persons with infectious TB disease or with specimens exists.

Health-care workers (HCWs): All paid and unpaid persons working in health-care settings.

Heating, ventilation, air conditioning (HVAC): Mechanical systems that provide either collectively or individually, heating, ventilating, or air conditioning for comfort within or associated with a building.

High-efficiency particulate air (HEPA) filter: A filter that removes all particles in the size range of particles that contain *M. tuberculosis* (0.3-µm). HEPA filters may be either portable or stationary. Use of HEPA filters in building ventilation systems requires expertise in installation and maintenance.

High-pressure liquid chromatography (HPLC): Laboratory method used to identify *Mycobacterium* species by analysis of species-specific fatty acids called mycolic acids present in the cell walls of mycobacteria.

HIV infection: Infection with the human immunodeficiency virus (HIV), the virus that causes AIDS (acquired immunodeficiency syndrome). A person with both LTBI and HIV infection is at high risk for developing TB disease.

Hemoptysis: The expectoration or coughing up of blood or blood-tinged sputum; one of the symptoms of pulmonary TB disease. Can also be seen in other pulmonary conditions such as lung cancer.

Hypersensitivity: A state in which the body reacts with an exaggerated immune response to a foreign substance. Hypersensitivity reactions are classified as immediate or delayed, types I and IV, respectively (see Delayed-type hypersensitivity).

Immunosuppression and immunocompromisation: A condition in which the immune system is not functioning normally. According to some style experts, *immunocompromised* is the broader term, and *immunosuppression* is restricted to states that were induced by medical treatment or procedures (i.e., iatrogenic), including causes that result from therapy for another condition. Immunocompromised persons are at increased risk of rapidly progressing to TB disease after infection with *M. tuberculosis*. Immunocompromised conditions also make TB disease more difficult to diagnosis, increasing the likelihood of a false-negative result for a test for *M. tuberculosis* such as TST and perhaps QFT.

Incentive: An item or service that rewards desired behavior such as adherence to anti-TB therapy (e.g., cookies, food, food vouchers, clothing vouchers, stickers). Incentives motivate patients to take medication and keep clinic appointments, and should be specifically tailored to each patient.

Incidence: The number of new events or cases of disease that develop in a population of individuals at risk during a specified time period.

Index case: The first person with TB disease who is identified in a particular setting and who triggers a contact investigation; the index case may or may not be the source case.

Induration: Area of firmness produced by an immune cell infiltration in response to an injected antigen. In tuberculin skin testing (TST) or anergy testing, the diameter of the indurated area is measured 48–72 hours after the injection in a direction perpendicular to the long axis of the forearm, and the result recorded in mm. The induration of the TST result, and **not** erythema (abnormal redness of the skin), should be measured.

Infection with *M. tuberculosis*: The term used for persons with positive TST results, negative bacteriologic studies (if done), and no clinical or radiographic evidence of TB disease. In most people who inhale TB bacteria and become infected, the body is able to fight the bacteria to stop the bacteria from growing. Infection with *M. tuberculosis* may or may not progress to TB disease. The bacteria are inactive, but they remain alive in the body and can become active later. See Latent TB infection (LTBI) and Reinfection.

Infectious: See Contagious.

Infectious droplet nuclei: Droplet nuclei produced by an infectious TB patient that can carry tubercle bacilli and be inhaled by others. Although usually produced from patients with pulmonary TB through coughing, aerosolizing procedures can also generate infectious droplet nuclei when applied to infected tissue.

Infectious period: The time period during which a person with TB disease may have transmitted *M. tuberculosis* organisms to others, initiated by the date(s) of symptom(s) onset or the date or the first positive finding consistent with TB disease, including specimen collected which suggests or confirms a diagnosis of TB (positive AFB smear result, positive culture result for *M. tuberculosis*), chest radiograph showing abnormality consistent with TB, or initiation of anti-TB treatment.

For patients with positive AFB sputum smear results: the infectious period extends from three months before the first positive smear result or symptom onset date (whichever is earlier) until two weeks after the time of the start of appropriate anti-TB treatment or until the patient is placed into AII or the date of the first negative smear result that is followed by consistently negative smear results.

For patients with negative AFB sputum smear results: the infectious period extends from one month before the symptom onset date or start of appropriate anti-TB treatment or when the patient was placed into AII (whichever was earlier) until two weeks after the start of appropriate anti-TB treatment or until AII began.

Infectious TB: TB disease of the lungs or throat, which can be spread to other people. Infectious TB may be indicated by a positive sputum smear result for acid-fast bacilli (AFB). Patients with extrapulmonary disease can also be infectious if the infected tissue is subject to an aerosolizing procedure.

In vitro: Within a glass, observable in a test tube, in an artificial environment.

In vivo: Within a living body.

Isolate (noun): A culture with growing living microorganisms (bacteria or other cells).

Isolation: Separation of a person or group of persons from others to prevent the spread of droplet nuclei. The term “airborne infection isolation (AII)” is used in this document in place of “isolation” (See AII and AII room).

Isoniazid (INH): A drug used to prevent TB disease in people who have latent TB infection (LTBI). INH is also one of the five drugs often used to treat TB disease.

Laryngeal TB: A highly infectious form of TB disease originating in the larynx.

Latent TB infection (LTBI): A condition following exposure to a person with infectious TB disease and subsequent infection with *M. tuberculosis* where the bacilli are alive but inactive in the body. People who have LTBI but who do not have TB disease are asymptomatic (have no symptoms), do not feel sick, and cannot spread TB to other people. They usually have a positive TST or QFT result. About 10% of infected persons will develop TB disease at some point in their lives, but the risk is considerably higher for persons who are immunosuppressed, especially persons infected with HIV. Persons with LTBI may be given treatment to prevent the infection from progressing to disease.

Manometer: An instrument used to measure pressure differentials (i.e., pressure inside an AII room relative to the corridor of the room).

Mantoux method: Tuberculin skin test performed by injecting 0.1 ml containing 5 TU PPD intradermally into the volar or dorsal surface of the forearm. The injection is made using a one-quarter to one-half-inch, 27 gauge needle and a tuberculin (preferable a safety-type) syringe. This is the recommended method for tuberculin skin testing (TST).

Mask: A device worn over the nose and mouth of a person with suspected or confirmed infectious TB disease to prevent infectious particles from being released into room air.

Medical evaluation: An examination to diagnose TB disease or LTBI, to select treatment, and to assess response to therapy. A medical evaluation may include the following:

- Medical history and TB symptom screen
- Clinical or physical examination
- Screening and diagnostic tests (such as TSTs, chest radiographs, bacteriological examination, and HIV testing)
- Counseling
- Treatment referrals

Meningeal TB: A serious form of TB disease involving the meninges, the covering of brain. Meningeal TB can result in serious neurologic complications.

Miliary TB: A serious form of TB disease that has spread to the whole body through the bloodstream. Miliary TB has a typical appearance on chest radiograph.

Mitogen: A transforming substance that stimulates the growth and transformation of lymphocytes such as macrophages and mast cells. Mitogen is used as a positive assay control in QuantiFERON (QFT) tests for infection with *M. tuberculosis*.

MOTT: See *Mycobacterium (M.) tuberculosis* complex.

MTC: See *Mycobacterium (M.) tuberculosis* complex.

Multidrug-resistant tuberculosis (MDR TB): TB disease caused by *M. tuberculosis* organisms that are resistant to at least isoniazid and rifampin.

***Mycobacterium tuberculosis* (*M. tuberculosis*):** The bacterium that causes LTBI and TB disease.

***Mycobacterium tuberculosis* complex:** Often abbreviated *MTC*, a group of closely related mycobacterial species that can cause LTBI and TB disease (i.e., *M. tuberculosis*, *M. bovis*, *M. africanum*, *M. canetti*, *M. microti*, and the BCG strain). Most TB disease in the United States is caused by *M. tuberculosis*.

***Mycobacterium* (*M.*) *tuberculosis* culture:** A laboratory test to determine the presence of *M. tuberculosis*. In the absence of cross contamination, a positive culture confirms the diagnosis of TB disease.

N95 disposable respirator: Air-purifying, filtering facepiece respirators with filters at least 95% efficient at removing 0.3 micron particles; not resistant to oil. (see respirator).

Negative pressure: The difference in air-pressure between two areas in a health-care setting. A room that is under negative pressure has a lower pressure than adjacent areas, which keeps air from flowing out of the room and into adjacent rooms or areas (See AII and AII room).

Nontuberculous mycobacteria (NTM): Refers to mycobacterium species other than those included as part of *Mycobacterium* (*M.*) *tuberculosis* complex. Although valid from a laboratory perspective, the term can be misleading because certain types of NTM cause disease with pathological and clinical manifestations similar to TB disease. Another term for NTM is MOTT for mycobacteria other than tuberculosis.

Nosocomial: Acquired in a hospital. The term “health care–associated” is used in this text.

NTM: See Nontuberculus mycobacteria.

Nucleic acid amplification (NAA) test: Laboratory test used to target and amplify a single DNA or RNA sequence for identification. This technique is highly sensitive and specific for identification of *M. tuberculosis*, and results are usually available within 1–3 days.

Outbreak (TB): When transmission of *M. tuberculosis* continues to occur (i.e., potentially ongoing or newly recognized transmission).

Periodic fit testing: Repetition of fit testing which should occur whenever a new model of respirator is used, whenever a physical characteristic of the user changes, or if the user is uncertain that the person is obtaining an adequate fit. See User seal-check.

Pleural effusion: Abnormal accumulation of fluid between the lining of the lung and the thorax. Persons with tuberculous pleural effusions may have concurrent unsuspected pulmonary or laryngeal TB disease. These patients should be considered infectious until TB disease is excluded.

Polymerase chain reaction (PCR): The first practical system for in vitro amplification of DNA and as such one of the most important recent developments in molecular biology. The PCR has become widely used not only in research, but in clinical diagnostics and forensic science.

Positive predictive value: The positive-predictive value of a TST is the probability that a person with a positive TST result is actually infected with *M. tuberculosis*. The positive predictive value is dependent on the prevalence of infection with *M. tuberculosis* in the population being tested and the specificity of the test (202;289;290).

Potential ongoing transmission: A risk classification for TB screening, including testing for *M. tuberculosis* infection when evidence of ongoing transmission of *M. tuberculosis* is apparent in the setting. Testing may need to be performed every 8–10 weeks until lapses in infection controls have been corrected and no further evidence of ongoing transmission is apparent. Use *potential ongoing transmission* as a temporary risk classification only. After corrective steps are taken, reclassify the setting as *medium risk*. It is recommended to maintain the classification of *medium risk* for at least one year.

Powered air-purifying respirator (PAPR): A respirator equipped with a facepiece, hood, or helmet, breathing tube, air-purifying filter, cartridge or canister, and a fan. Air is pulled through the air-purifying element and pushed through the breathing tube and into the facepiece, hood, or helmet (Supplement 4). PAPRs may be useful for people with facial hair.

Prevalence: The proportion of individuals in a population who have the disease at a specific instant and provides an estimate of the probability (risk) that an individual will be ill at a point in time.

Protection factor: General term for three specific terms: Assigned Protection Factor (APF), Simulated Workplace Protection Factor (SWPF), and Workplace Protection Factor (WPF) that refer to different means of defining adequacy of respirator fit. See APF, SWPF, and WPF.

Pulmonary TB: Disease that occurs in the lung parenchyma, usually producing a cough that lasts ≥ 3 weeks. Most TB disease is pulmonary.

Purified protein derivative (PPD) tuberculin: A material used in diagnostic tests for infection with *M. tuberculosis*. PPD is a purified tuberculin preparation that was developed in the 1930s and derived from old tuberculin. In the United States, it is administered as part of a tuberculin skin test (TST) given as an intradermal injection of 0.1 ml containing 5 TU (Mantoux method) and read 48–72 hours later. Also used in QFT. (See Tuberculin skin test).

Quality control (QC): A function to ensure that project tools and procedures are reviewed and verified according to project standards.

Quantiferon-TB test (QFT): An in vitro cytokine assay that assesses the cell-mediated immune response to *M. tuberculosis* in whole blood used to determine *M. tuberculosis* infection. Unlike the TST, the QFT requires only a single visit. The QFT is more specific than the TST and is less affected by prior BCG vaccination and infection with nontuberculous mycobacteria (NTM).

QFT converter: A change from a negative to a positive QFT result over a two-year period.

Radiography: Method of viewing internal body structures by using radiation to project an image onto a film, computer screen, or paper. A chest radiograph is taken to view the respiratory system of a person who is being evaluated for pulmonary TB disease. Abnormalities (e.g., infiltrates or cavities in the lungs and enlarged lymph nodes) described on a chest radiography can indicate the presence of TB disease.

Recirculation: Ventilation in which all or most of the air exhausted from an area is returned to the same area or other areas of the setting.

Recommended exposure limit (REL): Occupational exposure limit established by CDC's National Institute for Occupational Safety and Health (CDC/NIOSH). RELs are intended to suggest levels of exposure to which most HCWs can be exposed without experiencing adverse health effects. The CDC/NIOSH REL for ultraviolet (UV) radiation is wavelength dependent because different wavelengths have different adverse effects on the skin and eyes. At 254 nm, the predominant wavelength for germicidal UV lamps, the CDC/NIOSH REL is 0.006 joules per square centimeter (J/cm^2) for a daily 8-hour work shift.

Regimen: Part of the treatment plan that specifies which drugs are used, in what doses, according to what schedule, and for how long.

Reinfection: A second infection that follows recovery from a previous infection by the same causative agent. Often used when referring to an episode of TB disease resulting from a subsequent infection with *M. tuberculosis*.

Resistance: Ability of some strains of mycobacteria, including *M. tuberculosis*, to grow and multiply in the presence of certain drugs that ordinarily kill them. Such strains are referred to as drug-resistant strains and are felt to cause drug-resistant TB disease. (See Multidrug resistant TB.)

Respirator: A device worn by an individual to prevent the wearer from inhaling airborne contaminants.

Respiratory hygiene and cough etiquette: Procedures by which patients with suspected or confirmed infectious TB disease can minimize the spread of infectious droplet nuclei by decreasing the number of infectious particles that are released into the environment. Patients with a cough should be instructed to turn their heads away from people and cover their mouth and nose with their hands or preferably a cloth or tissue when coughing or sneezing. If patients do not have a cloth or tissue, these should be provided by the health-care setting. Dispose of tissues in accordance with your infection control plan.

Respiratory protection: The third level in the hierarchy of TB infection-control measures (after administrative and environmental controls) (Section D.3, Introduction).

Restriction fragment length polymorphism (RFLP): A technique in which organisms may be differentiated by analysis of patterns derived from cleavage of their DNA. If two organisms differ in the distance between sites of cleavage of a particular restriction endonuclease, the length of the fragments produced will differ when the DNA is digested with a restriction enzyme. The similarity of the patterns generated can be used to differentiate species (and even strains) from one another.

Reversion: A subsequent TST result which is appreciably smaller than a previous test; reversion has been observed to be more likely when the intervening time between TSTs increases.

Risk factor: Any condition or circumstance (i.e. causal agents) that has been shown to be associated with an increase in the frequency of disease, and that the association is not due to confounding or bias.

Screening (TB): Measures used to identify persons who have TB disease or LTBI (see Symptom screen).

Secondary case (TB): Cases of TB disease due to transmission from the source case or index case.

Setting, health-care: See Health-care setting.

Simulated Workplace Protection Factor (SWPF): A surrogate measure of the workplace protection provided by a respirator.

Smear (AFB smear): Laboratory technique for visualizing mycobacteria. The specimen (direct or concentrated) is spread onto a laboratory slide, stained, and examined using a microscope. Smear results should be available within 24 hours. The concentration of organisms per unit area of slide (the smear grade) correlates with the degree of infectiousness. However, a positive AFB smear result is not diagnostic of TB disease because organisms other than *M. tuberculosis*, for example nontuberculous mycobacteria (NTM), might be seen on an AFB smear result (see NTM and AFB).

Source case (TB): The case that was the original source of infection for secondary cases or contacts. This source case can be but is not necessarily the index case.

Source control: Source control is manipulation of a process preventing an emission (e.g., aerosolized *M. tuberculosis*) at the place of origin. Examples of source control methods are booths in which a patient coughs and produces sputum, biological safety cabinets (see BSC) in laboratories, and local exhaust ventilation.

Spirometry: A procedure to measure the volume of air entering and leaving the lungs.

Specimen: Any body fluid, secretion, or tissue sent to a laboratory where diagnostic tests, smears and cultures for *M. tuberculosis* may be performed.

Sputum: Mucus secretions coughed up from deep within the lungs (to be distinguished from saliva and nasal secretions). If a patient has pulmonary disease, an examination of the sputum by smear and culture can be helpful in evaluating the organism responsible for some infectious disease, such as TB. Sputum is different than and should not be confused with saliva or nasal secretions.

Sputum induction: Method used to obtain sputum from a patient who is unable to cough up a specimen spontaneously. The patient inhales a saline mist, which stimulates coughing from deep within the lungs.

Supervised TST administration: Procedure in which an expert TST trainer supervises a TST trainee who performs all procedures on the procedural observation checklist for administering TSTs (Table S2-3). Wheal size should be checked for all supervised TST administrations, and skin tests should be repeated if wheal size is inadequate (i.e., if <6 mm) (Section A.6.1).

Supervised TST reading: Procedure in which an expert TST trainer supervises a TST trainee who performs all procedures on the procedural observation checklist for reading TST results (Table S2-3). Quality control (QC) should include observation and counseling for the trainee reading TST results. TST training and coaching should continue until the HCW is able to perform

all procedures correctly and a satisfactory measurement is achieved (i.e., the trainer and the trainee read the TST results within 2 mm of each other). For example, if the trainer reads the TST result as 11 mm (may be considered the “gold standard” reading), the trainee’s reading should be between 9-13 mm to be considered correct. Only a single measured induration is recorded (Section A.6.2).

Susceptibility: See Drug-susceptibility test.

Suspect TB patient: A person in whom a diagnosis of TB disease is being considered, whether or not anti-TB therapy has been started. Persons should not remain in this category for >3 months. A patient may be determined to be a suspect TB patient if they meet one or more of the following criteria:

- Coughing for ≥ 3 weeks and have one or more other sign or symptom of TB disease (loss of appetite, unexplained weight loss, night sweats, bloody sputum or hemoptysis, hoarseness, fever, fatigue, or chest pain.) **or**
- Has a positive TST result and signs or symptoms of infection in the lung, pleura, or airways including larynx, **or**
- Has a positive AFB sputum smear result, **or**
- Has pending results from sputum culture or NAA test for *M. tuberculosis*

Symptomatic: Exhibiting signs or symptoms of a particular disease or disorder. Symptoms of pulmonary TB disease (or infection in the lung, pleura, or airways including larynx) include coughing for ≥ 3 weeks, loss of appetite, unexplained weight loss, night sweats, bloody sputum or hemoptysis, hoarseness, fever, fatigue, or chest pain.

Symptom screen: A symptom screen is a procedure used during a clinical evaluation in which the patient is asked if they have experienced any signs or symptoms of TB disease.

Targeted testing: A strategy to focus testing for infection with *M. tuberculosis* in persons at high risk for LTBI and those at high risk for progression to TB disease if infected. Targeted testing improves the risk and resource to benefit ratio.

TB case: A particular episode of clinical TB disease. This term refers only to the disease, not to the person with the disease. By law, TB cases and suspect TB cases must be reported to the state or local health department.

TB contact: A person who has shared the same air space with a person who has TB disease for a sufficient amount of time to allow possible transmission of *M. tuberculosis*.

TB disease: Tuberculosis (TB) disease is caused by bacteria called *Mycobacterium tuberculosis* (*M. tuberculosis*). The bacteria can attack any part of your body, but they usually attack the lungs. TB disease is diagnosed by isolation of *M. tuberculosis* in a culture (22). TB disease of the lungs or larynx can be transmitted when a person with the disease coughs, sings, laughs, speaks or breathes. TB disease may or may not be infectious.

TB exposure incident: A situation in which persons (e.g., HCWs, visitors, inmates) have been exposed to an individual with suspected or confirmed infectious TB disease (or to air containing *M. tuberculosis*) without the benefit of effective infection control measures.

TB infection: TB infection is the term used for persons with positive TST results, negative bacteriologic studies (if done), and no clinical, bacteriologic, or radiographic evidence of TB

disease (22). A better term is infection with *M. tuberculosis*. In most people who inhale TB bacteria and become infected, the body is able to fight the bacteria to stop them from growing. The bacteria become inactive, but they remain alive in the body and can become active later.

TB infection-control program: Early detection, isolation, and treatment of persons with infectious TB through a hierarchy of control measures, including use of 1) administrative controls to reduce the risk for exposure to persons with infectious TB disease; 2) environmental controls to prevent the spread and reduce the concentration of infectious droplet nuclei in the air; and 3) respiratory protection in areas where the risk for exposure to *M. tuberculosis* is high, such as in AII rooms. A TB infection-control plan should include surveillance of HCWs who have unprotected high-risk exposure to TB patients or their environment of care.

TB-screening: For administrative infection control purposes, initial TST, QFT, symptom screens, and any other follow-up tests such as chest radiograph or sputum examination for AFB and culture (see Symptom screen).

TB screening program: A plan that healthcare settings should implement to provide information that is important in caring for individual HCWs and information that facilitates detection of *M. tuberculosis* transmission. The TB screening program consists of four main components, 1) baseline testing for *M. tuberculosis* infection, 2) serial testing for *M. tuberculosis* infection, 3) serial screening for signs or symptoms of TB disease, and 4) TB training and education.

TB risk assessment: An initial and ongoing evaluation of the risk for transmission of *M. tuberculosis* in a particular health-care setting. A risk assessment considers factors such as the community rate of TB, number of TB patients encountered in the setting, and the speed with which patients with TB disease are suspected, isolated, and evaluated. The TB risk assessment determines the types of administrative and environmental controls and respiratory protection needed for a setting.

TB screening for HCWs: Policy which is focused on persons at risk for health-care-associated transmission of *M. tuberculosis*. TB screening for HCWs should be coordinated with officials of the state or local health department. TB screening data is used to evaluate the institution's infection control, surveillance and referral programs. Protection of privacy and maintenance of confidentiality should be ensured. Individual level clinical evaluation and treatment recommendations are referred to the preferred health-care provider.

TB skin test: See Tuberculin skin test.

Transmission: Spread of an infectious agent from one person to another. The likelihood of transmission of *M. tuberculosis* is directly related to the duration and intensity of exposure (See Exposure).

Treatment for latent TB infection (LTBI): Treatment for people with LTBI that prevents development of TB disease.

TST: See Tuberculin skin test.

TST conversion: In programs using the TST method of screening, a ≥ 10 millimeter (mm) increase in the size of the TST induration over a two-year period in an HCW with a documented negative two-step TST baseline result, or in a non-HCW with a negative TST result within two years. In programs using QFT, a change from negative to positive or conditionally positive to

positive result is considered a QFT conversion. A conversion (TST or QFT) is usually interpreted as presumptive evidence of new *M. tuberculosis* infection and poses an increased risk for progression to TB disease.

TST conversion rate: The percentage of a population that has converted their TST result within a specified time period. This is calculated by dividing the number of TST conversions among HCWs in the setting in a specified period of time (numerator) by the number of HCWs who received TSTs in the setting over the same period of time (denominator) multiplied by 100.

Tubercle bacilli: *M. tuberculosis* organisms.

Tuberculin: A sterile liquid containing proteins extracted from cultures of tubercle bacilli and used in tests for tuberculosis.

Tuberculin skin test (TST): Method used to assess the likelihood that a person is infected with *M. tuberculosis*. A small dose of PPD-tuberculin is injected just beneath the surface of the skin by the Mantoux method, and the area is examined 48–72 hours after the injection. The indurated margins should be read transverse (perpendicular) to the long the long axis of the forearm. The TST result is interpreted for HCWs in two distinct parts: 1) interpretation by standard criteria without regard to personal risk factors or setting specific factors; 2) interpretation by individualized criteria to determine need for treatment.

Tuberculosis (TB): Clinically active symptomatic disease caused by an organism in the *M. tuberculosis* complex (usually *M. tuberculosis* or, rarely, *M. bovis* or *M. africanum*).

Two-step skin testing: Procedure used for the baseline skin testing of persons who will routinely receive TSTs (e.g., HCWs or residents of long-term care facilities) to reduce the likelihood of mistaking a boosted reaction for a new infection. If an initial TST result is classified as negative, the second step of a two-step TST should be administered 1–3 weeks after the first TST was administered. If the second TST result is positive, it probably represents a boosted reaction, indicating infection was most probably occurred in the past. If the second TST result is also negative, the person is classified as not infected.

Ultraviolet germicidal irradiation (UVGI): Use of ultraviolet radiation to kill or inactivate microorganisms.

Ultraviolet germicidal irradiation (UVGI) lamp: Lamp that kills or inactivates microorganisms by emitting ultraviolet germicidal radiation, predominantly at a wavelength of 254 nm (intermediate light waves between visible light and X-rays). UVGI lamps can be used in ceiling or wall fixtures or within air ducts of ventilation systems as an adjunct other environmental control measures.

User seal-check: Formerly called “fit check,” procedure to determine if a respirator fits the wearer’s face correctly.

Variable air volume (VAV): VAV ventilation systems are designed to vary the air flow rates based on the temperature amount of tempered air necessary to maintain the desired temperature. Minimum levels are total and outside air are maintained. .

Wheal: Small bump that is produced when a TST is administered. The wheal disappears about ten minutes after TST placement.

DRAFT

DRAFT

DRAFT

Workplace protection factor (WPF): A measure of the protection provided in the workplace by a properly functioning respirator when correctly worn and used.

SUPPLEMENT 9: GLOSSARY OF ABBREVIATIONS

ACET	Advisory Council for the Elimination of Tuberculosis
ACGIH	American Conference of Governmental Industrial Hygienists
ACH	Air changes per hour
ACOG	American College of Obstetricians and Gynecologists
AERS	Adverse event reporting system
AFB	Acid-fast bacilli
AIA	American Institute of Architects
AIDS	Acquired immunodeficiency syndrome
AII	Airborne infection isolation
ALA	American Lung Association
ALT	Alanine aminotransferase
ANSI	American National Standards Institute
APF	Assigned Protection Factor
APIC	Association for Professionals in Infection Control and Epidemiology, Inc.
ART	Antiretroviral therapy
ASHRAE	American Society of Heating, Refrigerating, and Air-Conditioning Engineers, Inc.
AST	Aspartate aminotransferase
ATS	American Thoracic Society
BCG	Bacille Calmette-Guérin
BIDR	Blinded independent duplicate reading
BMBL	Biosafety in Microbiological and Biomedical Laboratories
BSL	Biosafety level
BSC	Biological safety cabinet
CAV	Contestant air volume
CDC	Centers for Disease Control and Prevention
CEL	Certified equipment list
CFM	Cubic feet per minute
CFR	Code of Federal Regulations
CoV	Corona virus
CPL	Compliance policy directive
CRT	Counseling, referral, and testing
DHHS	U.S. Department of Health and Human Services
DNA	Deoxyribonucleic acid
DTBE	Division of Tuberculosis Elimination
DOP	Diocetyl phthalate
DOT	Directly observed therapy
DTH	Delayed-type hypersensitivity
ED	Emergency departments
ELISA	Enzyme-linked immunosorbent assay
EMS	Emergency medical services
EPA	Environmental Protection Agency
ESRD	End-stage renal disease
FDA	U.S. Food and Drug Administration
FPM	Feet per minute
HAART	Highly active antiretroviral therapy
HCW	Health-care worker
HEPA	High-efficiency particulate air
HIV	Human immunodeficiency virus
HMO	Health maintenance organization

HPLC	High-pressure liquid chromatograph
HVAC	Heating, ventilation, air conditioning
ICU	Intensive care unit
IDSA	Infectious Disease Society of America
INH	Isoniazid
IOM	Institute of Medicine
IUATLD	International Union Against Tuberculosis and Lung Disease
JCAHO	Joint Commission on Accreditation of Healthcare Organizations
LTBI	Latent tuberculosis infection
MDR TB	Multidrug-resistant tuberculosis
MOTT	Mycobacterium other than tuberculosis
MTC	Mycobacterium tuberculosis complex
NAA	Nucleic acid amplification
NCID	National Center for Infectious Diseases
NIAID	National Institute of Allergy and Infectious Diseases
NIH	National Institutes of Health
NIOSH	National Institute for Occupational Safety and Health
NM	Nanometer
NNRTI	Non-nucleoside reverse transcriptase inhibitors
NPIN	National Prevention Information Network
NTCA	National TB Controllers Association
NTM	Nontuberculous mycobacteria
OR	Operating room
OSHA	Occupational Safety and Health Administration
PAPR	Powered air-purifying respirator
PCR	Polymerase chain reaction
PE	Protective environment
PET	Permissible exposure times
PI	Protease inhibitor
PLHCP	Physician or licensed health-care professional
PPD	Purified protein derivative
PPE	Personal protective equipment
QC	Quality control
QFT	QuantiFERON-TB test
REL	Recommended exposure limit
RFLP	Restriction fragment length polymorphism
RNA	Ribonucleic acid
RZ	Rifampin and pyrazinamide
SARS	Severe Acute Respiratory Syndrome
SES	Socioeconomic status
SGOT	Serum glutamic-oxalacetic transaminase
SGPT	Serum glutamic-pyruvic transaminase
SPF	Solar-protection factor
SWPF	Simulated workplace protection factor
TB	Tuberculosis
TU	Tuberculin unit
TST	Tuberculin skin test
UVGI	Ultraviolet germicidal irradiation
VCT	Voluntary counseling and testing
WHO	World Health Organization
WPF	Workplace Protection Factor

List of Tables

Table 1. TB risk assessment worksheet	35
Table 2. Risk classifications for health-care settings and recommended frequency of screening for <i>M. tuberculosis</i> infection among HCWs	42
Table 3. Risk classification examples	43
Table 4. Environmental controls record and evaluation	48
Table 5. Administrative, environmental, and respiratory controls for selected health-care settings	49
Table 6. Suggested components of an initial TB training and education program for health-care workers (HCWs)	85
Table S2-1. Criteria for obtaining medical and diagnostic evaluation for HCWs	127
Table S2-2. Factors affecting treatment decisions during the medical and diagnostic evaluation, by TST result.....	128
Table S2-3. Recommended quality control (QC) procedural observation checklist <i>Placing a tuberculin skin test (TST), Mantoux method</i>	132
Table S2-3. Recommended quality control (QC) procedural observation checklist <i>Reading a TST, palpation method</i>	134
Table S2-4. Indications for a two-step TST	138
Table S2-5: QFT Results and Interpretation	141
Table S2-6. Factors affecting treatment decisions during medical and diagnostic evaluation, by situation and risk of <i>M. tuberculosis</i> infection.....	142
Table 7: Common drug regimens for treatment of LTBI	152
Table S3-1. Air changes per hour (ACH) and time required for removal efficiencies of 99% and 99.9% of airborne contaminants	157
Table S3-2. Ventilation recommendations for selected areas in new or renovated health-care settings	160
Table S4-1. Nonpowered air-purifying respirator filter classes certified under 42 CFR 84	187
Table S4-2. Model Medical Questionnaire for Respirator Users	193
Table S4-3. Model Request for Medical Clearance for Respirator Use.....	195

List of Figures

Figure S3-1.	An enclosing booth designed to sweep air past a patient with TB disease and collect the infectious droplet nuclei on a HEPA filter.	156
Figure S3-3.	Empirical relationship between differential airflow differential pressure and leakage areas.	163
Figure S3-4.	Smoke tube testing and anemometer placement to determine the direction of airflow into and out of a room. The anemometer, if used, is placed with the sensor in the airflow path at the bottom of the door.	166
Figure S3-5.	Cross-sectional view of a room showing the location of negative pressure measurement	167
Figure S3-6.	Fixed, ducted room-air recirculation system using a HEPA filter inside an air duct.	171
Figure S3-7.	Fixed, ceiling-mounted room-air recirculation system using a HEPA filter. .	

Reference List

Reference List

- (1) CDC. Guidelines for preventing the transmission of *Mycobacterium tuberculosis* in health-care facilities, 1994. Centers for Disease Control and Prevention. MMWR 1994;43:1-132.
- (2) Bennett CL, Schwartz DN, Parada JP, Sipler AM, Chmiel JS, DeHovitz JA et al. Delays in tuberculosis isolation and suspicion among persons hospitalized with HIV-related pneumonia. Chest 2000;117:110-116.
- (3) Greenaway C, Menzies D, Fanning A, Grewal R, Yuan L, FitzGerald JM et al. Delay in diagnosis among hospitalized patients with active tuberculosis--predictors and outcomes. Am J Respir Crit Care Med 2002;165:927-33.
- (4) CDC. Trends in tuberculosis--United States, 1998-2003 [erratum appears in MMWR Morb Mortal Wkly Rep. 2004 Mar 26;53(11):246]. MMWR 2004;53:209-14.
- (5) CDC. Trends in tuberculosis morbidity--United States, 1992-2002. MMWR 2003;52:217-22.
- (6) CDC. Guidelines for preventing the transmission of tuberculosis in health-care settings, with special focus on HIV-related issues. MMWR 1990;39:1-29.
- (7) CDC. Guidelines for prevention of TB transmission in hospitals. Atlanta: DHHS, Public Health Service, CDC; 1982.
- (8) Fridkin SK, Manangan L, Bolyard E, Jarvis WR. SHEA-CDC TB survey, Part I: Status of TB infection control programs at member hospitals, 1989-1992. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1995;16:129-34.
- (9) Fridkin SK, Manangan L, Bolyard E, Jarvis WR. SHEA-CDC TB survey, Part II: Efficacy of TB infection control programs at member hospitals, 1992. Society for Healthcare Epidemiology of America. Infect Control Hosp Epidemiol 1995;16:135-40.
- (10) Institute of Medicine (IOM). Tuberculosis in the workplace. Washington, DC: National Academy Press; 2001.
- (11) Kellerman SE, Simonds D, Banerjee S, Towsley J, Stover BH, Jarvis W. APIC and CDC survey of *Mycobacterium tuberculosis* isolation and control practices in hospitals caring for children. Part 1: Patient and family isolation policies and procedures. Association for Professionals in Infection and Epidemiology, Inc. American Journal of Infection Control 1998;26:478-82.
- (12) Kellerman SE, Simonds D, Banerjee S, Towsley J, Stover BH, Jarvis W. APIC and CDC survey of *Mycobacterium tuberculosis* isolation and control practices in hospitals caring for children. Part 2: Environmental and administrative controls. Association

for Professionals in Infection control and Epidemiology, Inc. American Journal of Infection Control 1998;26:483-87.

- (13) Manangan LP, Simonds DN, Pugliese G, Kroc K, Banerjee SN, Rudnick JR et al. Are US hospitals making progress in implementing guidelines for prevention of Mycobacterium tuberculosis transmission? Arch Intern Med 1998;158:1440-1444.
- (14) Manangan LP, Collazo ER, Tokars J, Paul S, Jarvis WR. Trends in compliance with the guidelines for preventing the transmission of Mycobacterium tuberculosis among New Jersey hospitals, 1989 to 1996. Infect Control Hosp Epidemiol 1999;20:337-40.
- (15) Manangan LP, Bennett CL, Tablan N, Simonds DN, Pugliese G, Collazo E et al. Nosocomial tuberculosis prevention measures among two groups of US hospitals, 1992 to 1996. Chest 2000;117:380-384.
- (16) Fella P, Rivera P, Hale M, Squires K, Sepkowitz K. Dramatic decrease in tuberculin skin test conversion rate among employees at a hospital in New York City. American Journal of Infection Control 1995;23:352-56.
- (17) Louthier J, Rivera P, Feldman J, Villa N, DeHovitz J, Sepkowitz KA. Risk of tuberculin conversion according to occupation among health care workers at a New York City hospital. Am J Respir Crit Care Med 1997;156:201-5.
- (18) Maloney SA, Pearson ML, Gordon MT, Del Castillo R, Boyle JF, Jarvis WR. Efficacy of control measures in preventing nosocomial transmission of multidrug-resistant tuberculosis to patients and health care workers. Ann Intern Med 1995;122:90-95.
- (19) Stroud LA, Tokars JI, Grieco MH, Crawford JT, Culver DH, Edlin BR et al. Evaluation of infection control measures in preventing the nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in a New York City hospital. Infect Control Hosp Epidemiol 1995;16:141-47.
- (20) Wenger PN, Otten J, Breeden A, Orfas D, Beck-Sague CM, Jarvis WR. Control of nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis among healthcare workers and HIV-infected patients. Lancet 1995;345:235-40.
- (21) Horsburgh CR, Moore M, Castro KG. Epidemiology of tuberculosis in the United States. In: Rom WN, Garay SM, eds. Tuberculosis. 2 ed. Philadelphia: Lippincott, Williams & Wilkins; 2004: 31-45.
- (22) American Thoracic Society (ATS), CDC, Infectious Disease Society of America (IDSA). Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med 2000;161:1376-95.
- (23) American Thoracic Society (ATS), CDC, Infectious Disease Society of America (IDSA). Treatment of tuberculosis. MMWR 2003;52.
- (24) Wells WF. Aerodynamics of droplet nuclei. Airborne contagion and air hygiene. Cambridge: Harvard University Press; 1955: 13-9.

- (25) Canetti G. The Tuberculosis bacillus in the pulmonary lesion of man: Histobacteriology and its bearing on the therapy of pulmonary tuberculosis (Revised and enlarged edition of *Le Bacille de Koch dans la lesion tuberculeuse du poumon*). New York: Springer Publishing Company; 1955.
- (26) Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. *Bibl Tuberc* 1970;26:28-106.
- (27) Sutherland I, Bleiker MA, Meijer J, Styblo K. The risk of tuberculous infection in The Netherlands from 1967 to 1979. *Tubercle* 1983;64:241-53.
- (28) Comstock GW, Livesay VT, Woolpert SF. The prognosis of a positive tuberculin reaction in childhood and adolescence. *Am J Epidemiol* 1974;99:131-38.
- (29) American Thoracic Society (ATS), CDC. Targeted tuberculin testing and treatment of latent tuberculosis infection. *MMWR* 2000;49:1-51.
- (30) CDC. Core curriculum on tuberculosis: what every clinician should know. 4 ed. Atlanta: DHHS, Public Health Service, CDC.; 2000.
- (31) Howard TP, Solomon DA. Reading the tuberculin skin test. Who, when, and how? *Arch Intern Med* 1988;148:2457-59.
- (32) Leonhardt KK, Gentile F, Gilbert BP, Aiken M. A cluster of tuberculosis among crack house contacts in San Mateo County, California. *Am J Public Health* 1994;84:1834-36.
- (33) McElroy PD, Southwick KL, Fortenberry ER, Levine EC, Diem LA, Woodley CL et al. Outbreak of tuberculosis among homeless persons coinfectd with human immunodeficiency virus. *Clin Infect Dis* 2003;36:1305-12.
- (34) McElroy PD, Rothenberg RB, Varghese R, Woodruff R, Minns GO, Muth SQ et al. A network-informed approach to investigating a tuberculosis outbreak: implications for enhancing contact investigations. *Int J Tuberc Lung Dis* 2003;7:S486-S493.
- (35) Reyes JC, Robles RR, Colon HM, Marrero CA, Castillo X, Melendez M. Mycobacterium tuberculosis infection among crack and injection drug users in San Juan, Puerto Rico. *Puerto Rico Health Sciences Journal* 1996;15:233-36.
- (36) Taubes T, Galanter M, Dermatis H, Westreich L. Crack cocaine and schizophrenia as risk factors for PPD reactivity in the dually diagnosed. *Journal of Addictive Diseases* 1998;17:63-74.
- (37) CDC. Voluntary HIV testing as part of routine medical care--Massachusetts, 2002. *MMWR* 2004;53:523-26.
- (38) CDC. Advancing HIV prevention: new strategies for a changing epidemic--United States, 2003. *MMWR* 2003;52:329-32.

- (39) CDC. Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1995;44:1-16.
- (40) CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention. MMWR 1998;47:1-58.
- (41) Daley CL, Small PM, Schecter GF, Schoolnik GK, McAdam RA, Jacobs WR, Jr. et al. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med 1992;326:231-35.
- (42) Dooley SW, Villarino ME, Lawrence M, Salinas L, Amil S, Rullan JV et al. Nosocomial transmission of tuberculosis in a hospital unit for HIV-infected patients. JAMA 1992;267:2632-34.
- (43) Edlin BR, Tokars JI, Grieco MH, Crawford JT, Williams J, Sordillo EM et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:1514-21.
- (44) Kenyon TA, Ridzon R, Luskin-Hawk R, Schultz C, Paul WS, Valway SE et al. A nosocomial outbreak of multidrug-resistant tuberculosis. Ann Intern Med 1997;127:32-36.
- (45) Colditz GA, Brewer TF, Berkey CS, Wilson ME, Burdick E, Fineberg HV et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA 1994;271:698-702.
- (46) Nardell E, McInnis B, Thomas B, Weidhaas S. Exogenous reinfection with tuberculosis in a shelter for the homeless. N Engl J Med 1986;315:1570-1575.
- (47) Styblo K. Epidemiology of tuberculosis. The Hague, The Netherlands: Royal Netherlands Tuberculosis Association (KNCV); 1991/Mar./15.
- (48) Caminero J, Pena M, Campos-Herrero M, Rodriguez J, Afonso O, Martin C et al. Exogenous Reinfection with Tuberculosis on a European Island with a Moderate Incidence of Disease. Am J Respir Crit Care Med 2001;163:717-20.
- (49) de Viedma DG, Marin M, Hernangomez S, Diaz M, Ruiz Serrano MJ, Alcala L et al. Tuberculosis recurrences: reinfection plays a role in a population whose clinical/epidemiological characteristics do not favor reinfection. Arch Intern Med 2002;162:1873-79.
- (50) Sacks LV, Pendle S, Orlovic D, Blumberg L, Constantinou C. A comparison of outbreak- and nonoutbreak-related multidrug-resistant tuberculosis among human immunodeficiency virus-infected patients in a South African hospital. Clin Infect Dis 1999;29:96-101.

- (51) Small PM, Shafer RW, Hopewell PC, Singh SP, Murphy MJ, Desmond E et al. Exogenous reinfection with multidrug-resistant *Mycobacterium tuberculosis* in patients with advanced HIV infection. *N Engl J Med* 1993;328:1137-44.
- (52) van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. *N Engl J Med* 1999;341:1174-79.
- (53) Barrett-Connor E. The epidemiology of tuberculosis in physicians. *JAMA* 1979;241:33-38.
- (54) Brennen C, Muder RR, Muraca PW. Occult endemic tuberculosis in a chronic care facility. *Infect Control Hosp Epidemiol* 1988;9:548-52.
- (55) Catanzaro A. Nosocomial tuberculosis. *Am Rev Respir Dis* 1982;125:559-62.
- (56) Di Perri G, Cruciani M, Danzi MC, Luzzati R, De Checchi G, Malena M et al. Nosocomial epidemic of active tuberculosis among HIV-infected patients. *Lancet* 1989;2:1502-4.
- (57) Dooley SW, Tapper ML. Epidemiology of nosocomial tuberculosis. In: Wenzel RP, ed. *Prevention and control of nosocomial infections*. 3 ed. Baltimore: Williams & Wilkins; 1997: 357-94.
- (58) Ehrenkranz NJ, Kicklighter JL. Tuberculosis outbreak in a general hospital: evidence for airborne spread of infection. *Ann Intern Med* 1972;77:377-82.
- (59) Goldman KP. Tuberculosis in hospital doctors. *Tubercle* 1988;69:237-40.
- (60) Haley CE, McDonald RC, Rossi L, Jones WD, Jr., Haley RW, Luby JP. Tuberculosis epidemic among hospital personnel. *Infect Control Hosp Epidemiol* 1989;10:204-10.
- (61) Hutton MD, Stead WW, Cauthen GM, Bloch AB, Ewing WM. Nosocomial transmission of tuberculosis associated with a draining abscess. *J Infect Dis* 1990;161:286-95.
- (62) Jereb JA, Klevens RM, Privett TD, Smith PJ, Crawford JT, Sharp VL et al. Tuberculosis in health care workers at a hospital with an outbreak of multidrug-resistant *Mycobacterium tuberculosis*. *Arch Intern Med* 1995;155:854-59.
- (63) Kantor HS, Poblete R, Pusateri SL. Nosocomial transmission of tuberculosis from unsuspected disease. *Am J Med* 1988;84:833-38.
- (64) Lundgren R, Norrman E, Asberg I. Tuberculosis infection transmitted at autopsy. *Tubercle* 1987;68:147-50.
- (65) McGowan JE, Jr. Nosocomial tuberculosis: new progress in control and prevention. *Clin Infect Dis* 1995;21:489-505.
- (66) Menzies D, Fanning A, Yuan L, Fitzgerald M. Tuberculosis among health care workers. *N Engl J Med* 1995;332:92-98.

- (67) Menzies D, Fanning A, Yuan L, FitzGerald JM, Canadian Collaborative Group in nosocomial Transmission of Tuberculosis. Factors associated with tuberculin conversion in Canadian microbiology and pathology workers. *Am J Respir Crit Care Med* 2003;167:599-602.
- (68) Sepkowitz KA, Friedman CR, Hafner A, Kwok D, Manoach S, Floris M et al. Tuberculosis among urban health care workers: a study using restriction fragment length polymorphism typing. *Clin Infect Dis* 1995;21:1098-101.
- (69) Templeton GL, Illing LA, Young L, Cave D, Stead WW, Bates JH. The risk for transmission of *Mycobacterium tuberculosis* at the bedside and during autopsy. *Ann Intern Med* 1995;122:922-25.
- (70) Zaza S, Blumberg HM, Beck-Sague C, Haas WH, Woodley CL, Pineda M et al. Nosocomial transmission of *Mycobacterium tuberculosis*: role of health care workers in outbreak propagation. *J Infect Dis* 1995;172:1542-49.
- (71) Anonymous. HazardAlert! Clusters of "positive PPD skin tests" due to intradermal injection of Td. *NurseAdvice-ERR* 2003;1:2.
- (72) Larson JL, Lambert L, Stricof RL, Driscoll J, McGarry MA, Ridzon R. Potential nosocomial exposure to *Mycobacterium tuberculosis* from a bronchoscope. *Infect Control Hosp Epidemiol* 2003;24:825-30.
- (73) Weber DJ, Rutala WA. Lessons from outbreaks associated with bronchoscopy. *Infect Control Hosp Epidemiol* 2001;22:403-8.
- (74) D'Agata EM, Wise S, Stewart A, Lefkowitz LB, Jr. Nosocomial transmission of *Mycobacterium tuberculosis* from an extrapulmonary site. *Infect Control Hosp Epidemiol* 2001;22:10-12.
- (75) Ball R, Van Wey M. Tuberculosis skin test conversion among health care workers at a military medical center. *Military Medicine* 1997;162:338-43.
- (76) Menzies D, Fanning A, Yuan L, FitzGerald JM. Hospital ventilation and risk for tuberculous infection in canadian health care workers. Canadian Collaborative Group in Nosocomial Transmission of TB. *Ann Intern Med* 2000;133:779-89.
- (77) Williams J, Schneider N, Gilligan ME. Implementing a tuberculosis control program. *American Journal of Infection Control* 1995;23:152-55.
- (78) Beck-Sague C, Dooley SW, Hutton MD, Otten J, Breeden A, Crawford JT et al. Hospital outbreak of multidrug-resistant *Mycobacterium tuberculosis* infections. Factors in transmission to staff and HIV-infected patients. *JAMA* 1992;268:1280-1286.
- (79) CDC. *Mycobacterium tuberculosis* transmission in a health clinic--Florida, 1988. *MMWR* 1989;38:256; 263-258; 264.
- (80) CDC. Nosocomial transmission of multidrug-resistant tuberculosis to health-care workers and HIV-infected patients in an urban hospital--Florida. *MMWR* 1990;39:718-22.

- (81) CDC. Nosocomial transmission of multidrug-resistant tuberculosis among HIV-infected persons--Florida and New York, 1988-1991. *MMWR* 1991;40:585-91.
- (82) Dooley SW, Jarvis WR, Martone WJ, Snider DE, Jr. Multidrug-resistant tuberculosis. *Ann Intern Med* 1992;117:257-59.
- (83) Pearson ML, Jereb JA, Frieden TR, Crawford JT, Davis BJ, Dooley SW et al. Nosocomial transmission of multidrug-resistant *Mycobacterium tuberculosis*. A risk to patients and health care workers. *Ann Intern Med* 1992;117:191-96.
- (84) Larsen NM, Biddle CL, Sotir MJ, White N, Parrott P, Blumberg HM. Risk of tuberculin skin test conversion among health care workers: occupational versus community exposure and infection. *Clin Infect Dis* 2002;35:796-801.
- (85) Moro ML, Errante I, Infuso A, Sodano L, Gori A, Orceese CA et al. Effectiveness of infection control measures in controlling a nosocomial outbreak of multidrug-resistant tuberculosis among HIV patients in Italy. *Int J Tuberc Lung Dis* 2000;4:61-68.
- (86) Panlilio AL, Burwen DR, Curtis AB, Srivastava PU, Bernardo J, Catalano MT et al. Tuberculin skin testing surveillance of health care personnel. *Clin Infect Dis* 2002;35:219-27.
- (87) Fuss EP, Israel E, Baruch N, Roghmann MC. Improved tuberculosis infection control practices in Maryland acute care hospitals. *American Journal of Infection Control* 2000;28:133-37.
- (88) Stricof RL, DiFerdinando GT, Jr., Osten WM, Novick LF. Tuberculosis control in New York City hospitals. *American Journal of Infection Control* 1998;26:270-276.
- (89) Lambert L, Rajbhandary S, Qualls N, Budnick L, Catanzaro A, Cook S et al. Costs of implementing and maintaining a tuberculin skin test program in hospitals and health departments. *Infect Control Hosp Epidemiol* 2003;24:814-20.
- (90) Askew GL, Finelli L, Hutton M, Laraque F, Porterfield D, Shilkret K et al. *Mycobacterium tuberculosis* transmission from a pediatrician to patients. *Pediatrics* 1997;100:19-23.
- (91) Moore M, Schulte J, Valway SE, Stader B, Kistler V, Margraf P et al. Evaluation of transmission of *Mycobacterium tuberculosis* in a pediatric setting. *Journal of Pediatrics* 1998;133:108-12.
- (92) Schulte JM, Moore M, Kistler V, Margraf P, Christman R, Valway SE et al. Tuberculosis screening in private physicians' offices, Pennsylvania, 1996. *Am J Prev Med* 1999;16:178-81.
- (93) CDC. Drug-susceptible tuberculosis outbreak in a state correctional facility housing HIV-infected inmates--South Carolina, 1999-2000. *MMWR* 2000;49:1041-44.

- (94) Lobato MN, Roberts CA, Bazerman LB, Hammett TM. Public health and correctional collaboration in tuberculosis control: Successes and barriers. *Am J Prev Med* 2004;27:112-17.
- (95) Reichard AA, Lobato MN, Roberts CA, Bazerman LB, Hammett TM. Assessment of tuberculosis screening and management practices of large jail systems. *Public Health Reports* 2003;118:500-507.
- (96) Joint Commission on Accreditation of Healthcare Organizations (JCAHO). 2005 Critical access hospitals: Surveillance, preventions, and control of infection. 2004.
- (97) Nolte KD, Hanzlick RL, Payne DC, Kroger AT, Oliver WR, Baker AM et al. Medical examiners, coroners, and biologic terrorism: a guidebook for surveillance and case management. *MMWR* 2004;53:1-27.
- (98) CDC, Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for environmental infection control in health-care facilities: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC). *MMWR* 2003;52:1-44.
- (99) CDC. Effective TB interviewing for contact investigation. CDC. Atlanta, GA, 2004.
- (100) CDC. Guidelines for using the QuantiFERON-TB test for diagnosing latent *Mycobacterium tuberculosis* infection. Centers for Disease Control and Prevention. *MMWR* 2003;52:15-18.
- (101) Food and Drug Administration, CDC. The selection of patients for x-ray examinations: Chest x-ray screening examinations. 8-1-1983. 26-29.
- (102) American Institute of Architects. Guidelines for design and construction of hospital and health care facilities. Washington, D.C.: American Institute of Architects; 2001.
- (103) Francis J. Curry National Tuberculosis Center. Making the connection: An introduction to interpretation skills for TB control. 2003.
- (104) CDC. Reported tuberculosis in the United States, 2002. Atlanta: DHHS, Public Health Service, CDC.; 2003.
- (105) CDC. Key facts about the flue and flu vaccine. 10-6-2004. 1-3.
- (106) Lenehan GP. Universal respiratory etiquette: a modest proposal. *Journal of Emergency Nursing* 2004;30:3.
- (107) Piotrowski J. 'Respiratory etiquette'. CDC's SARS draft plan suggests masks for patients. *Mod Healthc* 2003;33:13.
- (108) Al Zahrani K, Al Jahdali H, Poirier L, Rene P, Menzies D. Yield of smear, culture and amplification tests from repeated sputum induction for the diagnosis of pulmonary tuberculosis. *Int J Tuberc Lung Dis* 2001;5:855-60.

- (109) Bell DL, V. The role of induced sputum in the diagnosis of pulmonary tuberculosis. *J Infect* 2003;47:317-21.
- (110) Conde MB, Soares SL, Mello FC, Rezende VM, Almeida LL, Reingold AL et al. Comparison of sputum induction with fiberoptic bronchoscopy in the diagnosis of tuberculosis: experience at an acquired immune deficiency syndrome reference center in Rio de Janeiro, Brazil. *Am J Respir Crit Care Med* 2000;162:2238-40.
- (111) Merrick ST, Sepkowitz KA, Walsh J, Damson L, McKinley P, Jacobs JL. Comparison of induced versus expectorated sputum for diagnosis of pulmonary tuberculosis by acid-fast smear. *American Journal of Infection Control* 1997;25:463-66.
- (112) Toman's tuberculosis case detection, treatment, and monitoring: questions and answers. 2 ed. Geneva: World Health Organization; 2004.
- (113) CDC. Notice to Readers: Update: nucleic acid amplification tests for Tuberculosis. *MMWR* 2000;49:593-602.
- (114) Willcox PA, Potgieter PD, Bateman ED, Benatar SR. Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope. *Thorax* 1986;41:681-84.
- (115) Abadco DL, Steiner P. Gastric lavage is better than bronchoalveolar lavage for isolation of *Mycobacterium tuberculosis* in childhood pulmonary tuberculosis. *Pediatr Infect Dis J* 1992;11:735-38.
- (116) Abadco DL, Amaro-Galvez R, Rao M, Steiner P. Experience with flexible fiberoptic bronchoscopy with bronchoalveolar lavage as a diagnostic tool in children with AIDS. *Am J Dis Child* 1992;146:1056-59.
- (117) Willcox PA, Benatar SR, Potgieter PD. Use of the flexible fibreoptic bronchoscope in diagnosis of sputum-negative pulmonary tuberculosis. *Thorax* 1982;37:598-601.
- (118) Chan S, Abadco DL, Steiner P. Role of flexible fiberoptic bronchoscopy in the diagnosis of childhood endobronchial tuberculosis. *Pediatr Infect Dis J* 1994;13:506-9.
- (119) Lillehei JP. Sputum induction with heated aerosol inhalations for the diagnosis of tuberculosis. *Am Rev Respir Dis* 1961;84:276-78.
- (120) Curtis AB, Ridzon R, Vogel R, McDonough S, Hargreaves J, Ferry J et al. Extensive transmission of *Mycobacterium tuberculosis* from a child. *N Engl J Med* 1999;341:1491-95.
- (121) American Academy of Pediatrics. Tuberculosis. 26 ed. Elk Grove Village, IL: American Academy of Pediatrics; 2003: 642-60.
- (122) Rabalais G, Adams G, Stover B. PPD skin test conversion in health-care workers after exposure to *Mycobacterium tuberculosis* infection in infants. *Lancet* 1991;338:826.

- (123) CDC, National Institutes of Health (NIH). Agent: *Mycobacterium tuberculosis*, *M. bovis*. In: Richmond JY, McKinley RW, eds. Biosafety in Microbiological and Biomedical Laboratories. 4 ed. Washington, DC: U.S. Government Printing Office; 1999: 104-6.
- (124) Association of State and Territorial Public Health Laboratory Directors, CDC. *Mycobacterium tuberculosis: Assessing your laboratory*. Atlanta, GA: CDC; 1995/Mar.
- (125) Tenover FC, Crawford JT, Huebner RE, Geiter LJ, Horsburgh CR, Jr., Good RC. The resurgence of tuberculosis: is your laboratory ready? *J Clin Microbiol* 1993;31:767-70.
- (126) Pitchenik AE, Robinson HA. The radiographic appearance of tuberculosis in patients with the acquired immune deficiency syndrome (AIDS) and pre-AIDS. *Am Rev Respir Dis* 1985;131:393-96.
- (127) Klein NC, Duncanson FP, Lenox TH, III, Pitta A, Cohen SC, Wormser GP. Use of mycobacterial smears in the diagnosis of pulmonary tuberculosis in AIDS/ARC patients. *Chest* 1989;95:1190-1192.
- (128) Chaulk CP, Kazandjian VA. Directly observed therapy for treatment completion of pulmonary tuberculosis: Consensus Statement of the Public Health Tuberculosis Guidelines Panel.[erratum appears in *JAMA* 1998 Jul 8;280(2):134. *JAMA* 1998;279:943-48.
- (129) Frieden TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City--turning the tide. *N Engl J Med* 1995;333:229-33.
- (130) Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. *N Engl J Med* 1994;330:1179-84.
- (131) Sokolove PE, Lee BS, Krawczyk JA, Banos PT, Gregson AL, Boyce DM et al. Implementation of an emergency department triage procedure for the detection and isolation of patients with active pulmonary tuberculosis. *Ann Emerg Med* 2000;35:327-36.
- (132) Aranha-Creado H, Prince D, Greene K, Brandwein H. Removal of *Mycobacterium* species by breathing circuit filters. *Infect Control Hosp Epidemiol* 1997;18:252-54.
- (133) Berry AJ, Nolte FS. An alternative strategy for infection control of anesthesia breathing circuits: a laboratory assessment of the Pall HME Filter. *Anesth Analg* 1991;72:651-55.
- (134) Demers RR. Bacterial/viral filtration: let the breather beware! *Chest* 2001;120:1377-89.
- (135) Langevin PB, Rand KH, Layon AJ. The potential for dissemination of *Mycobacterium tuberculosis* through the anesthesia breathing circuit. *Chest* 1999;115:1107-14.
- (136) Tait AR. Occupational transmission of tuberculosis: implications for anesthesiologists. *Anesth Analg* 1997;85:444-51.

- (137) Teo DTW, Lim TW. Transmission of tuberculosis from patient to healthcare workers in the anaesthesia context. *Annals of the Academy of Medicine* 2004;33:95-99.
- (138) Kao AS, Ashford DA, McNeil MM, Warren NG, Good RC. Descriptive profile of tuberculin skin testing programs and laboratory-acquired tuberculosis infections in public health laboratories. *J Clin Microbiol* 1997;35:1847-51.
- (139) Peerbooms PG, van Doornum GJ, van Deutekom H, Coutinho RA, van Soolingen D. Laboratory-acquired tuberculosis. *Lancet* 1995;345:1311-12.
- (140) Metchock BG, Nolte FS, Wallace RJ. *Mycobacterium*. In: Murray PR, Barron EJ, Pfaller MA, Tenover FC, Tenover FC, Tenover FC, Tenover FC, eds. *Manual of Clinical Microbiology*. 7 ed. Washington, D.C.: American Society for Microbiology.; 1999: 399-437.
- (141) Richmond JY. Anthology of biosafety: IV. Issues in public health. American Biological Safety Association; 2001.
- (142) CDC, National Institutes of Health (NIH). Primary containment for biohazards: Selection, Installation and Use of biological safety cabinets. 2 ed. Atlanta: DHHS, Public Health Service, CDC.; 2000.
- (143) CDC, National Institutes of Health (NIH). Biosafety in Microbiological and Biomedical Laboratories. 4 ed. Washington, D.C.: U.S. Government Printing Office; 1999.
- (144) Mehta AC, Minai OA. Infection control in the bronchoscopy suite. A review. *Clin Chest Med* 2000;20:19-32.
- (145) Wang KP, Mehta AC. *Flexible Bronchoscopy*. Blackwell Science, Inc.; 1995.
- (146) Jereb JA, Burwen DR, Dooley SW, Haas WH, Crawford JT, Geiter LJ et al. Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of *Mycobacterium tuberculosis* isolates. *J Infect Dis* 1993;168:1219-24.
- (147) Agerton T, Valway S, Gore B, Pozsik C, Plikaytis B, Woodley C et al. Transmission of a highly drug-resistant strain (strain W1) of *Mycobacterium tuberculosis*. Community outbreak and nosocomial transmission via a contaminated bronchoscope. *JAMA* 1997;278:1073-77.
- (148) CDC. Bronchoscopy-related infections and pseudoinfections--New York, 1996 and 1998. *MMWR* 1999;48:557-60.
- (149) Leers WD. Disinfecting endoscopes: how not to transmit *Mycobacterium tuberculosis* by bronchoscopy. *Can Med Assoc J* 1980;123:275-80.
- (150) Michele TM, Cronin WA, Graham NM, Dwyer DM, Pope DS, Harrington S et al. Transmission of *Mycobacterium tuberculosis* by a fiberoptic bronchoscope. Identification by DNA fingerprinting. *JAMA* 1997;278:1093-95.
- (151) Nelson KE, Larson PA, Schraufnagel DE, Jackson J. Transmission of tuberculosis by flexible fiberbronchoscopes. *Am Rev Respir Dis* 1983;127:97-100.

- (152) Ramsey AH, Oemig TV, Davis JP, Massey JP, Torok TJ. An outbreak of bronchoscopy-related *Mycobacterium tuberculosis* infections due to lack of bronchoscope leak testing. *Chest* 2002;121:976-81.
- (153) Spach DH, Silverstein FE, Stamm WE. Transmission of infection by gastrointestinal endoscopy and bronchoscopy. *Ann Intern Med* 1993;118:117-28.
- (154) Gershon RR, Vlahov D, Escamilla-Cejudo JA, Badawi M, McDiarmid M, Karkashian C et al. Tuberculosis risk in funeral home employees. *J Occup Environ Med* 1998;40:497-503.
- (155) Lauzardo M, Lee P, Duncan H, Hale Y. Transmission of *Mycobacterium tuberculosis* to a funeral director during routine embalming. *Chest* 2001;119:640-642.
- (156) McKenna MT, Hutton M, Cauthen G, Onorato IM. The association between occupation and tuberculosis. A population-based survey. *Am J Respir Crit Care Med* 1996;154:587-93.
- (157) Sterling TR, Pope DS, Bishai WR, Harrington S, Gershon RR, Chaisson RE. Transmission of *Mycobacterium tuberculosis* from a cadaver to an embalmer. *N Engl J Med* 2000;342:246-48.
- (158) Sugita M, Tsutsumi Y, Suchi M, Kasuga H, Ishiko T. Pulmonary tuberculosis. An occupational hazard for pathologists and pathology technicians in Japan. *Acta Pathol Jpn* 1990;40:116-27.
- (159) Ussery XT, Bierman JA, Valway SE, Seitz TA, DiFerdinando GT, Jr., Ostroff SM. Transmission of multidrug-resistant *Mycobacterium tuberculosis* among persons exposed in a medical examiner's office, New York. *Infect Control Hosp Epidemiol* 1995;16:160-165.
- (160) American Conference of Governmental Industrial Hygienists. Industrial ventilation: a manual of recommended practice. 24 ed. Cincinnati: ACGIH; 2001.
- (161) CDC. Prevention and control of tuberculosis in correctional facilities. Recommendations of the Advisory Committee for Elimination of Tuberculosis. *MMWR* 1996;45:1-27.
- (162) McLaughlin SI, Spradling P, Drociuk D, Ridzon R, Pozsik CJ, Onorato I. Extensive transmission of *Mycobacterium tuberculosis* among congregated, HIV-infected prison inmates in South Carolina, United States. *Int J Tuberc Lung Dis* 2003;7:665-72.
- (163) Mohle-Boetani JC, Miguelino V, Dewsnup DH, Desmond E, Horowitz E, Waterman SH et al. Tuberculosis outbreak in a housing unit for human immunodeficiency virus-infected patients in a correctional facility: transmission risk factors and effective outbreak control. *Clin Infect Dis* 2002;34:668-76.
- (164) Valway SE, Richards SB, Kovacovich J, Greifinger RB, Crawford JT, Dooley SW. Outbreak of multi-drug-resistant tuberculosis in a New York State prison, 1991. *Am J Epidemiol* 1994;140:113-22.

- (165) Valway SE, Greifinger RB, Papania M, Kilburn JO, Woodley C, DiFerdinando GT et al. Multidrug-resistant tuberculosis in the New York State prison system, 1990-1991. *J Infect Dis* 1994;170:151-56.
- (166) Cone JE, Harrison R, Katz E, Chan J, Dewsnup D, Osorio AM. Tuberculosis transmission to prison employees during an outbreak among prisoners at two California prisons. *Journal of Healthcare Safety, Compliance & Infection Control* 2004;4:75-79.
- (167) Ijaz K, Yang Z, Templeton G, Stead WW, Bates JH, Cave MD. Persistence of a strain of *Mycobacterium tuberculosis* in a prison system. *Int J Tuberc Lung Dis* 2004;8:994-1000.
- (168) Steenland K, Levine AJ, Sieber K, Schulte P, Aziz D. Incidence of tuberculosis infection among New York State prison employees. *Am J Public Health* 1997;87:2012-14.
- (169) Reyes H, Coninx R. Pitfalls of tuberculosis programmes in prisons. *BMJ* 1997;315:1447-50.
- (170) Jones TF, Craig AS, Valway SE, Woodley CL, Schaffner W. Transmission of tuberculosis in a jail. *Ann Intern Med* 1999;131:557-63.
- (171) CDC. Tuberculosis outbreaks in prison housing units for HIV-infected inmates -- California 1995-1996. *MMWR* 1999;48:79-82.
- (172) Dueli RC, Madden RM. Droplet nuclei produced during dental treatment of tubercular patients. A preliminary study. *Oral Surg Oral Med Oral Pathol* 1970;30:711-16.
- (173) Naidoo S, Mahommed A. Knowledge, attitudes, behaviour and prevalence of TB infection among dentists in the western Cape. *SADJ* 2002;57:476-78.
- (174) Cleveland JL, Kent J, Gooch BF, Valway SE, Marianos DW, Butler WR et al. Multidrug-resistant *Mycobacterium tuberculosis* in an HIV dental clinic. *Infect Control Hosp Epidemiol* 1995;16:7-11.
- (175) Kohn WG, Harte JA, Malvitz DM, Collins AS, Cleveland JL, Eklund KJ et al. Guidelines for infection control in dental health care settings--2003. *Journal of the American Dental Association* 2004;135:33-47.
- (176) Kohn WG, Collins AS, Cleveland JL, Harte JA, Eklund KJ, Malvitz DM et al. Guidelines for infection control in dental health-care settings--2003. *MMWR* 2003;52:1-61.
- (177) Murthy BV, Pereira BJ. A 1990s perspective of hepatitis C, human immunodeficiency virus, and tuberculosis infections in dialysis patients. *Semin Nephrol* 1997;17:346-63.
- (178) Tokars JI, Miller B. Tuberculin skin testing of ESRD patients. *Am J Kidney Dis* 1997;30:456-57.
- (179) Ahmed AT, Karter AJ. Tuberculosis in California dialysis patients. *Int J Tuberc Lung Dis* 2004;8:341-45.

- (180) Simon TA, Paul S, Wartenberg D, Tokars JI. Tuberculosis in hemodialysis patients in New Jersey: a statewide study. *Infect Control Hosp Epidemiol* 1999;20:607-9.
- (181) Fang HC, Chou KJ, Chen CL, Lee PT, Chiou YH, Hung SY et al. Tuberculin skin test and anergy in dialysis patients of a tuberculosis-endemic area. *Nephron* 2002;91:682-87.
- (182) CDC. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. Centers for Disease Control and Prevention [erratum appears in *MMWR Morb Mortal Wkly Rep* 1997 Sep 19;46(37):880]. *MMWR* 1997;46:1-10.
- (183) CDC. Prevention and control of tuberculosis among homeless persons. Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1992;41:13-23.
- (184) CDC. Public health dispatch: Tuberculosis outbreak in a homeless population - Portland, Maine, 2002-2003. *MMWR* 2003;52:1184.
- (185) Asch S, Leake B, Knowles L, Gelberg L. Tuberculosis in homeless patients: potential for case finding in public emergency departments. *Ann Emerg Med* 1998;32:144-47.
- (186) Prezant DJ, Kelly KJ, Mineo FP, Janus D, Karwa ML, Futterman N et al. Tuberculin skin test conversion rates in New York City Emergency Medical Service health care workers. *Ann Emerg Med* 1998;32:208-13.
- (187) Seitz,TA, Decker,J, Jensen,PA. Health hazard evaluation report: University of Medicine and Dentistry of New Jersey, University Hospital, Newark, NJ. 7-1-1995.
- (188) Dickinson E. Exposures in EMS. An EMS medical director's 3-step plan to protect providers from TB exposure. *J Emerg Med Serv JEMS* 1999;24:S6-S7.
- (189) Ismeurt RL, Long CO. Tuberculosis: a new threat from an old nemesis. *Home Healthcare Nurse* 1993;11:16-23.
- (190) Stamp D, Arnold MS. Tuberculosis in home care. Complying with OSHA. *Caring* 1995;14:16-18.
- (191) Bentley DW. Tuberculosis in long-term care facilities. *Infect Control Hosp Epidemiol* 1990;11:42-46.
- (192) Malone JL, Ijaz K, Lambert L, Rosencrans L, Phillips L, Tomlinson V et al. Investigation of healthcare-associated transmission of *Mycobacterium tuberculosis* among patients with malignancies at three hospitals and at a residential facility. *Cancer* 2004;*In Press*.
- (193) Stead WW. Special problems in tuberculosis. Tuberculosis in the elderly and in residents of nursing homes, correctional facilities, long-term care hospitals, mental hospitals, shelters for the homeless, and jails. *Clin Chest Med* 1989;10:397-405.

- (194) Stead WW. Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. *Ann Intern Med* 1995;122:906-12.
- (195) Linder JF, Enders SR, Craig E, Richardson J, Meyers FJ. Hospice care for the incarcerated in the United States: an introduction. *Journal of Palliative Medicine* 2002;5:549-52.
- (196) McKeogh MM. Tuberculosis in the hospice--a cause for concern? *Palliative Medicine* 1997;11:469-74.
- (197) CDC. Mantoux tuberculin skin test - Training materials kit. DHHS, Public Health Service, CDC. Atlanta, GA, 2003.
- (198) Duboczy BO, Brown BT. Multiple readings and determination of maximal intensity of tuberculin reaction. *Am Rev Respir Dis* 1960;82:60-68.
- (199) Aventis Pasteur. Tuberculin purified protein derivative (Mantoux) Tubersol diagnostic antigen. Toronto, Ontario, Canada: 2001/Sept.
- (200) Parkdale Pharmaceuticals I. Aplisol (Tuberculin purified protein derivative, diluted [stabilized solution]) diagnostic antigen for intradermal injection only. Rochester, MI: 2002/May.
- (201) CDC. The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. *MMWR* 1996;45:1-18.
- (202) Huebner RE, Schein MF, Bass JB, Jr. The tuberculin skin test. *Clin Infect Dis* 1993;17:968-75.
- (203) Karalliedde S, Katugaha LP, Urugoda CG. Tuberculin response of Sri Lankan children after BCG vaccination at birth. *Tubercle* 1987;68:33-38.
- (204) Mazurek GH, LoBue PA, Daley CL, Bernardo J, Lardizabal AA, Bishai WR et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent *Mycobacterium tuberculosis* infection. *JAMA* 2001;286:1740-1747.
- (205) Menzies R, Vissandjee B. Effect of Bacille Calmette-Guerin vaccination on tuberculin reactivity. *Am Rev Respir Dis* 1992;145:621-25.
- (206) Snider DE, Jr. Bacille Calmette-Guerin vaccinations and tuberculin skin tests. *JAMA* 1985;253:3438-39.
- (207) Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER et al. Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. *JAMA* 2004;291:2086-91.
- (208) Dye C. A booster for tuberculosis vaccines. *JAMA* 2004;291:2127-28.

- (209) Fine PE, Carneiro IAM, Milstien JB, Clements CJ. Issues relating to the use of BCG in immunization programmes - A discussion document. Geneva: World Health Organization, Department of Vaccines and Biologicals; 1999.
- (210) CDC, American Thoracic Society (ATS). Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. *MMWR* 2003;52:735-39.
- (211) Senate and House of Representatives of the United States of America. Americans with Disabilities Act of 1990, Titles I and V. 1990 (42):12101-12213.
- (212) Widdowson MA, Bosman A, van Straten E, Tinga M, Chaves S, van Eerden L et al. Automated, laboratory-based system using the internet for disease outbreak detection, the Netherlands. *Emerging Infectious Diseases* 2003;9:1046-52.
- (213) OSHA. Recording and reporting occupational injuries and illnesses. Code of Federal Regulations, 2003. 29: 1904-
- (214) Aznar J, Safi H, Romero J, Alejo A, Gracia A, Palomares JC. Nosocomial transmission of tuberculosis infection in pediatrics wards. *Pediatr Infect Dis J* 1995;14:44-48.
- (215) Bauer J, Kok-Jensen A, Faurschou P, Thuesen J, Taudorf E, Andersen AB. A prospective evaluation of the clinical value of nation-wide DNA fingerprinting of tuberculosis isolates in Denmark. *Int J Tuberc Lung Dis* 2000;4:295-99.
- (216) Blazquez J, Espinosa de Los Monteros LE, Samper S, Martin C, Guerrero A, Cobo J et al. Genetic characterization of multidrug-resistant *Mycobacterium bovis* strains from a hospital outbreak involving human immunodeficiency virus-positive patients.[erratum appears in *J Clin Microbiol* 1998 Aug;36(8):2398]. *J Clin Microbiol* 1997;35:1390-1393.
- (217) Brown TJ, Tansel O, French GL. Simultaneous identification and typing of multi-drug-resistant *Mycobacterium tuberculosis* isolates by analysis of *pncA* and *rpoB*. *J Med Microbiol* 2000;49:651-56.
- (218) Cohn DL, O'Brien RJ. The use of restriction fragment length polymorphism (RFLP) analysis for epidemiological studies of tuberculosis in developing countries. *Int J Tuberc Lung Dis* 1998;2:16-26.
- (219) French AL, Welbel SF, Dietrich SE, Mosher LB, Breall PS, Paul WS et al. Use of DNA fingerprinting to assess tuberculosis infection control. *Ann Intern Med* 1998;129:856-61.
- (220) Garzelli C, Lari N, Nguon B, Falcone G. Evidence of nosocomial transmission of tuberculosis among AIDS patients by DNA fingerprinting. *New Microbiol* 1996;19:285-91.
- (221) Haas DW, Milton S, Kreiswirth BN, Brinsko VL, Bifani PJ, Schaffner W. Nosocomial transmission of a drug-sensitive W-variant *Mycobacterium tuberculosis* strain among

- patients with acquired immunodeficiency syndrome in Tennessee. *Infect Control Hosp Epidemiol* 1998;19:635-39.
- (222) Lambregts-van Weezenbeek CS, Keizer ST, Sebek MM, Schepp-Beelen JC, van der Loo CJ. Transmission of multiresistant tuberculosis in a Dutch hospital [Dutch]. *Ned Tijdschr Geneeskd* 1996;140:2293-95.
- (223) Lemaitre N, Sougakoff W, Truffot-Pernot C, Cambau E, Derenne JP, Bricaire F et al. Use of DNA fingerprinting for primary surveillance of nosocomial tuberculosis in a large urban hospital: detection of outbreaks in homeless people and migrant workers. *Int J Tuberc Lung Dis* 1998;2:390-396.
- (224) Moro ML, Gori A, Errante I, Infuso A, Franzetti F, Sodano L et al. An outbreak of multidrug-resistant tuberculosis involving HIV-infected patients of two hospitals in Milan, Italy. Italian Multidrug-Resistant Tuberculosis Outbreak Study Group. *AIDS* 1998;12:1095-102.
- (225) Moss AR, Alland D, Telzak E, Hewlett D, Jr., Sharp V, Chiliade P et al. A city-wide outbreak of a multiple-drug-resistant strain of *Mycobacterium tuberculosis* in New York. *Int J Tuberc Lung Dis* 1997;1:115-21.
- (226) Narvskaya O, Otten T, Limeschenko E, Sapozhnikova N, Graschenkova O, Steklova L et al. Nosocomial outbreak of multidrug-resistant tuberculosis caused by a strain of *Mycobacterium tuberculosis* W-Beijing family in St. Petersburg, Russia. *European Journal of Clinical Microbiology & Infectious Diseases* 2002;21:596-602.
- (227) Samper S, Martin C, Pinedo A, Rivero A, Blazquez J, Baquero F et al. Transmission between HIV-infected patients of multidrug-resistant tuberculosis caused by *Mycobacterium bovis*. *AIDS* 1997;11:1237-42.
- (228) van Soolingen D, Hermans PW. Epidemiology of tuberculosis by DNA fingerprinting. *Eur Respir J Suppl* 1995;20:649s-56s.
- (229) Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce dL, Daley CL et al. Transmission of *Mycobacterium tuberculosis* from patients smear-negative for acid-fast bacilli [erratum appears in *Lancet* 1999 May 15;353(9165):1714]. *Lancet* 1999;353:444-49.
- (230) CDC. Screening for tuberculosis and tuberculosis infection in high-risk populations. Recommendations of the Advisory Council for the Elimination of Tuberculosis. *MMWR* 1995;44:19-34.
- (231) Reichler MR, Etkind S, Taylor Z, Castro KG. Tuberculosis contact investigations. *Int J Tuberc Lung Dis* 2003;7:S325-S327.
- (232) Reichler MR, Reves R, Bur S, Thompson V, Mangura BT, Ford J et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. *JAMA* 2002;287:991-95.
- (233) NTCA, CDC. Guidelines for the Investigation of Contacts to Infectious Tuberculosis Cases. *MMWR* 2004;In preparation.

- (234) OSHA. Occupational Exposure to Tuberculosis; Proposed Rule. Federal Register 1997;62:54159-309.
- (235) OSHA. Occupational Exposure to Tuberculosis; Proposed Rule; Termination of Rulemaking Respiratory Protection for M. Tuberculosis; Final Rule; Revocation. Federal Register 2003;68:75767-75.
- (236) OSHA. Directive Number: CPL 2.106, Enforcement Procedures and Scheduling for Occupational Exposure to Tuberculosis. 1996. 1-131.
- (237) OSHA. Occupational Safety and Health Standards, Subpart I - Personal Protective Equipment. Code of Federal Regulations, 2003. 29: 1910.139, Respiratory Protection for *M. tuberculosis*-
- (238) OSHA. Occupational Safety and Health Standards, Subpart I - Personal Protective Equipment. Code of Federal Regulations, 2003. 29: 1910.134, Respiratory Protection-
- (239) CDC. Protect yourself against tuberculosis: a respiratory protection guide for health care workers. DHHS, Public Health Service, CDC. Cincinnati, OH, 1996. DHHS (NIOSH) Publication Number 96-102.
- (240) CDC. Guide to the selection and use of particulate respirators certified under 42 CFR 84. DHHS, Public Health Service, CDC. Cincinnati, OH, 1996. DHHS (NIOSH) Publication Number 96-101.
- (241) CDC. TB respiratory protection program in health care facilities: administrator's guide. DHHS, Public Health Service, CDC. Morgantown, WV, 1999. DHHS (NIOSH) Publication Number 99-143.
- (242) American National Standards Institute. American national standard practices for respiratory protection. New York: ANSI; 1992/Aug./6.
- (243) CDC. Guide to industrial respiratory protection. DHHS, Public Health Service, CDC. Morgantown, WV, 9-1-1987. DHHS (NIOSH) Publication Number 87-116.
- (244) Food and Drug Administration (FDA). Surgical masks - Premarket notification [510(k)] submissions; Guidance for Industry and FDA. 5-15-2003. 1-17.
- (245) Campbell DL, Coffey CC, Lenhart SW. Respiratory protection as a function of respirator fitting characteristics and fit-test accuracy. American Industrial Hygiene Association Journal 2001;62:36-44.
- (246) Coffey CC, Lawrence RB, Campbell DL, Zhuang Z, Calvert CA, Jensen PA. Fitting characteristics of eighteen N95 filtering-facepiece respirators. JOEH 2004;1:262-71.
- (247) Nicas M, Neuhaus J. Variability in respiratory protection and the assigned protection factor. JOEH 2004;1:99-109.
- (248) Martyny J, Glazier C, Newman L. Current concepts: Respiratory protection. N Engl J Med 2002;347:824-30.

- (249) CDC. Laboratory performance evaluation of N95 filtering facepiece respirators, 1996. *MMWR* 1998;47:1045-49.
- (250) Coffey CC, Lawrence RB, Zhuang Z, Campbell DL, Jensen PA, Myers WR. Comparison of five methods for fit-testing N95 filtering-facepiece respirators. *Applied Occupational and Environmental Hygiene* 2002;17:723-30.
- (251) Lee K, Slavvec A, Nicas M. Respiratory protection against *Mycobacterium tuberculosis*: Quantitative fit test outcomes for five type N95 filtering-facepiece respirators. *JOEH* 2004;1:22-28.
- (252) Raad I, Hanna H, Osting C, Hachem R, Umphrey J, Tarrand J et al. Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction. *Infect Control Hosp Epidemiol* 2002;23:41-43.
- (253) Lenhart SW, Seitz T, Trout D, Bollinger N. Issues affecting respirator selection for workers exposed to infectious aerosols: Emphasis on healthcare settings. *Applied Biosafety* 2004;9:20-36.
- (254) McWilliams T, Wells AU, Harrison AC, Lindstrom S, Cameron RJ, Foskin E. Induced sputum and bronchoscopy in the diagnosis of pulmonary tuberculosis. *Thorax* 2002;57:1010-1014.
- (255) Riley RL, Mills CC, O'Grady F, Sultan LU, Wittstadt F, Shivpuri DN. Infectiousness of air from a tuberculosis ward. *Am Rev Respir Dis* 1962;85:511-25.
- (256) Noble RC. Infectiousness of pulmonary tuberculosis after starting chemotherapy: review of the available data on an unresolved question. *American Journal of Infection Control* 1981;9:6-10.
- (257) Coronado VG, Beck-Sague CM, Hutton MD, Davis BJ, Nicholas P, Villareal C et al. Transmission of multidrug-resistant *Mycobacterium tuberculosis* among persons with human immunodeficiency virus infection in an urban hospital: epidemiologic and restriction fragment length polymorphism analysis. *J Infect Dis* 1993;168:1052-55.
- (258) Long R, Zielinski M, Kunitomo D, Manfreda J. The emergency department is a determinant point of contact of tuberculosis patients prior to diagnosis. *Int J Tuberc Lung Dis* 2002;6:332-39.
- (259) Luby S, Carmichael S, Shaw G, Horan J, Gamble W, Jr., Jones J. A nosocomial outbreak of *Mycobacterium tuberculosis*. *Journal of Family Practice* 1994;39:21-25.
- (260) Nivin B, Nicholas P, Gayer M, Frieden TR, Fujiwara PI. A continuing outbreak of multidrug-resistant tuberculosis, with transmission in a hospital nursery. *Clin Infect Dis* 1998;26:303-7.
- (261) Mastorides SM, Oehler RL, Greene JN, Sinnott JT, Kranik M, Sandin RL. The detection of airborne *Mycobacterium tuberculosis* using micropore membrane air sampling and polymerase chain reaction. *Chest* 1999;115:19-25.

- (262) Sultan L, Nyka W, Mills C, O'Grady F, Wells W, Riley RL. Tuberculosis disseminators: A study of the variability of aerial infectivity of tuberculosis patients. *Am Rev Respir Dis* 1960;82:358-69.
- (263) Fennelly KP, Martyny JW, Fulton KE, Orme IM, Cave DM, Heifets LB. Cough-generated aerosols of *Mycobacterium tuberculosis*: a new method to study infectiousness. *Am J Respir Crit Care Med* 2004;169:604-9.
- (264) Keijman J, Tjhie J, Olde DS, Alink M. Unusual nosocomial transmission of *Mycobacterium tuberculosis*. *European Journal of Clinical Microbiology & Infectious Diseases* 2001;20:808-9.
- (265) Munoz FM, Ong LT, Seavy D, Medina D, Correa A, Starke JR. Tuberculosis among adult visitors of children with suspected tuberculosis and employees at a children's hospital. *Infect Control Hosp Epidemiol* 2002;23:568-72.
- (266) Ijaz K, Castro KG. Pediatric tuberculosis: all in the family? *Infect Control Hosp Epidemiol* 2002;23:562-63.
- (267) Wallgren A. On contagiousness of childhood tuberculosis. *Acta Pediatr Scand* 1937;22:229-34.
- (268) CDC. Tuberculosis outbreak in a community hospital--District of Columbia, 2002. *MMWR* 2004;53:214-16.
- (269) Garcia-Garcia ML, Valdespino-Gomez JL, Garcia-Sancho C, Mayar-Maya ME, Palacios-Martinez M, Balandrano-Campos S et al. Underestimation of *Mycobacterium tuberculosis* infection in HIV-infected subjects using reactivity to tuberculin and anergy panel. *Int J Epidemiol* 2000;29:369-75.
- (270) Ridzon R, Kenyon T, Luskin-Hawk R, Schultz C, Valway S, Onorato IM. Nosocomial transmission of human immunodeficiency virus and subsequent transmission of multidrug-resistant tuberculosis in a healthcare worker. *Infect Control Hosp Epidemiol* 1997;18:422-23.
- (271) Snider DE, Jr., Kelly GD, Cauthen GM, Thompson NJ, Kilburn JO. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. *Am Rev Respir Dis* 1985;132:125-32.
- (272) Schaaf HS, Shean K, Donald PR. Culture confirmed multidrug resistant tuberculosis: diagnostic delay, clinical features, and outcome. *Arch Dis Child* 2003;88:1106-11.
- (273) Cauthen GM, Dooley SW, Onorato IM, Ihle WW, Burr JM, Bigler WJ et al. Transmission of *Mycobacterium tuberculosis* from tuberculosis patients with HIV infection or AIDS. *Am J Epidemiol* 1996;144:69-77.
- (274) Espinal MA, Perez EN, Baez J, Henriquez L, Fernandez K, Lopez M et al. Infectiousness of *Mycobacterium tuberculosis* in HIV-1-infected patients with tuberculosis: a prospective study. *Lancet* 2000;355:275-80.

- (275) Klausner JD, Ryder RW, Baende E, Lelo U, Williame JC, Ngamboli K et al. Mycobacterium tuberculosis in household contacts of human immunodeficiency virus type 1-seropositive patients with active pulmonary tuberculosis in Kinshasa, Zaire [erratum appears in J Infect Dis 1993 Sep;168(3):802]. J Infect Dis 1993;168:106-11.
- (276) Nunn P, Mungai M, Nyamwaya J, Gicheha C, Brindle RJ, Dunn DT et al. The effect of human immunodeficiency virus type-1 on the infectiousness of tuberculosis. Tubercle & Lung Disease 1994;75:25-32.
- (277) Selwyn PA, Hartel D, Lewis VA, Schoenbaum EE, Vermund SH, Klein RS et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989;320:545-50.
- (278) Rose DN, Schechter CB, Adler JJ. Interpretation of the tuberculin skin test. J Gen Intern Med 1995;10:635-42.
- (279) Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J Respir Crit Care Med 1999;159:15-21.
- (280) CDC. Mantoux Tuberculin Skin Test (poster). DHHS, Public Health Service, CDC. Atlanta, GA, 2004.
- (281) Joseph H, Shrestha-Kuwahara R, Lowry D, Lambert LA, Panlilio AL, Raucher BG et al. Factors influencing health-care workers' adherence to worksite tuberculosis screening and treatment policies. American Journal of Infection Control 2004;In press.
- (282) Mantoux C. Intradermo-réaction de la tuberculine. Comptes rendus de l'Académie des sciences 1908;147:355-57.
- (283) Mendel F. Zur endovenösen applikation der medikamente. Therapeutische Monatshefte 1903;17:177-93.
- (284) Mendel F. Die von Pirquet'sche Hautreaktion und die intravenöse Tuberkulinbehandlung. Medizinische Klinik 1908;4:402-4.
- (285) Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee. Society for Healthcare Epidemiology of America. Association for Professionals in Infection Control. Infectious Diseases Society of America. Hand Hygiene Task Force. Guideline for Hand Hygiene in Health-Care Settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol 2002;23:Suppl-40.
- (286) CDC. National Health and Nutrition Examination Survey (NHANES): Tuberculosis skin test procedures manual. Atlanta: DHHS, Public Health Service, CDC.; 2000/Apr./1.
- (287) OSHA. Occupational Safety and Health Standards - Subpart Z - Toxic and Hazardous Substances. Code of Federal Regulations, 2003. 29: 1910.1030, Bloodborne Pathogens-

- (288) Sokal JE. Editorial; Measurement of delayed skin-test responses. *N Engl J Med* 1975;293:501-2.
- (289) Lee E, Holzman RS. Evolution and current use of the tuberculin test. *Clin Infect Dis* 2002;34:365-70.
- (290) Snider DE, Jr. The tuberculin skin test. *Am Rev Respir Dis* 1982;125:108-18.
- (291) Potter PA, Perry AG. *Fundamentals of nursing*. 5th ed. St. Louis, MO: Mosby, Inc.; 2001.
- (292) NTCA, NTNCC. *TB Nursing: A Comprehensive Guide to Patient Care*. 1997.
- (293) Canessa PA, Fasano L, Lavecchia MA, Torraca A, Schiattone ML. Tuberculin skin test in asymptomatic HIV seropositive carriers. *Chest* 1989;96:1215-16.
- (294) CDC. Purified Protein Derivative (PPD) - Tuberculin anergy and HIV infection: Guidelines for anergy testing and management of anergic persons at risk of tuberculosis. *MMWR* 1991;40:27-33.
- (295) Huebner RE, Schein MF, Hall CA, Barnes SA. Delayed-type hypersensitivity anergy in human immunodeficiency virus-infected persons screened for infection with *Mycobacterium tuberculosis*. *Clin Infect Dis* 1994;19:26-32.
- (296) Atkinson WL, Pickering LK, Schwartz B, Weniger BG, Iskander JK, Watson JC et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). *MMWR* 2002;51:1-35.
- (297) Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. *Am J Respir Crit Care Med* 1998;158:157-61.
- (298) Snider D. Pregnancy and tuberculosis. *Chest* 1984;86:10S-3S.
- (299) Sepkowitz KA, Feldman J, Louther J, Rivera P, Villa N, DeHovitz J. Benefit of two-step PPD testing of new employees at a New York City hospital. *American Journal of Infection Control* 1997;25:283-86.
- (300) Thompson NJ, Glassroth JL, Snider DE, Jr., Farer LS. The booster phenomenon in serial tuberculin testing. *Am Rev Respir Dis* 1979;119:587-97.
- (301) Cauthen GM, Snider DE, Jr., Onorato IM. Boosting of tuberculin sensitivity among Southeast Asian refugees. *Am J Respir Crit Care Med* 1994;149:1597-600.
- (302) Moreno S, Blazquez R, Novoa A, Carpena I, Menasalvas A, Ramirez C et al. The effect of BCG vaccination on tuberculin reactivity and the booster effect among hospital employees. *Arch Intern Med* 2001;161:1760-1765.
- (303) Slutkin G, Perez-Stable EJ, Hopewell PC. Time course and boosting of tuberculin reactions in nursing home residents. *Am Rev Respir Dis* 1986;134:1048-51.

- (304) Froeschle JE, Ruben FL, Bloh AM. Immediate hypersensitivity reactions after use of tuberculin skin testing. *Clin Infect Dis* 2002;34:E12-3.
- (305) Menzies D. What does tuberculin reactivity after bacille Calmette-Guerin vaccination tell us? *Clin Infect Dis* 2000;31 Suppl 3:S71-S74.
- (306) Villarino ME, Burman W, Wang YC, Lundergan L, Catanzaro A, Bock N et al. Comparable specificity of 2 commercial tuberculin reagents in persons at low risk for tuberculous infection. *JAMA* 1999;281:169-71.
- (307) Blumberg HM, White N, Parrott P, Gordon W, Hunter M, Ray S. False-positive tuberculin skin test results among health care workers. *JAMA* 2000;283:2793.
- (308) Greenberg SD, Frager D, Suster B, Walker S, Stavropoulos C, Rothpearl A. Active pulmonary tuberculosis in patients with AIDS: spectrum of radiographic findings (including a normal appearance). *Radiology* 1994;193:115-19.
- (309) Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med* 1999;340:367-73.
- (310) Jones BE, Ryu R, Yang Z, Cave MD, Pogoda JM, O'taya M et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. *Am J Respir Crit Care Med* 1997;156:1270-1273.
- (311) Tattevin P, Casalino E, Fleury L, Egmann G, Ruel M, Bouvet E. The validity of medical history, classic symptoms, and chest radiographs in predicting pulmonary tuberculosis: derivation of a pulmonary tuberculosis prediction model. *Chest* 1999;115:1248-53.
- (312) Chintu C, Mwaba P. Is there a role for chest radiography in identification of asymptomatic tuberculosis in HIV-infected people? *Lancet* 2003;362:1516.
- (313) Mosimaneotsile B, Talbot EA, Moeti TL, Hone NM, Moalosi G, Moffat HJ et al. Value of chest radiography in a tuberculosis prevention programme for HIV-infected people, Botswana. *Lancet* 2003;362:1551-52.
- (314) Siddiqui AH, Perl TM, Conlon M, Donegan N, Roghmann MC. Preventing nosocomial transmission of pulmonary tuberculosis: when may isolation be discontinued for patients with suspected tuberculosis? *Infect Control Hosp Epidemiol* 2002;23:141-44.
- (315) CDC. Performance evaluation programs for determining HIV-1 viral loads, testing for HIV p24 antigen, and identifying *Mycobacterium tuberculosis* using nucleic acid amplification tests. *MMWR* 1997;46:155-56.
- (316) Burnens AP, Vurma-Rapp U. Mixed mycobacterial cultures--occurrence in the clinical laboratory. *Int J Med Microbiol* 1989;271:85-90.
- (317) Malasky C, Jordan T, Potulski F, Reichman LB. Occupational tuberculous infections among pulmonary physicians in training. *Am Rev Respir Dis* 1990;142:505-7.

- (318) Makkar H, Mallampalli A, Matthew M, Gavino C, Stager C, Wanger A. Improved yield of *Mycobacterium tuberculosis* with sputum induction in addition to three expectorated sputa. *Am J Respir Crit Care Med* 2000;161:A298.
- (319) Shata AM, Coulter JB, Parry CM, Ching'ani G, Broadhead RL, Hart CA. Sputum induction for the diagnosis of tuberculosis. *Arch Dis Child* 1996;74:535-37.
- (320) Yajko DM, Nassos PS, Sanders CA, Madej JJ, Hadley WK. High predictive value of the acid-fast smear for *Mycobacterium tuberculosis* despite the high prevalence of *Mycobacterium avium* complex in respiratory specimens. *Clin Infect Dis* 1994;19:334-36.
- (321) Anderson C, Inhaber N, Menzies D. Comparison of sputum induction with fiber-optic bronchoscopy in the diagnosis of tuberculosis. *Am J Respir Crit Care Med* 1995;152:1570-1574.
- (322) Carr DT, Karlson AG, Stilwell GG. A comparison of cultures of induced sputum and gastric washings in the diagnosis of tuberculosis. *Mayo Clin Proc* 1967;42:23-25.
- (323) Hensler NM, Spivey CG, Dees TM. The use of hypertonic aerosol in production of sputum for diagnosis of tuberculosis: Comparison with gastric specimens. *Dis Chest* 1961;40:639-42.
- (324) Institute of Medicine (IOM). Ending Neglect: the elimination of tuberculosis in the United States. Washington, DC: National Academy Press; 2000.
- (325) Khilnani GC. Tuberculosis and pregnancy. *Indian Journal of Chest Diseases & Allied Sciences* 2004;46:105-11.
- (326) CDC, American Thoracic Society (ATS). Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001. *MMWR* 2001;50:733-35.
- (327) CDC. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. *MMWR* 2001;50:289-91.
- (328) CDC. Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. *MMWR* 2002;51:998-99.
- (329) Guld J. Response to BCG vaccination. In: Edwards LB, Palmer CE, Magnus K, eds. *Studies at WHO Tuberculosis Research Office*. Geneva: World Health Organization; 1953: 51-6.
- (330) Menzies RI. Tuberculin skin testing. In: Reichman LB, Hershfield ES, eds. *Tuberculosis: A comprehensive international approach*. 2 ed. New York: Marcel Dekker; 2000: 279-322.
- (331) Triep WA. De tuberculinereactie [Dutch]. The Hague, Netherlands: Royal Netherlands Tuberculosis Association (KNCV); 1957.

- (332) Youmans GP. Tuberculosis. Philadelphia: W.B. Sanders Company; 1979.
- (333) Iseman MD, Madsen LA. Drug-resistant tuberculosis. Clin Chest Med 1989;10:341-53.
- (334) Iseman MD. Treatment of multidrug-resistant tuberculosis [erratum appears in N Engl J Med 1993 Nov 4;329(19):1435]. N Engl J Med 1993;329:784-91.
- (335) CDC. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens. MMWR 2002;51:214-15.
- (336) Goble M. Drug-resistant tuberculosis. Semin Respir Infect 1986;1:220-229.
- (337) Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
- (338) Simone PM, Iseman MD. Drug-resistant tuberculosis: a deadly and growing danger. J Respir Dis 1992;13:960-971.
- (339) CDC. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis [erratum appears in MMWR Morb Mortal Wkly Rep 1993 Jul 26;42(27):536]. MMWR 1993;42:1-8.
- (340) American Society of Heating Refrigeration and Air-Conditioning Engineers. Health care facilities. 1999 ASHRAE Handbook: HVAC applications. Atlanta: ASHRAE; 2003: 7.1-7.13.
- (341) Mutchler JE. Principles of ventilation. The industrial environment - its evaluation and control. Washington, D.C.: DHHS, Public Health Service, CDC, NIOSH.; 1973: 573-82.
- (342) Riley RL, Knight M, Middlebrook G. Ultraviolet susceptibility of BCG and virulent tubercle bacilli. Am Rev Respir Dis 1976;113:413-18.
- (343) Riley RL, Nardell EA. Clearing the air. The theory and application of ultraviolet air disinfection. Am Rev Respir Dis 1989;139:1286-94.
- (344) American National Standards Institute, American Society of Heating RaA-CE. ANSI/ASHRAE Standard 62-2001 - Ventilation for acceptable indoor air quality. Atlanta: ASHRAE; 2001.
- (345) American National Standards Institute, American Society of Heating RaA-CE. ANSI/ASHRAE Addenda 62i,t,u,v,ab-2002 - Ventilation for acceptable indoor air quality. Atlanta: ASHRAE; 2002.
- (346) Hayden,CS, Fischbach,TJ, Johnston,OE, Hughes,RT, Jensen,PA. A model for calculating leakage areas into negative pressure isolation rooms. 1996.

- (347) Rice N, Streifel A, Vesley D. An evaluation of hospital special-ventilation-room pressures. *Infect Control Hosp Epidemiol* 2001;22:19-23.
- (348) Streifel AJ, Marshall JW. Parameters for ventilation controlled environments in hospitals. In: Moschandreas DJ, ed. *Design, construction and operation of healthy buildings. Solutions to global and regional concerns*. Atlanta: American Society of Heating, Refrigeration, and Air-Conditioning Engineers Press.; 1998: 305-9.
- (349) DeLuga GF. Designing laboratory ventilation. In: Richmond JY, ed. *Designing a modern microbiological/biomedical laboratory: lab design process & technology*. Washington, DC: American Public Health Association; 1997: 234.
- (350) Jensen PA, Hayden CS, Burroughs E, Hughes RT. Assessment of the health hazard associated with the use of smoke tubes in healthcare facilities. *Applied Occupational and Environmental Hygiene* 1998;13:172-76.
- (351) Pavelchak N, DePersis RP, London M, Stricof R, Oxtoby M, DiFerdinando G, Jr. et al. Identification of factors that disrupt negative air pressurization of respiratory isolation rooms. *Infect Control Hosp Epidemiol* 2000;21:191-95.
- (352) Hayden CS, Jensen PA. Positive advice on negative pressure for TB isolation rooms. *Health Facilities Management* 1997;10:43-45.
- (353) Hayden CS, Johnston OE, Hughes RT, Jensen PA. Air volume migration from negative pressure isolation rooms during entry/exit. *Applied Occupational and Environmental Hygiene* 1998;13:518-27.
- (354) American Society of Heating Refrigeration and Air-Conditioning Engineers. *Airflow around buildings*. 2001 ASHRAE Handbook: Fundamentals. Atlanta: ASHRAE; 2001: 16.1-16.12.
- (355) CDC. Hazard evaluation and technical assistance report: Onondaga County Medical Examiner's Office, Syracuse, New York. DHHS, Public Health Service, CDC. Cincinnati, OH, 1992. HETA 92-0171-2255.
- (356) CDC. Health hazard evaluations: Tuberculosis 1990-1999. DHHS, Public Health Service, CDC. Cincinnati, OH, 1-1-2001. DHHS(NIOSH) Publication No. 2001-116.
- (357) Esterhai JL, Jr., Reynolds MR, Chou L. Hazards to the orthopaedic trauma surgeon: occupational exposure to tuberculosis. Risk reduction, testing, and treatment. *J Orthop Trauma* 1996;10:366-70.
- (358) Opal SM, Asp AA, Cannady PB, Jr., Morse PL, Burton LJ, Hammer PG. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. *J Infect Dis* 1986;153:634-37.
- (359) Rhame FS, Streifel AJ, Kersey JH, Jr., McGlave PB. Extrinsic risk factors for pneumonia in the patient at high risk of infection. *Am J Med* 1984;76:42-52.

- (360) Sherertz RJ, Belani A, Kramer BS, Elfenbein GJ, Weiner RS, Sullivan ML et al. Impact of air filtration on nosocomial *Aspergillus* infections. Unique risk of bone marrow transplant recipients. *Am J Med* 1987;83:709-18.
- (361) Rippon JW, Gerhold R, Heath M. Thermophilic and thermotolerant fungi isolated from the thermal effluent of nuclear power generating reactors: dispersal of human opportunistic and veterinary pathogenic fungi. *Mycopathologia* 1980;70:169-79.
- (362) Brown RC. Air Filtration An Integrated Approach to the Theory and Applications of Fibrous Filters. 1st ed. Tarrytown, New York : Pergamon Press; 1993.
- (363) Woods JE. Cost avoidance and productivity in owning and operating buildings. *Occupational Medicine* 1989;4:753-70.
- (364) Cheng YS, Lu JC, Chen TR. Efficiency of a portable indoor air cleaner in removing pollens and fungal spores. *Aerosol Science and Technology* 1998;29:92-101.
- (365) ECRI. TB engineering controls: mobile high-efficiency-filter air cleaners. *Health Devices* 1995;24:368-418.
- (366) Marier RL, Nelson T. A ventilation-filtration unit for respiratory isolation. *Infect Control Hosp Epidemiol* 1993;14:700-705.
- (367) Miller-Leiden S, Lobascio C, Nazaroff WW, Macher JM. Effectiveness of in-room air filtration and dilution ventilation for tuberculosis infection control. *Journal of the Air & Waste Management Association* 1996;46:869-82.
- (368) Miller,SL, Hernandez,M. Evaluating portable air cleaner removal efficiencies for bioaerosols, NIOSH contract report PO-36755-R-00077B5D. 5-22-2002. 1-26.
- (369) Rutala WA, Jones SM, Worthington JM, Reist PC, Weber DJ. Efficacy of portable filtration units in reducing aerosolized particles in the size range of *Mycobacterium tuberculosis*. *Infect Control Hosp Epidemiol* 1995;16:391-98.
- (370) Woods JE, Rask DR. Heating, ventilation, air-conditioning systems: the engineering approach to methods of control. In: Kundsinn RB, ed. *Architectural design and indoor microbial pollution*. New York: Oxford University Press; 1988: 123-53.
- (371) American Society of Heating Refrigeration and Air-Conditioning Engineers. Air cleaners for particulate contaminants. 2004 ASHRAE Handbook: HVAC systems and equipment. Atlanta: ASHRAE; 2004: 24.1-24.13.
- (372) NSF. Class II (laminar flow) biohazard cabinetry - NSF/ANSI Standard 49-2002. National Sanitation Foundation International. Ann Arbor, MI, 2001.
- (373) Ko G, Burge HA, Muilenberg M, Rudnick S, First M. Survival of mycobacteria on HEPA filter material. *J Amer Biological Safety Association* 1998;3:65-78.
- (374) Qian Y, Willeke K, Grinshpun SA, Donnelly J. Performance of N95 respirators: reaerosolization of bacteria and solid particles. *American Industrial Hygiene Association Journal* 1997;58:876-80.

- (375) Reponen TA, Wang Z, Willeke K, Grinshpun SA. Survival of mycobacteria on N95 personal respirators. *Infect Control Hosp Epidemiol* 1999;20:237-41.
- (376) Rutala WA, Cole EC, Wannamaker NS, Weber DJ. Inactivation of *Mycobacterium tuberculosis* and *Mycobacterium bovis* by 14 hospital disinfectants. *Am J Med* 1991;91:267S-71S.
- (377) Commission Internationale de l'Eclairage, International Commission on Illumination CIE. International lighting vocabulary. Bureau Central de la Commission Electrotechnique Internationale. Geneva, 1987.
- (378) Illuminating Engineering Society of North America (IESNA). The IESNA Lighting Handbook - Reference and Application. 9 ed. New York: IESNA; 2000.
- (379) Riley RL, Wells WF, Mills CC, Nyka W, McLean RL. Air hygiene in tuberculosis: quantitative studies of infectivity and control in a pilot ward. *Am Rev Tuberc* 1957;75:420-431.
- (380) Riley RL. Ultraviolet air disinfection for control of respiratory contagion. In: Kundsinn RB, ed. Architectural design and indoor microbial pollution. New York.: Oxford University Press.; 1988: 175-97.
- (381) Stead WW. Clearing the air: the theory and application of ultraviolet air disinfection. *Am Rev Respir Dis* 1989;140:1832.
- (382) Xu,P. Ultraviolet germicidal irradiation for preventing infectious disease transmission. University of Colorado, Department of Civil, Environmental, and Architectural Engineering, 2001.
- (383) Xu P, Peccia J, Fabian P, Martyny JW, Fennelly KP, Hernandez M et al. Efficacy of ultraviolet germicidal irradiation of upper-room air in inactivating airborne bacterial spores and mycobacteria in full-scale studies. *Atmospheric Environment* 2003;37:405-19.
- (384) McLean RL. General discussion: the mechanism of spread of Asian influenza. *Am Rev Respir Dis* 1961;83:29-40.
- (385) Willmon TL, Hollaender A, Langmuir AD. Studies of the control of acute respiratory diseases among naval recruits. I. A review of a four -year experience with ultraviolet irradiation and dust suppressive measures, 1943 to 1947. *American Journal of Hygiene* 1948;48:227-32.
- (386) Perkins JE, Bahlke AM, Silverman HF. Effect of ultra-violet irradiation of classrooms on spread of measles in large rural central schools. *Am J Public Health* 1947;37:529-37.
- (387) Wells WF, Wells MW, Wilder TS. The environmental control of epidemic contagion: I. An epidemiologic study of radiant disinfection of air in day schools. *American Journal of Hygiene* 1942;35:97-121.

- (388) Wells WF, Holla WA. Ventilation in the flow of measles and chickenpox through a community: progress report, January 1, 1946 to June 15, 1949 - Airborne Infection Study, Westchester County Department of Health. JAMA 1950;142:1337-44.
- (389) Collins FM. Relative susceptibility of acid-fast and non-acid-fast bacteria to ultraviolet light. Appl Microbiol 1971;21:411-13.
- (390) David HL, Jones WD, Jr., Newman CM. Ultraviolet light inactivation and photoreactivation in the mycobacteria. Infect Immun 1971;4:318-19.
- (391) David HL. Response of Mycobacteria to ultraviolet light radiation. Am Rev Respir Dis 1973;108:1175-85.
- (392) Lurie MB. Resistance to tuberculosis: experimental studies in native and acquired defensive mechanisms. Cambridge, MA.: Harvard University Press.; 1964.
- (393) NTRDA. Guidelines for the general hospital in the admission and care of tuberculous patients. Am Rev Respir Dis 1969;631-33.
- (394) Schieffelbein CW, Jr., Snider DE, Jr. Tuberculosis control among homeless populations. Arch Intern Med 1988;148:1843-46.
- (395) First MW, Nardell EA, Chaisson RE, Riley R. Guidelines for the application of upper-room ultraviolet germicidal irradiation for preventing transmission of airborne contagion - Part 1: basic principles. ASHRAE Transactions: Symposia 1999;105:869-76.
- (396) First MW, Nardell EA, Chaisson RE, Riley R. Guidelines for the application of upper-room ultraviolet germicidal irradiation for preventing transmission of airborne contagion - Part 2: design and operation guidance. ASHRAE Transactions: Symposia 1999;105:877-87.
- (397) Miller SL, Macher JM. Evaluation of a methodology for quantifying the effect of room air ultraviolet germicidal irradiation on airborne bacteria. Aerosol Science and Technology 2000;33:274-95.
- (398) Kowalski WJ, Bahnfleth WP. UVGI design basics. HPAC - Heating/Piping/Air Conditioning 2000;100-110.
- (399) Green CF, Scarpino PV. The use of ultraviolet germicidal irradiation (UVGI) in disinfection of airborne bacteria. Environ Eng Policy 2003;3:101-7.
- (400) Riley RL, Permutt S, Kaufman JE. Convection, air mixing, and ultraviolet air disinfection in rooms. Archives of Environmental Health 1971;22:200-207.
- (401) Riley RL, Permutt S, Kaufman JE. Room air disinfection by ultraviolet irradiation of upper air. Further analysis of convective air exchange. Archives of Environmental Health 1971;23:35-39.

- (402) Riley RL, Permutt S. Room air disinfection by ultraviolet irradiation of upper air. Air mixing and germicidal effectiveness. Archives of Environmental Health 1971;22:208-19.
- (403) Riley RL, Kaufman JE. Air disinfection in corridors by upper air irradiation with ultraviolet. Archives of Environmental Health 1971;22:551-53.
- (404) Ko G, First MW, Burge HA. The characterization of upper-room ultraviolet germicidal irradiation in inactivating airborne microorganisms. Environmental Health Perspectives 2002;110:95-101.
- (405) Xu, P, Peccia, J., Hernandez, M., and Miller, S. The efficacy of upper room ultraviolet germicidal irradiation in inactivating airborne microorganisms under incomplete mixing conditions. Raleigh, NC, 2000. Proceedings of Engineering Solutions to Indoor Air Quality Problems. July 17-19.
- (406) Memarzadeh F, Jiang J. Methodology for minimizing risk from airborne organisms in hospital isolation rooms. ASHRAE Transactions 2000;733-49.
- (407) Ko G, First MW, Burge HA. Influence of relative humidity on particle size and UV sensitivity of *Serratia marcescens* and *Mycobacterium bovis* BCG aerosols. Tubercle & Lung Disease 2000;80:217-28.
- (408) Peccia J, Holly MW, Miller S, Hernandez M. Effects of relative humidity on the ultraviolet induced inactivation of airborne bacteria. Aerosol Science and Technology 2001;35:728-40.
- (409) Riley RL, O'Grady F. Airborne infection: transmission and control. New York: McMillan; 1961.
- (410) Riley RL, Kaufman JE. Effect of relative humidity on the inactivation of airborne *Serratia marcescens* by ultraviolet radiation. Appl Microbiol 1972;23:1113-20.
- (411) American National Standards Institute, American Society of Heating RaA-CE. Standard 55 - Thermal environmental conditions for human occupancy. Atlanta: ASHRAE; 1992.
- (412) American National Standards Institute, American Society of Heating RaA-CE. Standard 55a - Addendum to Thermal environmental conditions for human occupancy. Atlanta: ASHRAE; 1995.
- (413) Kethley TW, Branch K. Ultraviolet lamps for room air disinfection. Effect of sampling location and particle size of bacterial aerosol. Archives of Environmental Health 1972;25:205-14.
- (414) National Institute for Occupational Safety and Health. Criteria for a recommended standard: Occupational exposure to ultraviolet radiation. Atlanta: DHEW, Public Health Service, HSMHA; 1972.

- (415) International Agency for Research on Cancer (IARC). IARC monographs on the evaluation of carcinogenic risks to humans: solar and ultraviolet radiation. World Health Organization. Lyon, France, 1992.
- (416) Clerici M, Shearer GM. UV light exposure and HIV replication. *Science* 1992;258:1070-1071.
- (417) Stein B, Rahmsdorf HJ, Steffen A, Litfin M, Herrlich P. UV-induced DNA damage is an intermediate step in UV-induced expression of human immunodeficiency virus type 1, collagenase, c-fos, and metallothionein. *Molecular & Cellular Biology* 1989;9:5169-81.
- (418) Valerie K, Delers A, Bruck C, Thiriart C, Rosenberg H, Debouck C et al. Activation of human immunodeficiency virus type 1 by DNA damage in human cells. *Nature* 1988;333:78-81.
- (419) Valerie K, Rosenberg M. Chromatin structure implicated in activation of HIV-1 gene expression by ultraviolet light. *New Biologist* 1990;2:712-18.
- (420) Wallace BM, Lasker JS. Awakenings ... UV light and HIV gene activation. *Science* 1992;257:1211-12.
- (421) Zmudzka BZ, Beer JZ. Activation of human immunodeficiency virus by ultraviolet radiation. *Photochemistry & Photobiology* 1990;52:1153-62.
- (422) Everett MA, Sayre RM, Olson RL. Physiological response of human skin to ultraviolet light. In: Urbach F, ed. *The biologic effects of ultraviolet radiation. (with emphasis on the skin)*. Oxford, England.: Permagon Press; 1969: 181-6.
- (423) CDC. Hazard evaluation and technical assistance report: John C. Murphy Family Health Center, Berkeley, Missouri. DHHS, Public Health Service, CDC. Cincinnati, OH, 1992. HETA 91-0148-2236.
- (424) CDC. Hazard evaluation and technical assistance report: Jackson Memorial Hospital, Miami, Florida. 1995.
- (425) Brubacher J, Hoffman RS. Hazards of ultraviolet lighting used for tuberculosis control. *Chest* 1996;109:582-83.
- (426) Talbot EA, Jensen P, Moffat HJ, Wells CD. Occupational risk from ultraviolet germicidal irradiation (UVGI) lamps. *Int J Tuberc Lung Dis* 2002;6:738-41.
- (427) American Conference of Governmental Industrial Hygienists. 2003 TLVs and BEIs: Based on the documentation of the threshold limit values for chemical substances and physical agents and biological exposure indices. Cincinnati: ACGIH; 2003.
- (428) Dumyahn T, First M. Characterization of ultraviolet upper room air disinfection devices. *American Industrial Hygiene Association Journal* 1999;60:219-27.
- (429) Rahn RO, Xu P, Miller SL. Dosimetry of room-air germicidal (254 nm) radiation using spherical actinometry. *Photochemistry & Photobiology* 1999;70:314-18.

- (430) Ikeda RM, Birkhead GS, DiFerdinando GT, Jr., Bornstein DL, Dooley SW, Kubica GP et al. Nosocomial tuberculosis: an outbreak of a strain resistant to seven drugs. *Infect Control Hosp Epidemiol* 1995;16:152-59.
- (431) Fraser VJ, Johnson K, Primack J, Jones M, Medoff G, Dunagan WC. Evaluation of rooms with negative pressure ventilation used for respiratory isolation in seven midwestern hospitals. *Infect Control Hosp Epidemiol* 1993;14:623-28.
- (432) Sutton PM, Nicas M, Reinisch F, Harrison RJ. Evaluating the control of tuberculosis among healthcare workers: adherence to CDC guidelines of three urban hospitals in California. *Infect Control Hosp Epidemiol* 1998;19:487-93.
- (433) Streifel AJ. Design and maintenance of hospital ventilation systems and the prevention of airborne nosocomial infections. In: Mayall CG, ed. *Hospital Epidemiology and Infection Control*. 2 ed. Philadelphia: Lippincot Williams and Wilkins; 1999: 1211-21.
- (434) Bloom BR, Murray CJ. Tuberculosis: commentary on a reemergent killer. *Science* 1992;257:1055-64.
- (435) Nardell EA. Dodging droplet nuclei. Reducing the probability of nosocomial tuberculosis transmission in the AIDS era. *Am Rev Respir Dis* 1990;142:501-3.
- (436) Hyatt, EC. Respiratory studies for the National Institute for Occupational Safety and Health - July 1, 1972 through June 3, 1973. 1974. 1-44.
- (437) Lawrence RB, Campbell DL, Myers WR, Calvert CA, Jensen PA, Coffey CC. Determining the efficacy of fit-test protocols using N95 filtering-facepiece respirators - Alternative approaches. *J Inter Soc Respir Protect* 2003;20:45-56.
- (438) CDC. Approval of respiratory protective devices. Code of Federal Regulations, 2003. 42: 84-
- (439) OSHA. Directive Number: CPL 2-2.54A, Respiratory Protection Program Guidelines. 7-14-2000.
- (440) Hyatt EC. Current problems and new developments in respiratory protection. *American Industrial Hygiene Association Journal* 1963;24:295-304.
- (441) Lowry PL, Hesch PR, Revoir WH. Performance of single-use respirators. *American Industrial Hygiene Association Journal* 1977;38:462-67.
- (442) Alvarado CJ, Reichelderfer M. APIC guideline for infection prevention and control in flexible endoscopy. *American Journal of Infection Control* 2000;28:138-55.
- (443) American Society for Gastrointestinal Endoscopy. Reprocessing of flexible gastrointestinal endoscopes. *Gastrointest Endosc* 1996;43:540-546.
- (444) American Society for Testing and Materials. Standard practice for cleaning and disinfection of flexible fiberoptic and video endoscopes used in the examination of hollow viscera. West Conshohocken, PA.: ASTM; 2000.

- (445) Society of Gastroenterology Nurses and Associates (SGNA). SGNA monograph series: Standards for infection control and reprocessing of flexible gastrointestinal endoscopes. Chicago, IL, 1997.
- (446) World Congress on Gastroenterology (WCOG). Working party report to the WCOG, Sydney, 1990. J Gastroenterol Hepatol 1991;6:23-47.
- (447) Spalding EH. Chemical disinfection of medical and surgical materials. In: Lawrence CA, Block SS, eds. Disinfection, sterilization, and preservation. Philadelphia: Lea and Febiger; 1968: 517-81.
- (448) Food and Drug Administration, CDC. FDA and CDC Public Health Advisory: Infections from endoscopes inadequately reprocessed by an automated endoscope reprocessing system. 9-10-1999. 1-5.
- (449) American College of Obstetricians and Gynecologists (ACOG). ACOG technical bulletin. Pulmonary disease in pregnancy. Number 224--June 1996. Int J Gynaecol Obstet 1996;54:187-96.
- (450) Wharton M, Strikas RA, Harpaz R, Rotz LD, Schwartz B, Casey CG et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR 2003;52:1-16.